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Abstract 
Emerging evidence suggests that several atypical Rho GTPases participate in the 
development of serious human pathologies such as chronic lymphocytic leukaemia and 
neurodegeneration. However, these GTPases remain poorly characterised at the 
functional, structural and biochemical level. Furthermore, the interactors and signalling 
pathways associated with these enzymes remain obscure. This study aimed to elucidate 
the molecular functions and interactors of three highly atypical human GTPases for the 
first time: hMiro1, hMiro2 and RhoH. 
Using PCR-based cloning and molecular biology techniques, full-length and truncated 
versions of these highly unusual human GTPases were successfully expressed, purified 
and characterised. Colorimetric assays were utilised to assess the GTPase hydrolytic 
activity of the human Miros in vitro, while PC3 cell migration assays and fluorescent 
microscopy allowed for an evaluation of Miro GTPase influence in live cancer cells. 
Biophysical characterisation of the Miros and RhoH was performed using dynamic light 
scattering (DLS) and circular dichroism (CD) thermal denaturation, while label-free 
proteomics allowed for the identification of several novel putative Miro interaction 
partners. Meanwhile, RhoH association with the death-associated kinase DRAK2 was 
assessed in vitro using anti-phosphoserine/phosphothreonine assays.  
The results show, for the first time, that individual domains of the human Miros are 
capable of intrinsic hydrolytic activity against GTP. Biophysical assessment by DLS 
suggests the Miros exist monomerically and exhibit average thermal stability. 
Knockdown of the human Miros produced a significant reduction in cell proliferation, 
with knockdown phenotypes associated with mitochondrial perinuclear aggregation 
under fluorescent microscopy. 37 novel putative signalling interactors for the human 
Miros were identified by mass spectrometry. Meanwhile, assessment of RhoH-DRAK2 
interaction showed a novel association between these proteins in vitro, indicating that 
DRAK2 directly phosphorylates RhoH. 
The results improve current understanding of these important and unusual human 
GTPases and the molecular functions they engage in. The novel interactors identified may 
also prove clinically relevant in the future, particularly to the understanding and treatment 
of neurodegenerative disorders and chronic lymphocytic leukaemia. 
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Chapter 1: Introduction 
1.1 The Ras superfamily of small GTPases 
1.1.1 The Ras superfamily: a brief overview 
The Ras superfamily of small guanosine triphosphatases (GTPases), named after one of the 
most extensively studied oncogenes in human carcinogenesis, Ras, comprises over 150 distinct 
human members across six sub-families: Ras, Rho, Rab, Ran, Arf and Miro (Figure 1.1). 
Typically, these so-called ‘small’ GTPases are monomeric in nature, containing a canonical 
~21 kDa catalytic ‘G domain’ (1,2). This G domain enables the hydrolytic degradation of GTP 
to GDP and is central to the function of Ras superfamily GTPases, enabling these enzymes to 
act as binary molecular switches within a diverse range of signalling pathways (3,4). While 
features of this G domain are strongly conserved throughout the sub-families of the Ras 
superfamily, delineation of the sub-classes is afforded by further differences in protein 
regulation, post-transcriptional modifications, function, structure and downstream interactors 
(5-9). 
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Figure 1.1 The Ras Superfamily of small GTPases. The Ras superfamily and comprising sub-
families, with examples of members of each sub-family displayed. Typical functions associated with 
each sub-family are also shown. 
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Several members of the Ras superfamily are medically relevant (10-17), driving the study of 
their structure, function and binding partners. For example, approximately 30% of all tumours 
screened contain at least one mutation in a Ras superfamily encoding gene (18). Furthermore, 
germline mutations in members of the Ras superfamily or their regulatory proteins have been 
associated with several inherited developmental syndromes such as Costello syndrome (19), 
Cardiofaciocutaneous syndrome (20) and Noonan syndrome (21), amongst others (22). 
Furthermore, dysregulation of some members of the Ras superfamily has been associated with 
such diverse disorders as dementia (23,24), diabetes (25,26) and cardiovascular disease 
(27,28). More recently, several highly ‘atypical’ proteins of the Ras superfamily have been 
identified (29), the majority of which appear to reside within the Rho sub-family (30). As 
further discussed in section 1.3, these proteins exhibit traits that make them highly unusual 
relative to ‘classical’ members of the Ras superfamily. Nonetheless, these ‘atypical’ GTPases 
have been implicated in a range of pathologies when absent or dysregulated, such as leukaemias 
(31-33), amyotrophic lateral sclerosis (ALS) (34) and Parkinson’s (35,36). Thus, an 
understanding of the structure, function and regulation of these atypical proteins is highly 
desirable. 
1.1.2 An overview of classical Ras superfamily regulation 
Classically, proteins of the Ras superfamily cycle between an active GTP-bound state and an 
inactive GDP-bound state (37). In their active state, they typically bind effector proteins and 
activate downstream signalling pathways (38,39). While Ras superfamily GTPases typically 
possess intrinsic GTPase activity (2,37), their activity tends to be regulated by three types of 
regulatory protein: Guanine nucleotide exchange factors (GEFs) (40,41), GTPase activating 
proteins (GAPs) (41,42) and guanine nucleotide dissociation inhibitors (GDIs) (41,43,44), as 
shown in Figure 1.2 and discussed further in 1.2.4. It should be noted, however, that atypical 
members of the Ras superfamily may partly or completely elude this scheme of regulation (43). 
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Figure 1.2. Schematic illustration of classical Ras superfamily GTPase regulation between active 
and inactive states. Schematic diagram illustrating the quintessential regulation of a classical Ras 
GTPase by GAPs, GEFs and GDIs.  
As illustrated in Figure 1.2, classical activation of Ras superfamily GTPases to their GTP-
bound state is facilitated by guanine nucleotide exchange factor proteins (GEFs), which 
stimulate the exchange of GDP for GTP (37). Alternatively, deactivation is typically 
undertaken by activity of GAP regulatory proteins, which promote GTP hydrolysis and 
henceforth return the Ras superfamily protein to the inactive GDP-bound state (42). A more 
detailed description of the mechanism of GTP hydrolysis in Ras superfamily enzymes is 
provided in section 1.2.3. GTPases within a branch are often targeted by shared and distinct 
GEFs and GAPs. Across different branches of the Ras superfamily, GTPases are often targeted 
by structurally distinct GEFs and GAPs which act by similar mechanisms (2,37,42). 
Some members of the Ras superfamily are also modulated by a third class of regulatory 
proteins: GDIs (2,37,43,44). Rho, Rab and some Ras family members undergo post-
translational prenylation at their C-terminus, facilitating their attachment to endomembranes 
and allowing them to perform at their appropriate sites of action. GDIs facilitate the extraction 
of these prenylated proteins from endomembranes, preventing exchange of GDP for GTP and 
GTPase 
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promoting cytosolic sequesteration of these proteins away from their sites of action (37). The 
term GDI itself was coined upon discovery of RhoGDI, classified as an inhibitor of GDP 
dissociation (45). However, the primary function of Rho and Rab GDIs is now thought to centre 
around the maintenance of their target GTPases in inactive complexes in the cytoplasm (37). 
In mammals, only a small number of GDIs have been identified. RhoGDIs and RabGDIs target 
gernaylgeranylated Rho and Rab GTPases, respectively. Meanwhile, the GDI PDEδ favours 
farnesylated GTPases (41).  
1.1.3 An overview of classical Ras superfamily structure 
The canonical feature of Ras superfamily proteins is their ability to bind and hydrolyse GTP 
by virtue of a ~21 kDa G-domain. As illustrated in Figure 1.3, the classical G-domain model 
is comprised of six β-sheets (β1-β6) and five α-helices in addition to four to five conserved G-
box ‘loop’ elements referred to as G1-G5 (2). Two domains, known as the switch I and switch 
II domains, are integral to the binding of ɣ-phosphate oxygens of GTP and are involved in 
fundamental conformational changes between the GDP-bound (state 1) and GTP-bound (state 
2) states of these GTPases (37,46). Following GTP hydrolysis and the release of ɣ-phosphate, 
the switch domains relax into GDP-specific conformation (37). In addition to the G-domain, 
some small GTPases (primarily of the Ras and Rho sub-families) possess a C-terminal 
tetrapeptide CaaX motif (‘CaaX box’) required for localisation of these proteins to the plasma 
membrane (47,48). 
 
 
 
 
 
 
 
 
 
5 
 
N 
C 
G3 /  
  Switch II 
G2 /  
  Switch I 
G4 
G5 
 G1 
β1 
β2 
β3 
β4 
 
β5 
 
β6 
α2 
α3 α1 α4 α5 
α4 
α5 
α3 
α1 
α2 
β6 
 
β5 
β2 
 
β4 
β1 
 
β3 
 
G4 
G5 
 
G1 
C 
N 
G2 /  
Switch I 
G3 /  
Switch II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Typical structural aspects of a classical Ras superfamily GTPase. Anterior (a) and 
posterior (b) three-dimensional model of human H-Ras, a classical GTPase of the Ras family, with (c) 
additional schematic diagram displaying the G loops, switch regions, CaaX box, beta strands and alpha 
helices. In a–b, H-Ras is shown bound to Mg2+ and the GTP analogue GCP. Critical areas are labelled 
accordingly, with beta strands displayed in green and alpha helices shown in red. Note that the ligands 
adhere to the CPK chemical element colouring scheme as follows: Nitrogen (blue), Oxygen (red), 
Phosphorous (yellow). Model generated in MolSoft MolBrowser version 3.8 (MolSoft L.L.C) from 
entry 121P of the RCSB PDB (49). In (c), an identical colour coding system has been adopted from the 
3D structures (a) and (b), while the G domain as a whole is delineated as grey; the amino acid residues 
shown apply to H-Ras specifically. 
(a) 
(c) 
(b) 
G10AGGVGK
G
T35 
G2 
D57TA
G3 
N116KCD 
G4 
S145AK 
G5 
C186VLS 
Phosphate and Mg2+ 
binding 
Guanosine 
binding 
P-loop    Switch I    Switch II                                                                 CaaX box 
Effector binding 
β1 β2 β3 β4 β5 β6 α2 
 
α3 
 
α4 
 
α5 
 
α1 
 
6 
 
The features of the G-domain shown in Figure 1.3 are generally well-conserved across classical 
members of the Ras superfamily (with the exception of the Miros, which are highly atypical 
and discussed in detail in section 1.4). However, each sub-family within the Ras superfamily 
may exhibit unique structural aspects conserved within that particular sub-family only (50). 
With respect to the high number of atypical GTPases seen within the Rho-subfamily, it is 
pertinent to discuss classical structural aspects of this sub-family, including aspects unique to 
the Rhos alone. From a three-dimensional model of the classical Rho family member RhoA 
(Figure 1.4), it can be seen that classical Rho members contain several structural aspects that 
are also common to the Ras superfamily as a whole. Classical Rho GTPases possess a G-
domain encompassing the typical six β-sheets and five α-helices, along with the 
aforementioned conserved G-box G1-G5 loops. Two other important classical aspects, the 
switch I and switch II regions, are also present. Canonical members of the Rho sub-family also 
possess the C-terminal CaaX box. A distinguishing aspect of classical Rho proteins, however, 
is the presence of a surface-exposed alpha helical ‘Rho insert’ domain between the fourth α-
helix and fifth β-sheet (5). This domain is thought to be involved in Rho-specific signalling 
events (51) and has been shown to be necessary for some Rho-specific regulatory events; for 
example, the insert region of RhoA is essential for Rho kinase activation and subsequent 
cellular transformation events (52). 
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Figure 1.4. Typical structure of a ‘classical’ Rho sub-family member. Anterior (a) and posterior (b) 
three-dimensional model of human RhoA, a classical GTPase of the Rho sub-family, followed by a 
corresponding schematic diagram (c).  In (a) and (b), RhoA is bound to Mg2+ (green sphere) and the 
GTP analogue GSP. The GSP ligand adheres to the CPK chemical element colouring scheme as follows: 
Nitrogen (blue), Oxygen (red), Phosphorous (yellow). Critical areas are labelled accordingly, with beta 
strands displayed in green and alpha helices shown in red. Model generated in MolSoft MolBrowser 
version 3.8 (MolSoft L.L.C) from entry 1A2B of the RCSB PDB (53). In (c), an identical colour coding 
system has been adopted from the 3D structures (a) and (b), while the G domain as a whole is delineated 
as grey; the amino acid residues shown apply to H-Ras specifically. 
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1.2 Structure and function of classical Ras superfamily enzymes 
1.2.1 Conserved regions of classical Ras superfamily enzymes 
When comparing classical members of the Ras superfamily with atypical members, it is 
important to understand the conserved regions of the classical enzymes in some detail. As such, 
specific conserved regions will be examined in turn. Due to the presence of several atypical 
small GTPases within the Rho sub-family, the Rho-insert domain (unique to members of the 
Rho sub-family), will also be discussed here in further detail.  
1.2.1.1 The G1 loop (P loop) 
The G1 region, also known as the phosphate binding loop (or P loop), is composed of the 
following consensus sequence: GxxxxGK[S/T] (54). This loop region is vital for its role in the 
correct positioning and binding of alpha and beta phosphates in the guanine nucleotide, and is 
able to essentially ‘wrap around’ the guanine nucleotide phosphates, allowing nitrogen atoms 
of the main chain to interact with the negatively charged phosphates (55). Meanwhile, the 
lysine (K) of this motif exhibits a critical role in nucleotide binding via its ability to directly 
interact with the beta and gamma phosphate oxygens (55,56). The hydroxyl group of the serine 
or threonine located at the end of the motif is also involved with binding to the beta phosphate 
oxygen and the magnesium ion co-factor (55-57). 
The initial glycine residue in this motif is classically located at position 12 (G12) and is 
commonly mutated to a valine in mutant oncogenic Ras proteins (58), rendering these mutants 
constitutively active (GTP-bound) (59). Due to the high conservation of certain residues in this 
motif (notably the initial glycine), the G1 region is sometimes referred to as an identifying 
‘fingerprint’ region (55). 
1.2.1.2 The G2 loop 
The G2 loop, also referred to as the switch I region or effector binding loop (60), contains a 
highly conserved threonine that is essential for binding divalent magnesium (55,61), a common 
co-factor for members of the Ras superfamily (61,62). In HRAS and several other Ras 
members, the G2 motif is comprised of the following sequence: YDPTIEDSY (2,63). However, 
the G2 motif shows a great degree of variation across the Ras superfamily, with some residues 
shared within sub-families but only the threonine (T) exhibiting strong conservation across the 
superfamily (2,37,55). The G2 motif connects the α1-helix to the β2-strand of the classical G 
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domain (60) and mutations in the G2 region of HRAS have been demonstrated to disrupt HRAS 
binding to downstream effectors (64-66). 
1.2.1.3 The G3 loop 
Within the Ras superfamily, the consensus residue sequence for the G3 motif is: DxxG 
(2,54,55). The aspartic acid (D) residue here is invariant amongst members of the Ras 
superfamily, playing a role in the binding of the co-factor magnesium (63). The G3 motif 
glycine forms a hydrogen bond with the gamma-phosphate of GTP, securing nucleotide 
binding alongside residues of the G1 motif (55,60,67).  
1.2.1.4 The G4 loop 
The G4 region (consensus sequence: [N/T]KxD) is primarily involved in recognising the non-
phosphate areas of the guanine nucleotide (63). The conserved [N/T]KxD motif within this 
region, for example, interacts with the nucleotide guanine ring via the formation of hydrogen 
bonds; this confers specificity for GTP as a substrate, rather than ATP, and stabilises 
interactions with residues of the G1 motif (55,63). This [N/T]KxD motif plays crucial roles in 
binding the guanine nucleotide ring (68). X-ray crystallographic structures of Ras (69) and the 
GTP-binding domains of other proteins (70-72) show that the asparagine (N) residue of this 
motif forms a hydrogen bond with the N7 atom of the guanine moiety, while the aspartic acid 
(D) residue forms hydrogen bonds with the N1 and N2 atoms. The lysine (K) residue is also 
known to directly bind to the guanine nucleotide (55). As such, the G4 loop encompasses a 
critical region for the binding of the guanine nucleotide specifically, rather than other 
nucleotides.   
1.2.1.5 The G5 loop 
The G5 region, also known as the G5 loop, contains the consensus sequence [S/C]A[K/L/T] in 
Ras and acts as a recognition site for the guanine base (61). The residues of this region are 
thought, mostly, to produce electrostatic or hydrophobic associations with the guanine 
nucleotide and are generally not well conserved across the Ras superfamily (55,61). Despite 
low sequence conservation amongst members of the Ras superfamily, however, previous 
studies have demonstrated an important role for the G5 motif in influencing the intrinsic rate of 
GDP release from the G domain (73). The typically conserved alanine (A) within the G5 domain 
appears critical in this sense and is thought to form hydrogen bonds with the 6-keto group of 
the guanine moiety (74), with substitutions of this residue producing an increased rate of 
guanine nucleotide exchange (75) and contributing to increased rates of neoplastic 
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transformation in somatic cells (76-78) or the manifestation of Costello syndrome in germline 
A146 HRAS mutants (79). Further to this, the threonine (T) residue observed in many G5 
regions appears to directly bind the guanine nucleotide (61), with substitution mutations in this 
residue shown to produce an accelerated rate of GDP release from the G domain (73). 
1.2.1.6 The switch I and switch II regions 
The switch I (Ras residues 30–38) and switch II (Ras residues 59–67) regions of the Ras 
superfamily exhibit significant conformational changes when a typical small GTPase 
transitions from the GDP-bound state to the GTP-bound state (2,46,63). Indeed, the switch 
regions typically demonstrate an increased general flexibility in x-ray structures and nuclear 
magnetic resonance (NMR) studies (46,69,80,81). As shown in Figures 1.3 and 1.4, the G2 and 
G3 regions comprise part of the switch I and II regions, respectively.  
Interestingly, GDP-bound proteins often exhibit a much greater degree of structural diversity 
than GTP-bound proteins (55). In the GTP-bound form, two hydrogen bonds form between the 
gamma-phosphate oxygens to main chain NH groups of the highly conserved threonine (T) and 
glycine (G) present in switch I and switch II, respectively (Figure 1.5). This is sometimes 
referred to as the universal 'loaded spring' mechanism, where gamma-phosphate release 
following GTP hydrolysis allows the two switch regions to relax into the GDP-bound 
conformation (37). The extent of the conformational change between GTP and GDP-bound 
forms can vary significantly across the Ras superfamily (2,55). For some GTPases, additional 
elements may be involved. For example, Ran GTPases frequently exhibit a large 
conformational change in the switch I region involving the unravelling of an extra β-strand and 
the relocation of the COOH-terminal extension (sometimes referred to as the C-terminal 
switch) (82,83). Regardless of the extent of the conformational change, however, all 
conformational changes shown in classical small GTPases when transitioning between the 
GTP-bound and GDP-bound state are thought to be a consequence of the loaded spring 
mechanism (2,6,37,55). 
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Figure 1.5. Differences between GTP- and GDP- bound versions of the classical Ras 
GTPase, HRas. 3D representations of (a) GTP-bound HRas (PDB: 5P21) and (b) GDP-bound 
HRas (PDB: 4Q21), where alpha helices are displayed in red and beta sheets shown in teal 
green. Close-ups of the interactions between key residues of the Switch I and II regions of a 
canonical Ras superfamily GTPase and the gamma phosphate of GTP are shown in (c) (GTP-
bound GTPase) and (d) (GDP-bound GTPase). The switch I and II regions bind to the gamma 
phosphate via the main chain NH groups of the invariant threonine and glycine residues, 
producing a “loaded spring”. Release of the gamma phosphate following hydrolysis of GTP 
enables the switch regions to relax into an alternative conformation. In all images, Mg2+ is 
shown as a green sphere, while the Switch I and Switch II regions are shown in yellow and 
orange, respectively. Not that (c) and (d) were adopted from (84). 
 
(a)                                    GTP-bound (b)                                         GDP-bound 
(c) (d) 
G3/switch II 
 
G2/switch I 
 
G2/switch I 
 
G3/ 
switch II 
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1.2.1.7 Magnesium co-factor 
Divalent magnesium (Mg2+) has been well-established as a vital cofactor for many GTP-
binding proteins, necessary for both GTP hydrolysis and guanine nucleotide binding (62,85). 
In the presence of Mg2+, Ras shows a high binding affinity to the guanine nucleotides, 
exhibiting a dissociation constant on the order of sub-nanomolar concentrations (85-87). In 
some cases, EDTA-mediated removal of Mg2+ completely abrogates GTPγS binding capability 
(88,89) and intrinsic rates of GTP hydrolysis become undetectable in the absence of Mg2+ 
(86,88), indicating that Mg2+ is crucially required for the process of GTP hydrolysis by these 
GTPases. Indeed, the GEFs ARNO and Sos appear to stimulate GDP dissociation at least 
partially through destabilisation of bound Mg2+ from their respective GTPases (90-92). 
1.2.1.8 The C-terminal CaaX box 
The C-terminal CaaX box (or CaaX domain) represents a vital feature of many proteins of the 
Ras superfamily and particularly those of the Ras and Rho sub-families, allowing for the 
targeting of these enzymes to their site of action at the plasma membrane. This tetrapeptide 
sequence is recognised by farnesyltransferase and/or geranylgeranyltransferase I, and post-
translationally modified by covalent addition of a farnesyl or geranylgeranyl isoprenoid to the 
CaaX cysteine, respective of the transferase in question. Other proteins of the Ras superfamily 
are modified for targeting to their site of action by alternative means.  
1.2.2 Residues participating in nucleotide binding 
Across classical members of the Ras superfamily, several highly conserved residues 
participating in nucleotide binding have been observed; for clarity, these are shown in Table 
1.1, below. Additionally, an illustration of residues of the classical Rho GTPase Cdc42 
involved in binding GCP (a non-hydrolysable analogue of GTP) is provided (Figure 1.6). 
Further discussion regarding these residues in the GTP hydrolysis mechanism employed by 
classical Ras superfamily GTPases is provided in 1.2.3. Note that some highly conserved 
residues, such as G12, play important roles in enabling GTP hydrolysis but may not directly 
engage in nucleotide binding (for instance, the oncogenic G12V mutation in Ras hinders the 
correct orientation of a water molecule required for hydrolysis, rendering the GTPase 
constitutively active). 
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Table 1.1. Commonly conserved residues participating in nucleotide binding amongst Ras 
superfamily enzymes (residue positions correspond to H-Ras). 
Conserved 
residue 
(Ras) 
Location 
Role in nucleotide 
binding 
Reference(s) 
K16 G1 loop 
Interacts with β and γ 
phosphate oxygens 
(55,69) 
[S/T]17 G1 loop 
Interacts with β 
phosphate oxygens 
(55-57) 
F28 Switch I region 
Stabilises nucleotide 
base 
(93) 
T35 G2 loop /switch I region 
Forms a hydrogen bond 
with the nucleotide γ 
phosphate 
(37,55) 
G60 G3 loop/switch II region 
Forms a hydrogen bond 
with the nucleotide γ 
phosphate 
(94,95) 
N116 G4 loop 
Forms hydrogen bond 
with N7 atom of 
guanine moiety 
(55,69) 
K117 G4 loop 
directly binds to 
guanine nucleotide 
(55) 
D119 G4 loop 
Hydrogen bonds with 
N1 and N2 atoms 
(96,97) 
A146 G5 loop 
Forms hydrogen bonds 
with 6-keto group of 
guanine moiety 
(45,98) 
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Figure 1.6. Residues participating in nucleotide binding in the classical Ras and Rho 
GTPase (a) H-Ras and (b) Cdc42. Note that black dashed lines indicate hydrogen bonds, 
salt bridges, and metal interactions. Green solid line show hydrophobic interactions and 
green dashed lines show π-π and π-cation interactions. Image derived from 2D interaction 
diagrams provided on the Protein Database (PDB) deposit for H-Ras (3TGP) and CdC42 
(2QRZ) bound to non-hydrolysable analogues of GTP (GNP for H-Ras; GCP for Cdc42).  
(a) H-Ras 
(b) Cdc42 
15 
 
1.2.3 The GTP hydrolysis mechanism employed by classical Ras superfamily 
enzymes 
Analysis of relevant crystal structures, alongside mutagenesis studies and computational 
modelling, have provided clarity on the mechanism of GTP hydrolysis employed by 
enzymes of the Ras superfamily (61,99). A number of key residues have been identified 
in the active site of Ras superfamily GTPases that directly or indirectly participate in 
GTP hydrolysis, including: G61, K16, T35 and G60 (100-102). Further comprehension 
of the Ras GTPase hydrolytic reaction has been made possible by elucidation of crystal 
structures in the presence of aluminium or magnesium trifluoride, which imitate the 
hydrolysed γ-phosphate before dissociation and therefore model the reaction transition 
state (102-104). Taken together, the abundance of data available enables a deeper 
understanding of the GTP hydrolysis mechanism employed by Ras superfamily 
enzymes. However, some controversies remain (54,61,99,105,106). It should also be 
noted that the intrinsic hydrolytic activity of Ras superfamily GTPases is highly 
inefficient (54,61), exhibiting about 1% of the average reaction rate of heterotrimeric G 
proteins (54). Consequently, small GTPases typically require interaction with a GAP 
enzyme to undergo efficient hydrolysis (41,42).  
In canonical Ras enzymes, GTP hydrolysis is believed to occur through direct transfer 
of the GTP γ-phosphate group to H2O, with a significant role in catalysis undertaken by 
a glutamine (Q) in the switch II loop, directly adjacent to the G3 loop (typically present 
at position 61 in classical Ras and Rho GTPases), which acts as a catalytic base to 
activate a H2O molecule for nucleophilic attack (61). Analysis of relevant crystal 
structures show that the H2O molecule is located no further than 4 Å from the γ-
phosphate group of GTP and is oriented for the nucleophilic attack via hydrogen 
bonding with the γ-phosphate and carbonyl of the invariant threonine (typically at 
position 35) of the G2 loop (107). Indeed, analysis of the Ras-RasGAP complex 
indicates that RasGAP acts to catalyse GTP hydrolysis by stabilising the position of 
glutamine 61 of Ras (104), and mutations of this glutamine residue are known to 
significantly impair GTP hydrolysis (105). However, this glutamine residue appears too 
weak a base to accept a proton (61); indeed, while this residue is capable of stabilising 
the pentavalent intermediate state in the GTP hydrolysis reaction (105,108), it is 
generally accepted that the γ-phosphate group of GTP itself accepts the proton in a 
mechanism known as ‘substrate-assisted catalysis’ (106), with the reaction proceeding 
as an associative in-line transfer of the phosphate group with a pentavalent intermediate 
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and an inversion of configuration of stereochemistry (99). In this associative transfer, a 
negative charge accumulates on the γ-phosphate, an event that is directly followed by 
hydrolysis of the bond between the β and γ-phosphate with a charge transition to the β-
phosphate (61). However, a dissociative mechanism has also been previously suggested, 
assuming that the first catalytic step is the disruption of the bond between β- and γ-
phosphate (61,99).  
As previously mentioned, GDP·Mg2+·AlF4- (or AlF3OH
–) complexes are stable 
transition state analogues that preserve the ability for sustained interaction with GAP 
enzymes and are identical to the pentacoordinate intermediate state (109,110). Crystal 
structures of these complexes indicate that the carboxyamide group of the switch II 
glutamine (typically present at position 61 in canonical ras and Rho proteins) is capable 
of polarising and orienting the nucleophilic H2O molecule in the transition state for GTP 
hydrolysis (70). The presence of the ‘arginine finger’ in Ras and Rho GAP enzymes 
stabilises the transition state by neutralising the developing negative charge at the γ-
phosphate (111). Further analysis by in silico methods have additionally revealed that, 
upon GTP binding, re-orientation of the lysine (K), glycine (G) and valine (V) amides 
of the p-loop (typically at positions 16, 15 and 14, respectively) forces the GTP 
molecule into a strained, inflexible conformation (112). This leads to a charge 
redistribution, with the negative charge of the γ-phosphate transferred to the β-
phosphate group, decreasing the energy of transition activation barrier for the 
intermediate state of the reaction (113). According to comparisons of crystal structures 
and mutagenesis studies, the scheme of GTP hydrolysis employed by the G protein 
Giα1 appears to be highly similar to that utilised by many canonical enzymes of the Ras 
superfamily (61,70,99,102,107,109,110,112); this scheme has been displayed as Figure 
1.7. For ease of understanding, an additional schematic illustration (Figure 1.7) is 
provided; Figure 1.8 displays GAP-mediated hydrolysis in Ras superfamily enzymes 
specifically. 
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Figure 1.7 Mechanism of GTP hydrolysis employed by the Giα1 G domain. The mechanism 
of GTP hydrolysis employed by canonical Ras and Rho enzymes is thought to follow the 
general scheme displayed above, albeit with the R178 residue supplied by Ras and Rho GAP 
enzymes. In (a), the Giα1 enzyme is in the 'on' (GTP-bound) conformation (Giα1‧GTPγ‧Mg2+ 
enzyme-substrate complex; PDB 1gia). Here, a H20 molecule is located merely 3.8Å from the γ-
phosphate of GTP and oriented for a nucleophilic attack. In (b), a Giα1‧GDP‧AlF4-‧Mg2+ 
intermediate state model is shown (PDB 1gfi), with the AlF4– forming an octahedral complex 
where the γ-phosphate and a H20 molecule are placed in transaxial positions. In this figure, an 
arginine (donated by GAP proteins in Ras and Rho reactions) forms hydrogen bonds with the 
pentacoordinate intermediate and the oxygen bridging the phosphates, while the switch II 
glutamine and switch I threonine (Q61 and T35 in canonical Ras and Rho enzymes) are placed 
so that the attacking H2O molecule is polarised and well-oriented. In (c), the Giα1‧GDP‧Pi 
enzyme-products complex is shown (PDB 1git). The switch II glutamine is displaced and the 
Mg2+ coordination sphere disrupted. Meanwhile, an arginine (donated by GAP in Ras and Rho 
reactions) forms hydrogen bonds with β-phosphate and Pi. The threonine of G2 and its 
preceding lysine (not marked) re-orient and form hydrogen bonds with Pi. Conformational 
changes occur in switch I and switch II. In (d), the Giα1‧GDP complex is shown (PDB 1gg2). 
Switch II is disordered and switch I moves away from the nucleotide due to loss of the Mg2+ 
ligand. The catalytic site is disrupted. Figure adopted from Paduch and colleagues (61). 
(a) (b) 
(c) (d) 
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Figure 1.8. Mechanism of GAP-mediated GTP hydrolysis in classical Ras and Rho 
enzymes. The canonical arginine finger/switch II glutamine mechanism is shown. GAP 
provides an arginine (the arginine finger) to stabilise the partial negative charges that develop at 
the transition state and positions the conserved glutamine at position one to activate a water 
molecule (wat) for nucleophilic attack of the GTP γ-phosphate. The arginine fingers from 
representative structures of RasGAP, ArfGAP, RhoGAP, and Arl3GAP in complexes with their 
corresponding GTPase are overlaid. For clarity, the conserved glutamine from the DTAGQ 
motif of the G3 loop/switch II region (in red) is shown only for Ras. The term ‘wat’ represents 
the nucleophilic water molecule. Figure derived from Cherfils and Zeghouf (41). 
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1.3 Atypical members of the Ras superfamily 
Classical GTPases of the Ras superfamily, such as the Rho subfamily proteins Cdc42, 
Rac and RhoA, follow the canonical GEF/GAP/GDI scheme of regulation (Figure 1.2) 
and largely retain the classical structural characteristics described in section 1.1. Many of 
these – particularly the former three – have been extensively studied, with structures 
defined by x-ray crystallography (104,114-116) and NMR (117-120). However, while 
classical GTPases are distinguished by the characteristics described above, several 
‘atypical’ small GTPases exist that exhibit structural deviation from archetypical small 
GTPases and may follow alternative schemes of regulation (30). The atypical members 
will be discussed in the following sub-sections. 
1.3.1 Atypical members of the Ras superfamily: an overview 
As aforementioned, some GTPases of the Ras superfamily exhibit unique structural or 
functional features relative to their classical counterparts, making it appropriate to classify 
them as 'atypical'. The majority of these atypical proteins reside in the Rho subfamily 
(30). Rho GTPases are archetypically considered critical regulators of the actin filament 
system and therefore heavily involved in cell migration and morphology (2,30). As shown 
in Figure 1.9, the Rho subfamily is comprised of 20 members classified into 8 further 
sub-families. Out of these 8 sub-families, Rnd, Wrch-1/Chp, RhoH and RhoBTB are 
considered atypical relative to the Rho, Rac, Cdc42 and RhoD/RhoF subfamilies. 
Additionally, two atypical proteins previously regarded as Rho GTPases have been 
allocated to their own sub-family: the Miro sub-family (see section 1.4).  Beyond atypical 
Rho proteins, other small GTPases that may be regarded as atypical include the 
Rad/Gem/Kir (RGK) families of the Ras sub-family (121) and the centaurins, which are 
not typically included as members of the Ras superfamily but contain GTPase domains 
(60,122). 
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Figure 1.9. GTPases of the Rho sub-family, with atypical members highlighted. Unrooted 
dendritic-tree representation of the human Rho GTPases. The atypical Rho GTPases are 
distinguished by the grey circled area. The Rho GTPases can be further sub-dividied into 8 
additional sub-families or divisions (as shown in the boxed area at the top left). Figure adopted 
from Aspenstrom et al., 2007 (30). 
Atypical GTPases of the Ras superfamily may be distinguished from classical small 
GTPases in a number of ways (30,60). For example, GTP cycling is sometimes 
completely inapplicable to atypical GTPases. The atypical Rnd proteins and RhoH are 
GTPase deficient, remaining constitutively in the GTP-bound state (123,124). It is 
currently thought that this GTPase deficiency may also be associated with the RhoBTB 
GTPases (125), though RhoBTB2 has been shown to bind GTP (126) and RhoBTB3 
appears to bind ATP rather than GTP (127). Too, Wrch-1 and the Rac1 splice variant 
Rac1b appear to exist primarily in the GTP-bound conformation, bypassing the classical 
scheme of GTPase activation and deactivation (30). In fact, the regulation of atypical 
GTPases rarely adheres to the simple GAP/GEF/GDI scheme described in Figure 1.2 
(section 1.1). Very few GAPs, GEFs and GDIs have been identified which interact with 
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atypical GTPases of the Ras superfamily (30,60,128). Instead, these GTPases may be 
regulated by alternative means, such as protein:protein interactions involving domains 
not present in classical Ras superfamily members (30).  Several of these proteins are also 
known to be regulated at the level of transcription (123,124), or through targeted 
destruction (7,124,129,130).  
In addition to this, atypical small GTPases often exhibit functional deviations from their 
classical counterparts; they are often involved in dissimilar signalling pathways to 
classical small GTPases and may interact with unique binding partners (17,30,124). 
Perhaps most strikingly, some atypical GTPases of the Ras superfamily exhibit unusual 
domains not seen amongst classical member (Figure 1.10). For example, the atypical 
Miro GTPases contain two GTPase domains, in addition to calcium-binding EF hand 
domains (131). Furthermore, several residues normally strongly conserved in classical 
Ras superfamily GTPases (such as those in the G1–G5 loops and switch regions) may be 
substituted or absent in atypical Rho GTPases (see Figure 1.10 and correspondingly, 
Table 1.2 – Table 1.4). For example, Figure 1.11 indicates that the invariant T35 in the 
G2 region is absent in the GTPase domains of both hMiro1 and hMiro2. Furthermore, 
G60 is replaced by a glutamic acid residue in the hMiro1 GTPase domains and the hMiro2 
N-terminal GTPase domain. The Q61 residue required for crucial re-orientation of H2O 
(see section 1.2.3) is also substituted in all atypical Rho proteins shown in Figure 1.11. 
Despite stark differences between the atypical and classical Rho GTPases, however, the 
unusual ‘atypical’ proteins appear to engage in crucial cellular functions and are 
implicated in serious human pathologies such as myeloproliferative disorders (31-33) and 
neurodegeneration (34,129,132). Further understanding of these proteins and their 
cellular functions is therefore highly medically relevant. 
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Figure 1.10. Schematic representation of a selection of atypical GTPases of the Ras 
superfamily. Schematic diagrams of the atypical Rho GTPases are shown. The CAAX (Cystein–
Aliphatic–Aliphatic–Any amino acid) box is targeted by post-translational modification for 
targeting to the plasma membrane. However, the CAAX box of Wrch-1 may not be functional. 
The term ‘P-site’ denotes palmitoylation site, whereas ‘BTB’ domain represents what is known 
as the Broad complex/Tramtrack/Bric-a-brac domain. The term ‘NLS’ denotes nuclear 
localisation site. PEST (Proline–Glutamic acid–Serine–Threonine) is a motif associated with 
protein stability. The abbreviation ‘a.a.’ denotes amino acid residues. Figure adopted from a 
review by Aspenstrom and colleagues (30).
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Figure 1.11. Amino acid sequence alignment showing differences between select classical 
Ras superfamily GTPases and the atypical Rho GTPases studied herein.  NCBI identifiers 
are shown for each protein. Residue colouring specifies the following: red indicates small and 
hydrophobic residues, blue represents acidic residues, magenta marks basic residues and green 
shows residues bearing hydroxyl, sulphydryl or amine groups. * Residues V14, K16 and [S/T]17, 
as dicussed in section 1.2.3; †Residues 7–169 of hMiro1, representing the N-terminal GTPase 
domain; ‡Residues 415–592 of hMiro1, representing the C-terminal GTPase domain; §Residues 
3–169 of hMiro2, representing the N-terminal GTPase domain; 
‖
Residues 413–589 of hMiro2, 
representing the C-terminal GTPase domain. 
 
G1 G2 (T35) 
G3 
G4 G5 
Switch I 
Switch II 
Rho insert domain 
CaaX box 
Q61 
 
CAG38816.1 
AAM21117.1 
NP_426359.1 
CAB53579.5 
AAM21122.1 
AAI25105.1† 
AAI25105.1‡ 
Identifier 
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Table 1.2 Differences in the G domain loop regions: classical versus atypical Ras 
superfamily enzymes. 
Protein Identifier G1 G2 G3 G4 G5 
---- 
Consensus 
sequence 
GxxxxGK[S/T] T DxxG [N/T]KxD 
[S/C]A 
[L/T/K] 
HRas CAG38816.1 GAGGVGKS T DTAG NKCD SAK 
RhoA AAM21117.1 GDGACGKT T DTAG NKKS SAK 
Cdc42 NP_426359.1 GDGAVGKT T DTAG TQID SAL 
Rac1 CAB53579.5 GDGAVGKT T DTAG TKLD SAL 
RhoH AAM21122.1 GDSAVGKT T DTAG TQTD SAL 
hMiro1 NT 
AAI25105.1: 
7–169 
GEPRVGKT P DYSE NKSD SAK 
hMiro1 CT 
AAI25105.1: 
415–592 
GVKNCGKS D DISE AKSD NTA 
hMiro2 NT 
AAI25105.1: 
3–169 
GEAQVGKT P DYSE NKSD SAK 
hMiro2 CT 
AAI25105.1: 
413–589 
GARGVGKS E CEVG SKAD AGP 
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Table 1.3 Differences in the switch regions and CaaX box: classical versus atypical Ras 
superfamily enzymes. 
Protein Identifier Switch I Switch II CAAX box 
HRas CAG38816.1 D--PTIEDSY 
AGQEEYSAMRDQYMRTGEG CVLS 
RhoA AAM21117.1 V--PTVFENY AGQEDYDRLRPLYSPDTDV CLVL 
Cdc42 NP_426359.1 V--PTVFENY AGQEDYDRLRPLSYPQTDV CCIF 
Rac1 CAB53579.5 I--PTVFENY AGQEDYDRLRPLSYPQTDV CLLL 
RhoH AAM21122.1 K--PTVYENT AGNDAFRSIRPLSYQQADV CKIF 
hMiro1 NT 
AAI25105.1: 
7–169 
V--PPRAEEI SEAEQSDEQLHQEISQANV ---- 
hMiro1 CT 
AAI25105.1: 
415–592 
KIREDHKSYY SESEFLTEA-EII---CDV SSTF 
hMiro2 NT 
AAI25105.1: 
3–169 
V--PPRAEEI SEAEQTDEELREEIHKANV ---- 
hMiro2 CT 
AAI25105.1: 
413–589 
T--REQPPGY GTDGLLATSLDAT---CDV PSSF 
 
Table 1.4 Differences in the Rho insert domain: classical versus atypical Ras superfamily 
enzymes 
Protein Identifier Rho insert domain 
HRas CAG38816.1 -------------- 
RhoA AAM21117.1 DEHTRRELAKMKQE 
Cdc42 NP_426359.1 DPSTIEKLAKNKQK 
Rac1 CAB53579.5 DKDTIEKLKEKKLT 
RhoH AAM21122.1 -------MGPHRAS 
hMiro1 NT AAI25105.1: 7–169 ---------YSSME 
hMiro1 CT AAI25105.1: 415–592 ---------VKQEY 
hMiro2 NT AAI25105.1: 3–169 ---------GSSME 
hMiro2 CT AAI25105.1: 413–589 ---------GVAVS 
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Before proceeding, it is noteworthy to mention that some members of the Ras superfamily 
appear to act somewhat atypically, but retain classification as typical small GTPases. An 
example is the SRβ sub-unit of the eukaryotic signal recognition particle receptor that 
targets ribosome-nascent polypeptide chain complexes to the endoplasmic reticulum 
(133). SRβ forms the eukaryotic signal particle receptor alongside SRα (134). Although 
both SRα and SRβ are GTPases, SRα belongs to the SIMBI ('SRP, MinD, BioD') class of 
GTPases (135), while SRβ is classified as a member of the Arf sub-family of the Ras 
superfamily (133). SRβ may be mistakenly regarded as atypical for three main reasons. 
Firstly, SRβ is the only member of the Arf family that is permanently membrane-anchored 
by an N-terminal membrane anchor (136); meanwhile, other Sar1 and Arf proteins are 
transiently attached to the membrane in their GTP-bound state (137). Secondly, in 
contrast to the majority of Ras superfamily GTPases, which act monomerically, SRβ is 
active only as a heterodimer with SRα (133), and may form self-regulatory homodimers 
which are unable to bind SRα (138). Thirdly, the GTPase switch cycle mechanism of SRβ 
varies somewhat from that seen in other Arf members (133).  
Despite the characteristics outlined above, SRβ is considered a classical small GTPase 
because it retains many classical characteristics seen in other members of its sub-family, 
including structural similarities and a partly-shared switch cycle mechanism. Indeed, akin 
to classical Ras superfamily GTPases, SRβ cycles between active GTP-bound and 
inactive GDP-bound conformations (139,140). Furthermore, the function of SRβ does not 
diverge from that of other Arf proteins (targeting of macromolecular complexes to 
secretory membranes) and the regulation of SRβ does not differ significantly from other 
Arf proteins (133). Moreover, inherent variances exist within the Arf sub-family that are 
believed to correlate with the specific roles of each Arf member in targeting 
macromolecular complexes to secretory membranes; this provides an explanation for 
many of the peculiarities observed in SRβ (133). In short, while SRβ does exhibit some 
atypical features, it is not sufficiently unusual with regards to structure, function and 
regulation relative to other members of its sub-family. Meanwhile, the atypical Rho 
GTPases discussed above display highly unusual structural, functional or regulatory 
features relative to classical GTPases of the Rho sub-family. 
1.3.2 Known example of atypical Ras superfamily GTPases: the RhoBTB proteins 
The RhoBTB proteins comprise a subfamily of three known atypical Rho GTPases in 
humans: RhoBTB1, RhoBTB2 and RhoBTB3 (128,141). Identified in 2001 by Rivero 
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and colleagues (125), the RhoBTB family are large (~80 kDa) and comprised of an N-
terminal GTPase domain followed by a proline rich region, a tandem of two 
broadcomplex, tramtrack, bric-a-brac (BTB) domains, and a conserved C-terminal region 
(128,142).  In humans, RhoBTB1 and RhoBTB2 exhibit a high degree of amino acid 
sequence identity, while RhoBTB3 is considerably diverse (128).  
The RhoBTB proteins may be distinguished as truly atypical Rho GTPases for three 
reasons. Firstly, the RhoBTB proteins possess a highly atypical domain architecture, 
featuring domains that are quite distinct from anything else seen within the Ras 
superfamily (128,142). Secondly, the cellular roles of the RhoBTB proteins are distinct 
from the roles typically adopted by Rho GTPases (namely, reorganisation of the actin 
cytoskeleton) (127,143-147). Thirdly, regulation of RhoBTB activity may evade the 
classical scheme of Ras superfamily regulation altogether; current evidence suggests that 
the RhoBTB proteins exist in an auto-inhibitory state, and that regulation may not involve 
interaction with specific GEFs and GAPs, but rather with other proteins that relieve the 
RhoBTB auto-inhibited conformation, followed by auto-ubiquitination and destruction 
by the proteasome (128,148).  
As aforementioned, the structure of the RhoBTB proteins is highly atypical relative to 
classical Rho GTPases (Figure 1.10) (128). The BTB domains exhibited by these proteins 
are not typically observed in classical Rho GTPases (128). In humans, nearly 200 
different proteins contain BTB domains, usually in combination with other domains. The 
BTB domain is a protein:protein interaction domain engaging in homomeric and 
heteromeric associations with other BTB domains (149), and  RhoBTB proteins are also 
capable of forming both homodimers and heterodimers (148). However, the BTB 
domains found within the RhoBTBs exhibit unique features: a tandem of two BTB 
domains is not found elsewhere within the BTB protein family (150). Furthermore, the 
first BTB domain observed in the RhoBTB proteins is bipartite, being disrupted by an 
extension of unknown function that is rich in charged residues (128). 
The C-terminal region of RhoBTB1, RhoBTB2 and RhoBTB3 are also unusual compared 
with canonical Rho GTPases (128,150). This region may constitute a novel domain 
altogether, as it has not been identified in any other human proteins beyond the RhoBTB 
subfamily (128,150). The core of this unusual C-terminal domain comprises 
approximately 80 amino acid residues folding as four consecutive α-helices. In RhoBTB1 
and RhoBTB2, this region is predicted to end in a β-strand (151). Neither RhoBTB1 nor 
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RhoBTB2 contains a CaaX box, as typically observed in classical Rho GTPases (2,128). 
However, the C-terminal region of RhoBTB3 appears to end with a CaaX motif, 
suggested that it may be targeted for post-translational modification in a similar manner 
to classical Rho GTPases (148,152). 
The GTPase domains of RhoBTB1 and RhoBTB2 are Rho-related, but comprise atypical 
features, including: an unusually long Rho insert region compared with classical Rho 
GTPases, two insertions placed one immediately prior to switch I, and a two-residue 
deletion affecting switch II phosphate/magnesium binding (128). Additionally, the 
glycine residue at position G12 in Ras appears substituted by asparagine (128). These 
alterations do not appear to prevent GTP binding in RhoBTB1 and RhoBTB2 (126). 
Intriguingly, however, the GTPase domain of RhoBTB3 varies considerably from the 
other RhoBTBs, exhibiting the capability to bind ATP by virtue of some crucial amino 
acid substitutions in the G4 and G5 loops (127). Notably, despite the differences between 
RhoBTB3 and the other RhoBTB proteins, phylogenetic studies indicate that RhoBTB3 
should indeed reside within the RhoBTB subfamily (128,142). 
Several cellular roles have been proposed for the RhoBTB proteins. As aforementioned, 
however, these roles are distinct from what would typically be observed in classical Rho 
GTPases (128). Indeed, no interaction was observed between the RhoBTB proteins and 
the GTPase-binding domains of WASP, PAK1 or Rhotekin, three well-established 
effectors of many typical Rho GTPases (143). Furthermore, the RhoBTB proteins do not 
appear to play a major role in reorganisation of the actin cytoskeleton (143). Instead, 
interest in the RhoBTBs as potential tumour suppressors emerged when RHOBTB2 (also 
known as DBC2, deleted in breast cancer 2), was identified as the gene homozygously 
deleted in breast cancer samples (153). Subsequent investigations reinforced the 
association of RhoBTB proteins in tumorigenesis (154,155), though recent studies have 
also implicated the RhoBTBs in cell growth (145,147,153,156), apoptosis (157), 
chemokine expression (146) and vesicular transport (127,144). The first BTB domain of 
all three RhoBTB proteins is now also known to interact specifically with cullin 3, 
forming cullin-3 dependent ubiquitin ligase complexes capable of targeting proteins for 
ubiquitination and subsequent proteasomal degradation (148). 
Regulation of the RhoBTB proteins does not appear to occur through the GAP/GEF/GDI 
scheme utilised by typical members of the Ras superfamily. Indeed, an autoregulatory 
model for RhoBTB proteins has been proposed (148), stipulating that RhoBTB proteins 
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exist in an inactive state through an intramolecular interaction of the first BTB domain 
with the GTPase domain, preventing binding to cullin 3 and the formation of a ubiquitin 
ligase complex (148). The model suggests that interaction of RhoBTB with other proteins 
(including potential substrates) leads to alleviation of the autoinhibitory state and 
facilitates binding to cullin-3 (148).  
To conclude, while the RhoBTB proteins each contain a GTPase domain exhibiting 
similarities to the classical Rho GTPases (therefore qualifying them as Rho proteins), the 
RhoBTBs are highly unusual relative to classical Rho proteins with regards to domain 
architecture, function and regulation: consequently, the RhoBTB proteins can be regarded 
as atypical Rho GTPases. 
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1.4 Miro GTPases 
1.4.1 The Miro GTPases at a glance 
Initially characterised as atypical Rho GTPases (29), the Miro GTPases (‘mitochondrial 
Rho GTPases’) are so unusual that it is now considered appropriate to classify them into 
a separate sub-family: the Miro sub-family (142,158,159). Two genes encoding Miro 
GTPases are present in humans: Miro1 and Miro2 (also referred to as RhoT1 and RhoT2). 
Both human Miros consist of 618 amino acid residues, sharing 60% amino acid identity 
(29). As schematically illustrated in Figure 1.12, the Miro GTPases are comprised of two 
GTPase domains flanked by a pair of Ca2+ binding EF hand domains 
(29,131,132,158,160,161). Anchored to the mitochondrial outer membrane (MOM) by 
means of a C-terminal transmembrane sequence (162), the Miro proteins are accessible 
to the cytoplasm, where they appear to be involved in a variety of mitochondrial-related 
processes including the transportation, motility, morphology and homeostasis of 
mitochondria (97,132,163-166). Considering the importance of healthy mitochondria in 
neuronal function, in addition to the strong implication of dysfunctional mitochondria in 
neurodegenerative and psychiatric disorders such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD) and schizophrenia (167-171), a comprehensive understanding 
of the Miro proteins is of great medical relevance. 
 
 
 
 
 
 
 
Figure 1.12. Schematic representation of Miro GTPase structure. Schematic illustration of 
the molecular structure of Miro GTPases according to findings on the structure of Drosophila 
Miro (131). 
1.4.2 Molecular structure of Miro GTPases 
As shown in Figure 1.12, the Miro GTPases contain a C-terminal transmembrane domain 
required for targeting to the mitochondrial outer-membrane (MOM), where they are 
anchored at the C-terminus with the majority of the protein accessible to the cytoplasm 
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(159,162). The cytoplasmic region of these proteins comprises two structurally distinct 
GTPase domains, flanked by a pair of calcium-binding EF-hands. Of these GTPase 
domains, the N-terminal GTPase domain is the most well-studied, and structurally most 
similar to Rho GTPases (29). Conversely, the C-terminal GTPase domain appears most 
structurally similar to Rheb, a protein of the Ras sub-family (131,172). Despite the N-
terminal GTPase domain’s similarity to Rho GTPases, initial classification of the Miro 
GTPases as members of the Rho sub-family was disregarded when both GTP domains 
were found to lack the conserved Rho G3 DxxG motif (54,173) and Rho-specific insert 
helix (29,162), a surface-exposed alpha-helical domain unique to the Rho GTPases 
(174,175). A dot blot overlay assay confirmed that the two EF hand domains of Miro are 
able to bind Ca2+ (164) and the bordering regions of these EF hand domains appear to be 
highly conserved amongst eukaryotes (131,160). A recent crystallographic study showed 
that these bordering regions contain non-canonical ‘hidden’ EF hands (hEF hands) 
proceeded by single helices (LM helices 1 and 2) in the single Drosophila Miro 
orthologue, dMiro (131). In dMiro, these hEF hands exhibit a helix-loop-helix structure 
capable of stabilising local EF hands via formation of an anti-parallel EF hand β-scaffold. 
The structure of the LM helices, however, is similar to that of extrinsic ligands bound to 
EF hand proteins, as described for the protein complexes of moluscan myosin heavy chain 
and light chain (131,176), as well as Troponin I and Troponin C (177). This combination 
of EF-hEF hands followed by an LM helix has been observed in a variety of other Ca2+ 
binding proteins, including the retinal protein recoverin (178,179), the pollen protein 
polcalcin (180) and GCAP3, a human guanylate cyclase-activating protein (181). Similar 
to other EF-hand containing proteins, it has been suggested that the Miros may require 
interaction partners in order to undergo conformational changes. 
1.4.3 Evolution and function of the Miro GTPases 
Prior phylogenetic analysis has revealed the presence of at least one homologue of Miro 
in the genome of almost every eukaryotic organism, with no clear homologues apparent 
in prokaryotes (160). Exceptions include eukaryotes possessing hydrogenosomes and 
mitosomes in lieu of typical aerobic mitochondria, in addition to a minority of eukaryotes 
exhibiting aerobic mitochondria, such as the phylum Apicomplexa (160). Interestingly, 
the N-terminal GTPase domain is absent in Miro homologues of the order 
Trypanosomatid (160,173). Instead, this GTPase domain is replaced by a novel domain 
containing a sequence unique to any currently defined domain sequences. Additionally, 
Miro homologues present in this order lack functional versions of the second EF hand 
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domain. This is in contrast to Miro homologues present in Stramenopiles and 
Amoebozoa, which contain a non-functional C-terminal GTPase domain absent of 
typically well-conserved residues (160,173). The C-terminal GTPase domains of Miro 
homologues in the class Oligohymenophorea are also unusual. In this class, the C-
terminal GTPase domain sequences are not conserved, even within the class itself (160). 
Such discrepancies in structure across eukaryotic lineages implies that the functional 
demands of Miro can differ significantly amongst eukaryotes, and that Miro proteins have 
been independently modified to address this. 
The notion of functional discrepancy across eukaryotic Miros is also implied when 
current literature on the topic of Miro functionality is surveyed. As summarised in table 
1.5, Miro function across species can be diverse, though some conserved functions are 
also apparent. In virtually all organisms studied, at least one expressed Miro protein 
appeared to significantly affect mitochondrial morphology. Miro involvement in 
mitochondrial transport and homeostasis is also widely seen. Interestingly, very recent 
research suggests that human Miro1 and 2 bind together as one complex, and that 
functional ablation of both Miros is required to produce the classical Miro1 ablation 
phenotype previously reported (83). This perhaps indicates that Miro2 function is 
dependent on cell type or context, and exhibits a degree of redundancy in some 
circumstances.  
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Table 1.5. Miro functions and interactors across species. 
Organism(s) Protein 
name(s) 
Function(s) Confirmed 
interactor(s) 
Reference(s) 
Mammals 
(including 
Homo sapiens, 
Mus musculus 
and Rattus 
norvegicus) 
Miro-1 
and  
Miro-2 
Mitochondrial 
transport/ 
trafficking 
GRIF-1 
/OIP98/huMilt2/ 
TRAK2 
 
(163) 
 
 
OIP106/huMilt1/ 
TRAK1 
(163) 
Kinesin (164) 
Dynein (182) 
DISC1/        
DISC1-Boymaw 
(183) 
Alex3 (in 
Eutherians) 
 
(184) 
HUMMR (in 
neurones) 
 
(185) 
  Mitophagy PINK1 (186) 
   Parkin 
 
(186) 
  Mitochondrial 
morphology 
 
Mitofusin 1/2 (187) 
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Organism(s) Protein 
name(s) 
Function(s) Confirmed 
interactor(s) 
Reference(s) 
  Mitochondrial 
distribution 
during 
cytokinesis 
Cenp-F (83) 
 
 
 
Drosophila 
melanogaster 
dMiro Mitochondrial 
transport 
Mitochondrial 
morphology 
Milton (188) 
Saccharomyces 
cerevisiae 
Gem1p Mitochondria-
ER interaction 
 
 
 
Mitochondrial 
morphology 
Inheritance of 
mitochondria 
Mdm34p 
Mmm1p 
Mdm10p 
Mdm12p 
 
- 
 
- 
(189) 
Dictyostelium 
discoideum 
gemA Mitochondrial 
homeostasis 
- (173,190) 
Arabidopis 
thaliana 
Miro-1, 
Miro-2 
and 
Miro-3 
Inheritance of 
mitochondria 
Mitochondrial 
morphology 
- 
 
- 
(161,173) 
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1.4.4 Miro as a facilitator of mitochondrial transport 
Perhaps the most well-documented function of the Miros is the transport of mitochondria 
(17,83,97,132,159,162-165). Mitochondrial transport is facilitated by the action of 
kinesins and dyneins, acting as anterograde and retrograde motors, respectively 
(191,192). In this context, the term ‘anterograde’ refers to the movement of mitochondria 
away from the nucleus and towards synapses in neurones. Conversely, the term 
‘retrograde’ denotes the movement of mitochondria back towards the nucleus or cell 
body. In axons, this movement of mitochondria occurs along linear arrays of uniformly 
polarised microtubules, with the ends of these microtubules located at the cell body 
referred to as the ‘minus’ ends and the ends situated at distal areas regarded as ‘plus’ ends 
(Figure 1.13). Deficiencies in mitochondrial transport are most striking in neuronal cells, 
where efficient transport of mitochondria from the cell body to areas of high energy 
demand, such as synaptic terminals, is critical for cell function and survival (193). 
However, retrograde mitochondrial movement also appears crucial in neuronal health: 
transgenic mice with retrograde transport exhibited motor neuron degeneration and loss, 
denervation of muscle and marked decline in strength and endurance (98). 
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Figure 1.13. Schematic representation of neurone structure and axonal transport. A 
peripheral neurone containing a cell body that obtains signals from presynaptic neurons and an 
axon that carries action potentials from the cell body to the synaptic terminal, which repsonds by 
releasing neurotransmitters to a post-synaptic neurone or muscle cell. Normal neurone 
development and function is dependent upon the long-distance transport of cytoplasmic 
components including vesicles (yellow), mitochondria (red) and endocytic organlles (orange) 
along the axon. This enables organlles and other newly-synthesised materials to be transported 
from cell body to distal areas, and also for aged materials to be transported back to the cell body 
for recyling. Both forms of transport require motor proteins that attach to 'cargo' and pull it along 
microtubules (green) towards either the microtubule plus (distal) ends or minus (towards cell 
body) ends. Diagram adopted from (194). 
Indeed, a search for previously unidentified genes necessary for axonal and synaptic 
function in Drosophila melanogaster revealed key roles for Drosophila Miro (dMiro) in 
the transport of mitochondria from the neuronal cell body to distal areas. Most closely 
related to Miro-1 in humans, dMiro represents the single Miro protein expressed in 
Drosophila. Distribution of mitochondria in mutant dMiro neurones was significantly 
altered relative to wildtype controls, with neat clustering of mitochondria observed 
towards the soma of mutant larval neurones and an absence of mitochondria noted at 
distal regions, including neuromuscular junctions (NMJs). This apparent inability to 
transport mitochondria produced larvae with slim body, small muscle size and 
Cell body 
Synaptic terminal 
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progressive locomotive defects with ascending paralysis, culminating in death at the 
larval or early-pupal stage. This phenotype was rescued by the induction of wild-type 
dMiro expression in neurones but not muscle cells, suggesting a critical role for dMiro in 
neurones (132).  
Further studies in Drosophila implied the formation of a protein complex comprised of 
dMiro and the kinesin-associated protein Milton, enabling the anterograde transport of 
mitochondria via apparent recruitment of kinesins (188). Two mammalian homologues 
of Milton, TRAK1 (also known as OIP106) and TRAK2 (also known as OIP98/Grif-1), 
which can form complexes with mammalian Miro1 and Miro2 and with microtubule 
motors, have also been shown to co-localise with the hMiros (163), indicating that these 
proteins act as a component of a conserved protein complex necessary for the transport 
of mitochondria (Figure 1.14). Within this complex, Milton/TRAK acts as an adaptor 
protein, connecting the motor proteins to Miro, which is bound to the mitochondrial outer 
member by virtue of the Miro C-terminal localisation sequence. Both TRAK1 and 
TRAK2 are necessary for axonal and dendritic mitochondrial transport, although they 
appear to engage differing transport machineries to achieve this. TRAK1 binds to both 
kinesin-1 and dynein/dynactin and is predominantly localised in axons, while TRAK2 
preferentially binds dynein/dynactin and exhibits dendritic localisation (195). The 
interaction of TRAK1 with both the kinesin (anterograde) and dynein (retrograde) motors 
may enable movement in both directions in the axon while TRAK2’s more favourable 
interactions with dynein may encourage retrograde movement at distal ends. It is 
presently unknown whether Milton is able to bind both the kinesin and dynein motors in 
Drosophila. 
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Figure 1.14. Schematic diagram of the mitochondrial motor/adaptor complex thought to be 
necessary for mitochondrial transport. The anterograde motor Kinesin-1 (also referred to as 
kinesin heavy chain or Kif5) and the retrograde motor (the dynein/dynactin complex) facilitate 
the transport of many cellular cargoes but are bound to mitochondria by their interactions with 
two mitochondrion-specific proteins: Miro and milton (or the milton homologues TRAK1 and 
TRAK2 in mammals). Miro is anchored to the mitochondrial outer membrane while Milton serves 
as an adaptor protein, linking the motor proteins to Miro and therefore the mitochondria. Adopted 
from (191). 
Interestingly, while the Miro/Milton(TRAK) transport complex shown in Figure 1.12 is 
widely accepted, the direct Ca2+-dependent binding of hMiro1 to kinesin motor Kif5 has 
been demonstrated, indicating that a degree of redundancy for a Milton-like adaptor 
protein (164). In contrast to this, however, TRAK2 and hMiro1 have been shown to 
directly form a protein complex and co-localise with mitochondria in mammalian brain 
tissue extracts (163). Furthermore, the GTPase state of the hMiro1 N-terminal GTPase 
domain appears to recruit TRAK2 to mitochondria in mammalian cell lines, producing 
downstream effects on anterograde mitochondrial movement (163). Indeed, over-
expression of hMiro1 appears to increase TRAK2 recruitment to mitochondria and 
encourage anterograde mitochondrial transport. Correspondingly, abolishing the kinesin-
binding domain in TRAK2 impairs anterograde movement of mitochondria (163). This 
suggests that mitochondrial transport in mammals is mediated by a mechanism dependent 
on the N-terminal GTPase domain for recruitment of TRAK to the mitochondria, and that 
the resulting Miro-TRAK-kinesin protein complex is required for anterograde movement 
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of mitochondria along microtubules. It should be noted, however, that although initial 
studies exclusively documented the effect of Miro on anterograde transport, live-imaging 
of GFP-tagged mitochondria in Drosophila later suggested that dysfunctional dMiro 
results in the impairment of both anterograde and retrograde mitochondrial transport 
(165). A more recent study found that retrograde mitochondrial transport was mediated 
by action of the Miro C-terminal GTPase domain (196), despite prior suggestions that 
this domain was merely an artefact (159). 
Despite the indication that a Milton/TRAK adaptor may be redundant in some contexts 
due to direct Miro-kinesin motor binding (164), both TRAK1 and TRAK2 have been 
directly linked to mitochondrial motility. Indeed, recent studies implicate a link between 
neuronal nutrient availability and mitochondrial motility through glucose signalling and 
the subsequent modification of TRAK1 and 2. Extracellular glucose was shown to 
activate O-GlcNAc transferase (OGT), an enzyme catalysing post-translational O-
glycosylation of target proteins (197). Proteomic investigations suggest that activated 
OGT targets TRAK1 and 2 for GlcNAcylation (198), leading to the arrest of 
mitochondrial motility (199). Taken together, the present literature suggests a 
Miro/Milton(TRAK)/motor transport complex engaged in the transportation and motility 
of mitochondria that is sensitive to signalling both from within the complex (163), from 
intracellular components (164) or from external factors such as extracellular glucose 
(199). 
1.4.5 Miro as a facilitator of mitochondrial transport: the influence of Ca2+ 
While the necessity of the Miro/TRAK/motor complex in mitochondrial transport is now 
commonly accepted, the role of cytosolic Ca2+ in this complex remains disputed. 
Cytosolic Ca2+ is required for mitochondrial transport, with transport of mitochondria 
arrested in the presence of increased intracellular Ca2+ (200). Interestingly, Miro has also 
been implicated in Ca2+ regulation (201,202). However, various hypotheses exist on the 
link between Miro, Ca2+ and mitochondrial transport (Figure 1.15). One model stipulates 
that increased cytosolic Ca2+ results in dissociation of the kinesin motor from 
microtubules and the subsequent interaction of kinesin with Miro on the mitochondrion, 
resulting in the dissociation of motors from the microtubules (166) (Figure 1.15a). An 
alternative model indicates that Miro binds directly to kinesin without the need for the 
Milton adaptor, and that increased cytosolic Ca2+ inhibits Miro’s interaction with kinesin, 
leading to the direct uncoupling of Miro from kinesin (164), (Figure 1.15b). However, 
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the arrest of mitochondrial transport in neurones has also been linked to the mitochondrial 
tethering protein syntaphilin (SNPH), resulting in a third model. In this model, the so-
called "Engine-Switch and Brake" model, increased cytoplasmic Ca2+ is thought to 
dissociate kinesin from Miro (203) (Figure 1.15c). Following dissociation, kinesin 
interacts with SNPH, disrupting the ATPase activity of kinesin and resulting in the arrest 
of mitochondrial motility. Thus, SNPH performs as an engine-off switch by detecting the 
Ca2+-induced arrest of mitochondria, and as a brake by securing static mitochondria to 
the MT. 
 
 
 
 
 
 
 
 
Figure 1.15. Schematic representation of models of Ca2+-mediated mitochondrial arrest. (a) 
Increased cytosolic Ca2+ promotes the detachment of kinesin from the microtubules and results 
in interaction of the kinesin motor domains with Miro, leading to mitochondrial arrest. (b) 
Increased cytosolic calcium leads to dissociation of Miro from the kinesin motors, resulting in 
detachment of the mitochondrion from the microtubule. (c) An alternative model implicates the 
detachment of kinesin from Miro and the subsequent interaction of kinesin with SNPH. Figure 
adopted from Birsa et al. (204). 
A third proposition is that intramitochondrial Ca2+, rather than cytoplasmic Ca2+, plays a 
critical role in mediating mitochondrial transport, and that Miro is involved in 
orchestrating intramitochondrial Ca2+ levels in the matrix (201). Mitochondria are able to 
buffer cytoplasmic Ca2+ via uptake of Ca2+ through the mitochondrial calcium uniporter 
(MCU). The uptake of Ca2+ through the MCU has been shown to be inversely related to 
mitochondrial velocity in axons, thus illuminating a mechanism by which cytoplasmic 
Ca2+ influences mitochondrial trafficking. Two independent studies have demonstrated 
(a)                             (b)            (c) 
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that expression of Miro1 at the mitochondrial outer membrane affects the concentration 
of Ca2+ in the mitochondrial matrix (97,201). However, the importance of Ca2+ sensing 
in Miro proteins has not yet been fully established. As elevated intramitochondrial Ca2+ 
has been associated with slower movement or stopping of mitochondria and a subsequent 
increase in ATP production, these results taken as a whole indicate a previously 
hypothesised link between mitochondrial motor machinery, mitochondrial trafficking and 
the mediation of bioenergetic efficiency in mitochondria (205,206). 
1.4.6 Miro in mitochondrial morphology 
In addition to facilitating mitochondrial transport, the Miro GTPases may modulate 
mitochondrial morphology. Mitochondria are dynamic organelles that continually move, 
fuse and divide; indeed, the dynamic balance of mitochondrial fission and fusion events 
is a major factor in determining mitochondrial morphology (207,208). However, the exact 
roles the Miro GTPases play in mitochondrial morphology remain unclear. Initial 
functional studies in mammalian cells showed perinuclear aggregation of mitochondria 
when a mutant of hMiro1 bearing a constitutively active N-terminal GTPase domain was 
over-expressed. A similar effect was obtained from over-expression of a mutant of 
hMiro1 harbouring a dominant-negative N-terminal GTPase domain, though to a lesser 
extent. These results imply that a balanced level of Miro activity in the N-terminal 
GTPase domain of hMiros is necessary for the maintenance of normal mitochondrial 
morphology (29).  
Despite aforementioned structural differences in the Miros of earlier eukaryotes, the 
influence of Miro on mitochondrial morphology appears strongly conserved. In 
Arabidopsis thaliana, a flowering plant, three Miro homologues are expressed: MIRO1 
(At5g27540), MIRO2 (At3g63150) and MIRO3 (At3g05310) (161). Although Miro3 is 
expressed exclusively in the endosperm (209,210), Miro1 and Miro2 in this species 
appear to be ubiquitously expressed and have been shown to co-localise with 
mitochondria (161). An insertational mutation of Arabidopsis Miro1 resulted in impaired 
pollen tube growth and early embryonic lethality (161,211) This phenotype was enhanced 
when the Miro2 gene was mutated in a similar fashion, though defective female 
gameogenesis with delayed polar nuclear fusion was also noted with Miro2 mutants 
(211). Separate to Miro2 mutation, Miro1 mutants impaired mitochondrial inheritance 
during cell division, though mutant mitochondria appeared to remain influenced by 
protoplasmic streaming in an actin-dependent manner. Interestingly, bloated 
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mitochondria were observed with the Miro1 mutant phenotype. However, these bloated 
mitochondria possessed normal inner membrane structures. In light of the evidence 
obtained and the absence of an obvious Milton homologue in the Arabidopsis genome, it 
has been suggested that the predominant role of the Miros in Arabidopsis is the 
maintenance of mitochondrial morphology rather than mitochondrial transport (161,212). 
The single Miro protein in Saccharomyces cerevisiae, Gem1p, appears to require both 
GTPase domains and functional EF hands for the maintenance of normal mitochondrial 
morphology (158). This is in disagreement with many later reports regarding the apparent 
lack of functionality in the C-terminal GTPase domain of the human Miros. A 662-amino 
acid protein, Gem1p shares 30% amino acid identity with the human Miros . When 
Gem1p was ablated in S.cerevisiae (Gem1p∆ cells), mitochondria exhibited both 
abnormal distribution and abnormal morphology, with a collapsed, globular or ‘grape-
like’ appearance observed amongst mitochondria (158). However, mitochondria 
displaying abnormal morphology retained inner cristae structures when viewed under 
TEM. Although these results indicate a conserved role for Miro in regulating 
mitochondrial morphology, Gem1p does not appear to be integral to mitochondrial fusion 
and fission (158,213). Of additional note, Gem1p did not appear to influence the actin 
cytoskeleton directly, and the endoplasmic reticulum and nuclei of Gem1p∆ cells 
appeared normal relative to controls. 
A role for Miro in mitochondrial morphology has also been observed in Drosophila, with 
overexpression of wildtype dMiro producing significant aggregation of mitochondria in 
dopaminergic neurones (129) and abnormally elongated mitochondria in larval motor 
neurones (165). In vivo, however, the effects of dMiro on mitochondrial morphology 
appear to be dependent on context and cell-type, suggesting that dMiro is not directly 
involved in modulating mitochondrial morphology but perhaps that one or more binding 
partners are necessary to exert the effects on mitochondrial morphology observed 
previously. Indeed, a recent effort to identify regulators of Miro showed that Vimar in 
Drosophila, and its mammalian homologue RAP1GDS1, is involved in the regulation of 
mitochondrial morphology (214). Vimar and its homologues function as GEF proteins, 
regulating mitochondrial fission in response to intracellular Ca2+ (214). Prior reports 
indicated that under normal cellular conditions, Miro was capable of increasing 
mitochondrial size through inhibition of the dynamin-related protein Drp1 (129,215); 
however, it now appears that Miro interacts directly with Vimar homologues and 
promotes mitochondrial fission when intracellular Ca2+ increases (214). Furthermore, 
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mitochondrial enlargement observed in a Drosophila model of Parkinson’s disease was 
rescued through ablation of Vimar expression (214). The function of Vimar appears to be 
conserved in RAP1GDS, its mammalian homologue (214). 
1.4.7 Influences on ATP homeostasis and apoptosis 
According to northern blot analysis on human tissue, both Miro 1 and Miro 2 appear to 
be ubiquitously expressed in humans (29). However, while Miro 1 appears abundantly 
expressed in heart and skeletal muscle, Miro 2 expression is most prominent in heart, 
liver, kidney, pancreas and skeletal muscle tissue. This is particularly interesting with 
regards to the high energy demand these cell types commandeer, suggesting perhaps that 
the Miro GTPases may be involved in ATP homeostasis or cellular bioenergy 
homeostasis. In S.cerevisiae, the Gem1p abrogation strain grew significantly slower on 
glycerol minimal media relative to wildtype cells, suggesting that Gem1p is necessary for 
correct mitochondrial respiration (158). Too, the single Miro homologue GemA in 
Dictyostelium discoideum appears to play a role in mitochondrial respiration, with gemA 
knockout mutants exhibiting impaired cell growth on nutrient media alongside reduced 
ATP content and increased oxygen consumption. However, glucose consumption, 
mitochondrial membrane potential and the production of ROS in gemA knockout mutants 
remained unaltered (160).  
As previously discussed, mitochondria are involved in the buffering of intracellular Ca2+, 
with the Miro GTPases appearing to play a role. Further to this, Miro sub-cellular 
localisation in some species has been demonstrated at mitochondrial-endoplasmic 
reticulum (ER) contact sites (189,216). In yeast, mitochondria are connected to the ER-
mitochondria encounter structure (ERMES) tethering complex believed to consist of an 
ER membrane protein (Mmm1), two outer mitochondrial membrane proteins (Mdm10 
and Mdm34) and a cytosolic protein (Mdm12), all of which collectively form a bridge 
between mitochondria and the ER, with the Miro homologue Gem1 presenting as a 
discretionary sub-unit (189,216). The ERMES complex has been implicated in 
phospholipid exchange between mitochondria and the ER, although also appears to be 
involved in orchestrating mitochondrial protein import, mitochondrial DNA replication 
and some mitochondrial dynamics. A 2013 study conducted by Murley et al. 
demonstrated a spatial and functional link between ERMES, the yeast Miro Gem1 and 
ER-associated mitochondrial division (217). This study indicated that Gem1 performed 
as a negative regulator of ER-mitochondrial contact, aiding in mitochondrial dissociation 
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from the ER and thus facilitating in the spatial resolution and distribution of newly 
generated mitochondrial tips subsequent to mitochondrial division. Taken together, these 
results are indicative of a role for yeast Miro and the ERMES complex in mediating 
mitochondrial division, biogenesis and distribution. Whether this function role is 
conserved in higher organisms remains unknown. However, it is notable that mammalian 
Miro1 has also been shown to localise to ER-mitochondrial contact sites, implying a role 
for mammalian Miro in a putative mammalian version of the ERMES complex. 
One suggested function of Miros localised at mitochondria-ER contact sites is the 
orchestration of mitocondria-ER Ca2+ signalling. At mitochondria-ER contact sites, Ca2+ 
is released from the ER to mitochondria, aiding in normal mitochondrial function (218). 
Intramitochondrial Ca2+ is required for ATP production via the activation of TCA cycle 
enzymes and the enhancement of electron chain complexes and the ATP synthase 
complex (219). Transfer of Ca2+ from the ER to the mitochondria is proposed to occur 
through the following proteins: the Ca2+ channel inositol 1,4,5-trisphosphate receptor 
Ins(1,4,5)P3R on the ER, the voltage-dependent anion-selective channel protein 1 
(VDAC1) on the mitochondrial outer membrane and the mitochondrial Ca2+ uniporter 
(MCU) on the mitochondrial inner membrane (220). Mitochondria-ER contact sites may 
provide a critical supply of Ca2+ for mitochondrial membrane proteins that are dependent 
on Ca2+  binding for their functions but are unable to bind Ca2+ under normal cytoplasmic 
concentrations of Ca2+ (220). As aforementioned, Miro has been implicated in the 
modulation of intramitochondrial Ca2+ levels with overexpression of Miro1 linked to 
increased mitochondrial Ca2+ uptake while overexpression of Miro1 mutants harbouring 
defective EF-hands negatively influenced this uptake (164). Thus, one may hypothesise 
that Miro is able to influence ATP production in mitochondria through mediation of 
intramitochondrial Ca2+ content, particularly at mitochondria-ER contact sites. 
Interestingly, the mitochondrial GTPase mitofusin-2 (Mfn2), known to interact with 
Miro, is a recognised constituent of the mitochondria-ER contact sites in mammalian cells 
(221). It may therefore be postulated that Miro-Mfn2 interaction is involved with 
mitochondria-ER communication.  
Overload of Ca2+ due to a local influx can stimulate apoptosis via opening of the 
mitochondrial permeability transition pore (MPTP), resulting in cytochrome c release and 
propagation of the caspase cascade (222). It has therefore been proposed that the function 
of Miro in mediating homeostasis of intramitochondrial Ca2+ may be associated with 
some pro-apoptotic effects linked to the Miros. Early research on the human Miros (29) 
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concentrated on the creation of Miro mutants containing amino acid substitutions in the 
N-terminal GTPase domain, making this GTPase domain either constitutively active 
(G13V) or dominant negative (S18N) with respect to GTP/GDP-bound status. Ectopic 
expression of Miro1 mutants bearing the constitutively active N-terminal GTPase domain 
(Miro1 V13) induced a collapse of the mitochondrial network in non-neuronal cells, with 
mitochondria exhibiting perinuclear aggregation. Too, ectopic expression of this mutant 
was associated with increased presence of the apoptotic marker M30 (recognising 
caspase-cleaved cytoskeleton-18) relative to both control cells and cells ectopically 
expressing S18N Miro mutants. Correspondingly, the introduction of caspase inhibitors 
reduced this increase in M30, suggesting a role for the GTP/GDP-bound status of the 
Miro1 N terminal GTPase domain in apoptosis. However, while overexpression of Miro 
in other organisms has produced a similar pattern of mitochondrial aggregation, other 
studies have failed to demonstrate a clear link between Miro overexpression and apoptosis 
(29). At present this link therefore remains obscure. 
1.4.8 Miro GTPases in health and pathology 
1.4.8.1 The Miro GTPases in the health and pathology non-neuronal cells 
 
Mitochondria comprise crucial organelles within a cell, and particularly those with high 
energy demands or the need to supply distal areas of the cell with energy at an alternative 
rate to other areas (for example, neuronal cells). It is not surprising, therefore, that the 
Miro proteins have been implicated in both neurodegenerative diseases and certain 
cancers when dysregulated. With regards to the latter, neoplastic cells typically demand 
greater energy supplies to support high proliferation and consequently often exhibit 
mitochondrially-induced metabolic changes (223,224). Interestingly, a recent study on 
the effect of Ca2+ uptake into mitochondria at mitochondria-ER contact sites has shown 
an apparent fundamental need for basal mitochondrial Ca2+ in the survival of transformed 
primary human fibroblasts (225) this is remarkable given the implied function of Miro in 
mediating intramitochondrial Ca2+ uptake at mitochondria-ER sites. Other than metabolic 
changes in neoplastic cells and the apparent importance of Ca2+ uptake at mitochondria-
ER sites, knockdown of the Miro1-facilitated movement of mitochondria has been shown 
to decrease the velocity and directional persistence of epithelial cancer cells (96). The 
velocity and persistence in direction of neoplastic cells is a critical factor in tumorigenesis 
and particularly metastasis, the latter of which is a major marker of advanced pathology 
in cancer patients and the cause of 90% of cancer patient deaths (226). Despite emerging 
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evidence, however, further data is required to clarify the potential roles for the Miro 
GTPases in the development and progression of cancers. 
Intriguingly, the Miros may also play a role in simple infection-related pathology. It is 
now thought that effector proteins from pathogens may specifically target the Miros due 
to their involvement in mitochondrial movement (94). Effective mitochondrial transport 
is believed to be a component of innate immune responses, therefore the Miros may 
present a suitable target for the disruption of mitochondrial-related innate immune 
responses. The Vibrio cholerae protein VopE was recently demonstrated to co-localise 
with mitochondria during Vibrio infection of mammalian cells, and appears to bind to the 
N-terminal GTPase domain of the mammalian Miros directly (94). The authors of this 
study propose that VopE acts as a Miro-specific GTPase-activating protein (GAP), 
disrupting the movement of mitochondria and therefore disrupting mitochondrial-related 
innate immunity. Hence, dysfunctional Miro activity has not only been implicated in 
cancer, but also with defective mitochondrial innate immunity. 
Beyond the manipulation and involvement of Miro GTPases in this manner, however, a 
study by Ahmad et al. (2014) implicated Miro in a far more beneficial role for the 
maintenance of cell health, through mediating the transfer of mitochondria from 
mesenchymal stem cells (MSC) to epithelial cells (EC) (227). This form of mitochondrial 
transfer is thought to help rejuvenate damaged cells during times of stress. In this study, 
overexpression of Miro1 increased the velocity of mitochondrial transfer to ECs and 
enhanced rescue of epithelial injury, while Miro1 knockdown reduced these positive 
effects. Indeed, recent mammalian cell studies indicate important roles for Miro in 
microtubule dynamics and cytokinesis. Here, the N-terminal GTPase domain and EF-
hands of hMiro1 and 2 were shown to recruit the centromere-kinetochore complex 
associating protein Centromere protein F (Cenp-F), enabling the management of 
intracellular mitochondrial distribution through mitochondrially-influenced control of 
microtubules dynamics (83). The C-terminal region of Cenp-F appears to bind Miro, with 
Cenp-F ablation displaying the same phenotype as abrogation of both human Miros. 
Interestingly, ablation of both hMiro1 and hMiro2 function was required to achieve 
phenotypes previously reported to occur with abolishment of Miro1 alone. Thus, it may 
be that Miro2 retains a degree of redundancy in some cellular contexts, while appearing 
functionally important in other situations. The authors postulated that interaction between 
Cenp-F and the Miros allowed for connections to occur between mirochondria and the 
tips of growing microtubules, enabling mitochondria to track microtubule tips, perhaps in 
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a manner previously described for ER tip-tracking (95). Hence, the Miro GTPases appear 
to be involved in numerous intracellular processes in non-neuronal cells, through their 
involvement in mitochondrial transport and their apparent influence on microtubule 
dynamics when functioning alongside interactors. 
1.4.8.2 Miro GTPases in neuronal pathology 
 
The Miro GTPases appear to play a critical role in the maintenance of neuronal health. 
This is perhaps unsurprising when one considers the crucial role the Miros appear to play 
in mitochondrial transport (discussed previously) coupled with the need for mitochondria 
to travel vast distances in neuronal cells down axons (sometimes 1 meter long) from the 
cell body towards distal regions for nervous transmission (228,229). Indeed, altered Miro 
function has been associated with such neurological pathologies as Parkinson’s Disease 
(129,186), amyotrophic lateral sclerosis (ALS) (230), and schizophrenia (231).  
1.4.8.3 Animal models of Miro abrogation 
 
As previously discussed, this link between neuropathology and impaired Miro function 
was first indicated by Guo et al. (2005), with dMiro-/- Drosophila larvae exhibiting a slim 
body, small muscle size, progressive locomotor defects and early death in a manner 
reminiscent of severe neurodegenerative disease (132). This remarkable phenotype was 
rescued when WT dMiro was introduced to neuronal cells but not muscle cells, and the 
effect was believed to be a consequence of defective mitochondrial anterograde transport 
in dMiro-/- neuronal cells. Notably, the authors of this study also investigated the presence 
of abnormal pre-synaptic vesicle accumulation in dMiro-/- neuronal cells and found an 
impairment but not absolute blockage of vesicular transport in dMiro mutants. 
Interestingly, mutations affecting axonal transport often present with abnormal pre-
synaptic vesicle accumulation, and typically this state of accumulation is a marker of 
neuropathology (232-234). While vesicular transport appeared impaired in dMiro mutant 
neurones, however, this effect was qualitatively and quantitatively diverse from the 
significant defects in mitochondrial transport observed. Thus, while the impairment of 
vesicular transport in this respect may contribute in a lesser regard to the dMiro mutant 
phenotype, it would appear unlikely that both transport defects were the consequence of 
a shared mechanism. 
Other than the dMiro mutant flies, recent global and neurone-specific Miro1 mouse 
knockouts were developed with striking results (235). Mice globally deficient of Miro1 
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were cyanotic and died shortly following birth, with fetal ultrasound revealing no cardiac 
abnormalities prior to birth, but post-mortem autopsy demonstrating unexpanded lungs, 
suggesting death due to an inability to breathe (235). Despite this, Miro1 global knockout 
mice lung tissue appeared histologically normal, with no abnormalities in lung 
morphology observed. This indicates that Miro1 may play a crucial role in embryonic 
lung development (235). Indeed, defects in neuronal respiratory control pathways were 
noted in the global Miro1 knockout mouse, with the nucleus ambiguus notably absent and 
impaired phrenic nerve innervation of the diaphragm muscle, alongside reduced axonal 
branching of the phrenic nerve (235). Taken together, this suggests that Miro1 plays a 
key role in the embryonic development of respiratory neurology. The Miro1 neurone-
specific knockout mouse phenotype was also striking, exhibiting rapidly progressing 
upper motor neuron disease symptoms and early death after approximately 4 weeks. At 
birth, the neurone-specific Miro1-/- mice appeared indistinguishable from WT littermates. 
However, by 2 weeks Miro1-/- mice exhibited hind-limb clasping, a known early marker 
for neuronal impairment. These mice failed to gain weight as they matured and developed 
a stiff tail, spinal curvature (kyphosis), hind-limb spasticity and progressive locomotive 
defects (235). This phenotype was reflective of the development of upper human 
amyotrophic lateral sclerosis (AML), with symptoms becoming progressively worse and 
premature death occurring at approximately 35 days (235). Interestingly, the researchers 
of this study implicated impaired retrograde transport of mitochondria in the development 
of this phenotype, rather than the anterograde transport impairment strongly implicated 
in earlier studies. However, the previously observed perinuclear aggregation of 
mitochondria was shown in mouse embryonic fibroblasts obtained from Miro1-/- mice 
(235). No significant differences were reported in mitochondrial respiration or 
mitochondrial membrane potential in Miro1-/- cells relative to controls, indicating that 
defective transport is the main culprit in developing the phenotype shown but that this 
transport is not influenced by defective mitochondrial respiration or membrane potential. 
In contrast to other research, this study indicated that Miro1 is not essential for 
mitochondrial uptake of Ca2+ or the Ca2+-related inhibition of mitochondrial motility 
(235).  
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1.4.8.4 Implications in Parkinson’s Disease pathways 
 
Overexpression of dMiro in Drosophila has been demonstrated as toxic, producing an 
age-dependent loss of dopaminergic (DA) neurones, the neurones specifically affected in 
Parkinson’s Disease (PD) patients (129). The exact process by which this dMiro 
overexpression produces toxicity remains obscure. However, Miro GTPases are known 
to be associated with proteins involved with PD when dysfunctional: the mitochondria-
localized Pten-induced kinase 1 (PINK1) and Parkin, an E3 ubiquitin ligase usually 
localised in the cytoplasm. Under normal circumstances, PINK1 and Parkin proteins form 
crucial components of a mitochondrial quality control system aimed at targeting damaged 
mitochondria for isolation and mitophagy, in order to sustain cellular metabolic 
requirements and prevent damage caused by defective mitochondria. Loss-of-function 
mutations in PINK1 and Parkin are associated with rare recessive forms of PD. 
Mitochondrial damage results in PINK1 accumulation on the outer mitochondrial 
membrane (OMM) and recruitment of Parkin from the cytosol to mitochondria. Upon 
recruitment, Parkin ubiquitinates various substrates on the OMM [VDAC1, Drp1 
(dynamin-related protein 1), Mfns, TOM20 (translocase of outer mitochondrial 
membrane 20) and TOM40], allowing for initiation of mitophagy by the 
ubiquitin/proteasome pathway (236). Interestingly, Miro appears to interact with PINK1 
and Parkin and is ultimately targeted for ubiquitination by Parkin when mitochondrial 
damage occurs (186). In a Drosophila PD model involving loss of PINK1 function, 
reduced dMiro function improved the degenerative phenotype shown in PINK1 mutant 
DA neurones (129). This suggests a role for mitochondrial transport and Miro in PINK1-
related PD pathogenesis (129), a notion further supported by the profound effects seen in 
altered PINK1 function on the transportation of axonal mitochondria in Drosophila larval 
motor neurones or mammalian hippocampal neurones. Indeed, Miro appears to be 
specifically targeted for degradation by PINK1 and Parkin in vivo in Drosophila or in 
cultured mammalian cells treated with the mitochondrial toxin CCCP (129,186). Whether 
Miro is a direct substrate of PINK1-mediated phosphorylation or whether this 
phosphorylation is a perquisite for the regulation of Miro stability by PINK1 and Parkin, 
however, remains unknown (129,186,204). Miro has been previously shown to undergo 
PINK1-mediated phosphorylation at Ser-156 and that phosphorylation at this site is 
necessary for degradation of Miro by Parkin (186). However, more recent studies disagree 
with this finding, suggesting that this serine residue is not necessary for Miro stability and 
that parkin forms a lone target for PINK1 phosphorylation (129). Whatever the case, loss 
50 
 
of hMiro in HeLa cells resulted in the perinuclear aggregation of mitochondria and 
facilitated in increased mitophagy, a phenotype previously associated with activation of 
the PINK1/parkin pathway (129). It has also been postulated that Miro may form a 
constituent of the Parkin receptor complex, as hMiro1 appears capable of stabilising 
phosphor-mutant versions of Parkin on the OMM (36). The regulation of Miro stability 
and turnover by PINK1 and parkin could perhaps act to isolate damaged mitochondria 
from the network, promoting their transport to the cell body and subsequent degradation. 
However, further studies are required to elucidate the relationship between Miro, PINK1 
and Parkin. 
1.4.8.5 Miro in other neurological disorders 
 
Beyond Parkinson’s, altered Miro function has been implicated in the pathogenesis of 
other neurological disorders featuring abnormal mitochondrial distribution, morphology 
or function. Inhibition of dMiro has been shown to activate the PAR-1/MARK family 
kinases, for example, subsequently promoting the pathological phosphorylation of tau 
(23). Abnormal phosphorylation of tau has been broadly associated with 
neurodegenerative disorders known as tauopathies (237), such as: Alzheimer’s (238), 
frontotemporal dementia (239) and progressive suprenuclear palsy (240). In fact, 
activation of the PAR-1/MARK-tau pathway has been demonstrated in animal models of 
Alzheimers in addition to patient samples (23,241-243). Other than this, Miro and 
TRAK1 have been shown to interact with DISCI (Disrupted in Schizophrenia 1) to 
increase axonal mitochondrial transport (231). DISCI function is presently unclear but 
appears to play roles in neuronal development and has been identified as a possible risk 
factor for schizophrenia, bipolar disorder and depression when dysregulated (231). A 
sequence variant of DISCI, 37W, showed impaired ability to promote mitochondrial 
anterograde transport, dysregulated coupling of mitochondria to the transport machinery 
complex and perinuclear aggregation of mitochondria. Interestingly this variant is able to 
associate with Miro1, akin to WT DISCI. Although further research is required, this study 
illuminates a potential link between Miro1 functionality and signalling complexes 
associated with severe psychiatric or neurological disorders. Furthermore, an ALS-related 
variant of the vesicle-associated membrane protein associated protein B (VAPB) has been 
demonstrated to decrease Miro association with tubulin via Ca2+ level increase in the 
cytoplasm, producing the overall result of impaired mitochondrial anterograde transport. 
This effect was rescued when a Ca2+ insensitive mutant of Miro1 was overexpressed (230). 
Another research paper found that Miro1 and Miro2 interact with hypoxia up-regulated 
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mitochondrial movement regulator (HUMMR), which appears to play a critical role in 
maintaining mitochondrial anterograde transport in cells exposed to hypoxia (185). As 
cerebrovascular events leading to transient hypoxia have been previously linked to 
psychiatric (244-246) and neurodenegenerative disorders (247,248). This may, again, 
illuminate a link between the Miros and neurological pathology
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Chemicals, enzymes and kits 
2.1.1.1 Antibiotics 
 
Kanamycin and ampicillin were dissolved in sterile deionised water and filtered using a 
0.2 µm Minisart® filter unit (Sartorius) attached to a sterile syringe of appropriate volume 
(Plastipak®, Becton Dickinson) before use. Penicillin-streptomycin was provided as a 
concentrated solution by the supplier. All antibiotics were diluted with appropriate media 
to the working concentrations displayed in Table 2.1. 
Table 2.1 Stock and working concentrations of antibiotics in media. 
Antibiotic Stock concentration  Working concentration Supplier 
Ampicillin 100 mg/mL 200 µg/mL Sigma 
Kanamycin 50 mg/mL 50 µg/mL Melford 
Penicillin 10, 000 U/mL 10 U/mL Life Technologies 
Streptomycin 10, 000 µg/mL 10 µg/mL Life Technologies 
 
2.1.1.2 Enzymes 
 
All enzymes, buffers and reaction co-constituents used are shown in Table 2.2; these were 
stored at -20oC, with buffers and components maintained in 20µL aliquots to avoid 
damage from repeat free-thaw cycles. 
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Table 2.2 Enzymes, buffers and reaction co-constituents. 
Enzyme Co-constituents  Supplier 
KOD Polymerase MgCl2, dNTPs, reaction buffer Toboyo Global 
XhoI Reaction buffer New England Biolabs 
NdeI Reaction buffer New England Biolabs 
Bam HI Reaction buffer New England Biolabs 
T4 DNA Ligase Reaction buffer New England Biolabs 
 
2.1.1.3. Kits 
 
With the exception of the miniprep cell re-suspension buffer, all kits and components 
were stored at room temperature. These kits and corresponding suppliers are listed in 
Table 2.3, below. 
Table 2.3. Kits utilised throughout project. 
Kit Supplier Catalogue identifier 
QIAprep Spin Miniprep Kit Qiagen Cat No./ID 27104 
QIAquick Gel Extraction Kit Qiagen Cat No./ID 28704 
QIAquick PCR Purification Kit Qiagen Cat No./ID 28104 
Malachite Green Assay Kit Cayman Chemical Item #10009325 
PiColorLock™ Phosphate Detection Kit Innova Biosciences Product #303 
 
2.1.1.4 Antibodies 
 
To prevent damage from recurrent freeze-thaw cycles, all antibodies were stored at                   
-20oC in 5-10 µL aliquots. Unless otherwise indicated, all antibodies were diluted in 1 x 
PBS. The primary antibodies utilised throughout this project are detailed in Table 2.4, 
while Table 2.5 lists the secondary antibodies used. Each antibody shown in Table 2.4 
arrived with a certificate of quality and specificity from the respective supplier. However, 
to ensure the suitability of the antibodies, positive and negative controls were utilised for 
antibody-related experiments wherever possible. Typically, a positive control comprised 
a sample of the target protein previously confirmed by other methods, such as LC-MS. 
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Negative controls were quintessentially samples wherein the target protein was absent but 
a similar protein (for example, another GTPase) was present; this assisted in assessing the 
specificity of each antibody for its respective target protein. 
 
 Table 2.4. List of primary antibodies. 
 
 
Table 2.5 List of secondary antibodies. 
Primary Antibody (1o Ab) Origin  Dilution Supplier Catalogue identifier 
Anti-RhoT1 monoclonal Mouse 1:1000 AbCam ab55035 
Anti-RhoT2 polyclonal Rabbit 1:2000 ProteinTech 11237-1-AP 
Anti-RhoH polyclonal Rabbit 1:1500 AbCam ab138123 
Anti-Hexahistidine monoclonal Mouse 1:2000 BioRad 620-0203 
Anti-Myc polyclonal Rabbit 1:1000 Cell Signalling 2272 
Anti-phosphoSer/phosphoThr 
polyclonal 
Rabbit 1:1500 AbCam ab17464 
Anti-GAPDH Rabbit 1:1000 Cell Signalling #2118 
Seconday Antibody (2o Ab) Origin  Dilution Supplier Catalogue number 
Anti-mouse HRP-linked polyclonal Rabbit 1:1000 AbCam ab97046 
Anti-rabbit HRP-linked polyclonal Goat 1:1500 Dako D048701-2 
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2.1.2 Bacterial strains and vectors 
2.1.2.1 Bacterial strains 
 
The bacterial strains used throughout this project are enumerated in Table 2.6. All 
bacterial strains were stored at -80oC in 20% (v/v) glycerol.  
 Table 2.6 E.coli strains used throughout this project. 
 
 
 
 
 
 
 
 
Various strains were trialled in order to obtain suitable amounts of soluble target protein. 
For example, while BL21 (DE3) is regarded as a robust ‘workhorse’ strain for protein 
over-expression (249,250), C41 (DE3) and C43 (DE3) cells have been previously 
demonstrated to enhance over-expression of difficult-to-express or toxic target proteins 
(251,252). Alternatively, Tuner cells may be utilised when tight adjustment of expression 
levels are required in all cells within a culture (253). Specifically, DE3 strains were used 
owing to the fact they contain the λDE3 lysogen in the host chromosome; the λDE3 
lysogen carries the gene for T7 RNA polymerase, allowing for the expression of 
recombinant proteins using the pET expression as further described in 2.1.2.2. 
2.1.2.2. Vectors 
 
A pEGFP-C vector encoding GFP-tagged RhoH was supplied by the Rajat Varma Lab 
(National Institute of Health, USA). Meanwhile, the Pontus Aspenström Group 
(Karolinska Institutet, Sweden) donated pRK5-Myc vectors encoding full-length human 
Miro1 and 2. Vectors encoding full-length and truncated DRAK2 were purchased from 
Addgene. These vectors had been previously sequenced and were either utilised outright 
or used as template DNA for PCR reactions, depending on context. The empty expression 
vectors pET28a and pET15b-TEV were utilised for cloning purposes to enable 
Bacterial strain Application  
E.coli TOP10 Cloning host 
E.coli BL21 (DE3) Target protein over-expression 
E.coli Tuner (DE3) Target protein over-expression 
E.coli C41 (DE3) Target protein over-expression 
E.coli C43 (DE3) Target protein over-expression 
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subsequent expression of DNA segments encoding constructs of interest. Table 2.7 
enumerates all of the vectors used throughout this study. 
Table 2.7 Vectors used throughout this study. Relevant properties of each plasmid, 
including whether it possesses a multiple cloning site (MCS) or the capacity for ligation 
independent cloning (LIC) are also given. 
Vector Relevant Properties  Supplier 
pET-28a His-tag (N, C), Kanr, T7 lac, lacIq, thrombin 
cleavage site, MCS 
Novagen 
pET15b-TEV His-tag (N),Ampr, T7 lac, lacIq, TEVcleavage 
site, MCS 
NIGMS Protein Structure 
Initiative Site 
pNIC28-Bsa4 His-tag (N), Kanr, T7, lac, lacIq, TEVcleavage 
site, MCS, LIC 
Oxford University Structural 
Genomics Consortium 
pRK5-Myc Myc-tag, Ampr, MCS, mammalian Karolinska Institutet 
pEGFP-C GFP-tag, MCS, mammalian Rajat Varma Lab 
 
The pET-28a, pET15b-TEV and pNIC28-Bsa4 vectors each made use of the pET 
expression system pioneered by Studier and Moffatt (254). This system is renowned as a 
simple and powerful tool, enabling the controlled overexpression of target proteins in 
transformed bacterial cells (254,255). Vectors exploiting the pET system contain a T7 
promoter upstream of a multiple cloning site (MCS) into which the gene encoding the 
target protein is inserted. Typically, an antibiotic resistance gene is also present in the 
pET vector to assist in the selection of transformed bacterial cells.  
For the pET vectors used throughout this project, a lac operator sequence was present 
immediately downstream of the T7 promoter, carrying the natural promoter and coding 
sequence for the lac repressor (lacI). When expressed, the lac repressor acts at the lac 
promoter on the pET vector and at the lacUV5 promoter in the host chromosome of DE3 
strains, repressing transcription of both the target gene in the vector and the T7 RNA 
polymerase gene in the host chromosome, respectively. Allolactose, or a suitable 
analogue, such as IPTG, is able to bind to the lac repressor, causing a conformational 
change in the lac repressor and its dissociation from the lac operator. In this way, 
expression of target proteins throughout this project could be easily controlled by addition 
of IPTG to media containing the transformed DE3 expression host of choice. 
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2.1.3 Oligonucleotides 
2.1.3.1. Oligonucleotide primers for amplification of full length hMiro1 
 
Forward: 5’-TGCCATAGCATATGAAGAAAGACGTGCGGAT-3’ 
Reverse: 5’-TGCCATAGCTCGAGTCATCGCTGTTTCAATAATGC-3’ 
2.1.3.2. Oligonucleotide primers for amplification of full length hMiro2 
 
Forward: 5’- TGCCATAGCATATGAGGCGGGACGTGCGCATCCTGTTACT-3’ 
Reverse:  
5’- TGCCATAGCTCGAGTCACTGGCTCTTCACCAGGACCCTGTAGAGTG-3’ 
2.1.3.3. Oligonucleotide primers for amplification of the hMiro1 N-terminal 
GTPase domain (K3-P169) 
 
Forward: 5’-TGCCATAGCATATGAAGAAAGACGTGCGGAT-3’ 
Reverse: 5’-TGCCATAGCTCGAGTCAAGGATGAAGAACAGCTTTCTGTG-3’ 
2.1.3.4. Oligonucleotide primers for amplification of the hMiro1 C-terminal 
GTPase domain (Q415-P580) 
 
Forward: 5’-TGCCATAGCATATGCAAAGAAATGTGTTCAGATGTAATG-3’ 
Reverse: 5’-TGCCATAGCTCGAGTCACGGATACATGGCCATTGTT-3’ 
2.1.3.5. Oligonucleotide primers for amplification of the hMiro1 ‘xtal’ construct 
(E177-R590) 
 
Forward: 5’-TGCCATAGCATATGGAGGAGAAGGAGATGAAACCA-3’ 
Reverse: 5’- TGCCATAGCTCGAGTCAAGCTCTTGGGGTCAGCTTGT-3’ 
2.1.3.6. Oligonucleotide primers for amplification of the hMiro2 N-terminal 
GTPase domain (R3-P169) 
 
Forward: 5’-TGCCATAGCATATGCGGGACGTGCGCATCCTGTTA-3’ 
Reverse: 5’-TGCCATAGCTCGAGTCATGGGATGCAGGACGGCCTT-3’ 
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2.1.3.7. Oligonucleotide primers for amplification of the hMiro2 C-terminal 
GTPase domain (Q413-F589) 
 
Forward: 5’-TGCCATAGCATATGCAGCGGAGCGTCCTCCTGT-3’ 
Reverse: 5’-TGCCATAGCTCGAGTCAGAAGGAAGAGGGATGCAGCTCT-3’ 
2.1.3.8. Oligonucleotide primers for amplification of the hMiro2 ‘xtal’ construct 
(E177-P586) 
 
Forward: 5’- TGCCATAGCATATGGAGGCCAAGCAGTTGAGG -3’ 
Reverse: 5’-TGCCATAGCTCGAGTCAGGGATGCAGCTCTGCGTG -3’ 
2.1.3.9. Oligonucleotide primers for amplification of RhoH full length wildtype 
 
Forward: 5’-TGCCATAGCATATGCTGAGTTCCATCAAGTGCGT-3’ 
Reverse:     
5’- TGCCATAGCTCGAGTCATTAGAAGATCTTGCACTCATTGATGGAG-3’ 
2.1.3.10. Oligonucleotide primers for amplification of RhoH S4-A174 
 
Forward: 5’-TGCCATAGCATATGTCCATCAAGTGCGTGTTGGTG-3’ 
Reverse: 5’-TGCCATAGCTCGAGTCATGGCCTGGTTGACGGCAGTT-3’ 
2.1.3.11. Oligonucleotide primers for amplification of RhoH V10-S184 
 
Forward: 5’- TGCCATAGCATATGGTGGGCGACTCTGCTGTG-3’ 
Reverse: 5’- TGCCATAGCTCGAGTCAGGAGAAGAGCCTCCTTCTGTT-3’
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2.1.4 Media 
2.1.4.1 Luria Bertani (LB) media for culturing E.coli 
 
The components for the creation of 1 litre of LB media are shown in Table 2.8, below. 
Note that the components were dissolved in distilled water and the media brought to a pH 
of 7.0. Prior to use, the completed media was autoclaved as discussed in Appendix 1 and 
subsequently allowed to cool.  
 
Table 2.8. Components in 1 litre of LB-broth. 
LB broth component Amount in 1 litre 
Tryptone 10 g 
Yeast extract 5 g 
Sodium chloride 10 g 
 
 
2.1.4.2 Modified terrific broth (TB media) for culturing E.coli 
 
To produce 1 litre of TB media, the components shown in Table 2.10 were fully dissolved 
in distilled water and the resulting media brought to a pH of 7.0 prior to autoclaving 
(Appendix 1). Before inoculation with E.coli, the media was allowed to cool to room 
temperature. 
 
Table 2.9. Components in 1 litre of TB-broth. 
LB broth component Amount in 1 litre 
Tryptone 12 g 
Yeast extract 24 g 
Glycerol 4 mL 
 
 
2.1.4.2 Solid media for culturing E.coli 
 
To prepare agar plates, LB media was supplemented with 2% bacterial agar No1. The LB-
agar was subsequently autoclaved (Appendix 1) and allowed to cool to approximately 
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50oC prior to addition of any required selective antibiotics. Then, while still in liquid 
form, the LB-agar was poured into Petri dishes and allowed to solidify. 
 
2.1.4.3 Media for culturing mammalian cells 
 
COS7, PC3 and MCF-7 cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
I.U/mL penicillin and 100 μg/mL streptomycin. During growth of mammalian cells for 
transfection purposes, DMEM supplemented with FBS and L-glutamine was used as 
described above, but with the absence of penicillin-streptomycin. 
2.1.4.4 Opti-MEM® Reduced Serum Media for transfection or siRNAi 
 
During transfection procedures, plasmid DNA or siRNA were incubated in Opti-MEM® 
Reduced Serum Media (Life Technologies), a modified form of DMEM buffered with 
HEPES and sodium bicarbonate and supplemented with sodium pyruvate, thymidine, L-
glutamine, hypoxanthine, trace elements and growth factors. 
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2.1.5 Buffers 
2.1.5.1 For agarose gel electrophoresis 
2.1.5.1.1 6x DNA loading buffer (bromophenol blue) 
 
The components of the 6x bromophenol blue DNA loading buffer are shown in Table 
2.10, below. The 6x bromophenol blue DNA loading buffer was made up in sterile 
deionised water.  
 
Table 2.10. Components of 6x bromophenol blue DNA loading dye. 
6x bromophenol blue DNA loading buffer component Amount required 
Glycerol 30% 
Bromophenol blue 0.25% 
 
 
The bromophenol blue loading buffer was utilised during analytical agarose gel 
electrophoresis or when target fragment size was suspected to run significantly higher 
than 300 bp; this was a precaution to prevent contamination of bromophenol blue when 
performing agarose gel purification, as bromophenol blue is known to run at 
approximately the same rate as a 300 bp DNA fragment through a 1% agarose gel.  
 
2.1.5.1.2 6x DNA loading buffer (xylene cyanol) 
 
The components of the 6x xylene cyanol DNA loading buffer are shown in Table 2.11. 
6x xylene cyanol DNA loading buffer was made up in sterile deionised water. 
 
Table 2.11. Components of 6x xylene cyanol DNA loading dye. 
6x xylene cyanol DNA loading buffer component Amount required 
Glycerol 30% 
Xylene cyanol 0.25% 
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The xylene cyanol loading buffer was used when agarose gels were desired for agarose 
gel purification and the target fragment size was suspected to run significantly lower than 
3000 bp (xylene cyanol runs at the same rate as a DNA fragment of approximately 3000 
bp when a 1% agarose gel is utilised). 
2.1.5.1.3 Tris-Acetate-EDTA (TAE) running buffer (50x) 
 
Tris-Acetate-EDTA (TAE) running buffer was produced in 50x stocks, and diluted to 1x 
in distilled water when required. The recipe for producing 1 litre of 50x Tris-Acetate-
EDTA (TAE) running buffer is shown in Table 2.12, below. 
 
Table 2.12. Components of 50x TAE running buffer for agarose gel electrophoresis. 
 
 
 
 
 
 
50x TAE running buffer (1L) Amount required 
Tris-base 242 g 
Glacial acetic acid 57.1 mL 
0.5 M EDTA, pH 8 100 mL 
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2.1.5.2 For SDS-PAGE electrophoresis and staining 
2.1.5.2.1 SDS-PAGE running buffer (10x) 
 
Running buffer for SDS-PAGE electrophoresis was produced in 10x stocks and stored at 
4oC. When required, a 1x solution was made up by diluting the stock in distilled water. 
The recipe for producing 1 litre of 10x SDS-PAGE running buffer is shown in Table 2.13, 
below. When producing 10x stock, each component was dissolved separately in deionised 
water in the order shown in Table 2.13. Prior to addition of SDS, the buffer was brought 
to approximately 900 mL and the pH adjusted to 8.8.  
 
Table 2.13. Components of 10x SDS-PAGE running buffer. 
10x SDS-PAGE running buffer (1L) Amount required 
Tris-base 30.3 g 
Glycine 144 g 
SDS 10 g 
 
 
2.1.5.2.2 6x SDS-PAGE loading buffer 
 
To produce 10 mL of 6x SDS-PAGE loading buffer, the components shown in Table 2.14 
were dissolved in sterile deionised water. 6x SDS-PAGE loading buffer was stored at 4oC 
until required.  
 
Table 2.14 6x SDS-PAGE loading buffer components.  
6x SDS-PAGE loading buffer (10 mL) Amount required 
1 M Tris-HCl pH 6.8 0.6 mL 
50% glycerol 5 mL 
10% SDS 2 mL 
Β-mercaptoethanol 0.5 mL 
1% bromophenol blue 1 mL 
Sterile deionised water 0.9 mL 
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2.1.5.2.3 12% (w/v) Acrylamide resolving gel components 
 
The components required for standard 12% (w/v) acrylamide SDS-PAGE resolving gels 
are shown in Table 2.15, below. Note that this recipe is sufficient to produce two 0.75 
mm gels. The components of Buffer B are additionally supplied in Table 2.16. 
 
Table 2.15 12% (w/v) acrylamide resolving gel components.  
 
12% (w/v) acrylamide resolving gel solution Amount required for 2 0.75mm gels 
40% (v/v) 37.5:1 acrylamide: bisacrylamide solution 3 mL 
Buffer B 2.5 mL 
Deionised water 4.5 mL 
Ammonium persulphate (APS) 100 µL 
TEMED 20 µL 
 
 
Table 2.16 Components used to make up 100 mL of Buffer B for use in making SDS-
PAGE resolving gels. 
 
 
 
 
 
 
 
 
2.1.5.2.4 12% (w/v) Acrylamide stacking gel components  
 
The components for producing standard SDS-PAGE stacking gels is shown in Table 2.17. 
This recipe is sufficient to produce two 0.75mm gels. The components of Buffer C are 
exhibited in Table 2.18. Bromophenol blue was an optional addition, aiding in 
visualisation of the stacking gel wells by producing a blue colour contrasting to the 
transparent wells. 
 
Buffer B (100mL) Amount required for 100mL 
2M Tris-HCl pH 8.8 75 mL 
10% SDS 4 mL 
Deionised water 21 mL 
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Table 2.17 SDS-PAGE stacking gel components. 
SDS-PAGE stacking gel solution Amount required for 2 gels 
40% (v/v) 37.5:1 acrylamide: bisacrylamide solution 0.5 mL 
Buffer B 1 mL 
Deionised water 2.5 mL 
1% Bromophenol blue 30 µL 
Ammonium persulphate (APS) 60 µL 
TEMED 20 µL 
 
 
Table 2.18 Components used to make up 100 mL of Buffer C, used when producing 
SDS-PAGE stacking gels. 
 
 
 
 
 
 
2.1.5.2.5 Coomassie stain for SDS-PAGE gels 
The components required for production of 1 litre of coomassie stain are shown in Table 
2.19. 
Table 2.19 Components required to make up 1 litre of coomassie stain. 
Coomassie stain (1L) Amount required 
Coomassie brilliant blue R250 1 g 
Glacial acetic acid 100 mL 
Methanol 300 mL 
Deionised water 600 mL 
 
Buffer B (100mL) Amount required 
1M Tris-HCl pH 6.8 50 mL 
10% SDS 4 mL 
Deionised water 46 mL 
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2.1.5.2.6 Destain for SDS-PAGE gels 
 
The components required for production of 1 litre of destain solution are provided in 
Table 2.20, below. 
Table 2.20 Components required to make up 1 litre of destain solution. 
Destain solution (1L) Amount required 
Glacial acetic acid 100 mL 
Methanol 100 mL 
Deionised water 800 mL 
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2.1.5.3 For protein purification 
2.1.5.3.1 Lysis (“start”) buffer for IMAC purification of His-tagged proteins 
 
Lysis (“start”) buffer for the IMAC purification of His-tagged proteins consisted of: 
 50 mM HEPES (pH 7.4)  
 500 mM NaCl  
 5 mM imidazole  
 5% glycerol 
 
2.1.5.3.2 Elution buffer for IMAC purification of His-tagged proteins 
Standard final elution buffer for the IMAC purification of His-tagged proteins was 
composed of the following: 
 50 mM HEPES (pH 7.4)  
 500 mM NaCl  
 500 mM imidazole  
 5% glycerol 
2.1.5.3.3 Gel filtration buffer 
Gel filtration buffer consisted of the following components: 
 50 mM HEPES (pH 7.4)  
 500 mM NaCl  
 5 mM DTT 
 2% glycerol 
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2.1.5.4 For further protein work 
2.1.5.4.1 Bradford assay reagents 
Bovine serum albumin (BSA) was made to a concentration of 2 mg/mL and stored at -
20oC for subsequent dilution to produce defined BSA standards. Bradford Reagent 
(Brilliant blue G in phosphoric acid and methanol) was stored at 4oC and allowed to warm 
to room temperature prior to each use. 
2.1.5.4.2 Protein crystallisation screens 
 
All crystallisation buffers utilised are shown in Appendix 2. 
2.1.5.4.3 Phosphate buffered saline (PBS)  
 
All phosphate buffered saline (PBS) was made up in 18.2Ω water and autoclaved prior to 
use. A 1x PBS solution comprised the following: 1.1 mM KH2PO4, 155.2 mM NaCl and 
3mM Na2HPO4-7∙H2O. Generally, a 10x PBS stock was generated, autoclaved and 
diluted to 1x on a purpose-by-purpose basis. To maintain sterility, PBS diluted from stock 
was diluted in 18.2Ω water and autoclaved. 
2.1.5.4.4 Semi-dry transfer buffer for Western blotting 
 
Transfer buffer for the transfer of proteins from SDS-PAGE gel to a blotting membrane 
through the semi-dry method was achieved via use of the following buffer: 25 mM Tris, 
192 mM glycine, 20% (v/v) methanol adjusted to a pH 8.3. 
2.1.5.4.5 Blocking solution for Western blotting 
 
Blocking solution for all Western blots contained 5% (w/v) skimmed milk powder 
(Marvel) in 1 x PBS with 0.025% (v/v) Tween-20.  
2.1.5.4.6 Radioimmunoprecipitation assay (RIPA) buffer 
 
Radioimmunoprecipitation assay (RIPA) buffer was freshly prepared for each use in 
sterile 18.2Ω H20 and filter-sterilised (2.2.1.1) prior to application. At all times, this buffer 
was kept on ice or at 4oC. Standard RIPA buffer was composed of: 50 mM Tris pH 7.4, 
150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100 and 0.1% SDS. Before use, 
P8340 protease inhibitor cocktail (Sigma Aldrich, UK) was added to a final 1 x 
concentration according to manufacturer’s instructions.  
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2.2 Methods 
2.2.1 General practice 
Guidelines for good laboratory practice were adhered to wherever possible, with 
laboratory equipment utilised according to manufacturer’s recommendations and advice 
from senior laboratory members. Where necessary, aseptic technique was applied (all 
microbiological techniques, for example). 
2.2.1.1 Sterilisation 
 
Unless otherwise stated, all solutions and apparatus were sterilised by autoclaving at 
121oC for 20 minutes at 1.05 bar pressure. Where it was not possible to autoclave, 
solutions were filter sterilised using a 0.2 µm Minisart® filter unit (Sartorius) attached to 
a sterile syinge of appropriate volume (Plastipak®, Becton Dickinson).
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2.2.2 Microbiological Methods 
2.2.2.1 Preparation of chemically competent E.coli cells 
 
Competent cells of the necessary E.coli strains were prepared by an altered version of the 
CaCl2 method described by Cohen et al. (256). A single colony of the desired E.coli strain 
was aseptically transferred from an LB-agar plate into 100 mL of LB broth. The 
inoculated broth was incubated at 37oC with 200 RPM shaking. When an OD600 of 0.6 
was obtained, the culture was transferred into 50 mL Falcon tubes and incubated on ice 
for 10 minutes. The culture was pelleted by centrifugation at 4000 x g for 10 minutes at 
4oC and the supernatant discarded. The cell pellet was then re-suspended by gentle 
pipetting in 10 mL of ice-cold CaCl2 (100 mM) and incubated on ice for a further 10 
minutes prior to re-centrifugation at 4000 x g for 10 minutes (4oC). The supernatant was 
discarded and the pellet re-suspended in 2mL ice-cold CaCl2 (100 mM). The cells were 
incubated on ice for at least 2 hours, after which they were dispensed into 100 µL aliquots 
in pre-frozen Eppendorf tubes and stored at -80oC until required. 
2.2.2.2 Transformation of chemically competent E.coli cells 
 
Transformation of the required E.coli strains was accomplished by an altered version of 
the heat shock procedure described by (257). Aliquots of the necessary competent cells 
were retrieved from -80oC storage and thawed on ice for 10 minutes. 20 - 100 ng of the 
desired plasmid DNA (1-2 µL) was transferred to each appropriate aliquot of competent 
cells and allowed to incubate on ice for 20 minutes. Following incubation, the cells were 
rapidly transferred to a 42oC water bath for 90 seconds and immediately placed back on 
ice for 2 minutes. 200 µL LB broth was added to each aliquot and the cells were incubated 
at 37oC for 45-60 minutes, after which they were plated out onto LB agar plates 
containing an appropriate concentration of the necessary antibiotic. Plates were incubated 
at 37oC in a static incubator overnight (approximately 16 hours) and subsequently 
assessed for the presence of colonies. All transformation procedures occurred alongside 
negative controls, involving the heat shock of competent cells in the absence of vector; 
this ensured that the cells had not developed resistance to the selective antibiotic in the 
absence of the antibiotic-resistance marker conferred by the chosen plasmid. 
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2.2.2.3 Plating bacteria 
 
2% agar plates were prepared by addition of 2 g agar to 100 mL LB-broth, followed by 
autoclaving at 120oC. Autoclaved LB-agar was allowed to cool to approximately 45oC 
before addition of the necessary antibiotic (if required). The warm LB-agar was 
subsequently poured into sterile petri dishes and left to solidify at room temperature. The 
plates were surface dried in an oven at 65oC for 5-10 minutes and allowed to cool to room 
temperature. Bacterial suspensions were dispensed evenly across the surface of the agar 
using sterile disposable plastic spreader. When all of the bacterial suspension had been 
absorbed into the agar, the plate was inverted and incubated at 37oC for approximately 16 
hours. 
2.2.2.4 Growth of bacteria for plasmid extraction 
 
To obtain a high copy number of the desired plasmid DNA, TOP10 E.coli transformed 
with the necessary plasmid transferred into 5-10 mL LB media containing the appropriate 
antibiotic and grown overnight at 37oC with 200 RPM orbital shaking. The LB media was 
inoculated from an agar plate, glycerol stock or liquid culture using a sterile wire loop.  
2.2.2.5 Growth of bacteria for start cultures in protein expression experiments 
 
The necessary E.coli strain harbouring the plasmid of choice was grown overnight in LB 
supplemented with the selective antibiotic (37oC with 200 RPM orbital shaking). Cultures 
were inoculated from an agar plate, glycerol stock or liquid culture using a sterile wire 
loop or pipette tip. Cultures were grown either in sterile 28 mL glass universals or small 
glass conical flasks. 
2.2.2.6 Growth of bacteria for expression trials 
 
Following the transformation of one or more suitable expression strains with the plasmid 
DNA of choice, small scale expression trials were conducted to assess optimal conditions 
for recombinant protein over-expression. Expression trials required the production of a 
starter culture containing the transformed bacteria of choice (section 2.2.2.5). Initial 
expression tests involved inoculation of 50 mL growth media with 500 µL of the 
appropriate start culture, where either LB, TB or autoinduction media was utilised 
depending on requirements. All bacterial growth media was supplemented with the 
appropriate antibiotic. For cells grown in LB or TB media, the recombinant E.coli strains 
were grown at 37oC with 200 RPM shaking in baffled flasks until mid-exponential phase 
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(OD600 0.6-0.8), at which point they were cooled to the desired temperature and IPTG 
added to a final concentration of 0.1, 0.5 or 1.0 mM. Cultures were subsequently 
incubated at 18oC, 25oC or 37oC for a suitable amount of time. Autoinduction was based 
on the Terrific Broth formulation from ‘ForMedium’, wherein induction occurs as a result 
of the uptake of lactose from bacteria after glucose (preferentially uptaken by bacteria for 
energy metabolism) is depleted in the medium. The amount of glucose present in auto-
induction media is formulated to become depleted at a high cell density, leaving only 
lactose available for bacterial energy metabolism and therefore resulting in induction of 
target protein expression. Where autoinduction media was concerned, cells were 
incubated at 18oC, 25oC or 37oC for up to three days. Samples from autoinduction cultures 
were harvested every 6 hours. In all cases, induced cultures were harvested by 
centrifugation at 4000 x g for 20 minutes. Subsequent re-suspension of the pellet was 
undertaken in lysis buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole and 
5% glycerol), and the resulting suspension of cells either immediately processed (section 
2.2.4.3) or frozen for later use.  For preps exhibiting proteasomal degradation, such as the 
Miro full-length preps, the commercial protease inhibitor cocktail P8849 (Sigma-Aldrich, 
UK) was added according to the manufacturer’s instructions immediately following cell 
resuspension. 
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2.2.3 DNA methods 
2.2.3.1 Preparation of donated plasmid DNA 
 
In all cases, donated plasmid DNA was provided as a blot on filter paper. To extract 
pDNA from the filter paper, the paper was cut into small fragments using a sterile scalpel 
and transferred to clean Eppendorf tube. 30 µL of QIAPrep elution buffer was added to 
each tube of blotted DNA and incubated at 50oC for 30 minutes, followed by a further 
incubation at room temperature for 30 minutes. 10 µL of the elution buffer was 
subsequently transferred to a sterile Eppendorf tube and incubated on ice for 10 minutes 
prior to incubation with TOP10 competent cells for heat shock transformation (2.2.2.2). 
Transformation of TOP cells with donated plasmid DNA was as previously described 
(2.2.2.2) with slight alterations: TB media was used as the recovery medium following 
heat shock, and the cells incubated at 37oC for at least 1 hour to ensure suitable recovery 
of transformed bacteria. 
2.2.3.2 Plasmid DNA extraction and purification from recombinant E.coli cells 
 
A single colony from a freshly streaked plate was aseptically transferred to 5 mL LB 
medium in a sterile 28 mL glass universal, where both the plate and LB medium contained 
the antibiotic to which recombinant cells harbouring the desired plasmid were resistant. 
The inoculated medium was subsequently incubated at 37oC with orbital shaking at 200 
RPM. Following incubation, the bacterial cells were harvested by centrifugation at 5400 
x g for 15 minutes (4oC). 
2.2.3.3 Polymerase Chain Reaction (PCR) 
 
Numerous different protocols were used (see Appendix 3 for detailed information 
regarding each protocol). In each case, PCR success was assessed by agarose gel 
electrophoresis using 10 µL of the completed PCR reaction. 
2.2.3.4 PCR clean-up 
 
Purification of PCR products was accomplished by use of the QIAquick PCR Purification 
Kit (Qiagen, UK), where all centrifugation steps occurred at 17, 900 x g in a conventional 
table-top microcentrifuge at room temperature. 5 volumes of Buffer PB were added to 1 
volume of the PCR reaction and mixed by pipetting, with the resulting solution transferred 
to an unused QIAquick column attached to a 2 mL collection tube and centrifuged for 60 
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seconds. The flow through was discarded. 750 µL Buffer PE was subsequently added to 
the QIAquick column and the column centrifuged for 60 seconds. Again, the flow-
through was discarded. The QIAquick column was then centrifuged for a further 60 
seconds to remove latent Buffer PE. Elution of DNA from the column was then achieved 
by addition of 30 µL Buffer EB to the column, which was subsequently placed in a sterile 
Eppendorf tube and incubated for 1 minute at room temperature prior to 60 seconds 
centrifugation. To determine the success of the purification, 5 µL of the eluted sample 
was subjected to agarose gel electrophoresis as described in section 2.2.3.7.   
2.2.3.5 Quantification of DNA 
 
DNA was quantified spectroscopically at 260 nm using the NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific, UK) connected to a laptop containing the 
NanoDrop 2000/2000c software package. Between each use, the NanoDrop 2000 sample 
pedestal (lower optical surface) was gently wiped clean with a lens tissue to remove 
residual sample, blank or water. Liquid measured spectroscopically by the NanoDrop 
2000 was dispensed at 1 µL onto the lower optical surface (sample pedestal) and the 
instrument lever arm (containing the upper optical surface) lowered to produce a liquid 
column between the optical surfaces. To initiate the apparatus, sterile deionised water was 
first dispensed onto the sample pedestal. Subsequently, QIAprep Buffer EB was 
dispensed onto the sample pedestal and a blank measurement taken. Sample DNA could 
then be dispensed onto the sample pedestal for spectrophotometric quantification, with 
DNA concentration calculated by the NanoDrop 2000 software and provided in µg/mL. 
2.2.3.6 Restriction digestions 
 
Typically, restriction digests occurred in a volume of 30 µL, where 3 µL of a suitable 10x 
buffer provided by NEB was utilised in addition to 2 µL of each enzyme. DNA 
concentrations differed from digest to digest depending on context, with up to 5 µg DNA 
digested. Digestions were conducted at 37oC for 1-4 hours. 
2.2.3.7 Agarose gel electrophoresis 
 
1% (w/v) agarose gels were prepared by heating agarose in 1 x TAE buffer (2.1.5.1.3) 
until fully dissolved. Following heating, the agarose solution was allowed to cool to 
approximately 60oC and poured into a gel casting tray of the necessary size. Bubbles were 
avoided by slow pouring and the use of a sterile pipette tip to remove bubbles immediately 
after pouring. An appropriately sized comb was inserted into the solution and the gel 
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allowed to set for approximately 15 minutes. Set gels were placed into agarose gel 
electrophoresis tanks and submerged in 1 x TAE buffer prior to removal of the gel comb 
by hand. Samples were prepared by the addition of 2 µL of an appropriate 6 x DNA 
loading buffer per 10 µL of sample. Appropriate loading buffer was defined as a buffer 
containing a dye that would run much faster or slower during electrophoresis than the 
expected DNA sample bp size; this was to aid visualisation of DNA and to avoid 
contamination of dye substances during gel purification procedures. Either bromophenol 
blue 6x loading buffer (2.1.5.1.1) or xylene cyanol 6x loading buffer (2.1.5.1.2) was used. 
Samples were mixed and loaded carefully into wells using a micropipette. In addition to 
loading samples, 10 µL of suitable side standard was loaded into an empty well in order 
to determine the size of DNA fragments post-electrophoresis. The electrophoresis 
apparatus was attached to a power pack and electrophoresis initiated at 120 volts until a 
suitable separation of DNA had been obtained. 
2.2.3.8 Visualisation of DNA and photography of agarose gels 
 
Following electrophoresis, agarose gels were stained by submersion in 10 µg/mL 
ethidium bromide solution for 15 minutes. An ethidium bromide solution was repeatedly 
used for analytical gels until staining appeared diminished, at which point a new solution 
was created. For gels required for agarose gel purification, however, ethidium bromide 
was freshly prepared in sterile deionised water and used each time. Following staining, 
DNA fragments were visualised by the ultraviolet (UV) source emitted by the Bio-Rad 
Gel Doc 2000 gel documentation system, accompanied by Quantity One software. 
Physical copies of gel visualisations were obtained using a Mitsubishi Video Copy 
Processor (Model P91) attached to the gel documentation device, fed with Mitsubishi 
thermal paper (K65HM-E/High density type, 110 mm x 21 mm). Soft copies of images 
were maintained on an external hard-drive. 
2.2.3.9 Agarose gel purification 
 
Agarose gel purification is a technique in which a DNA band is excised from an agarose 
gel following agarose gel electrophoresis (2.2.3.7), in order to isolate a DNA fragment of 
a desired size. All agarose gel purifications were implemented via aid of the QIAquick 
Gel Extraction Kit (Qiagen), with every centrifugation occurring at 17,900 x g in a 
benchtop micro-centrifuge for 60 seconds. First, the sample to be purified is subjected to 
agarose gel electrophoresis. The gel is then visualised under low intensity 'prep' UV light, 
to locate the fragment of interest and liberate the gel segment containing the fragment by 
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use of a clean scalpel. The gel segment of interest was placed into a pre-weighed micro-
centrifuge tube and subsequently re-weighed to obtain the weight of the gel slice. For 
every 100 mg of agarose gel, 300 µL of QG buffer was added to the tube. The gel was 
then dissolved by incubation of 50oC for 10 minutes with brief vortexing every 2-3 
minutes. Once fully dissolved, 100 µL of isopropanol was added for every 100 mg of gel, 
and the sample loaded into a QIAprep spin filter tube placed in a 2 mL collection tube. 
The sample was centrifuged and the resulting flow through discarded. Subsequently, 500 
µL of QG buffer was added to the spin filter column and centrifuged for one minute, with 
the flow-through again discarded. 750 µL buffer PE was then added to the spin filter 
column, which was again centrifuged and the flow-through discarded. After another 
centrifugation to remove residual ethanol from the PE buffer, the spin filter column was 
placed into a sterile 1.5 mL Eppendorf tube and 30 µL of EB buffer added to the centre 
of the spin filter column. The column was allowed to sit at room temperature for 1 minute 
and subsequently centrifuged to elute the gel purified sample into the sterile Eppendorf 
tube. The filter was discarded and the purified sample retained for use. Purification was 
assessed by removing 2 µL of purified sample and diluting it in a separate tube with 8 µL 
of sterile distilled water. The sample was then assessed by agarose gel electrophoresis as 
described previously. Verified purified samples were either used immediately or stored 
at -20oC. 
2.2.3.10 Ligation 
 
All ligations were performed at a 3:1, 5:1 and 8:1 insert to vector ratio, with 
concentrations determined by use of the NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific), as described in 2.2.3.5. The components of a typical ligation are shown 
in Table 2.21. The components were added to a target volume of 10 – 25 µL, with the 
lowest possible volume used in each case. The components were added together in a 
sterile 1.5 mL Eppendorf tube, mixed by tapping and pulse spun before incubation at 
room temperature for 25 minutes. Following incubation, 2 µL of each reaction was added 
to an aliquot of competent TOP10 cells on ice in order to perform the heat shock 
procedure described in 2.2.2.2. The remaining ligation reaction mixture was frozen for 
further use if necessary. 
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Table 2.21 Components of a typical ligation reaction. Where the amount of DNA 
fragment added was dependent on the desired ratio, length of fragment (bp) and 
concentration (ng/µL). 
Component Amount 
Desired plasmid (vector) cut with appropriate restriction enzymes 100 ng (~5 µL) 
10 x ligation buffer 2 µL 
DNA fragment cut with appropriate restriction enzymes 7 µL 
Sterile deionised water 5 µL 
T4 DNA Ligase (3 U/µL) 1 µL 
 
2.2.3.11 Site-directed mutagenesis (SDM) procedure 
 
Site-directed mutagenesis (SDM) was performed with reference to the Stratagene 
instruction manual for the QuickChange: Site-Directed Mutagenesis Kit, though the kit 
itself was not utilised. Mutant primers (Appendix 4) with a length of 25-45 bases and GC 
content of ≥ 40% were designed with the target mutation at the centre of the primer and 
a Tm (melting temperature) of ≥ 78oC. The Tm for each primer was determined as 
follows:  
Tm = 81.5 + 0.41 (%GC) - 675/ N - % mismatch 
Where N = primer length in bases  
%GC = percentage of guanine and cytosine residues in the primer 
%mismatch = percentage of the primer non-complementary at the point of the mutation 
 
To aid in primer design, the online program PrimerX was utilised (258), available at: 
http://www.bioinformatics.org/primerx/index.htm  
 
Mutant plasmids were subsequently generated by PCR, using the target plasmid to mutate 
as PCR template. The subsequent PCR products were then digested with 1 µL of DpnI 
(10 U/µL) restriction enzyme for 1 hour at 37oC. Chemically competent TOP10 E.coli 
cells were then transformed with the DpnI treated DNA as described in 2.2.2.2. 
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Components of all SDM reactions and exact details of the PCR programs used to produce 
mutant plasmids by SDM can be found in Appendix 4. 
2.2.4 Protein methods 
2.2.4.1 SDS-PAGE electrophoresis 
 
12% SDS-PAGE gels were used as standard throughout this project. All gels were 
produced manually in-house. Gels were poured between two clean glass plates of 10.1 x 
7.2 cm and 10.1 x 8.2 cm dimensions, with a 1 mm spacer ridge present on the larger 
plate. Prior to pouring, the plates were clamped together, ensuring that the lower sections 
were aligned. The plates were then secured with vertical downward pressure in a casting 
stand with rubber cushioning. The components for the resolving gel (section 2.1.5.1.6) 
were dispensed into a Falcon tube and poured into the space between the two plates, 
leaving a gap of approximately 1-2 cm below the top of the smallest plate. Water or 
isopropanol was then layered over the top of the resolving gel to ensure a straight gel and 
prevent drying out during polymerisation. The resolving gel was allowed to set for 
approximately 15 minutes and the water layered on top removed by filter paper 
absorption. The components of the stacking gel (section 2.1.5.2.4) were then added 
together separately into a Falcon tube and mixed prior to pouring between the SDS-PAGE 
plates. To produce wells, a 10-toothed comb was then immediately placed between the 
plates to the top. The stacking gel was allowed to set for approximately 20 minutes and 
the comb subsequently removed, leaving defined wells which were rinsed with distilled 
water prior to securing the gel vertically into electrophoresis apparatus. The 
electrophoresis apparatus was placed into an SDS-PAGE tank which was then filled with 
SDS-PAGE 1 x running buffer (secion 2.1.5.1.4). Samples were prepared by addition of 
5 µL of SDS-PAGE loading buffer (section 2.1.5.1.5) to 20 µL of sample, with all 
separate samples loaded into a unique well. 4 µL of BioRad Precision Plus All Blue was 
also loaded into an empty well as a molecular weight side standard for each gel. Prior to 
loading with a micropipette, all samples were boiled for 5 minutes at 120oC and 
subsequently pulse spun in a micro centrifuge. Samples and side standards were loaded 
with a P20 Gilson pipette using an appropriately sized tip. Electrophoresis was 
undertaken by connecting the SDS-PAGE electrophoresis equipment to a BioRad 
powerpack (BioRad, UK) and applying an electric field at 200 volts, 120 milliamps until 
the visible dye front surpassed the bottom of the gel (approximately 60 minutes). Each 
gel was then liberated from between the plates and stained (2.2.4.2). 
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2.2.4.2 Visualisation of protein bands and photography of SDS-PAGE gels 
 
After electrophoresis, the SDS-PAGE gels were removed from the plates and placed into 
Coomassie blue stain for 60 minutes with 50 RPM shaking followed by immersion in de-
staining buffer overnight at room temperature with 100 RPM shaking until bands were 
visible and the background was significantly de-stained. Gels were subsequently 
photographed via use of the Bio-Rad Gel Doc 2000 gel documentation system connected 
to Quantity One software. Hard copies of gels were produced using a Mitsubishi Video 
Copy Processor (Model P91) connected to the Gel Doc system, which printed onto 
Mitsubishi thermal paper (K65HM-E/High density type, 100 mm x 21 mm). 
2.2.4.3 Isolation of intracellular proteins from recombinant E.coli 
 
Cultured expression strains were centrifuged in 450 mL centrifuge tubes for 20 min at 
4,000 xg. The supernatant was discarded and the cells re-suspended in 10 mL lysis 
buffer. Subsequently, the cells were lysed by sonication through 10 cycles of 30 second 
pulses at an amplitude of 14, with 15 second rest intervals between each pulse. The 
resulting lysate was decanted into a sterile 50 mL centrifuge tube and centrifuged at 4°C 
for 60 min at 16,000 x g. The soluble fraction was retained in a sterile plastic universal 
and on ice until purification (2.2.4.4) was performed.  
2.2.4.4 Ion metal affinity chromatography for His-tagged Protein purification 
 
For high yield protein purification, an automated FPLC system (AKTA PRIME, GE 
Lifesciences) was utilised, connected to two consecutively attached 1 mL Ni Sepharose 
HisTrap columns (GE Lifesciences). The columns were stored in 20% ethanol at 4oC 
prior to use, with 30 mL double distilled water pumped through the columns at 0.5 
mL/min to remove the ethanol. Before storage, the columns were stripped with 100 mM 
EDTA at 1.5 mL/min for 10 column volumes. 18.2 Ω distiller water was then pumped 
through the columns at 1.5 mL/min for 5 column volumes prior to recharging the columns 
with 10 volumn volumes of 500 mM NiSO4 at 1.5 mL/min. Another 5 column volumes 
of 18.2 Ω distilled water was then pumped through the columns at a rate of 1.5 mL/min 
prior to equilibration of the columns with 10 column volumes of start buffer (section 
2.1.5.1.9) at a rate of 1 mL/min. The sample to be IMAC-purified was then loaded onto 
the columns at 1 mL/min through a sample inlet tube attached to the automated FPLC 
system. Once all of the sample had been loaded, 20 mL of lysis (“start”) buffer was then 
loaded through the sample inlet tube at 1 mL/min to ensure that the entirety of the sample 
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was loaded onto the columns. Finally, the protein was eluted at a flow rate of 1.5 mL/min 
using a linear gradient of imidazole (elution buffer; 2.1.5.10) extending from 5 mM to 
500 mM. The location of the target protein was assessed by monitoring A280 using a UV 
spectrometer attached to the FPLC, and samples collected in 2 mL fractions using an 
automated fraction collector. Purity of eluted protein samples was assessed by SDS-
PAGE electrophoresis of appropriate fractions. 
2.2.4.5 Gel filtration chromatography 
 
Gel filtration represents a simple chromatographic method for separating molecules 
according to size. A variety of gels are available, comprised of porous beads suspended 
in an eluent. The gels are available with pores of a controlled range of sizes, serving as a 
molecular sieve for separating molecules by size. The largest molecules are unable to fit 
through the pores in the gel matrix, and thus are eluted first, while the smaller molecules 
access the pores and are retained in the gel matrix for a longer time period. 
A sephacryl™ S-200 HR HiPrep™ 16/60 column (GE Lifesciences) attached to an 
automated FPLC system (AKTA PRIME, GE Lifesciences) was utilised for gel filtration 
purposes. Prior to each use, this column was stored in 20% ethanol at room temperature. 
Removal of storage ethanol occurred at 0.5 mL/min with 60 mL double distilled water 
initially. Another 30mL of double distilled water was subsequently pumped through the 
column at 1mL/min. The column was then equilibrated with 60mL gel filtration buffer 
(section 2.1.5.11) at 1 mL/min. Once equilibrated, purified protein from an affinity 
column was concentrated to 2 mL and pre-loaded into a 2 mL superloop connected to 
AKTA PRIME sample input port. A syringe filled with gel filtration buffer was then 
attached to the sample input port, the system set manually to “inject” and the sample 
within the loop injected onto the column at 0.5 mL/min according to AKTA PRIME 
manufacturer’s instructions. As per manufacturer’s recommendations, the entirety of the 
sample was injected and the system reset to “load” position before removal of the syringe 
at the sample input port. Each gel filtration was then performed at 1 mL/min until a length 
of 180 mL had passed through the column, with 3 mL fractions collected via the 
automated sample collection carousel. All results obtained were compared against a gel 
filtration calibration curve prepared using the low molecular weight calibration set from 
GE Healthcare, United Kingdom (see Appendix 6). 
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2.2.4.6 Concentration of target protein 
 
Concentration of proteins was undertaken at 10oC by centrifugation at 4000 x g in 15 mL 
concentrators of the appropriate kDa cut-off. After concentrating all fractions containing 
the desired protein to approximately 1 mL, protein concentration was quantified by 
Bradford’s assay (2.2.4.7) and the protein retained for downstream processing.  
2.2.4.7 Determination of protein concentration 
 
Bradford reagent (Sigma Aldrich, UK) was performed to estimate protein concentration. 
The Bradford method involved the production of BSA standards (diluted in target buffer) 
with concentrations ranging from 1 - 10 µg/mL. After warming the Bradford reagent to 
room temperature, 5 µL of protein standards were added in triplicate to separate wells in 
a sterile 96 well plate. 5 µL of the target buffer was then added in triplicate to separate 
wells. Finally, 5 µL of the sample was added in triplicate to separate wells. Additionally, 
1:10 and 1:50 sample:buffer versions of the sample were dispensed in triplicate in 
separate wells. 250 µL of Bradford reagent was added to each well and mixed on a shaker 
for ~30 seconds. The samples were incubated at room temperature for 5 minutes and the 
absorbance of each well read at 595 nm. The production of a standard curve of BSA 
concentration was then used to estimate the protein concentration of the desired sample. 
2.2.4.8 Semi-dry Western blotting 
 
Throughout this project, Western blotting was applied as a method for the detection of 
specific target proteins in recombinant E.coli lysate, purified protein samples and lysate 
obtained from COS7 cells. First, samples, controls and visible marker (BioRad Precision 
Plus All Blue) of interest were subjected to SDS-PAGE gel electrophoresis as described 
in 2.2.4.1. Following electrophoresis, the gel was submerged in semi-dry transfer buffer 
(2.1.5.4.4) in a clean container. The blotting paper and blotting membrane to be used were 
also placed in the same transfer buffer, in separate clean containers. However, if a PVDF 
membrane was to be used, the membrane was first placed briefly in methanol before 
submersion into transfer buffer. The gel, blotting paper and membrane were incubated in 
transfer buffer at room temperature for 10 minutes and subsequently placed on a 
horizontal semi-dry transfer block in the following order: blotting paper, membrane, gel, 
blotting paper. A sterile pipette was used to flatten the assembled blotting items, ensuring 
the removal of bubbles and excess buffer. The transfer block was then connected to a 
powerpack and the protein bands allowed to transfer from gel to membrane for 30 minutes 
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at 20 volts. Success of the transfer was evaluated by the extent of transfer of the visible 
marker from SDS-PAGE gel to membrane. Following a successful transfer, the blotting 
membrane was placed into blocking solution (2.1.5.4.5) and blocked either for 30 minutes 
at room temperature with moderate shaking or at 4oC overnight. The membrane was 
subsequently washed with 2 washes of 1 x PBS (2.1.5.4.3) prior to incubation with the 
primary antibody of choice in 0.05% blocking solution 2.1.5.4.5). The blot was left to 
incubate with primary antibody either for 2 hours at room temperature with moderate 
shaking or overnight at 4oC with mild shaking, the latter of which was preferred if the 
quality of antibody had yet to be determined. Incubation with the primary antibody was 
followed by five washes implemented under moderate shaking of five minutes each of 
the following: PBS, PBST, PBST, PBST, PBS. The secondary antibody (diluted in PBS) 
was then added  and left to incubate for 90 minutes at room temperature with moderate 
shaking. Finally, the five washes were repeated and enhanced chemiluminescence (ECL) 
solution (BioRad, UK) prepared by mixing the luminol and peroxidase components in 
equal quantities. The membrane was incubated with ECL for 5 minutes in the dark with 
moderate shaking prior to visualisation with a G:BOX Chemi XT4 chemiluminescent 
visualisation device (Syngene, UK) using GeneSys Software v 1.01 (Syngene, UK). 
2.2.4.9 Protein crystallisation 
 
Crystallisation attempts were executed according to the vapour diffusion method using 
24-multi well plates (Falcon® MutltiwellTM 24 well, Becton Dickinson, UK). The rim of 
each well was coated in vacuum grease and 500 µL of appropriate crystallisation buffer 
(Appendix 2) aliquoted into each well. Pre-silanised cover slips were polished with silk 
scarf and 1 µL protein solution at 5mg/mL or higher concentrated added with 1 µL of the 
appropriate crystallisation buffer (taken from the corresponding well) to form a 2 µL drop. 
The cover slip containing the 1:1 (v/v), and 2:1 protein:precipitant was subsequently 
inverted and sealed above the appropriate well. This method was utilised for all 
crystallisation buffers. The plates were labelled appropriately and incubated at 22oC. The 
incubated plates were monitored for crystal growth every day for 4 weeks, then 
subsequently every 3 days for week for 12 weeks. 
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2.2.5 In vitro characterisation methods 
2.2.5.1 Malachite green assessment of phosphate release 
 
The malachite green colorimetric method is typically regarded as the gold standard in 
analysing the release of phosphate by hydrolytic enzyme activity. The assay works on the 
principle of a colour change when malachite green molybdate and free orthophosphate 
complex under acidic conditions. The absorbance of the green molybdophosphoric acid 
complex at 620-640 nm is directly indicative of free organic phosphate concentration. 
Thus, a malachite green assay kit (Cayman Chemicals Ltd.) was utilised to assess 
nucleotide hydrolytic activity of enzymes, with the absorbance of phosphate standards 
provided by the manufacturer assessed in triplicate to generate a standard curve for 
phosphate concentration. This enabled the absorbance values obtained from nucleotide 
hydrolysis assays to be converted into amount of phosphate generated. All assays were 
performed according to the manufacturer’s instructions, with absorbance values read at 
635 nm on a FLUOStar Omega plate reader maintained at 25oC. 2 mM of MgCl2, CaCl2 
or both was added to each reaction as a co-factor, accordingly. Assays were performed 
with either 0.25 mM, 0.5 mM or 1 mM nucleotide substrate (ATP, GTP, UTP or CTP), 
depending on context. Assay buffer with substrate added was used as a blank control to 
assess acid hydrolysis of nucleotides in the absence of GTPase. 
2.2.5.2 PiColourLock™ assessment of phosphate generation 
 
PiColourLock™ Gold, a modified form of the standard malachite green assay kit (Innova 
Biosciences) was utilised as a secondary means of verifying the hydrolytic capacity of 
target enzymes. As with 2.2.5.1, a standard curve for phosphate concentration with this 
kit was generated based on the manufacturer’s instructions. This standard curve was used 
to assess phosphate generation by target enzymes when assays were performed according 
to standard operating procedure advertised by the manufacturer. Assays were performed 
in triplicate in 96-well plates at 25oC or 37oC. A typical reaction mixture comprised the 
following: the enzyme of choice, GTP and one of more cations (MgCl2, CaCl2 or both 
cations). After 30 or 60 minutes, the reaction was stopped by addition of the 
‘PiColourLock™ Gold Mix’. This plate was shaken gently and incubated for 5 minutes 
at room temperature prior to addition of the PiColourLock™ stabiliser compound. After 
15 minutes, the absorbance of each well was read at 635 nm on a FLUOStar Omega plate 
reader maintained at 20oC. Assay buffer containing GTP was utilised as a control. 
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Absorbance values were generated by subtracting blank absorbance from each raw value, 
and mean values used to generate bar charts. 
2.2.5.3 Phosphorylation assays to assess kinase activity on target proteins  
 
The kinases (DRAK2 constructs) and their putative protein targets (RhoH constructs) 
were bacterially expressed in C43 (DE3) or BL21 (DE3) E.coli as described previously 
(2.2.2.5 – 2.2.2.6). All kinases and targets harboured hexahistidine tags and, as such, were 
isolated from their expression hosts (2.2.4.3) and subject to IMAC purification (2.2.4.4) 
followed by gel filtration (2.2.4.5) to achieve sufficient purification and remove 
imidazole. Confirmation of the identity of each protein was performed by Western 
blotting (2.2.4.8) using antibodies specific to the target, or by single-band LC-MS 
analysis (2.2.6.2).  
To perform each phosphorylation assay, a reaction mixture for each condition was created 
in triplicate. Typically, a reaction mixture consisted of a set concentration of a specific 
kinase (10µM or 20µM) in combination with either 5 times or 10 times a specified 
putative target, with the reaction occurring in gel filtration buffer (2.1.5.3.3) 
supplemented with 2 mM MgCl2 and 1 mM ATP. ATP was the final component added to 
the reaction mixture. Samples were taken at 0 minutes, 10 minutes and 45 minutes 
following the addition of ATP and frozen immediately at -80oC in 1.5 mL sterile 
Eppendorfs. 
To analyse the success of each reaction, samples were later thawed and an appropriate 
amount of SDS-PAGE buffer (2.1.5.2.2) added. The samples were then subjected to SDS-
PAGE electrophoresis (2.2.4.1) and Western blotting performed (2.2.4.8) using the 
ab17464 Anti-phosphoSer/phosphoThr polyclonal (AbCam) in the dilutions shown in 
Table 2.4 (2.1.1.4). To ensure loading consistency for Western blotting and confirm the 
presence of RhoH and DRAK2 constructs on the blotting membrane, select blots were 
stripped and re-probed with either an anti-RhoH or anti-DRAK2 primary antibody in the 
dilutions shown in Table 2.4 (section 2.1.1.4). Additionally, all SDS-PAGE gels used in 
Western blotting were dyed in Coomassie blue (section 2.2.4.2) post-transfer to further 
assess Western blotting loading efficiency. 
2.2.5.4 Dynamic light scattering (DLS) for determination of oligomeric state 
 
Dynamic light scattering (DLS) is a technique for measuring particle size within the sub-
micron region and has been previously established as a method of determining oligomeric 
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state. DLS measurements are based on Brownian motion (pedesis), the random motion of 
particles in solution as a result of collisions with the surrounding medium. 
DLS experiments were performed using a Zetasizer Nano S dynamic light scattering 
instrument (Malvern, UK) at the Institute for Cell and Molecular Bio Sciences (ICamB), 
Newcastle University. A solution of 0.5 mg/mL protein suspended in an appropriate 
buffer (50 mM HEPEs pH 7.4, 500 mM NaCl, 5mM DTT, 2% glycerol) was centrifuged 
at 4°C, 16900 x g for 5 minutes. 60 µL was then added to a 45 µL quartz glass cuvette 
(Hellma; 10.5.251-QS), which had been extensively cleaned with 2% (v/v) Hellmanex, 
deionised water and 100% Ethanol and air-dried before use. Four replicate runs were 
performed for each sample in addition to a blank run with buffer alone. Samples were 
subjected to a 633 nm laser and light scattering detected at 173o by an avalanche 
photodiode. Size measurements and analysis were performed using Zetasizer software 
version 4 (Malvern, UK) and results plotted using Excel (Microsoft) and SigmaPlot 
(Systat).  
 
2.2.5.5 Analysis of protein stability by circular dichroism (CD) thermal 
denaturation 
 
Circular dichroism (CD) thermal deanturation experiments were performed using a J-810 
spectropolarimeter (Jasco). 400 µL of 0.5 mg/mL protein in a solution containing 50 mM 
HEPES pH 7.4, 500 mM NaCl, 5mM DTT and 2% glycerol was added to a 0.1 cm quartz 
glass cuvette (Hellma; 110-1-40 QS) that had been extensively cleaned with 2% (v/v) 
Hellmanex, deionised water and 100% Ethanol and air dried before use. The temperature 
was increased from 20°C to 95°C at a rate of 2°C/min using a Peltier temperature control 
device. CD absorbance was measured at a wavelength of 220 nm every 0.2°C. A 
sensitivity of 100 mdeg was used, with a slit width of 2 nm. Tm values were determined 
by examining the peak minima of the first order derivative plot of each melting curve. 
For presentation, units were converted to fraction folded using the absorption values at 
25°C and 95°C to represent fully folded and fully unfolded protein respectively. Due to 
limitations on the amount of sample, each sample was only measured once.
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2.2.6 Mammalian cell culture methods 
2.2.6.1 General conduct 
 
All mammalian cell culture techniques were performed aseptically under laminar flow in 
a class II biological safety cabinet. 70% ethanol was utilised to sterilise the cabinet prior 
to use. Additionally, all items placed into the safety cabinet were sterilised with 70% 
ethanol before use. Enhanced cleanliness was observed in the laboratory under which 
mammalian culture methods were implemented, with lab coats and other items from 
microbiological laboratories prohibited.  
2.2.6.2 Culture of mammalian cells 
 
Several adherent cell lines were sampled for protocol optimisation and initial mammalian 
cell experiment set-up, namely: COS7, MCF-7, hVSMC, PC3 and HEK-293 (see 
Appendix 5 for further information). Cells were maintained at 37oC/5% CO2 in complete 
DMEM media as described previously (2.1.4.3). hVSMCs required additionally 
components for growth (Appendix 6). Mammalian cells were permitted to grow until 70-
90% confluent prior to passaging (2.2.5.2).  
2.2.6.2 Mammalian cell passage 
 
Adherent mammalian cells were subject to passage when 70-90% confluent. Passage 
involved the removal of media from confluent cells under sterile conditions, followed by 
the washing of the cell monolayer twice with phosphate buffered saline (PBS). PBS was 
removed and 0.25% trypsin-EDTA added at a volume able to cover the monolayer. The 
cells were allowed to incubate with trypsin-EDTA at 37oC for 5 minutes until cellular 
adherence to the culture vessel was visibly disrupted under a microscope. To stop the 
trypsinisation reaction, complete media was added at an excess volume to the trypsin-
EDTA present. The resulting solution containing the target mammalian cells was spun at 
1200 x g for 5 minutes, producing a pellet comprised of the target mammalian cells. 
Supernatant was removed from this pellet, and the pellet re-suspended in 1 mL complete 
media. A fraction of this re-suspended pellet, typically 200 µL, was transferred to a new 
culture flask containing the fresh complete media of choice. Complete media for the target 
mammalian cells and 0.25% trypsin-EDTA were warmed to 37oC in a water bath prior to 
use.  
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2.2.6.3 Counting cells 
 
Cell counting was performed using a glass haemocytometer, plastic coverslip and trypan 
blue to assess cell viability. Prior to use, the haemocytometer and coverslip were sterilised 
with 70% ethanol. The coverslip to be used was moistened and affixed to the 
haemocytometer, with Newton’s refraction rings observed to indicate correct adhesion of 
the coverslip. The haemocytometer was placed under laminar flow and the cell suspension 
to be assessed swirled gently and 100 µL transferred into a sterile 1.5 mL Eppendorf. 400 
µL 0.4% trypan blue solution was added to the 100 µL cell suspension and mixed gently. 
100 µL of the resulting solution of trypan blue and cells was applied to the 
haemocytometer and unstained (live) cells counted with a hand tally counter under 10x 
objective under a microscope, with four 16 corner squares of cells assessed in this manner. 
The average cell count was multiplied by 104 and further multiplied by five to correct for 
the trypan blue dilution. The final value obtained represented the number of viable cells 
per mL of original cell suspension.     
2.2.6.4 Plasmid DNA transfection of mammalian cells 
 
LipofectamineTM 2000 reagent was utilised for the transfection of exogenous plasmid 
DNA (pDNA) into mammalian cells, according to method optimisation based initially on 
the manufacturer’s instructions. 250,000 cells were plated into each well of a 6-well plate 
using the appropriate complete media and allowed to grow at 37oC/5% CO2 until 65-70% 
confluent (approximately 20 hours for COS7 cells). When sufficiently confluent, this 
complete media was removed from each well and the mammalian cell monolayer washed 
twice with PBS. 2mL of the usual basal media for the target cells was added to each well; 
this media contained 10% FBS and 2 mM L-glutamine albeit was devoid of antibiotics. 
For each well, 1000 ng of the pDNA of choice was diluted in a separate, sterile Eppendorf 
containing 125 µL Opti-MEM® media. For each well, 6.25 µL LipofectamineTM 2000 
reagent was also diluted in 125 µL Opti-MEM® media in a separate sterile Eppendorf. 
The diluted pDNA for each well was then added to the corresponding diluted 
LipofectamineTM 2000 reagent and incubated for 25 minutes. The pDNA-lipid complexes 
were then added to each well accordingly. Typically, cells were allowed to incubate for 
24–48 hours prior to lysis and extraction of proteins for downstream analysis. 
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2.2.6.5 Reverse siRNA transfection of mammalian cells 
 
The reverse transfection technique for siRNA was utilised to transfect MCF-7 and PC3 
cells in 24-well plates, allowing for completion of sets of siRNA-mediated knockdown 
in a shorter timeframe. Within each well, 3 pmol desired siRNA was diluted in 100 µL 
Opti-MEM® media and mixed gently. 1 µL of Lipofectamine™ RNAiMAX was 
subsequently added to each well containing diluted siRNA and allowed to incubate for 
20 minutes at room temperature. During this 20 minute incubation, cells were trypsinised 
and pelleted as previously described (2.2.6.2). The pelleted cells were re-suspended in the 
typical complete media for these cells, though without antibiotics present. The cells were 
re-suspended so that 100, 000 cells were present per mL, and 500 µL of this re-suspended 
solution added to each well (50, 000 cells per well). The plate was then rocked gently 
back and forth and incubated at 37oC/5% CO2 for 36 hours prior to downstream 
processing as described in 2.2.5.6. 
2.2.6.6 Lysis of mammalian cells for downstream processing 
 
Following transfection of pDNA or reverse transfection of siRNA, target cells were lysed 
and subject to protein extraction. This first involved removal of growth media and 
washing the cell monolayer twice with 5-10 mL ice-cold PBS. The cells were then 
trypsinised and pelleted in 1.5 mL Eppendorfs using the method described in 2.2.6.2. The 
resulting cell pellets were re-suspended on ice in 30 µL of radioimmunoprecipitation 
assay buffer (RIPA buffer) supplemented with the P8340 protease inhibitor cocktail 
(Sigma Aldrich, UK), allowing for cell lysis to occur. Incubation was permitted for 30 
minutes with occasional mixing by tapping. Each Eppendorf was then spun at 15,000 x g 
for 18 minutes (4oC) and the subsequent supernatant retained on ice in a fresh sterile 
Eppendorf. The protein concentration of each resulting supernatant was determined using 
the Bradford method (2.2.4.7), and 20 µg of each sample loaded onto a separate well of 
an SDS-PAGE gel for subsequent downstream SDS-PAGE electrophoresis (2.2.4.1). This 
was then utilised for assessing knockdown or overexpression efficiency using Western 
blotting (2.2.4.8) or proteomic studies through geLC/MS (2.2.7.2).  
2.2.6.7 Assessment of mammalian cell migration 
Migration experiments were performed using an xCELLigence RTCA DP instrument 
(Roche Diagnostics GmbH, Germany) placed in a humidified incubator maintained at 
37°C and 5% CO2. For each experiment, a CIM-Plate 16 (ACEA Biosciences Inc., China) 
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was used, comprised of an upper and lower chamber separated by a microporous 
membrane containing randomly distributed pores of median 8 µm diameter. Cells were 
maintained in low serum (0.1% FBS) medium for 24 hours prior to each migration 
experiment.  190 µL complete RPMI media (containing 10% FBS) were added to the 
lower chambers and 50 µL serum-free media added to each upper chamber. The CIM-
Plate 16 was placed in the RTCA DP device at 37°C and 5% CO2 and allowed to 
equilibrate for 15 minutes. During this time, a baseline measurement was performed to 
establish background signal produced by serum-free media. Cells to be used (control cells 
or cells subjected to siRNA knockdown by reverse transfection as described 
previously)were trypsinised, pelleted and resuspended in serum-free RPMI media, the 
cells were subsequently counted and 2x104 cells from each necessary sample seeded in 
the upper chamber. Each condition was performed in duplicate or triplicate, depending 
on the experiment and signal was detected on a schedule of every 15 minutes for 24 hours. 
All data were recorded by RTCA software (v 1.2.1.1002) and raw data exported to MS 
Excel for analysis, with each set of replicates assessed and any unsatisfactory replicates 
excluded from analysis. Mean values were derived from each set of replicates and graphs 
produced showing cell index versus time in hours, where cell index may be defined as 
impedence versus baseline reading.  Subsequently, the area under the curve of each mean 
value set was used to produce overall comparisons between control and knockdown 
samples. 
2.2.6.8 Preparation of cells for fluorescent microscopy 
 
Cells were grown on glass coverslips in 6-well plates using complete media until 70-90% 
confluent. Subsequently, the media was removed and the cells washed with PBS. A stock 
(1 mM) solution of Mitotracker Red FM (Life Technologies, UK) in DMSO was diluted 
to a final concentration of 250 nM in fresh complete RPMI media warmed to 37oC. This 
solution was added to the cells and allowed to incubate at 37oC/5% CO2 for 30 minutes. 
The MitoTracker Red FM dye is a cationic fluorophore readily sequestered into the matrix 
space of polarised mitochondria. Unlike other cationic fluorophores such as rhodamine 
123 and tetramethylrhodamine methylester (TMRM), Mitotracker Red FM contains a 
reactive chloromethyl group capable of forming covalent bonds with thiol groups of 
mitochondrial membrane proteins; this enables the Mitotracker to be retained within 
mitochondria even upon loss of mitochondrial membrane potential (259). 
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The coverslips bearing the cells were washed twice in ice-cold PBS and the cells fixed in 
methanol for 10 minutes at -20oC. Following fixation, the cells were washed three times 
in ice-cold PBS. A drop of VECTASHIELD® mounting medium with DAPI (Vector 
Laboratories, UK) was added to the cells. The coverslip inverted and placed onto a 
Polysine® adhesion slide (VWR, UK) so that the cells and mounting medium were 
directly touching the slide. Processed samples were assessed under a Leica DM 5000 
fluorescent microscope (Leica Microsystems, UK) at magnifications varying from 20x to 
100x using differential interference contrast (DIC) and fluorescent filters to assess DAPI 
and Mitotracker-associated fluorescence. Areas non-uniformly stained or otherwise 
anomalous were disregarded and excluded from further analysis. Images were captured 
at 20x, 40x, 63x and 100x using a Leica DFC 310 FX digital camera attached to the 
fluorescent microscope (Leica, Milton Keynes, UK). 
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2.2.7 Omics methods 
2.2.7.1 General practice for omics sample collection and processing 
 
A common issue in the processing of samples for proteomics is contamination by human 
keratin from those undertaking the processing and handling of samples. To prevent 
contamination and any unintentional impact on results, gloves were worn at all times 
(including preparation of tubes and tips for autoclave sterilisation) and samples processed 
under laminar flow as much as possible. Long hair was kept beneath a hair net and 70% 
ethanol utilised to sterilise all surfaces and equipment prior to use. Additionally, sample 
preparation was undertaken as efficiently as possible, with all samples and reagents kept 
on ice in the presence of the aforementioned P8340 protease inhibitor cocktail. When 
running SDS-PAGE gels for later band or fragment excision, empty lanes were run 
between samples to minimise sample cross-contamination. 
2.2.7.2 Proteomics processing of single SDS-PAGE bands of interest 
 
When analytical SDS-PAGE electrophoresis indicated the presence of an interesting 
protein, the band representing this protein was excised from the gel using a sterile scalpel 
under laminar flow. The excised gel segment was further cut into small pieces and added 
to a sterile 1.5 mL Eppendorf. Subsequent pulse centrifugation ensured the gel fragments 
were located at the bottom of the tube. Removal of Coomassie blue (an inhibitor of later 
trypsin digestion) was performed via 3-5 washes of 100 µL of 100mM ammonium 
bicarbonate/acetonitrile (1:1, vol/vol) with shaking. This solution was removed and 
reduction performed in 200 µL 10 mM DTT (made in 50 mM ammonium bicarbonate) at 
56oC for 60 minutes in a closed water bath. The gel fragments were allowed to cool, 
reduction solution removed and alkylation performed in the dark for 30 minutes using 
200 µL 54 mM iodoacetamide (prepared in 50 mM ammonium bicarbonate). 50 µL 100% 
acetonitrile was added to the gel fragments and allowed to incubate at room temperature 
until the gel pieces became white and shrunken. The acetonitrile was removed and the 
samples subjected to drying in a centrifugal evaporator (speedvac) for 15 minutes to 
encourage dissipation of latent acetonitrile. The gel fragments were then pre-incubated 
on ice for 60 minutes with 5 µg Typsin Gold (Promega) solution prepared in 50mM acetic 
acid.  20 µL ammonium bicarbonate was then added to each tube to cover gel pieces and 
maintain moisture during trypsin digestion. The trypsin digestion itself was performed 
overnight at 37oC in a water bath with occasional gentle shaking. After at least 12 hours, 
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the digestion was arrested by addition of 100 μl 1:2 (vol/vol) 5% formic acid/acetonitrile 
to each tube. The tubes were then incubated with shaking for 30 min at room temperature 
and the supernatant retained due to the presence of extracted peptides. The addition of 30 
μl of 0.1% (vol/vol) trifluoroacetic acid to each sample followed by 5 minutes incubation 
ensured further peptide extraction, the supernatant retained once again due to the presence 
of peptides within it. The resulting pooled liquid was subjected to freeze-drying overnight 
in a Christ Alpha 1-2 LD Freeze Dryer, and the resulting lyophilised samples each re-
suspended in 30 µL of LC-MS Buffer A (5% acetonitrile and 0.1% formic acid in LCMS-
grade water). 6 µL of sample was loaded into a vial and 3 µL injected for LC-MS. 
2.2.7.3 Proteomics processing for complex protein mixtures 
 
Complex protein mixtures were subject to Bradford’s assay to determine protein 
concentration (2.2.4.7). 20 µg of each sample was then loaded onto a separate lane of a 
12% SDS-PAGE gel (2.2.4.1). SDS-PAGE electrophoresis was performed at 200V, albeit 
for only 20-30 minutes, until the samples had run approximately half way down the gel. 
The gel was stained in Coomassie blue and destained as previously described (2.2.4.2). 
Once sufficiently destained, the gel was then placed on a sterile surface in a laminar flow 
hood and each lane slice horizontally into 8 separate fractions. Each separate fraction was 
sliced into smaller segments and placed into a tube onto which the sample details and 
fraction number were recorded (1 denoting highest molecular weight, 8 denoting lowest 
molecular weight). Each fraction was then subjected to the same process described in 
2.2.7.2. 
2.2.7.4 Liquid chromatography mass spectrometry 
 
Separation of peptides was performed by an Ultimate 3000 nano LC-MS/MS system 
(Dionex LC packings, Amsterdam, The Netherlands) in combination with an Ultimate 
3000 RS autosampler. The autosampler was held at 4oC and utilised to inject 3 µL of 
sample onto the column. Separation of peptides was accomplished with an EasySpray 
column (PepMap C18, 2 µm 100 A, 75 µm x 50 cm) maintained at 45oC. The eluent 
profile utilised for each sample is detailed in Table 2.22. 
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Table 2.22. LC-MS/MS eluent programme 
Time (min) Buffer A Buffer B Flow Rate (µL/min) 
0.0 95% 5% 0.2 
0.1 95% 5% 0.2 
120.0 60% 40% 0.2 
120.1 10% 90% 0.2 
128.0 10% 90% 0.2 
128.1 95% 5% 0.2 
140.0 95% 5% 0.2 
 
Analysis was undertaken with a Q ExactiveTM hybrid quadrupole-orbitrapTM mass 
spectrometer (Thermo Fisher Scientific Inc.) equipped with a nanoelectrospray ionization 
source operated at 2.3 kV. The ion transfer tube was held at 280oC throughout analysis 
and positive ion mode selected for ion production. Data were obtained using a data 
dependent Top 10 methodology, with scans acquired in the Orbitrap mass analyser over 
a range of 150-1500 m/z, mass resolution set to 70,000 and target value set to 1.00E+06. 
The ten most intense peaks with a charge state of ≥2 were subsequently fragmented in the 
HCD collision cell and tandem mass spectra obtained in the Orbitrap with mass resolution 
set to 17,500 and target value set to was 1.00E+05. Maximum ion accumulation times 
were 100 ms for the full MS scan and 50 ms for the tandem mass spectra. The mass 
spectrometery system was linked to a high performance personal computer harbouring 
corresponding Exactive Tune software (Thermo Fisher Scientific Inc.). This software 
enabled real-time assessment of each LC/MS run as it occurred. Samples were analysed 
in random order to minimise bias, and data automatically saved in the Thermo 
Fisher .RAW data format. Prior to any use of LC/MS for peptide analysis, all necessary 
components of the Q Exactive system were washed and equilibrating using the NUOmics 
standard operating procedure. 
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2.2.7.5 Analysis of data using Progenesis software 
 
Thermo Fisher .RAW data files were retained and loaded onto Progenesis 64 (Nonlinera 
Dynamics) software for analysis, with any unsatisfactory runs removed from analysis. 
Areas during the wash and prior to the time taken for the sample to reach the electrospray 
port were excluded. Alignment was performed using the automatically assigned 
alignment tool and further validated using a manually assigned reference. Upon alignment 
review, manual vectors were implemented where necessary to improve alignment. 
Peptides were reviewed and those with a charge state <2 or >8 were excluded from 
subsequent analysis. The 'between group' comparison was selected for experimental 
design. Peak picking was executed and reviewed. The identification of peptides and 
generation of suggested identities was then accomplished by exporting MS/MS MGF files 
to Mascot or X!Tandem. Parameters utilised for X!Tandem and Mascot searches are 
provided in Appendix 7 And 8, respectively. Subsequently, Mascot-derived files were 
imported back into Progenesis where conflicts were resolved and identities refined. 
Confidence in the identification of a given protein was based on the number of peptides 
matched to any one protein. PCA plots were generated from the data and a report 
comparing sample groups versus control groups generated by the Progenesis software. 
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Chapter 3: Cloning, expression and purification of the human Miro 
GTPases 
3.1 Introduction 
Although preliminary gene functions for the hMiros were described more than a decade 
ago , the biochemical and signalling characteristics of these enzymes remains obscure. 
Only limited three dimensional structures of truncated versions of Miros have been 
demonstrated (131), while biochemical characterisation has been limited to the 
confirmation of EF-hand calcium-binding ability using dot blot overlay assays (164). The 
hydrolytic activity of the N-terminal and C-terminal GTPase domains has not been 
reported, with the C-terminal GTPase domain frequently under-studied relative to the N-
terminal GTPase domain. In light of this, the primary objective of the work undertaken 
in this chapter was to obtain yields of pure hMiro1 and hMiro2 appropriate for structural 
studies (elucidation of protein three dimensional structure through crystallisation) and in 
vitro biochemical characterisation.  
The results demonstrate the successful sub-cloning of full-length wildtype hMiro1 and 
hMiro2 into the bacterial expression vector pET-28a. Additionally, the successful cloning 
of truncated versions of hMiro1 and 2 into an engineered version of pET15b is shown, 
using PCR-based amplification of target sequences. The successful purification of both 
full-length wildtype and truncated versions of hMiro1 and hMiro2 for functional and 
structural characterisation is shown, in addition to subsequent identification of target 
proteins by Western blotting and mass spectrometry. 
3.2 Cloning, expression and purification of full-length wildtype hMiro1 
and hMiro2 
First, the cloning, expression and purification of full-length wildtype hMiro1 and hMiro2 
was attempted. PRK5-Myc mammalian expression vectors encoding full-length wildtype 
versions of hMiro1 and 2 were kindly donated by the Pontus Aspenström Group at the 
Karolinska Institutet, Sweden (29). These vectors were used to sub-clone hMiro1 and 
hMiro2 separately into the bacterial expression vector pET-28a. The pET-28a vector 
allows for the expression of recombinant proteins containing an N-terminal hexahistidine 
tag (His-tag). In each instance, undigested pET-28a was subjected to an overnight 
restriction digest with NdeI/XhoI restriction enzymes (section 2.2.3.6), followed by gel 
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purification (2.2.3.9). The pRK5-Myc vectors encoding hMiro1 and hMiro2 were 
subjected to NdeI/XhoI restriction digest in parallel, with the genes encoding hMiro1 or 
hMiro2 isolated and purified using an identical gel purification procedure. Gel purified 
products were subjected to a standard ligation procedure at room temperature (section 
2.2.3.10). Products of ligation were transformed into chemically competent TOP10 
E.coli, yielding transformants on kanamycin plates. Plasmid DNA (pDNA) from up to 
five transformants was subsequently assessed for the presence of a correctly-sized insert 
by means of an analytical restriction digests (Figures 3.1 and 3.2; section 2.2.3.6). Plasmid 
DNA from one clone each of hMiro1 and hMiro2 in pET-28a was confirmed by 
sequencing using the T7 promoter and T7 terminator sequencing primers, with no 
mutations detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Analytical restriction digest results showing full-length hMiro1 sequence 
liberated from pET-28a. 1% agarose gel showing the presence of the Miro1 encoding 
sequence (indicated by arrow) in a vector isolated from TOP10 E.coli transformants. 
Undigested (U) vector versus NdeI/XhoI restriction digested (D) pDNA from five 
transformed TOP10 colonies is shown (lanes 2-11). Bioline Hyperladder I marker is 
indicated as ‘marker’ in lane 1. 
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Figure 3.2. Analytical restriction digest results displaying full-length hMiro2 
sequence separated from pET-28a.  1% agarose gel showing Miro2 encoding sequences 
in pDNA isolated from TOP10 E.coli transformants. Undigested (U) pDNA versus 
NdeI/XhoI restriction digested (D) pDNA isolated from five transformed colonies (lanes 
2-11). Lane 1 displays marker (Hyperladder I, BioLine). 
 
BL21 (DE3), C41 (DE3) and C43 (DE3) chemically competent E.coli cells were 
transformed with the pDNA for each successful hMiro clone. The recombinant E.coli 
strains were grown and subjected to auto-induction (Table 3.1) based on the Terrific Broth 
formulation from ForMedium, United Kingdom. This broth contains both glucose and 
lactose, with the amount of glucose formulated to become depleted at a high cell density, 
leaving only lactose available for bacterial energy metabolism and therefore resulting in 
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induction of target protein expression when a specific cell density is reached. Auto-
induction trials suggested an optimum induction temperature of 18oC using C43 (DE3) 
cells. Further experiments were conducted by inducing over-expression at this 
temperature using either 0.1mM, 0.5mM or 1mM IPTG after the recombinant E.coli 
reached mid-exponential growth phase (2.2.2.6). These IPTG-mediated induction 
experiments indicated that the optimum expression conditions for both hMiro1 and 
hMiro2 was 18oC overnight in C43 (DE3) cells using a final concentration of 1mM IPTG 
(Table 3.2). For all expression experiments, cells were harvested and sonicated as 
previously described (2.2.4.3). Cell debris was removed by centrifugation and both 
human Miros were purified initially by immobilised metal affinity chromatography 
(IMAC) (Figure 3.3 a and b; method described in 2.2.4.4). However, both recombinant 
proteins appeared to elute from the IMAC column at the same imidazole concentration as 
a number of contaminants. Thus, further purification via gel purification was attempted, 
producing pure versions of hMiro1 and hMiro2. 
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Table 3.1. Expression optimisation of hMiros using auto-induction trials and the 
C43 expression host. Expression of hMiro1 and hMiro2 using auto-induction LB broth, 
where - indicates no visible expression, + indicates some visible expression, ++ indicates 
notable expression and +++ indicates maximum over-expression.  
 
 
 
 
 
 
 
 
 
 
Miro1 over-expression 
 
Miro2 over-expression 
 37oC 25oC 18oC 37oC 25oC 18oC 
T
im
e 
(h
o
u
rs
) 
6 - - - - - - 
12 - - - - - - 
18 + - - ++ + - 
24 + + ++ ++ ++ + 
32 + ++ +++ ++ ++ ++ 
36 + ++ ++ ++ ++ +++ 
40 + ++ ++ + ++ ++ 
44 + ++ + + ++ ++ 
48 + + + + ++ + 
52 - + + + + + 
56 - + + - + + 
60 - - - - - - 
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Table 3.2. hMiro bacterial expression optimisation using IPTG induction and the 
C43 expression host. Expression of hMiro1 and hMiro2 using IPTG induction (0.1mM, 
0.5mM or 1mM) in LB broth, where - indicates no visible expression, + indicates some 
visible expression, ++ indicates notable expression and +++ indicates maximum over-
expression. 
 
Miro1 over-expression  
(18oC overnight) 
 
Miro2 over-expression 
(18oC overnight) 
0.1mM 
IPTG 
0.5 mM 
IPTG 
1mM 
IPTG 
0.1mM 
IPTG 
0.5 mM 
IPTG 
1mM 
IPTG 
++ ++ +++ + + +++ 
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Figure 3.3. Coomassie-stained 12% SDS-PAGE gel showing IMAC purification of 
over-expressed (a) hMiro1 and (b) hMiro. N-terminally His-tagged, full-length hMiro1 
was purified from BL21 (DE3) E.coli cells by IMAC. For both gels (a) and (b), BioRad 
Precision Plus marker is shown in lane 1. Lanes 2 and 3 respectively show uninduced and 
induced samples in both (a) and (b).   
The presence of hMiro1 and hMiro2 in purified samples was confirmed by Western 
blotting (Figure 3.4 a and b; Figure 3.5 b and c). Gel filtration was subsequently used to 
further purify hMiro1 and hMiro2 in Western-confirmed samples (see 2.2.4.5), where a 
sephacryl™ S-200 HR HiPrep™ 16/60 column attached to an ÄKTA PRIME FPLC 
system was used with appropriate gel filtration buffer (50 mM HEPES 7.4, 500 mM NaCl, 
5 mM DTT, 2% glycerol) to successfully isolate both hMiro GTPases from contaminants 
(Figure 3.5 a). Pure fractions of the full-length recombinant proteins were subsequently 
concentrated to 1–1.5 mg/mL (2.2.4.6), with Bradford’s assay utilised to determine 
protein concentration (section 2.2.4.7). Concentrated samples were intended for use in 
structural studies and in vitro characterisation. However, attempted concentration of the 
full-length hMiro proteins proved problematic, predominantly due to the propensity for 
these expressed, purified proteins to aggregate in all buffers tested. Furthermore, the 
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purity and yield were unreproducible in subsequent preps. Consequently, an alternative 
approach to studying structure and in vitro biochemical properties was adopted: the 
cloning, expression and purification of separate hMiro domains of interest, as discussed 
in section 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Anti-hMiro1 (a) and Anti-hMiro2 (b) Western blots. Western blot of 
IMAC-purified hMiro1 (a) and hMiro2 (b) samples, where ‘125mM’ and ‘175mM’ 
correspond to the concentration of imidazole at which samples eluted from the column, 
and ‘18oC’ and ‘25oC’ refer to the temperatures used during IPTG-induced over-
expression.  
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Figure 3.5. Size analysis of over-expressed full-length hMiro1 and hMiro2 samples 
based on SDS-PAGE and Western blotting. (a) Successfully ion-exchange purified 
samples run on a 12% SDS-PAGE gel. (b) Anti-hMiro1 immunoblot. (c) anti-hMiro2 
immunoblot. Concentrated samples were approximately 1–1.5 mg/mL. 
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3.3 Cloning, expression and purification of hMiro1 and hMiro2 domains 
of interest 
Due to the issues associated with expression and purification of full-length hMiro1 and 
hMiro2, an alternative approach to studying the structure and function of hMiro1 and 2 
was adopted: the division of each protein into domains of interest for individual study. As 
previously discussed, the putative C-terminal ‘GTPase’ domains of both hMiro1 and 
hMiro2 are highly novel, being only distantly related to the Ras superfamily and largely 
uncharacterised . With this novelty in mind, the elucidation of the structure and function 
of these hitherto uncharacterised C-terminal ‘GTPase’ domains was sought (hMiro1 and 
hMiro2 CT), beginning with PCR-based amplification of the nucleotide sequences 
encoding these regions (2.2.3.3, Appendix 3). The N-terminal domains of both hMiro1 
and hMiro2 (hMiro1 and hMiro2 NT), displaying approximately 30% amino acid identity 
with RhoA , were also separately cloned and expressed, allowing for comparative analysis 
to their C-terminal GTPase counterparts. While the N-terminal GTPase domain of the 
hMiros is considered less novel in the literature, cloning the ordered GTPase region of 
the hMiro N terminus was hoped to provide a more complete understanding of the hMiros 
when characterised. While cloning of these separate domains was in process, a truncated 
version of the Drosophila Miro (dMiro) was successfully crystallised by Klosowiak and 
colleagues. The portion of dMiro crystallised comprised the EF-domains and C-terminal 
GTPase domain. As shown in Table 3.3, each hMiro shares around ~50% amino acid 
identity with dMiro. Considering this, an attempt to mimic the successful crystallisation 
of the dMiro construct was attempted: constructs of hMiro1 and hMiro2 were engineered 
with similar domain cut-off points to the successfully crystallised dMiro construct (see 
schematic illustration, Figure 3.6), based on an amino acid sequence alignment of dMiro 
compared with hMiro1 and hMiro2 (Figure 3.7); the resulting engineered constructs were 
named the ‘xtal’ constructs. The cloning, expression and purification of the GTPase 
domains and crystal constructs of hMiro1 and hMiro2 is discussed separately in the 
following sections of this chapter. The cut-off values selected for each hMiro1 and 
hMiro2 construct are provided in Table 3.4 (following page). 
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Table 3.3. Percentage identity matrix illustrating amino acid identity between the 
hMiros and dMiro.  
 
 
 
 
 
Figure 3.6. Schematic illustration of Miro domain architecture, displaying the 
GTPase domains in addition to the cut-off areas for the ‘xtal’ constructs. 
 
Table 3.4. Details of each designed construct.  
 
 
 
 
 
 
 
 hMiro1 hMiro2 dMiro 
hMiro1 100% 60.3% 52.3% 
hMiro2 60.3% 100% 49.6% 
dMiro 52.3% 49.6% 100% 
 NT construct CT construct Xtal construct 
hMiro1 K3–P169 Q415–P580 E177–R590  
hMiro2 R3–P169 Q413–F589 E177–P586 
 N-terminal 
GTPase domain 
C-terminal 
GTPase domain 
EF-hands EF-hands N C 
‘xtal’ construct 
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Figure 3.7 Comparison of amino acid sequences: dMiro, hMiro1 and hMiro2. 
Annotated CLUSTAL OMEGA alignment of the amino acid composition of dMiro, hMiro1 and 
hMiro2, with identifiers provided to the right. Asterisks (*) specify positions in which 
single, fully conserved residues are present, while colons (:) denote the conservation of 
residues with strongly similar properties. Periods (.) specify conservation of residues with 
weakly similar properties. Colour coding is used to represent the properties of each 
residue (red, small and hydrophobic residues; blue, acidic residues; magenta, basic 
residues; green, residues bearing hydroxyl, sulphydryl or amine groups; grey, unusual 
amino acid residues). G loops are shaded in grey and EF-hand domains shaded green. The 
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switch boxes are delineated in black-outlined boxes. The beginning and end of each 
GTPase domain is indicated. 
3.3.1 Cloning, expression and purification of the hMiro1 and hMiro2 C-terminal 
GTPase domains 
3.3.1.1 Cloning of the hMiro1 and hMiro2 C-terminal GTPase domains 
 
The previously described pRK5-Myc vectors encoding full-length hMiro1 and 2 were 
utilised as DNA templates in separate PCR reactions, using primers designed to amplify 
the nucleotide sequences encoding the C-terminal GTPase domains of hMiro1 and 
hMiro2, respectively (section 2.1.3). Primers were designed so that appropriate, 
compatible restriction enzyme sites were incorporated at the ends of each hybridisation 
sequence (NdeI/XhoI in all cases). These sequences were successfully amplified via PCR 
using as described in 2.2.3.3 and shown in figure 3.8. 
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Figure 3.8. 1% agarose gel showing hMiro C-terminal GTPase domain PCR 
products. PCR-based amplification of the gene sequences encoding hMiro 1 415-580 
(lanes 1-5) and hMiro2 413-589 (lanes 7-11), respectively. Lanes 6 and 12 contain marker 
(Bioline Hyperladder I).  Lanes 13 and 14 correspond to negative controls containing all 
components of the optimised reaction except the DNA template. 
Successfully amplified nucleotide sequences were subjected to PCR clean-up as 
previously described (section 2.2.3.4). Subsequently, a typical overnight restriction digest 
procedure was performed on purified PCR products, using restriction enzymes 
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(NdeI/XhoI) targeting the sites incorporated into the initial primers (section 2.2.3.6). 
Digested nucleotide sequences were gel-purified (2.2.3.9) and ligated into pET15b-TEV 
(method described in 2.3.10) to generate a set of plasmids separately encoding the 
truncated mutants of interest. The products of ligation were transformed into chemically 
competent TOP10 E.coli cells and pDNA isolated from transformants. Each isolated 
aliquot of pDNA was screened in an analytical restriction digest (NdeI/XhoI) to check for 
correctly-sized inserts (Figure 3.9; 2.2.3.6).  pDNA was then sent for sequencing using 
the standard sequencing primers T7 promoter and T7 terminator, with no unwanted 
mutations identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. 1% agarose gel showing target hMiro1 and hMiro2 N-terminal GTPase 
sequences following restriction digest of constructed plasmids. Analytical restriction 
digest of pDNA extracted from TOP10 E.coli transformants after ligation of pET15b-
TEV/hMiro1 415-580 PCR products (lanes 2-7) and pET15b-TEV/hMiro2 413-589 
products (lanes 8-13), respectively. Lane 1 contains Hyperladder I (BioLine). For each 
lane in which plasmid is shown, ‘U’ represents undigested plasmid and ‘D’ represents 
plasmid that has undergone a double restriction digest with the specify the restriction 
enzymes.  
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3.3.1.2. Expression trials: hMiro1 and hMiro2 C-terminal GTPase domains  
 
The pDNA for each clone was transformed into separate aliquots of chemically competent 
C43 or BL21 E.coli cells. Recombinant E.coli strains were grown until mid-exponential 
phase (section 2.2.2.6), followed by IPTG induction at a final concentration of 0.1mM, 
0.5 mM or 1 mM and incubation either at 37oC for 4 hours, 25oC overnight or 18oC 
overnight. Appropriate final IPTG concentrations and induction temperatures were 
determined by initial small-scale expression trials (figures 3.11-3.14). 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.10. 12% SDS PAGE gel showing expression trial data for the C-terminal 
GTPase domain of Miro1 (Coomassie stained).  
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Figure 3.11. Further expression trial results for the C-terminal GTPase domain of 
Miro1 and Miro2. 12% Coomassie-stained SDS-PAGE gel showing expression trial data 
for the C-terminal GTPase domain of Miro1 and Miro2. 
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Figure 3.12. 12% Coomassie-stained SDS-PAGE gel showing expression trial results 
for the C-terminal GTPase domain of Miro2. 
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Figure 3.13. Further expression trial data for the C-terminal GTPase domain of 
Miro2. 12% Coomassie-stained SDS-PAGE gel utilised. Uninduced and induced culture 
lysate was compated to partially IMAC-purified lysate (eluate).  
 
From these initial expression trials, over-expression of the C-terminal ‘GTPase’ domain 
of hMiro1 was strongly indicated at several conditions. Over-expression of the hMiro2 
‘GTPase’ domain was not immediately indicated by expression trials, though bands 
consistently appeared at around 37 kDa, suggesting possible dimerisation. As shown in 
figures 3.13–3.14 and indicated in table 3.5 (below), over-expression of the C-terminal 
‘GTPase’ domain of hMiro1 appeared optimal at 18oC, using 0.1 mM–0.5 mM IPTG. 
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Table 3.5. Expression optimisation of hMiros C-terminal GTPase domains using 
IPTG induction. Expression of hMiro1 and hMiro2 using IPTG induction (0.1mM or 
1mM) in 50 mL LB broth, where - indicates no visible expression, + indicates some 
visible expression, ++ indicates notable expression and +++ indicates maximum over-
expression. 
 
Confirmation of over-expression of the hMiro1 C-terminal GTPase domain was 
undertaken by LC-MS analysis of excised SDS-PAGE bands, using a previously 
demonstrated method (260) in conjunction with the Bruker Daltonics HCT system 
(section 2.2.7.4). Analysis of LC-MS data using the MASCOT MS/MS Ions Search tool 
(261) was indicative of over-expression of the desired polypeptide (Figure 3.12), with the 
top score identified as ‘hypothetical protein’ EAW80247.1 matching the hMiro1 amino 
acid sequence on the National Centre for Biotechnology Information (NCBI) database. 
This analysis showed 21% sequence coverage when corrected for the C-terminal GTPase 
domain alone, with all peptides matching against the amino acid composition of the hMiro 
C-terminal ‘GTPase’ domain provided in NCBI. 
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Figure 3.14. MASCOT MS/MS Ions Score Histogram and analysis, indicating the 
presence of peptides in the hMiro1 C-terminal GTPase domain in the digested 
sample. Screenshot of the Mascot Score Histogram and Peptide Summary Report. 
3.3.1.3. Expression up-scale: hMiro1 and hMiro2 C-terminal GTPase domains 
 
The most promising conditions from the expression trials were scaled up. For the C-
terminal ‘GTPase’ domain of hMiro2, 2 litre cultures induced with 0.5 mM IPTG at 18oC 
were utilised, as expression trials were inconclusive. Cells were harvested, broken open 
and cell-free supernatant obtained as discussed in section 2.2.4.3. Subsequently, the 
recombinant polypeptides were purified by IMAC using a Nickel NTA column attached 
to an ÄKTA Prime fast protein liquid chromatography (FPLC) system (section 2.2.4.4). 
Figures 3.15 (hMiro1) and 3.16 (hMiro2) indicate the successful purification of these 
over-expressed recombinant polypeptides. 
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Figure 3.15. Successful purification of the hMiro1 C-terminal construct (Q415 –
P580) by ion-metal affinity chromatography (IMAC). Chromatogram obtained from 
the ÄKTA PRIME automated FPLC system shown, alongside 12% SDS-PAGE gels of 
samples of the fractions from the purification process containing the purified hMiro1 C-
terminal construct. Coomassie staining was utilised for SDS-PAGE gels. 
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Figure 3.16. Purification of the hMiro2 C-terminal construct (Q413–F589) by ion-
metal affinity chromatography (IMAC). Chromatogram obtained from the ÄKTA 
PRIME automated FPLC system shown, alongside 12% SDS-PAGE gels of samples of 
the fractions from the purification process containing the purified hMiro2 C-terminal 
construct. Coomassie staining was utilised for SDS-PAGE gels. 
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Suitably IMAC-pure fractions of apparent hMiro1 and hMiro2 C-terminal ‘GTPase’ 
domain were concentrated (figure 3.22a; section 2.2.4.6) and buffer-exchanged (section 
2.2.4.6) into gel filtration buffer (2.1.5.3.3). For hMiro2, it was necessary to perform size 
exclusion using centrifugal concentrators to remove high molecular weight contaminants 
prior to concentration and buffer exchange (figure 3.22 b). To confirm the identity of the 
concentrated and buffer-exchanged polypeptides, Western blotting was performed 
(2.2.4.8), using monoclonal antibodies raised against hMiro1 (Figure 3.23a) and hMiro2 
(Figure 3.23b). Bands on these blots indicated that hMiro-like polypeptides had been 
successfully over-expressed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Concentrated C-terminal GTPase domains of (a) hMiro1 and (b) 
hMiro2 following IMAC purification. 12% SDS-PAGE gels stained in Coomassie, 
showing the (a) hMiro1 and (b) hMiro2 C-terminal GTPase domains. 
 
 
(a)                                               (b) 
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Figure 3.18. Western blotting of the hMiro1 (a) and hMiro2 (b) C-terminal GTPase 
domains. Immunoblots showing detection of (a) hMiro1 and (b) hMiro2 using 
chemiluminescent detection. 
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3.3.2. Cloning, expression and purification of hMiro1 and hMiro2 ‘crystal’ 
truncates 
As previously mentioned, a truncated version of the Dropsophila Miro, dMiro, was 
successfully crystallised (131) whilst cloning of the C-terminal GTPases of hMiro1 and 
hMiro2 was in process. In the hope of producing successful crystals of hMiros truncated 
in a similar manner, ‘xtal constructs’ of hMiro1 and hMiro2 were engineered for cloning 
and expression purposes. The ‘xtal’ constructs comprised the EF-hands and C-terminal 
GTPase domain of each hMiro, as discussed in 3.2. 
 
3.3.2.1. Cloning of the hMiro1 and hMiro2 ‘crystal’ truncates 
 
Following the successful cloning, expression and purification of the hMiro1 and hMiro2 
C-terminal ‘GTPase’ domains, the ‘crystal constructs’ were subject to the same process 
and methodology as described in section 3.2. Primers were designed for cloning of the 
nucleotide sequences encoding the hMiro1 and hMiro2 ‘crystal constructs’ (residues 177-
589 for hMiro1 and residues 177-586 for hMiro2; section 2.1.3) into the bacterial 
expression vector pET15b-TEV. PCR-based amplification of the desired domains was 
successfully accomplished using previously described mammalian vectors donated by the 
Pontus Aspenström group as template (figure 3.19 a and b).  
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Figure 3.19. Successful PCR-based amplification of the nucleotide sequences 
encoding the ‘crystal construct’ domains of hMiro1 and hMiro2, respectively. 1% 
agarose gels showing successful PCR-based amplification of the gene sequences 
encoding hMiro 1 177–590 (a, lanes 3-7) and hMiro2 177–586 (b, lanes 4–11), 
respectively. Lanes 1 (a) and 2–3 (b) contain negative control reactions. Marker (Bioline 
Hyperladder I) is shown in lane 2 of gel (a) and 1 of gel (b). 
Amplified sequences were subjected to PCR-clean up procedures prior to restriction 
digest and ligation into pET15bTEV. Products of ligation were transformed into TOP10 
E.coli cells, with at least 3 transformed colonies screened for the presence of the hMiro 
sequences of interest as an insert. Following confirmation of insert presence (figure 3.20 
a and b), one suitable clone for each construct was transformed into C43 E.coli and 
expression trials initiated. 
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Figure 3.20. 1% agarose gels showing results of analytical restriction digest to screen 
for hMiroXTAL inserts into pET15bTEV. Analytical restriction digest of plasmid 
DNA extracted from TOP10 E.coli transformants after ligation of pET15b-TEV/hMiro1 
177-589 PCR products (lanes 2-7, a) and pET15b-TEV/hMiro2 177-586 products (lanes 
2-7, b), respectively. Lane 1 of both (a) and (b) contains Hyperladder I (BioLine). For 
each lane in which plasmid is shown, ‘U’ represents undigested plasmid and ‘D’ 
represents plasmid that has undergone a double restriction digest with the appropriate 
restriction enzymes (NdeI/XhoI).  
3.3.2.2. Expression trials: of hMiro1 and hMiro2 ‘crystal’ truncates 
Expression trials for expression of the hMiro ‘crystal constructs’ was undertaken as 
previously indicated (section 3.2). However, as a final IPTG concentration of 0.5 mM 
appeared largely successful in previous cultures, a constant IPTG concentration of 0.5 
mM was implemented in these trials, with temperature variables assessed (18oC, 25oC 
and 37oC). As shown in figures 3.21–3.34 and summarised in table 3.6, expression trials 
were suggestive of the successful expression and purification of the target hMiro1 
recombinant polypeptide. Expression of hMiro2 was suggested by the presence of a band 
in the induced sample, though expression trial data yielded no obvious bands in IMAC 
column eluates. The most successful conditions indicated by the expression trials were 
correspondingly up-scaled. 
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Figure 3.21. 12% Coomassie-stained SDS-PAGE gel showing expression trial data 
for the hMiro1 ‘crystal construct’. 50mL culture induced at 37oC for 4 hours to a final 
IPTG concentration of 0.5mM. Note the presence of bands of around the expected 
molecular weight for the target recombinant polypeptide (~47.6 kDa) in eluates 
containing 150 mM and 300 mM imidazole. 
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Figure 3.22. 12% SDS-PAGe gel showing further expression trial results for the 
hMiro1 ‘crystal construct’. 50mL culture induced at 18oC overnight (16 hours) to a final 
IPTG concentration of 0.5mM. Note the presence of bands of around the expected 
molecular weight for the target recombinant polypeptide (~47.6 kDa) in eluates 
containing 150 mM and 300 mM imidazole. Gel stained in Coomassie blue. 
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Figure 3.23. 12% SDS-PAGe gel displaying expression trial data for the hMiro2 
‘crystal construct’. 50mL culture induced at 37oC for 4 hours to a final IPTG 
concentration of 0.5mM. Note the presence of bands of around the expected molecular 
weight for the target recombinant polypeptide (~47.6 kDa) in eluates containing 150 mM 
and 300 mM imidazole. Coomassie staining utilised. 
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Figure 3.24. 12% SDS-PAGE gel showing further expression trial data for the 
hMiro2 ‘crystal construct’. 50mL culture induced at 18oC overnight (16 hours) to a final 
IPTG concentration of 0.5mM. Note the presence of bands of around the expected 
molecular weight for the target recombinant polypeptide (~47.6 kDa) in eluates 
containing 150 mM and 300 mM imidazole. Coomassie staining applied to gel. 
 
Table 3.6. Expression optimisation of hMiro ‘crystal construct’ polypeptides using 
IPTG induction. Expression of hMiro1 and hMiro2 using IPTG induction (0.5 mM) in 
50 mL LB broth, where - indicates no visible expression, + indicates some visible 
expression, ++ indicates notable expression and +++ indicates maximum over-
expression. 
 
hMiro1 ‘crystal construct’ hMiro2 ‘crystal construct’ 
18oC 37oC 18oC 37oC 
+++ ++ + + 
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3.3.2.3. Expression up-scale: hMiro1 and hMiro2 ‘crystal’ truncates 
The most promising conditions from the ‘crystal construct’ expression trials were scaled 
up, using 2L cultures in LB broth for each construct. Cells were harvested, broken open 
and cell-free supernatant obtained as discussed previously (section 2.2.4.3). For protein 
purification, the ÄKTA Prime IMAC approach was utilised (section 2.2.4.4). As 
illustrated in Figure 3.25 (hMiro1) and Figure 3.26 (hMiro2), up-scale of expression and 
purification appeared to produce pure fractions of both the hMiro1 and hMiro2 target 
polypeptides. IMAC-purified samples were assessed for the presence of the target 
polypeptides by both Western blotting (Figure 3.27 a and b) and in-gel trypsinisation 
followed by LC-MS analysis (see section 2.2.7.4); these approaches indicated the 
presence of the hMiro1 and 2 ‘crystal construct’ polypeptides in IMAC-purified samples. 
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Figure 3.25. Purification of the hMiro1 xtal construct (E177–R590) by ion-metal 
affinity chromatography (IMAC). Chromatogram obtained from the ÄKTA PRIME 
automated FPLC system shown, alongside 12% SDS-PAGE gels of samples of the 
fractions from the purification process containing the purified xtal construct. Coomassie 
staining used for SDS-PAGE gels. 
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Figure 3.26. Purification of the hMiro2 xtal construct (E177–P586) by ion-metal 
affinity chromatography (IMAC). Chromatogram obtained from the ÄKTA PRIME 
automated FPLC system shown, alongside 12% SDS-PAGE gels of samples of the 
fractions from the purification process containing the purified hMiro2 xtal construct. 
SDS-PAGE gels shown are Coomassie-stained. 
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Figure 3.27. Western blot of hMiro1 (a) and hMiro2 (b) IMAC-purified ‘crystal 
construct samples. Chemilumiscent visualisation of Western blots using antibodies 
raised against (a) hMiro1 and (b) hMiro2.  
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3.3.3. Cloning, expression and purification of hMiro1 and hMiro2 N-terminal 
GTPase domains 
3.3.3.1. Cloning of the hMiro1 and hMiro2 N-terminal GTPase domains 
Following the successful cloning, expression and purification of the hMiro1 and hMiro2 
C-terminal GTPase domains and ‘crystal constructs’, the N-terminal GTPase domains of 
both hMiros were subject to the same process and methodology described above. Primers 
were designed for cloning of the nucleotide sequences encoding the hMiro1 and hMiro2 
N-terminal GTPase domains into the bacterial expression vector pET15b-TEV. PCR-
based amplification of the hMiro N-terminal GTPase domains was successfully 
accomplished using vectors encoding the full-length, wildtype versions of hMiro1 and 
hMiro2 as template (Figure 3.28 a and b). Ligation of PCR products into pET15b 
(2.2.3.10), followed by transformation into TOP10 (2.2.2.2) and screening of extracted 
pDNA was performed as previously described (2.2.3.6). As shown in figure 3.29, all 
transformants screened contained a gene sequence of the expected size following 
analytical restriction digest. 
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Figure 3.28. Successful PCR-based amplification of the nucleotide sequences 
encoding the N-terminal GTPase domain of (a) hMiro1 and (b) hMiro2. 1% agarose 
gels showing PCR-based amplification of the gene sequences encoding hMiro1 3–169 
(lanes 3 –7, a) and hMiro2 3 –169 (lanes 3 –6, b). Lane 2 (a) and 2 (b) contain marker 
(Bioline Hyperladder I).  Lanes 1 (a) and 1 (b) show negative controls containing all 
components of the optimised reaction except the DNA template.  
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Figure 3.29. Analytical restriction digest of plasmid DNA extracted from TOP10 
E.coli transformants after ligation of pET15b-TEV/hMiro1 3–169 PCR products 
(lanes 1–6) and pET15b-TEV/hMiro2 3–169 products (lanes 8–13), respectively. 
Lanes 7 and 14 contain Hyperladder I (BioLine). For each lane in which plasmid is shown, 
‘U’ represents undigested plasmid and ‘D’ represents plasmid that has undergone a 
double restriction digest with the appropriate restriction enzymes. 1% agarose gel. 
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3.2.3.2. Expression trials: hMiro1 and hMiro2 N-terminal GTPase domains  
 
The hMiro1 and hMiro2 N-terminal GTPase domain expression trials were undertaken as 
previously discussed (section 2.2.2.6), though with varying temperature conditions 
utilised and a constant IPTG concentration of 0.5 mM applied. All trials were attempted 
in the C43 E.coli strain. Figures 3.30–3.33 illustrate the results obtained at each tested 
condition, with a summary of results shown in the form of Table 3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30. 12% SDS-PAGE gel showing expression trial data hMiro1 N-terminal 
GTPase domain. 50 mL culture induced at 37oC for 4 hours to a final IPTG concentration 
of 0.5 mM. Note the apparent presence of over-expressed protein in the lysate, and largely 
in the insoluble fraction.  
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Figure 3.31. 12% SDS-PAGE gel showing expression trial data hMiro1 N-terminal 
GTPase domain. 50 mL culture induced at 18oC for 16 hours to a final IPTG 
concentration of 0.5 mM. The presence of the target polypeptide is not strongly indicated. 
Gel stained in Coomassie blue. 
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Figure 3.32 12% SDS-PAGE gel displaying expression trial data hMiro2 N-terminal 
GTPase domain. 50 mL culture induced at 37oC for 4 hours to a final IPTG concentration 
of 0.5 mM. Note the apparent presence of over-expressed protein in the induced culture 
(lane 3), lysate (lane 4) and insoluble fraction (lane 5) at around double the expected 
molecular weight for the hMiro2 N-terminal GTPase domain. Coomassie staining utilised. 
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Figure 3.33 12% SDS-PAGE gel showing expression trial data hMiro2 N-terminal 
GTPase domain. 50 mL culture induced at 37oC for 4 hours to a final IPTG concentration 
of 0.5 mM. Note the apparent presence of over-expressed protein in the induced culture 
(lane 3), lysate (lane 4) and insoluble fraction (lane 5) at around double the expected 
molecular weight for the hMiro2 N-terminal GTPase domain. Arrows point to expected 
molecular weight (~20 kDa) and the bands showing roughly double the expected 
molecular weight. Coomassie staining used. 
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Table 3.7. Expression optimisation of hMiros N-terminal GTPase domains using 
IPTG induction. Expression of hMiro1 and hMiro2 using IPTG induction (0.1mM or 
1mM) in 50 mL LB broth, where - indicates no visible expression, + indicates some 
visible expression, ++ indicates notable expression and +++ indicates maximum over-
expression.  
 
hMiro1 N-terminal GTPase domain hMiro2 N-terminal GTPase domain 
18oC 37oC 18oC 37oC 
+ + + + 
 
 
Although some over-expression was indicated in the SDS-PAGE gels, bands were of 
around twice the molecular weight expected. It was unclear whether these bands were 
mere contaminants or whether the target recombinant polypeptides may have been 
forming dimers. Thus, Western blotting was applied to samples. As shown in Figure 3. 
44, the blots indicated the presence of a hMiro2 polypeptide of double the molecular 
weight of the expected recombinant N-terminal GTPase domain, suggesting that this 
domain is indeed liable to dimerization. However, no indication of a hMiro1 polypeptide 
was shown using anti-hMiro1. As the antibodies utilised were raised against full-length 
versions of hMiro1 and hMiro2, this negative result may be a consequence of lack of 
epitopes in the single hMiro1 N-terminal GTPase domain. Trypsinisation of the excised 
gel fragment and analysis by LC-MS was therefore performed, with results indicating that 
the correct recombinant protein had been over-expressed (Figure 3.34). 
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Figure 3.34. Western blotting of hMiro1 and hMiro2 N-terminal GTPase domains. 
Anti-hMiro1 and anti-hMiro2 antibodies raised in mouse were utilised for the 
chemiluminescent detection of hMiro1 and hMiro2 domains using a secondary anti-
mouse antibody conjugated to HRP. 
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Chapter 4 reµsults: in vitro characterisation of the human Miros 
4.1 Introduction 
4.1.1 Objectives 
In recent years, an increasing body of work has been performed with the aim of 
elucidating Miro function in vivo, using a variety of model organisms (132,165,235,262). 
Although these studies have enriched our understanding of Miro function, many 
biochemical and biophysical properties of these enzymes remain obscure. As such, the 
work implemented in this chapter sought to characterise the human Miros in vitro. 
Primary objectives encompassed, firstly, an assessment of the hydrolytic capabilities of 
the human Miros, including an assessment of each individual GTPase domain. In 
particular, an evaluation of the C-terminal “GTPase” domain of each human Miro was 
pertinent, as these domains are poorly represented in the literature and are often 
disregarded as artefacts. Secondly, knockdown studies were undertaken with the 
objective of filling knowledge gaps currently present in the literature and assessing the 
functional consequences of dual hMiro1 and hMiro2 knockdown in fast-growing PC3 
cancer cells. Thirdly, the oligomeric state of the human Miros was evaluated by 
biophysical assessments. Canonical Ras and Rho proteins are quintessentially 
monomeric, thus an appraisal of the oligomeric state of these highly unusual enzymes 
was desirable. Finally, thermal stability of the hMiro1 and hMiro2 ‘crystal’ constructs 
was undertaken in an attempt to further characterise the biophysical properties of these 
enzymes.  
4.2 Analysis of the GTP hydrolytic activity of hMiro1, hMiro2 and 
isolated hMiro GTPase domains 
The hydrolytic capacity and catalytic efficiency of the hMiro1 and hMiro2 N-terminal 
GTPase domains remained unknown prior to this study, despite the exhibition of strong 
primary structure similarity between these domains and the G domains of Ras, and 
particularly Rho, enzymes. Furthermore, a complete lack of understanding regarding the 
function and biochemical properties of the hMiro C-terminal GTPase domains existed. 
To elucidate the hydrolytic activity of hMiro1 and hMiro2, the purified truncated proteins 
discussed in chapter 3 were buffer-exchanged into gel filtration buffer (2.1.5.3.3). Protein 
concentration was estimated using the Bradford assay (section 2.2.4.7) and molarity 
calculated using the estimated amount of protein per mL and computed molecular weight. 
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Several different assay methods were attempted for measuring GTP hydrolytic activity, 
all of which operated on the principle of measuring inorganic phosphate release either 
through fluorescent or colorimetric detection. In the presence of GTP, an enzyme capable 
of GTP hydrolysis should yield GDP and free inorganic phosphate. These methods 
therefore provided a means for measuring substrate turnover and product generation. 
4.2.1 Fluorometric detection using novel phosphate sensor method 
Initially, a novel fluorescent detection method was used. This method was centred around 
conformational changes in a pure, recombinant E.coli ‘Phosphate Sensor’ protein (Life 
Technologies, United Kingdom) labelled with the fluorophore MDCC and was advertised 
as a novel, highly sensitive method capable of detecting picomolar concentrations of free 
inorganic phosphate. Upon binding inorganic phosphate, the Phosphate Sensor undergoes 
a conformational change resulting in a large increase in fluorescence (263).  As the hMiro 
GTPase domains remained completely uncharacterised in vitro prior to this study, a 
sensitive method of phosphate detection was highly desirable. However, due to technical 
incompatibilities, it was not feasible to fully apply this method and instead, the ‘gold 
standard’ malachite green method was utilised (4.2.2). 
4.2.2 Colorimetric detection using the malachite green assay 
As the Phosphate Sensor fluorometric method proved unusable in context, a standard 
Malachite Green colorimetric assay kit was attempted (Cayman Chemical). The 
Malachite Green method is based on the formation of a complex between free 
orthophosphate and malachite green molybdate under acidic conditions, absorbing at 620-
640nm (Figure 4.1).  
 
 
Figure 4.1. Malachite green reaction. Overview of the malachite green colorimetric reaction. 
 
With the Malachite Green method, it was possible to utilise a 96-well plate method and 
henceforth monitor multiple kinetic assays simultaneously.  
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4.2.3 Colorimetric detection using the PiColourLock™ Gold assay kit 
A second kit was utilised to validate results from the standard malachite green kit. 
Although still considered the gold standard, the malachite green assay can result in 
precipitation when used for a substantial amount of time, resulting in an unstable end-
point signal. The PiColourLock™ Gold kit (Innova Biosciences, United Kingdom) is 
advertised as an improved colorimetric detection method based on the malachite green 
detection of phosphate, albeit producing an enhanced stability end-point signal less prone 
to precipitation. Furthermore, this kit contains a patented stabiliser to reduce acid 
hydrolysis of substrates and further improve end-point stability. 
4.2.4 Generation of phosphate standard curve 
4.2.4.1 For Cayman Chemicals Malachite Green Kit 
For assessment of the amount of phosphate generated by the Miro GTPase domains, it 
was necessary to create a standard curve for absorbance of phosphate at varying 
concentrations, using the chosen assay buffer (Figure 4.2). This was performed using 
phosphate standards provided by the manufacturer, according to the instructions 
provided. Later calculation of µM phosphate produced under each condition was 
undertaken via the method described in 2.2.5.1, Chapter 2. 
 
Figure 4.2. Standard curve for phosphate signal using the Malachite Green assay kit. 
Phosphate samples were prepared in triplicate according to the guidelines of the Cayman 
Chemicals Malachite Green assay kit. The samples were prepared, incubated and read according 
to manufacturer’s guidelines.  
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4.2.4.2 For PiColourLock™ Gold assay kit 
The PiColourLock™ Gold kit obtained from Innova Biosciences also required the 
creation of a phosphate standard curve in assay buffer. Standard curve generation was 
undertaken according to the manufacturer’s instructions, using phosphate standards 
provided as part of the kit. The curve obtained is shown as Figure 4.3, below. Subsequent 
calculation of µM phosphate produced under each test condition was calculated using this 
standard curve and the method described in Appendix 9. 
 
Figure 4.3. Standard curve for phosphate signal using the PiColourLock™ Gold assay kit. 
Phosphate standards were prepared, incubated and read according to manufacturer’s guidelines.  
4.2.5. hMiro1 and hMiro2 N-terminal GTPase domains are capable of hydrolysing 
GTP in the presence of MgCl2, CaCl2 or both cations 
The N-terminal GTPase domains of both hMiro1 and hMiro2 resembles the G domains 
of many classical Ras superfamily proteins, but particularly canonical Rho proteins. As 
such, this domain was expected to hydrolyse GTP in the presence of Mg2+, a 
quintessential cofactor of Ras superfamily proteins (62,86,89,90). However, some 
GTPases are known to bind Ca2+ or calmodulin (264-266). Indeed, the Rho GTPases often 
act within Ca2+ signalling pathways  (267). Correspondingly, phosphate detection assays 
were performed for the N-terminal GTPase constructs of hMiro1 and hMiro2 in the 
presence of either Mg2+, Ca2+ or both divalent cations. The results show that both Miro1 
(Figure 4.3) and 2 N-terminal GTPase domains (Figure 4.4) are capable of hydrolysing 
GTP in the presence of either Mg2+, Ca2+ or both cations. All reactions were undertaken 
at 25oC, using 50 µM protein.
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Figure 4.4. GTP hydrolytic activity of the hMiro1 N-terminal GTPase domain. (A) 
Plot of time in minutes against phosphate generation as detected by the standard malachite 
green assay (Cayman Chemicals, USA). (B) Total phosphate generation after 45 minutes 
using the PiColorLock™Gold system (Innova Biosciences, UK). Blank readings 
comprised assay buffer, both cations and GTP to assess for phosphate released by acid 
hydrolysis. Error bars represent standard error of the mean.  
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Figure 4.5. GTP hydrolytic activity of the hMiro2 N-terminal GTPase domain. (A) 
Kinetic assay using the malachite green assay kit (Cayman Chemicals, USA), with µM 
phosphate plotted against time in minutes. (B) Total phosphate generation after 45 
minutes using the PiColorLock™Gold kit (Innova Biosciences, UK). Blank readings 
comprised assay buffer, both cations and GTP to assess for phosphate released by acid 
hydrolysis. Error bars represent standard error of the mean. 
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4.2.6. hMiro1 and hMiro2 C-terminal GTPase domains exhibit hydrolytic activity 
against GTP in the presence of MgCl2, CaCl2 or both cations 
The C-terminal domains of the human Miros are highly unusual (17,29). Indeed, these 
domains have been previously questioned as relic domains in the literature (268,269). 
However, prior to this work, biochemical assays had not been performed to definitively 
assess the hydrolytic capacity of these domains. Thus, Malachite Green assays were 
performed with both the isolated Miro C-terminal GTPase domains. As shown in Figure 
4.5 for hMiro1 and Figure 4.6 for hMiro2, both of the C-terminal GTPase domains for 
these enzymes are, remarkably, able to hydrolyse GTP in the presence of MgCl2, CaCl2 
or both cations.  
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Figure 4.6. GTP hydrolytic activity of the hMiro1 C-terminal GTPase domain. (A) Kinetic 
assay using the malachite green assay kit (Cayman Chemicals, USA), with µM phosphate plotted 
against time in minutes. (B) Total phosphate generation after 45 minutes using the 
PiColorLock™Gold kit (Innova Biosciences, UK). Blank readings comprised assay buffer, both 
cations and GTP to assess for phosphate released by acid hydrolysis. Error bars represent standard 
error of the mean.
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Figure 4.7. GTP hydrolytic activity of the hMiro2 C-terminal GTPase domain. (A) Kinetic 
assay using the malachite green assay kit (Cayman Chemicals, USA), with µM phosphate 
plotted against time in minutes. (B) Total phosphate generation after 45 minutes using the 
PiColorLock™Gold kit (Innova Biosciences, UK). Blank readings comprised assay buffer, both 
cations and GTP to assess for phosphate released by acid hydrolysis. Error bars represent 
standard error of the mean. 
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4.2.6. hMiro1 and hMiro2 ‘crystal constructs’ show hydrolytic activity against GTP 
in the presence of MgCl2, CaCl2 or both cations 
The hMiro1 and hMiro2 ‘crystal’ constructs each contained the EF-hand regions of each 
hMiro, plus the C-terminal GTPase domain. Although these constructs were engineered 
in the hopes of producing crystals for x-ray crystallography, they also represented the 
longest hMiro constructs engineered that showed appropriate and reproducible expression 
and purification. These constructs were tested for hydrolytic activity against GTP for 
numerous reasons: to evaluate hydrolytic activity in the longest constructs available, and 
to assess whether the EF-hand regions held regulatory roles for the C-terminal GTPase 
domain (for example, through auto-inhibition or structural obstruction). The results 
shown in Figures 4.7 and 4.8 indicate that the C-terminal domains of hMiro1 and hMiro2 
are capable of hydrolysing GTP in the presence of MgCl2, CaCl2 or both cations, 
regardless of the presence or absence of the EF-hand domains. Interestingly, the presence 
of CaCl2 appeared to mildly increase GTPase activity, with a greater amount of phosphate 
generally produced in the presence of either CaCl2 or both cations. However, this was 
statistically significant across replicates relative to GTP hydrolytic activity in the 
presence of MgCl2 alone. 
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Figure 4.8. GTP hydrolytic activity of the hMiro1 xtal construct. (A) Kinetic assay 
using the malachite green assay kit (Cayman Chemicals, USA), with µM phosphate 
plotted against time in minutes. (B) Total phosphate generation after 45 minutes using the 
PiColorLock™Gold kit (Innova Biosciences, UK). Blank readings comprised assay 
buffer, both cations and GTP to assess for phosphate released by acid hydrolysis. Error 
bars represent standard error of the mean. 
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Figure 4.9. GTP hydrolytic activity of the hMiro2 xtal construct. (A) Kinetic assay 
using the malachite green assay kit (Cayman Chemicals, USA), with µM phosphate 
plotted against time in minutes. (B) Total phosphate generation after 45 minutes using the 
PiColorLock™Gold kit (Innova Biosciences, UK). Blank readings comprised assay 
buffer, both cations and GTP to assess for phosphate released by acid hydrolysis. Error 
bars represent standard error of the mean. 
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4.2.7 The hMiro1 and hMiro2 C-terminal GTPase domains display substrate 
promiscuity, showing hydrolytic activity against ATP and UTP 
GTPases of the Ras superfamily typically exhibit substrate specificity towards GTP. 
However, owing to the unusual nature of the hMiro GTPases, each individual domain 
was assessed for the ability to hydrolyse ATP, CTP and UTP. The N-terminal GTPase 
domain of both hMiro1 and hMiro2 displayed specificity towards GTP as substrate Figure 
4.9 for hMiro1, Figure 4.10 for hMiro2). These domains display largely classical Ras 
superfamily characteristics, so this was an expected result. However, as shown in Figure 
4.11 for hMiro1 and 4.12 for hMiro2, the C-terminal GTPase domain for both Miros 
displayed the ability to hydrolyse ATP and UTP in addition to GTP. This may reflect the 
highly atypical nature of the C-terminal GTPase domains. CTP hydrolysis was not shown 
in any domain tested. In all assessments, MgCl2 was utilised as cofactor. 
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Figure 4.10. The hMiro1 N-terminal GTPase domain cannot hydrolyse ATP, UTP or CTP. 
(A) Kinetic assay using the malachite green assay kit (Cayman Chemicals, USA), with µM 
phosphate plotted against time in minutes. (B) Total phosphate generation after 45 minutes using 
the PiColorLock™Gold kit (Innova Biosciences, UK). Blank readings comprised assay buffer, 
both cations and GTP to assess for phosphate released by acid hydrolysis. Error bars represent 
standard error of the mean. 
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Figure 4.11. The hMiro2 N-terminal GTPase domain displays an absence of hydrolytic 
activity towards ATP, UTP and CTP. (A) Kinetic assay using the malachite green assay kit 
(Cayman Chemicals, USA), with µM phosphate plotted against time in minutes. (B) Total 
phosphate generation after 45 minutes using the PiColorLock™Gold kit (Innova Biosciences, 
UK). Blank readings comprised assay buffer, both cations and GTP to assess for phosphate 
released by acid hydrolysis. Error bars represent standard error of the mean. 
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Figure 4.12. The hMiro1 C-terminal GTPase domain shows hydrolytic activity against ATP 
and UTP but not CTP. Samples were prepared in triplicate and assays undertaken at 25oC 
according to the guidelines of the Cayman Chemicals Malachite Green assay kit. Readings are 
provided as blank-corrected readings. Blank readings comprised assay buffer, both cations and 
GTP to assess for phosphate released by acid hydrolysis.  
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Figure 4.13. The hMiro2 C-terminal GTPase domain displays hydrolytic activity against 
ATP and UTP but not CTP. Samples were prepared in triplicate and assays undertaken at 25oC 
according to the guidelines of the Cayman Chemicals Malachite Green assay kit. Readings are 
provided as blank-corrected readings. Blank readings comprised assay buffer, both cations and 
GTP to assess for phosphate released by acid hydrolysis.  
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4.2.8 hMiro1 and hMiro2 GTPase domains: assessment of enzymatic kinetic 
parameters 
To assess the kinetic parameters for Miro1 and 2 GTPase domain hydrolytic activity 
towards GTP and ATP, reaction rates were calculated at varying substrate concentrations 
ranging from 0.5 mM – 2 mM substrate. All assays were performed in triplicate at 25oC 
in previously described assay buffer supplemented with 2 mM MgCl2 and either ATP or 
GTP at a specified concentration (0.5 mM, 1 mM, 1.5 mM or 2mM). Assay scatter plots 
from which kinetic parameters were derived are shown in Figure 4.13, while Lineweaver-
Burke plots for each set of assays are displayed in Figure 4.14; these plots were used to 
calculate values for Vmax and Km displayed in Table 4.1, which displays a summary of the 
kinetic parameters obtained in this work, alongside Kcat rates of typical Ras superfamily 
enzymes as described in the literature. As shown in Table 4.1, the Kcat values calculated 
for the hMiro1 and hMiro2 GTPase domain are not dissimilar to the reaction rate 
constants (Kcat values) reported in the literature for typical Ras superfamily members, 
which ranged from 0.0031/min to 1.120/min (270-273). All of the Kcat values obtained 
for hMiro1 and hMiro2 fell within this range, although tended to be slightly higher than 
those reported in the literature for Ras superfamily enzymes (270-276). Kinetic values for 
dynamin and SEPT2 are also provided, which share similarities with Ras GTPase domain 
architecture, including the presence of G loops (277,278). All of the values shown in 
Table 4.1 describe intrinsic hydrolysis rates only. Unfortunately, most of the kinetic data 
available in the literature focuses on GAP-mediated hydrolysis, rather than the intrinsic 
hydrolysis, of small GTPases (270-273). Furthermore, where intrinsic hydrolysis rates 
were described, other kinetic values associated with intrinsic hydrolysis (such as Vmax and 
KM) were excluded (270-276). This, amongst other factors such as variances in 
experimental conditions (including, crucially, temperature), make it difficult to compare 
the values reported in the literature to those obtained here. However, in brief: the results 
obtained from kinetic studies indicate that both hMiro1 and hMiro2 NT and CT domains 
are able to hydrolyse GTP in the absence of GAP enzymes at rates similar to that  
observed for the basal GTP hydrolytic rates of classical Ras superfamily enzymes, 
including H-Ras, K-Ras, Cdc42, Ran, Rap1a and the Rac enzymes. Furthermore, the CT 
domain of  hMiro1 and hMiro2 is capable of intrinsic hydrolysis of ATP at rates similar 
to that seen for GTP hydrolysis in canonical Ras superfamily enzymes.  These results are 
examined in further detail in the discussion section, 4.5
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Figure 4.14. Hydrolytic activity of hMiro1 and 2 individual GTPase domains using varying substrate concentrations. (A) hMiro1 N-terminal GTPase domain using GTP as 
substrate. (B) and (C) hMiro1 C-terminal GTPase domain, using GTP and ATP as substrate, respectively. (D) hMiro2 N-terminal GTPase domain using GTP as substrate. (E) and (F) 
hMiro2 C-terminal GTPase domain, using GTP and ATP as substrate, respectively Samples were prepared in triplicate and assays undertaken at 25oC according to the guidelines of 
the Cayman Chemical s Malachite Green assay kit. Readings are provided as blank-corrected readings. Blank readings comprised assay buffer, both cations and substrate to assess for 
phosphate released by acid hydrolysis.
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Figure 4.15. Lineweaver-Burke plot for hMiro1 N-terminal GTPase domain against GTP. The data 
were performed in triplicate, with error bars representing the standard deviation from the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. Lineweaver-Burke plot for hMiro2 N-terminal GTPase domain against GTP. The data 
were performed in triplicate, with error bars representing the standard deviation from the mean. 
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Figure 4.17. Lineweaver-Burke plot for hMiro1 C-terminal GTPase domain against GTP. 
The data were performed in triplicate, with error bars representing the standard deviation from 
the mean. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18. Lineweaver-Burke plot for hMiro2 C-terminal GTPase domain against GTP. 
The data were performed in triplicate, with error bars representing the standard deviation from 
the mean. 
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Figure 4.19. Lineweaver-Burke plot for hMiro1 C-terminal GTPase domain against ATP. 
The data were performed in triplicate, with error bars representing the standard deviation from 
the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Lineweaver-Burke plot for hMiro2 C-terminal GTPase domain against ATP. 
The data were performed in triplicate, with error bars representing the standard deviation from 
the mean.
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Table 4.1. Kinetic parameters for intrinsic hydrolysis of the hMiro constructs and typical Ras superfamily enzymes. Where ‘NT’ refers to the N-terminal 
GTPase domain and ‘CT’ refers to the C-terminal GTPase domain for each respective hMiro. Values for Km and Vmax were derived from the Lineweaver-Burk plots 
displayed in Figures 4.14-4.19. Kcat was calculated by dividing Vmax by 50µM, the total amount of enzyme used in each assay well. 
 
hMiro1 
GTPase domains 
hMiro2 
GTPase domains 
H-Ras 
(272) 
K-Ras 
(271) 
Rac1 
(270) 
Rac2 
(270) 
Rac3 
(270) 
Cdc42 
(273) 
Rap1a 
(272) 
Ran 
(272) 
Dynamin 
(278) 
Sept2  
(277) 
Temperature 
(oC) 
25 25 25 25 25 25 37 20 25 25 25 30 37 37 22 23 
MgCl2 in 
buffer (mM) 
2 2 2 2 2 2 5 10 2 2 2 5 5 5 2 5 
Construct NT CT CT NT CT CT WT WT WT WT WT WT WT WT WT WT 
Substrate GTP GTP ATP GTP GTP ATP GTP GTP GTP GTP GTP GTP GTP GTP GTP GTP 
Vmax (µM/min) 12.026 11.044 5.755 53.155 3.909 4.240 – – – – – – – – – – 
KM (mM) 5.715 4.959 2.094 22.673 0.917 1.207 – – – – – – – – 0.0034 0.00052 
Kcat (min) 0.241 0.221 0.115 1.063 0.078 0.085 0.028 0.041* 0.11 0.16 0.18 1.120 0.0031 0.0032 0.19 0.0162* 
Kcat/KM 
(min/mM) 
0.042 0.045 0.055 0.047 0.085 0.070 – – – – – – – – 55.882 31.154 
*Value originally provided with seconds as unit; adjusted here to represent minutes.
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4.3 Function of the human Miro GTPases in mammalian cell lines: 
knock-down studies 
4.3.1 Migration assays using PC3 cells 
Migration assays were performed as described in 2.2.6.7, with knockdown conditions 
achieved using the reverse siRNA-mediated knockdown method detailed in 2.2.6.5. Each 
assay was performed for 24 hours, with conditions assessed in triplicate per assay. 
Overall, three separate assays were performed at different dates; this allowed for an 
investigation of hMiro knockdown at different PC3 cellular passages, and provided an 
enhanced confidence in the results obtained. As shown in Figure 4.20, knockdown of 
hMiro1 and hMiro2 produced numerical (albeit not significant) reductions in PC3 cell 
proliferation over the course of 24 hours. The effect was most prominent in hMiro1 
knockdown conditions. A dual knockdown approach, in which both hMiro1 and hMiro2 
were simultaneously knocked down, did not produce the lowest overall reduction in 
migration relative to control cells. Instead, hMiro1 knockdown alone produced the 
greatest reduction in PC3 cell proliferation. Although this result was surprising, it may be 
associated with the known difficulties of simultaneously knocking down two separate 
genes using the siRNA-mediated knockdown method utilised. Further data and 
information is provided in Appendix 10. 
 
 
 
 
 
 
 
 
Figure 4.21. Knockdown of hMiro1, hMiro2 or both hMiros in PC3 cells reduces cell 
migration relative to controls. Knockdown conditions against control cell migration, where 
migration is classified as the sum of cell index over time using the area under the curve (AUC) 
approach. Here, the mean AUC of PC3 migration across 3 separate assays is provided. 
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4.3.2 Fluorescent microscopy  
In order to assess any morphological changes arising from hMiro knockdown conditions, 
control and knockdown PC3 cells were prepared for fluorescent microscopy and viewed 
under a Leica DM5000 fluorescent microscope as previously described 2.2.6.8. In these 
microscopy studies, mitochondria were labelled with MitoTracker Deep Red FM, while 
nuclei were labelled with DAPI. Cells were also viewed under differential interference 
contrast (DIC), allowing for delineation of each cell without interference from fluorescent 
signals. Slides were prepared and viewed in triplicate for each condition. A summary of 
the primary findings from these microscopy studies is provided in the form of Table 4.2, 
below. Changes in mitochondrial morphology were not noticeable using the equipment 
available. Representative fluorescent microscopy images for control and knockdown cells 
are provided in the proceeding pages as follows: 20x objective magnification field view 
(Figure 4.21), 63x objective magnification (Figure 4.22) 100x objective magnification 
(Figure 4.23). 
 
Table 4.2 Primary observations of fluorescent microscopy of control and knockdown PC3 
cells. 
Condition Primary observation(s) 
Control MitoTracker signal distributed across cytoplasm; normal cell morphology. 
hMiro1 knockdown MitoTracker signal remains close to DAPI signal; cell morphology unchanged. 
hMiro2 knockdown MitoTracker signal remains close to DAPI signal; cell morphology unchanged. 
Dual knockdown 
MitoTracker signal remains close to DAPI nuclear stain signal; cell morphology 
frequently swollen. 
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Figure 4.22. Fluorescent microscopy analysis of control PC3 cells versus hMiro1, hMiro2 or dual (hMiro1 and hMiro2) knockdown cells. 20x objective lens 
utilised. 
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Figure 4.23. Fluorescent microscopy analysis of control PC3 cells versus hMiro1, hMiro2 or dual (hMiro1 and hMiro2) knockdown cells. 63x objective lens 
used. 
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Figure 4.24. Fluorescent microscopy analysis of control PC3 cells versus hMiro1, hMiro2 or dual (hMiro1 and hMiro2) knockdown cells. 100x objective lens 
utilised.
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4.4 Biophysical characterisation of the Miro GTPases 
Dynamic light scattering (DLS) and circular dichroism (CD) thermal denaturation were 
performed as described in 2.2.5.4 and 2.2.5.5, respectively. As shown in Figure 4.24, both 
Miro1 and Miro2 Xtal constructs produced singular peak in DLS experiments 
(monomodal distribution). DLS, also known as Photon Correlation Spectroscopy or 
Quasi-Elastic Light Scattering, exploits the phenomenon of Brownian motion and 
represents an established technique for determination of the size and size distribution of 
molecules (279). The Brownian motion of particles in suspension results in the scattering 
of laser light at different intensities when the light hits the moving particles, with smaller-
sized particles exhibiting faster Brownian motion (279,280). The average size, size 
distribution and polydispersity of particles in solution can be quantified by measuring the 
time scale of light intensity fluctuations (280). Mathematical analysis of these fluctuations 
enables the determination of the diffusion coefficient, and therefore the particle size, 
using the Stokes-Einstein relationship (280). The results shown in Figure 4.25 were used 
alongside Zetasizer software version 4 (Malvern, UK) to indicate the size of each 
hMiroXTAL construct. Figure 4.25 indicates pooled analyses of five separate DLS runs for 
each MiroXTAL construct, with (a) indicating a median particle size of 7.5 nm in diameter, 
corresponding to around 75Å. However, average particle size was calculated in Zetasizer 
as 5.56 ± 0.57 nm (approximately 55.6 Å), corresponding to around the expected size of 
hMiro1XTAL (E177–R590) with the hexahistidine tag attached, which was estimated to be 
~5.2 nm (280,281). Figure 4.25 (b), however, indicates a median particle size of around 
8 nm in diameter, corresponding to around 80Å. The average particle size calculated in 
Zetasizer was 5.72 ± 0.56 nm (approximately 58.2 Å), which was in the expected range 
for the calculated size of hMiro2XTAL (E177–P586) with the hexahistidine tag attached (~5.2 
nm). As suggested by Zetasizer, analysis by average size, rather than median, was 
performed due to the large amount of data obtained and a low frequency of outlier 
readings. The monomodal distribution shown for hMiro1 and hMiro2 results is suggestive 
of a pure sample, while the average size calculated for each constructs suggests that these 
enzymes present monomerically (dimers would present with a higher diameter than the 
results indicate). Canonical monomeric Rho proteins, such as RhoA, would be expected 
to show a monomodal distribution with an average diameter of ~3.9–4 nm based on 
empirical results of several model proteins and enzymes (280,281). 
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Figure 4.25. Both hMiro1 and hMiro2 exhibit monomeric behaviour in vitro. Dynamic light 
scattering (DLS) of IMAC and gel-purified hMiro1 and hMiro2 constructs, with results showing 
single peaks corresponding to the correct size in nanometers (nm) for each hMiroXTAL construct. 
 
Thermal denaturation data are shown on the following page in Figures 4.26 (hMiro1) and 
4.27 (hMiro2), respectively.  The data shown displays the melting temperature (Tm) for 
the hMiro1 (Figure 4.26) and hMiro2 xtal (Figure 4.27) constructs. The thermal melt for 
each construct, measured at 220 nm, gave a melting temperature (Tm) of 54.4 
oC for 
hMiro1XTAL and 57.4 
oC for hMiro2XTAL, where Tm  describes the temperature at which 
protein unfolding occurred. Thermal denaturation experiments were performed in order 
to gain insight as to the thermal stability of hMiro1 and hMiro2, and suggested that 
hMiro1XTAL and hMiro2XTAL possess similar thermal stabilities to each other and average 
thermal stabilities compared to many globular proteins (282) including H-Ras (283), as 
examined further in the discussion (section 4.5). 
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Figure 4.26. Thermal denaturation of hMiro1XTAL. CD spectra at selected temperatures, 
showing thermal unfolding of the hMiro1XTAL construct. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27. Thermal denaturation of hMiro2XTAL. CD spectra at selected temperatures, 
showing thermal unfolding of the hMiro2XTAL construct 
Tm = 54.4 oC 
Tm = 57.4 oC 
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4.5 Discussion 
4.5.1 Hydrolytic activity of hMiro1 and hMiro2 GTPase domains 
GTPase hydrolytic activity was observed in all hMiro domains for the first time in vitro, 
using both the malachite green and PiColourLock™ Gold method. This was largely 
unsurprising for the N-terminal GTPase domains, considering the sequence similarities 
these domains share with Ras superfamily G domains and Rho GTPase domains in 
particular. In contrast to the hMiro N-terminal GTPase domains, the GTP hydrolytic 
activity of the C-terminal GTPase domains was wholly unexpected; these C-terminal 
GTPase domains had been previously disregard in the literature as artefact domains, and 
are only distantly related to other Ras superfamily GTPases, with the closest homologues 
being Rab42 for the hMiro1 C-terminal GTPase domain (40% identity) and  Ras-like 
GTPase 11B for the hMiro2 C-terminal GTPase domain (27% identity) according to 
pBLAST searches. Both the isolated C-terminal GTPase domains and hMiroXTAL 
constructs exhibited hydrolytic activity towards GTP, suggesting that the EF hand 
domains present in the hMiroXTAL constructs are not functionally obstructive or inhibitory 
towards GTPase activity. The EF hand domains have previously been implicated in 
calcium-based pauses in mitochondrial transport (164). However, their lack of influence 
here suggests the EF hand domains do not achieve this effect through alteration of GTPase 
activity, at least in the constructs tested. In the absence of full length activity assays and 
other functional studies, it remains unknown whether intra domain interactions regulate 
the catalytic activity of individual GTPase domains or whether these domains are 
regulated by alternative means. 
All constructs displayed hydrolytic activity in the presence of Mg2+, Ca2+ or both Mg2+ 
and Ca2+. No statistically significant differences in inorganic phosphate release were 
shown between these three cation conditions. However, hydrolytic activity was 
completely abrogated in the absence of divalent cations. Thus, similarly to typical Ras 
superfamily GTPases, the hMiro1 and 2 GTPase domains appear to require a divalent 
cation co-factor to enable hydrolytic activity. It is interesting, however, that these domains 
can use either Mg2+ or Ca2+ interchangeably. Mg2+ is generally regarded as an essential 
co-factor for classical members of the Ras Superfamily, enabling high affinity nucleotide 
binding (284). In the presence of Mg2+, many Ras superfamily enzymes display extremely 
high binding affinities to guanine nucleotides (85-87). Indeed, chelation of Mg2+ by 
EDTA has been shown to dramatically decrease nucleotide binding capability in Rab3A 
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and Sec4 GTPases (88,89). Furthermore, certain GEFs have been shown to promote GDP 
dissociation partially through destabilisation of bound Mg2+ (90,91).  
Although Ca2+ influences many classical Ras superfamily GTPases through a variety of 
mechanisms, such as through regulation of GAP and GEF enzymes or through the direct 
binding of calmodulin to the GTPase, canonical Ras superfamily enzymes have not been 
shown to bind Ca2+ as a co-factor in lieu of Mg2+. As mentioned previously however, the 
function of Mg2+ may alter substantially across enzymes of the Ras superfamily even 
when structural similarities in the G domain are preserved, as has been noted for the Rho 
GTPases. It is possible, therefore, that some enzymes may be able to utilise Mg2+ or Ca2+ 
interchangeably as co-factors for GTP hydrolytic activity. Ca2+ itself typically binds to 
the carboxylate moieties of acidic residues (285) and requires six to eight co-ordinates 
(286). In fact, Ca2+ and Mg2+ preferentially bind to many of the same residues, namely: 
oxygen atoms of glutamic acid or aspartic acid, or main chain oxygen atoms. Both can 
also bind to the oxygen atoms of serine, threonine, asparagine or glutamine. Occasionally, 
binding between these cations and the nitrogen of histidine is also seen (286,287). 
Generally, however, Ca2+ binds with lower free energy gain (287-291) and displays a 
higher ionic radius than that of Mg2+ with the same co-ordination number (286,287). For 
example, the ionic radii of 6- and 8- co-ordinated Ca2+ are 1.00 and 1.12 Å, respectively, 
while relative values for Mg2+ are 0.72 and 0.89 Å (286). Relative to Mg2+, Ca2+ also 
exhibits a greater propensity for bidentate carboxylate binding, albeit a lower affinity for 
water (292).  
Interestingly, the aspartic acid (D) of the G3 motif / Switch II (DxxG in classical GTPases) 
is present in the N-terminal GTPase domains, but not the C-terminal GTPase domains. 
This residue is typically involved in co-factor binding, but does not appear to greatly 
affect specificity or preference towards Mg2+ in the N-terminal GTPase domains relative 
to their C-terminal counterparts. In the class Ras protein H-Ras the G3 motif is DTAG, 
while in the C-terminal GTPase domain of the hMiros the closest possible G3-like motif 
is thought to be HDIS in hMiro1 and CEVG in hMiro2. In the hMiro1 and hMiro2 N-
terminal GTPase domains, the G3 motifs appear to be DYSE. While many of these 
residues may facilitate the binding of either Mg2+ or Ca2+, the differences seen at the 
primary structure level between the hMiro GTPase domains and classical members of the 
Ras superfamily may confer this unusual ability to bind either divalent ion for the 
purposes of hydrolytic activity. It is also possible that, upon folding into the native 3D 
conformation, each hMiro GTPase domain produces a Mg2+ binding site resembling that 
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of the classical Ras enzymes but with the capacity to also bind Ca2+, and that this may 
simply not be obvious when observing at the primary structure level. Indeed, recent 
crystallographic studies on Mg2+ and GDP-bound dMiro suggest that the following 3D 
ligand in the C-terminal GTPase domain associates with Mg2+: JLVVSXFLKOJNIY-
UHFFFAOYSA-N (where J indicates isoleucine or leucine and X indicates any amino 
acid). This is, in fact, identical to RhoA (PDB: 5C4M) and HRas (4RSG) Mg2+ binding 
ligands according to crystallographic studies. Interestingly, previous crystallographic 
studies on human HRas have demonstrated an ability for this enzyme to bind Ca2+ in the 
presence of DTT in a manner that shifts the GTPase towards the “on state” via the 
following ligand: BHPQYMZQTOCNFJ-UHFFFAOYSA-N (where Z indicates E or Q 
and B indicates D, N or J). Correspondingly, it seems entirely possible that the hMiro 
GTPases may bind either Mg2+ or Ca2+ as a co-factor during nucleotide hydrolysis. 
Intriguingly, dMiro crystal structures (PDB: 4C0K and 4C0L) indicate that the EF-hand 
domains are also able to bind both Ca2+ and Mg2+. It is perhaps possible that this co-factor 
promiscuity is linked to putative calcium buffering functions for the hMiros. However, 
further experimental work is required to explore this.  
Although both the hMiro1 and hMiro2 N-terminal GTPase domains displayed substrate 
specificity for GTP, the C-terminal GTPase domains of these enzymes were capable of 
hydrolysing UTP and ATP in addition to GTP. No constructs tested displayed hydrolytic 
activity against CTP. In classical small GTPases, substrate specificity towards non-
phosphate regions of GTP is thought to occur, at least partly, through the G4 motif 
([N/T]KxD). In Ras, the lysine (K) and aspartic acid (D) residues of this motif are known 
to bind directly to the guanine ring, with substitution of the aspartic acid with asparagine 
resulting in increased substrate promiscuity in Ha-Ras p21 (293). These lysine and 
aspartic acid residues are present in all hMiro GTPase domains, although surrounding 
residues comprising the immediate tetrapeptide motif are quite different, as shown in 
Table 4.3, below. Again, of course, it is possible that the native 3D conformations of these 
enzymes serve to facilitate nucleotide binding promiscuity in a manner not explicitly 
obvious when observing the primary structure. 
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Table 4.3. G4 motif residues exhibited by classical Ras superfamily enzymes in comparison 
to those shown by hMiro GTPase domains. Red indicates small and hydrophobic residues, blue 
indicates acidic residues, magenta indicates basic residues and green marks residues harbouring 
hydroxyl, sulphydryl or amine groups. 
GTPase domain G4 motif ([N/T]KxD) 
HRas G domain NKCD 
RhoA G domain NKKD 
hMiro1N-terminal GTPase domain NKSD 
hMiro2 N-terminal GTPase domain NKSD 
hMiro1 C-terminal GTPase domain AKSD 
hMiro2 C-terminal GTPase domain SKAD 
 
As for the kinetic values for basal GTPase activity attained, observed Kcat turnover 
values were similar to those previously reported for the intrinsic GTPase activities of 
canonical Ras superfamily enzymes (270-276) and for the GTPases dynamin and Sept2 
(277,278), which contain G loop regions related to those exhibited by Ras superfamily 
members (277,278). Kcat values represent ‘turnover’ number, or the number of substrate 
molecules turned over per enzyme per unit time. In this case, Kcat can be considered to 
represent the number of Pi molecules released by the enzyme in question per minute due 
to GTP hydrolysis. As can be seen, the Kcat values obtained are low across the board, 
with a value of 1.063/min the highest value achieved in the hMiro experiments 
undertaken (corresponding to hMiro2 NT hydrolysing GTP) and Cdc42 exhibiting the 
highest Kcat amongst the canonical Ras superfamily enzymes listed in Table 4.1 with a 
Kcat of 1.120/min (273).  
Km and Kcat/Km values were not reported in the literature sources for canonical Ras and 
Rho enzymes. Km, also known as the ‘Michaelis constant’ is regarded as an inverse 
measure of affinity: for practical purposes, Km represents the concentration of substrate 
which permits the enzyme to achieve half Vmax (263). It therefore follows that a low Km 
value corresponds to a high enzyme-substrate affinity (294). Interestingly, the hMiro1 
CT domain showed more than twice the affinity for ATP than GTP (with Km values of 
4.959 for GTP and 2.094 for ATP, respectively). In contrast, the hMiro2 CT domain 
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displayed only a slightly higher affinity for GTP (Km: 0.917) than ATP (Km: 1.207). the 
Km values obtained here were rather high compared to the Km values of Dynamin 
(0.0034 mM) and Sept2 (0.00052 mM). For the hMiro domains tested, the hMiro1 NT 
and CT had similar Km values of 12.026 mM and 11.044 mM, respectively (mean Km: 
11.535 mM). Meanwhile, hMiro2 NT had a Km value of 53.155 mM and hMiro2 CT a 
Km value of 0.917 mM. The Km values for ATP hydrolysis were 2.094 for hMiro1 CT 
and 1.207 for hMiro2 CT. In an analysis of kinetic data from thousands of enzymes in 
databases, Bar-Even and colleagues found a median Km of 0.1 mM across all enzymes 
tested, with around 60% of enzymes exhibiting Km values of 0.01–1mM (294). 
However, many enzymes showed Km values exceeding 10mM (294). The relatively 
high Km values shown here indicate that the hMiro1 and hMiro2 G domains possess a 
lower affinity for GTP than other GTPases and many enzymes for their substrate. As for 
the Kcat/Km values obtained, all hMiro domains assessed showed a Kcat/Km value of 
<0.1, while dynamin and Sept2 exhibited values of 55.882 and 31.154, respectively. 
This suggests that the hMiro domains are not very efficient catalysts for GTP and ATP 
hydrolysis compared with dynamin and Sept7, seemingly as a result of the high Km 
values (and thus low affinities for substrate) observed for the hMiro1 and hMiro2 
constructs.  
The high Km values obtained for the hMiro constructs, relative to the GTPases dynamin 
and Sept2 (277,278) in addition to the Km values discussed by Bar-Even and colleagues 
(294), may be associated with several factors. The nucleotide binding site may not be as 
accessible in the hMiro domains as in other GTPases, for example, or nucleotide 
binding may be adversely affected due to substitutions in amino acids usually strongly 
conserved for nucleotide binding. Indeed, an assessment of the G loop regions of the 
hMiro1 and hMiro2 NT and CT domains (see Table 4.4, following) indicates an absence 
of a normally strongly conserved threonine (T) at position 35 in canonical Ras 
superfamily enzymes. The hMiro NT domains and hMiro2 CT also lack the conserved 
glycine usually observed at residue 60. These residues typically engage in hydrogen 
bonding with the gamma phosphate of GTP as part of the ‘loaded spring’ mechanism 
described previously (37). Otherwise, the lysine (K) and serine/threonine [S/T] residues 
normally conserved at positions 17 and 18 and involved with beta and gamma 
phosphate oxygen interactions (55,69) are observed in all hMiro domains. Too, the 
valine (V) at position 14, involved in forcing the GTP into a strained position for 
hydrolysis (112), is conserved in all but hMiro1 NT. The nucleotide-binding lysine and 
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aspartic acid residues of the G4 loop (96,97) are also conserved in hMiro1 and hMiro2 
NT and CT domains. Thus, several residues involved in nucleotide binding (61,99) are 
conserved in the hMiro1 and hMiro2 domains, but others have been substituted. This 
may partly explain the high Km values observed for the hMiro NT and CT domains. 
Indeed, analysis of a recently published crystal structure of a truncated version of 
hMiro1, containing the EF-hand domains and CT domain, indicates a lack of binding a 
non-hydrolysable analogue of GTP (295), which may influence affinity; gamma 
phosphate binding was observed for the same non-hydrolysable GTP analogue bound to 
Cdc42 (296). It is noteworthy to mention that some of the residues discussed above are 
also absent in dynamin and sept2. However, these enzymes are not representative of 
classical members of the Ras superfamily and that only indirect comparisons of the 
kinetic data attained should be conducted in this context, as discussed below.    
Table 4.4 Differences in the G domain loop regions: classical versus atypical Ras 
superfamily enzymes 
Protein Identifier G1 G2 G3 G4 G5 
---- 
Consensus 
sequence 
GxxxxGK[S/T] T DxxG [N/T]KxD [S/C]A[L/T/K] 
HRas CAG38816.1 GAGGVGKS T DTAG NKCD SAK 
RhoA AAM21117.1 GDGACGKT T DTAG NKKS SAK 
Cdc42 NP_426359.1 GDGAVGKT T DTAG TQID SAL 
Rac1 CAB53579.5 GDGAVGKT T DTAG TKLD SAL 
RhoH AAM21122.1 GDSAVGKT T DTAG TQTD SAL 
hMiro1 
NT 
AAI25105.1: 
7–169 
GEPRVGKT P DYSE NKSD SAK 
hMiro1 
CT 
AAI25105.1: 
415–592 
GVKNCGKS D DISE AKSD NTA 
hMiro2 
NT 
AAI25105.1: 
3–169 
GEAQVGKT P DYSE NKSD SAK 
hMiro2 
CT 
AAI25105.1: 
413–589 
GARGVGKS E CEVG SKAD AGP 
Dynamin AAA88025.1 GGQSAGKS G DTPG TKLD VNR 
Sept2 AAH33559.1 GESGLGKS G DILQ AKAD GSN 
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Several limitations should be borne in mind when considering the kinetic data obtained 
and comparing it to kinetic values derived from the literature. It should also be noted 
that the use of Lineweaver-Burke plots to obtain kinetic data is associated with a large 
degree of error, as taking the reciprocal of Vmax can greatly increase small errors of 
measurement (297). Additionally, as aforementioned, comparing the kinetic data 
obtained during this study to data available in the literature is difficult for several 
reasons, namely due to differences across studies in: detection methods for Pi detection, 
experimental conditions (including temperature) and data interpretation. Reaction 
temperatures associated with literature-derived hydrolysis rates ranged from 20oC (271) 
to 37oC (272). This is significant, as increases in temperature are associated with higher 
reaction rates (298). Indeed, for many chemical reactions occurring at room 
temperature, 
an increase in temperature by 10oC is commonly thought to double the reaction rate 
(299,300). This generalisation is useful for acknowledging the effect of temperature on 
reaction rates, although it should be viewed cautiously and noted that for enzymatic 
reactions, temperatures above 40–50oC will likely result in enzyme denaturation and a 
corresponding reduction in reaction rate (301). No reactions described in the literature 
were performed at >37oC (physiological temperature), thus thermal denaturation should 
not have occurred. However, the range of temperatures reported is an important factor 
that should be considered when interpreting results against kinetic data obtained from 
the literature. Kinetic experiments for the hMiro NT and CT domains were undertaken 
at 25oC, whereas only the values for the Rac enzymes shown in Table 4.1 appear to 
have been obtained from experiments also performed at 25oC. Furthermore, various 
experimental techniques were utilised in kinetic experiments described in the literature, 
namely the use of: HPLC (272), colorimetric (271,278), fluorescent (270,271,273) and 
radioactivity (277) detection methods. The study involving dynamin basal GTP 
hydrolysis rates appeared to be the only study that made use of the malachite green 
method (278). Analysis of raw data obtained from hydrolytic activity assays was also 
varied across the studies, with some researchers employing the use of Lineweaver-
Burke plots in the same manner performed herein (271,278) while others utilised 
automatic fitting software such as EnzFitter (Sigma-Aldritch, USA) (273). Of additional 
note, it should be considered that only sparse data is available on the intrinsic hydrolytic 
activities of the Ras GTPases, perhaps due to a focus on GAP-mediated hydrolysis in 
the literature (270-276). This is likely due to the fact that GAP enzymes are considered 
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critical regulatory enzymes for the Ras superfamily (2,302) and can vastly increase 
hydrolytic reaction rates (2,302,303); for example, the rate of GTP hydrolysis by the 
Rho enzyme Cdc42 is increased by more than 2,000 times the basal rate in the presence 
of the Cdc42GAP regulatory enzyme (303). Taken together, the differences listed 
indicate that direct comparisons across these studies should not be performed. 
Nonetheless, indirect comparisons of the measurements obtained, compared with kinetic 
values found in the literature, provide an insight into the capabilities of hMiro1 and 
hMiro2 intrinsic GTP hydrolysis. 
4.5.2. Knockdown studies 
The data obtained from knockdown studies is partly consistent with previous work, 
indicating that knockdown of the hMiros results in a reduction in cell migration and 
apparent perinuclear aggregation of mitochondria (29,96). However, the results were not 
statistically significant. Around 30–50% of dual knockdown cells displayed a swollen 
morphology, indicating hydropic degeneration: a marker of almost all forms of injury to 
cells and a feature typically exhibited by senescent cells (304). Although hydropic 
degeneration can occur through a variety of mechanisms (304,305), perhaps the most 
likely cause in this scenario is deficient mitochondrial transport resulting from hMiro1 
and 2 ablation (29,96). A disruption in the ability of mitochondria to produce or deliver 
ATP to ATP-dependent ion-pumps at the plasma membrane, for example, can result in a 
build-up of intracellular sodium ions and a subsequent influx of water into the cell, 
producing bloating (306). It is unusual that the hMiro1 knockdown produced the greatest 
decrease in net migration during 24 hour migration assays, while this swollen morphology 
is only seen in dual knockdown cells. However, it is possible that only ~30-50% of the 
dual knockdown cells viewed had achieved knockdown of both hMiro1 and 2; several of 
the dual knockdown condition cells may only achieved knockdown of hMiro1 or 2. 
Additionally, knockdown may have failed altogether in some cells. Regardless of this, 
the results indicate a difference between control cells and knockdown cells. 
4.5.3 Biophysical characterisation of hMiro1 and hMiro2 
The biophysical properties assessed for hMiro1 and hMiro2 were very similar, with both 
constructs showing a similar size and thermal stability. The hMiro ‘xtal’ constructs were 
utilised in all biophysical characterisation studies, as these constructs represented the 
closest suitable constructs to full length hMiro1 and hMiro2. 
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4.5.3.2 Dynamic light scattering 
 
Canonical members of the Ras superfamily are quintessentially monomeric. However, 
due to the atypical nature of the Miros, dynamic light scattering (DLS) was undertaken 
to clarify the oligomeric state of hMiro1 and hMiro2. Here, DLS experiments produced 
single peaks, with average sizes calculated as 5.56 ± 0.57 nm for hMiro1 hMiro1XTAL 
(E177–R590) and 5.72 ± 0.56 nm  for hMiro2XTAL (E177–P586), which corresponded to the 
expected sizes of these enzymes and thus indicated that hMiro1 and hMiro2 exist 
monomerically. It has become increasingly apparent that fly and mammalian Miro 
proteins engage in a mitochondrial transport complex with several other proteins  (191). 
This function of the Miros, in addition to the DLS results obtained herein, strongly 
suggest that the hMiros function as proteins that engage in prolonged interactions with 
other proteins rather than homo-oligomerising. In summary, these results indicate the 
presence of the human Miros in monomeric form. Considering that hMiro1XTAL and 
hMiro2XTAL are very similar dMiro, this may not simply be a construct effect and it is 
noteworthy that the human Miros may function as monomers under physiological 
conditions.  
4.5.3.3 Thermal denaturation 
 
The thermal melt for each construct, measured at 220 nm, gave a melting temperature 
(Tm) of 54.4 
oC for hMiro1XTAL and 57.4 
oC for hMiro2XTAL, where Tm is defined as the 
temperature at which the protein unfolds. Relative to previous studies on the 
thermodynamics of various proteins, these Tm values are not unusually high or low, 
indicating that both hMiros possess average thermal stability. For example, a 1997 study 
on water-soluble globular proteins showed a mean Tm of 68.7
oC, with values ranging 
from 24.9–103.85oC but most proteins displaying a Tm between 50–60 oC (282). 
Furthermore, the Tm of human H-Ras has previously been noted as 52.5
oC (283), while a 
set of Ras yeast paralogues showed Tm values ranging from 35–63 oC (307). Tm values 
exhibited by thermostable extremozymes have been documented to exceed 100oC (308), 
with some showing Tm values as high as 176.9 
oC (309). A correlation between protein 
stability and the arrangement of non-surface ionisable side-chains has been recently 
indicated, with thermophilic proteins typically possessing a smaller core network of 
residues with ionisable side-chains (307).   
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However, comparisons of thermodynamic properties between proteins should be 
considered carefully. The thermal stability and Tm of a given protein result from numerous 
complex factors associated with the protein itself and the environment in which is it 
present. For example, the hMiroXTAL constructs were suspended in the following buffer 
environment: 25 mM HEPES pH 7.4, 500 mM NaCl, 2 mM DTT and 2% glycerol. While 
these conditions appeared to be necessary for storing the hMiro constructs and preventing 
aggregation even at low temperatures (4 – 10oC), all of these components have previously 
been found to affect the thermostability of proteins. For instance, although HEPES is 
frequently recommended as a buffer for CD, studies on the Escherichia coli protein RecA 
demonstrated that buffer choice in CD experiments can affect the melting temperature 
obtained by more than 50% (310). In this study, a phosphate buffer system produced a 
melting temperature of >105oC regardless of pH (tested range: pH 6.5 - 8.5). When Tris, 
HEPES and MES were used in place of this phosphate buffer, Tm values were much 
lower. Furthermore, variation in recorded melting temperature at each pH was seen across 
all buffer systems utilised. For example, the melting temperature at pH 7.0 for Tris, MES, 
HEPES and phosphate buffering systems were respectively recorded as 65oC, 88oC, 78oC 
and >105oC. Interestingly, while these buffers affected thermostablity, they did not 
significantly affect the enzymatic function of RecA.  
NaCl, DTT and glycerol have also been shown to influence protein thermostability. It has 
been long-established that NaCl has a significant impact on protein stability by altering 
interactions of the aqueous solvent with the protein by preferential hydration (the 
Hofmeister effect) (311). In some proteins, NaCl also influences thermal stability by 
screening electrostatic interactions between charged protein surface residues (312). For 
instance, if these surface charges are primarily repulsive of one another, the presence of 
NaCl will improve the stability of the folded protein by screening these electrostatic 
interactions. DTT is typically used to reduce protein disulphide bonds and prevent 
intramolecular and intermolecular disulphide bond formation between cysteine residues 
of proteins  (313). In several studies, DTT has been shown to lower protein thermal 
stability when it is added to the protein buffer (314). This effect is not universal, however. 
In the biophysical experiments described in this chapter, DTT was utilised to discourage 
hMiro aggregation following expression and purification. Alternatively, glycerol was 
typically added to the hMiro buffers both as a cryoprotectant and stability-enhancing co-
solvent, encouraging protection from freezing damage and discouraging aggregation, 
respectively. Glycerol is believed to encourage the native protein into a more compact 
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state, inhibiting unfolding and stabilising aggregation-prone intermediates through 
interactions with hydrophobic surface areas (315). As such, glycerol addition has been 
shown to improve Tm in various proteins (316). 
In short, the factors that may influence the thermal stability and melting temperature of a 
protein are extensive and complex. This, alongside the limited CD experiments 
undertaken for these constructs, should be taken into account when considering the Tm 
values obtained. Overall, however, the CD data obtained indicates a relatively average 
thermostability for the hMiros. 
4.5.4 Conclusions 
Both the N- and C-terminal GTPase domains for hMiro1 and 2 are capable of hydrolysing 
GTP. While the N-terminal GTPase domains display substrate specificity towards GTP, 
the C-terminal GTPase domains display hydrolytic activity towards ATP and, to a much 
lesser extent, towards UTP. Knockdown of hMiro1, 2 or both hMiros (dual knockdown) 
in PC3 cells produces a decrease in cellular migration relative to control cells, with 
perinuclear aggregation of mitochondria exhibited by knockdown cells. Dual knockdown 
was also associated with a swollen cell morphology in ~30-50% of cells. Both hMiros 
appear to exist monomerically and present with average thermostability, showing Tm 
values ranging from 54.4oC to 57.4oC. 
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Chapter 5: Investigating Miro GTPase signalling pathways using 
proteomics and computer-based prediction software 
5.1 Introduction 
5.1.1 Objectives 
Recent improvements in biological mass spectrometry and analysis software have 
allowed proteomics to emerge as a powerful tool for the characterisation of signalling 
pathways (317,318). The objective of the work undertaken in this chapter was to elucidate 
Miro GTPase signalling pathway components through the use of molecular biology, cell 
culture techniques and proteomics.  An investigation of this kind has not been performed 
previously, and was hoped to enable the profiling and identification of pathways regulated 
by the hMiros. 
5.1.2 Overview of proteomics applications 
Intracellular biochemical reactions are principally regulated by highly specialised 
enzymes (319), which typically act within orchestrated signalling pathways with other 
proteins or intracellular components (320-326). Thus, proteins and their respective 
signalling pathways are prime mediators of cellular function and phenotype (327-330). 
Consequently, the identification, quantitation and characterisation of intracellular 
proteins is critical for understanding the molecular mechanisms associated with cellular 
physiology and phenotype. The term ‘proteome’ first arose in 1995, defined as 'the total 
protein complement of a genome' (331). This initial definition reflected what was known 
about protein expression at the time, acknowledging that not all proteins encoded by the 
genome are expressed at any one point and that protein expression is subject to a range 
of factors including physiological state (332), cell type (333) and developmental stage 
(334). Indeed, the abundance of a given protein is the result of four primary influences: 
protein synthesis, protein processing, protein secretion and protein degradation (335). 
Correspondingly, correlation between mRNA and protein levels is known to differ by 20-
100 fold (336,337).  
The term 'proteomics' itself relates to proteins expressed in a specified cell, tissue or 
organism. Proteomics approaches have been used to address a wide array of biological 
questions, including the investigation of changes to the proteome under pathological 
conditions relative to healthy control conditions (338-342), leading to the direct clinical 
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application of proteomic information (343,344). Indeed, proteomics is now established as 
a valuable tool in drug development (345,346) and biomarker discovery (347,348).  
Although the emergence of robust, reliable mass spectrometers capable of analysing 
complex mixtures has brought vast improvements to the field of proteomics, proteomics-
based experiments are still fraught with challenges at every stage: from sample 
preparation (349) and data acquisition (350-352) to database searching (353,354) and the 
interpretation of (often vast) datasets (355,356). Several different approaches and 
techniques are available for use at each phase of a proteomics experiment. However, a 
schematic diagram of a generalised overall approach for ‘shotgun’ proteomics (also 
referred to as ‘discovery’ proteomics) is provided below (Figure 5.1).  
 
Figure 5.1. Schematic of a general ‘shotgun’ proteomics approach. Schematic of 
general ‘shotgun’ proteomics approach, adopted from a recent review (357). IEF denotes 
isoelectric focusing, while SCX denotes a strong cation exchange resin commonly used 
to fractionate proteins in some shotgun approaches. LC denotes liquid chromatography. 
 
The ‘shotgun’ approach essentially involves the use of a LC-MS tandem mass 
spectrometry device to identify peptides that have been digested from a complex solution 
of proteins derived from a sample of interest. It is important to note that at least three 
biological replicates (preferably more) are necessary for the acquisition of reliable 
proteomics data, as variation between biological replicates for mammalian cell lines has 
been shown to vary by ~24-29% (358). Sample preparation and the LC-MS equipment 
used will also introduce technical variations. With this in mind, sample preparation (stage 
Sample
E.g. cell or tissue lysate
Fractionation
Gel, LC, IEF etc. 
(optional)
Proteolytic 
digrestion
Trypsin
Peptide 
fractionation
SCX, IEF etc. (optional)
LC-MS/MS
Peptide fragment
Protein database
Protein identification
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1 of figure 5.1) should be followed in a meticulous fashion, as numerous variables may 
affect proteome composition (359); even small deviations from a precise sample 
preparation method may influence final results. Proteins such as human keratin, from the 
researcher(s) involved in the study, may also contaminate samples and manifest as hits 
downstream of the process during data analysis (360). As such, all stages of a proteomics 
experiment should be implemented in a precise and careful manner, preferably under a 
laminar flow hood to avoid sample contamination (360). Preparation may take anywhere 
from hours to weeks, depending on the nature of the study and the samples to be assessed.  
Samples to be investigated, once prepared, are typically extracted and digested. An array 
of methods are available for the extraction of proteins, though the chosen approach is 
often dependent on the nature of the original sample (361-363). Digestion is typically 
accomplished by exploitation of trypsin alone (364), although some approaches 
incorporate the inclusion of additional proteases such as Lys-C, Lys-N, ArgC, AspN or 
GluC (365). Digestion is generally preformed at 37oC for at least four hours. Proc et al., 
suggested an optimal digestion time of 9 hours using trypsin alone (366), although it is 
considered conventional to digest overnight (367). Attempts to hasten the digestion 
process have involved the use of immobilised trypsin matrices (368) and high intensity 
focused ultrasound (369), the latter of which has been reported to digest protein samples 
in 60 seconds or less with comparable efficiency to a traditional overnight method. In 
some cases, successful digestion is followed by fractionation of peptides. Fractionation 
can be achieved through a variety of methods, such as peptide isoelectric focusing (pIEF) 
or strong cation exchange (SCX) chromatography, although some experiments will 
involve earlier fractionation of proteins prior to digestion (370). The primary aim of 
fractionation involves depleting unnecessary, highly abundant proteins to facilitate the 
discovery of specific protein groups within a sample (371). Depending on the aim of the 
experiment, however, fractionation may not be required. The resulting peptides are 
subsequently prepared for mass spectrometry and samples separated according to specific 
requirements suitable for the equipment and particular experiment at hand.  
Analysis of raw data files is typically handled by highly specialised analysis software in 
conjunction with specialised database searching software such as MASCOT (372) or 
X!Tandem (373), which use algorithms to match experimental spectra with theoretical 
spectra based on enzymatic cleavage of proteins, and correspondingly suggest protein 
‘hits’ (372,374). MASCOT makes use of a proprietary scoring algorithm developed from 
the molecular weight search (MOWSE) algorithm (375), comparing each experimental 
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spectra to a database of theoretic spectra originally derived from genomic information. 
Using this system, peptides that are predicted to arise from the same protein are grouped 
and the hit, or match, is assigned a confidence value corresponding to how well fitted the 
experimental spectra is to the theoretical spectra. A threshold value is implemented to 
assess whether the match has occurred by chance (372). X!Tandem operates in a similar 
manner, with the workflow separated into two distinct stages. First, a comparison of the 
experimental spectra to spectra in the database is performed. This is followed by the 
generation of a database containing only the identified protein ‘hits’. The second stage 
then comprises the identification of modified peptides that match proteins in the generated 
databased. This two-staged method is employed to increase confidence scores, with 
scoring in X!Tandem based on probability scoring in a similar manner to MASCOT. A 
histogram is generated for each spectrum-to-sequence assignment and the protein with 
the highest score typically considered the correct identification. Probability scores are 
subsequently generated from the log transformed hyperscores to establish whether the 
match occurred by chance (376-378). Several methods for further validating protein hits, 
including resolution of conflicting hits, is generally available through specialised 
computer software. Ultimately, a list of protein hits is generated based on automated 
assessment of initial raw data and a degree of user input, enabling further downstream 
analysis according to experimental hypotheses or objectives.  
The work presented in this chapter comprises efforts to utilise, for the first time, 
proteomics approaches in the identification of Miro signalling pathway components. 
including an establishment of protein expression alternations when the GTP hydrolytic 
capacity of the hMiro GTPase domains are altered, and a comparison of protein 
expression levels between these conditions in cultured mammalian cells. 
5.2 Biological samples: hMiro overexpression and knockdown 
5.2.1 hMiro overexpression studies 
Pioneering studies on hMiro function involved the ectopic overexpression of wildtype 
and mutant hMiro proteins in mammalian cell lines, where mutations were designed to 
produce hMiro proteins bearing either constitutively active (V13) or dominant negative 
versions (N18) of the N-terminal GTPase domain (29,96). The mutants were produced 
based on known constitutively active and dominant negative mutations in Ras and Rho 
enzymes, where G12V or G13V produce constitutively GTP-bound enzymes through 
steric hinderance of GAP enzymes (58), and S18N mutants are associated with a loss of 
 198 
 
Mg2+ and steric occlusion of the conserved nucleotide-binding phenylalanine (F) residue 
at position 28 (93). Furthermore, it is generally accepted that S18N mutants sequester 
GEF enzymes, depleting the intracellular pool and thus blocking activation usually 
mediated by these GEFs (379-381). It is generally accepted that S18N mutants remain 
constitutively bound to GDP (58). While these mutants were originally developed when 
it was unknown whether Miro GAP and GEFs existed, these mutants are known to exert 
biological effects (29) and have been used in the literature as constitutively active and 
dominant negative mutants, respectively (29,97,268,382,383). Indeed, overexpression of 
hMiro1 V13 mutants appeared to increase apoptotic rate relative to control cells and 
encouraged mitochondrial aggregation (29). Later studies involved the assessment of 
further mutants, including point mutations to the C-terminal GTPase domain and 
mutations disabling function of the EF hand domains (∆EF) (268). The results, overall, 
implicated the status of the hMiro GTPase domains in mitochondrial morphology and 
aggregation, with hMiro1 mutations and mutations of the N-terminal GTPase domains 
producing the most striking phenotypes (162).  
Here, in an attempt to elucidate the signalling pathways involved in hMiro GTPase 
domain and EF hand status, panels of plasmids encoding hMiro1 and 2 mutants were 
designed with the objective of ectopically expressing distinct hMiro mutants in 
mammalian cell lines. The expression of these mutants was hypothesised to trigger 
discreet intracellular signalling events, producing changes in the proteome that could be 
detected and assessed. pRK5-Myc plasmids encoding hMiro1 and hMiro2 WT, V13, N18 
and ∆EF were kindly donated by the Pontus Aspenström Group (Karolinska Institutet, 
Sweden); these plasmids were utilised as template for site-directed mutagenesis to 
produce the panel of mutant-encoding plasmids shown in Table 5.1 (hMiro1 plasmids) 
and Table 5.2 (hMiro2 plasmids). All mutant-encoding plasmids were shipped for 
sequencing at an independent, commercial laboratory and showed the desired point 
mutations with no unwanted changes present (see Figure 5.2). 
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Table 5.1. Panel of hMiro1 plasmids intended for use in proteomics investigations. WT, V13, N18 and ∆EF encoding plasmids were provided by the Pontus 
Aspenström Group (Karolinska Institutet, Sweden). Note that for ∆EF mutants, functional abrogation of the EF hands was achieved by substitutions at position 208 
and 328 with lysine (K). 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid Intended effect 
hMiro1 WT Full-length, wildtype hMiro1 
hMiro1 S432N Wildtype N-terminal GTPase domain and dominant negative C-terminal GTPase domain 
hMiro1 G425V Wildtype N-terminal GTPase domain and constitutively active C-terminal GTPase domain 
hMiro1 N18 hMiro1 with dominant negative N-terminal GTPase domain and wildtype C-terminal GTPase domain 
hMiro1 N18/S432N hMiro1 with dominant negative N-terminal and C-terminal GTPase domains 
hMiro1 N18/G425V hMiro1 with dominant negative N-terminal GTPase domain and constitutively active C-terminal GTPase domain 
hMiro1 V13 hMiro1 with constitutively active N-terminal GTPase domain and wildtpye C-terminal GTPase domain 
hMiro1 V13/S432N hMiro1 with constitutively active N-terminal GTPase domain and dominant negative C-terminal GTPase domain 
hMiro1 V13/G425V hMiro1 with constitutively active N-terminal and C-terminal GTPase domains 
hMiro1 ∆EF Full-length, wildtype hMiro1 with abolished EF hand calcium binding function 
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Table 5.2. Panel of hMiro2 plasmids designed for use in proteomics investigations. WT, V13, N18 and ∆EF encoding plasmids were provided by the Pontus 
Aspenström Group (Karolinska Institutet, Sweden). For ∆EF mutants, EF hand were rendered functionally obsolete by substitutions at position 208 and 328 with lysine 
(K). 
 
 
 
Plasmid Intended effect 
hMiro2 WT Full-length, wildtype hMiro1 
hMiro2 S430N Wildtype N-terminal GTPase domain and dominant negative C-terminal GTPase domain 
hMiro2 G423V Wildtype N-terminal GTPase domain and constitutively active C-terminal GTPase domain 
hMiro2 N18 hMiro1 with dominant negative N-terminal GTPase domain and wildtype C-terminal GTPase domain 
hMiro2 N18/S430N hMiro1 with dominant negative N-terminal and C-terminal GTPase domains 
hMiro2 N18/G423V hMiro1 with dominant negative N-terminal GTPase domain and constitutively active C-terminal GTPase domain 
hMiro2 V13 hMiro1 with constitutively active N-terminal GTPase domain and wildtpye C-terminal GTPase domain 
hMiro2 V13/S430N hMiro1 with constitutively active N-terminal GTPase domain and dominant negative C-terminal GTPase domain 
hMiro2 V13/G423V hMiro1 with constitutively active N-terminal and C-terminal GTPase domains 
hMiro2 ∆EF Full-length, wildtype hMiro1 with abolished EF hand calcium binding function 
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Figure 5.2. Sequence trace sections for hMiro1-encoding mutants, with relevant codons 
highlighted. Mutations were introduced to hMiro1 WT (A-B), hMiro1N18 (C-D) and 
hMiro1V13 (E-F) plasmids previously donated and sequenced by the Pontus Aspenström Group, 
Sweeden. (G) Respective plasmids visualised on 1% agarose gel. 
hMiro1 WT 
hMiro1 N18 
hMiro1 V13 
8, 000 
6, 000 
(G) 
M bp 
10, 000 
5, 000 
4, 000 
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Figure 5.3. Sequence trace sections for hMiro2-encoding mutants, with relevant codons 
highlighted. Mutations were introduced to hMiro2 WT (A-B), hMiro2N18 (C-D) and 
hMiro2V13 (E-F) plasmids previously donated and sequenced by the Pontus Aspenström Group, 
Sweeden. (G) SDM plasmids visualised on 1% agarose gel. 
hMiro2 WT 
hMiro2 N18 
hMiro2 V13 
8, 000 
6, 000 
(G) 
M bp 
10, 000 
5, 000 
4, 000 
3, 000 
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Plasmids confirmed to encode the desired hMiro mutant were transfected into COS7, 
HEK-293 or VSMC cells, respectively. Consistent with prior studies, the COS7 cells 
appeared the easiest cells to transfect for overexpression studies. Due to the strong 
phenotypes observed in the COS7 line in prior hMiro work using these plasmids, this cell 
line was selected. Wildtype and mutant hMiro was ectopically expressed as described in 
2.2.6.4. Cells were incubated for 72 hours and subsequently processed for geLC-MS, as 
detailed in Chapter 2, sections 2.2.6.6 and 2.2.7.3. To confirm overexpression, 10 µg of 
each sample was retained and subjected to Western blotting (2.2.4.8); Figure 5.4 displays 
a typical Western blot exhibiting successful overexpression of target hMiros relative to 
control cells. 
 
 
 
 
 
 
 
 
 
Figure 5.4. Immunoblot displaying successful overexpression of both wildtype and mutant 
hMiros.  
20 µg of each validated sample was loaded onto a 12% SDS-PAGE gel and processed 
through the geLC-MS method discussed in section 2.2.7.3. LC-MS was undertaken 
(2.2.7.4) and samples analysed using Progenesis (2.2.7.5). Unfortunately, due to 
persistent technical issues with the available mass spectrometer throughout this study, a 
limited of samples were fully processed. The samples processed corresponded to the 
mutants V13, N18 and control samples for both hMiro1 and hMiro2.   
 
 
kDa   3              4             5              6             7            8 1 
(+
) co
n
tro
l 
M
ark
er 
(-) co
n
tro
l 
h
M
iro
1
 W
T
 
h
M
iro
1
 V
1
3
 
h
M
iro
1
 N
1
8
 
h
M
iro
1
 Δ
E
F
 
M
o
ck
 
 204 
 
5.2.2 Biological samples: hMiro knockdown samples 
Knockdown samples were prepared as described in 2.2.6.5. Due to improved 
methodology tested by the NUOmics team, knockdown samples were not fractionated on 
the SDS-PAGE gel, and instead were intended to be loaded onto the LC-MS apparatus as 
one fraction with a longer gradient applied. Unfortunately, due to consistent technical 
issues with the Q-Exactive, the data retrieved from these samples was unsuitable for 
analysis. However, a full set of samples were prepared and will be processed for future 
confirmatory work. 
5.3 Computer-based prediction of hMiro interaction partners 
Experimental methods for detecting protein-protein interactions often yield false 
discoveries (384). Additionally, data derived from proteomics is typically complex and 
noisy. To enable further refinement of proteomics analysis, computer-based prediction 
of hMiro interaction partners was undertaken. Several approaches for the computer-
based prediction of protein-protein interactions are available. However, the STRING 
online resource is highly regarded in the literature (385-387), providing a database of 
known and predicted protein-protein interactions through integration of several different 
methods including: collation of experimental data, automated literature (text) mining 
and the gathering of data from curated databases (388). Additionally, STRING infers 
functional relationships between proteins by assessing co-expression (whether other 
proteins are expressed and repressed in a similar manner to the query protein), co-
occurrence (assessing genes that appear in the same phylogenetic lineage as the gene 
encoding the query protein), gene fusion (assessing whether the gene encoding the 
query protein is known to undergo fusion with other genes) and gene neighbourhoods 
(the extent to which there are genes frequently nearby the gene encoding the query 
protein; useful mostly for prokaryotic proteins) (388). After identifying putative 
interactors for the query protein, STRING is able to search curated databases such as the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) to examine whether any patterns 
of functional enrichment exist: essentially, whether the putative interactors are 
frequently associated with specific biological pathways or functions. With this 
considered, in silico predictions of hMiro1 and 2 interaction partners were first 
undertaken using the STRING database. STRING allows for the prediction of both 
direct interactions (1st shell) and indirect interactions (2nd shell), displayed as either 
coloured or clear globes, respectively. 
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Basic results from STRING are provided as Figure 5.5, with results for both hMiro1 and 
2 shown. These results exhibit the 10 putative direct interactors (1st shell) with the 
highest confidence scores when all interaction sources are combined, with information 
on these interactors provided in tabular form alongside the visual output. For each 
output, top-scoring functional enrichment data related to biological processes and 
KEGG pathways are given in Table 5.3 for hMiro1 and 5.4 for hMiro2, respectively. 
STRING generated extensive lists of putative hMiro interactors and signalling networks 
(example table of hits displayed in Appendix 11, showing a small number of the 
hundreds of suggestions); these were used for cross-referencing proteomics results.
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              (A)                                                                                                       (B) 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Basic results from the STRING online tool for (A) hMiro1 and (B) hMiro2. (A) Visual output of 10 putative direct interactors (1st shell) with the 
highest confidence scores when all interaction sources are combined. Note that RhoT1 and RhoT2 refer to hMiro1 and hMiro2, respectively. 
 207 
 
Table 5.3. Pathways predicted to be associated with hMiro1. Based on automated functional enrichment analysis of the simple results shown in Figure 5.5 (A), 
with functional enrichment relating to biological processes and KEGG pathways are displayed in the table. 
Pathway description  Observed gene count False discovery rate 
Regulation of small GTPase mediated signal transduction 7 4.62E-08 
Regulation of intracellular signal transduction 9 4.42E-06 
Regulation of signal transduction 10 8.13E-06 
Intracellular signal transduction 8 0.000497 
Small GTPase mediated signal transduction 6 0.000545 
Negative regulation of oxidative stress-induced neuron intrinsic apoptotic signalling pathway 2 0.00402 
Regulation of I-kappaB kinase/NF-kappaB signalling 4 0.00526 
Regulation of protein targeting to mitochondrion 3 0.0163 
Regulation of mitochondrial fission 2 0.0253 
Single organism signalling 9 0.0311 
Regulation of dopamine secretion 2 0.0325 
Cellular response to toxic substance 2 0.0438 
Ubiquitin-mediated proteolysis 3 0.0125 
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Table 5.4. Pathways predicted to be associated with hMiro2. Based on automated functional enrichment analysis of the simple results shown in Figure 5.5 (B), 
with functional enrichment relating to biological processes are shown. 
 
 
 
Pathway description Observed gene count False discovery rate 
regulation of small GTPase mediated signal transduction 10 1.50E-15 
regulation of intracellular signal transduction 11 3.40E-10 
small GTPase mediated signal transduction 8 2.82E-07 
intracellular signal transduction 9 1.27E-05 
actin cytoskeleton organization 5 0.00108 
regulation of cell shape 3 0.0358 
single organism signalling 9 0.0358 
cell communication 9 0.0399 
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5.4 Proteomics analysis of prepared samples 
Proteome analysis of COS7 cells bearing overexpressed hMiro mutants was undertaken 
and compared to control (mock transfection) conditions. Initial analysis of the data 
included a comparison of X!Tandem versus MASCOT, the two most widely used 
databases. For analytical purposes contaminant proteins (keratin, etc.)  were omitted from 
analysis. The two programmes identified similar numbers of proteins, as shown in Table 
5.5. Interestingly, the X!Tandem database consistently generated a greater number of hits. 
While direct comparisons of full protein lists generated by different database searching 
algorithms can be problematic (389), recent studies have shown improved confidence 
scores and increased peptide identifications when the results of multiple database 
programmes are combined (390).  
The proteome was mapped for each condition in duplicate, with raw data processed using 
Progensis to identify any trends. First, principle component analysis (PCA) plots were 
generated to compare the automatically assigned alignment generated by Progenesis to a 
manually assigned alignment. This was necessary to validate the reference selected by 
Progenesis. No difference in trends nor any visible difference in distinct groupings were 
found between the PCA plots, suggesting that the Progenesis automatic assignment of 
alignment was suitable for use. Data was subsequently processed using Progenesis 
software and protein expression across each condition compared, enabling the 
identification of unique proteins expressed under each condition (Figure 5.6). To further 
refine results, comparisons were drawn between predicted interaction partners for each 
hMiro and the proteomics data. Each hMiro was assessed separately, with the unique 
proteins identified under control, V13 and N18 conditions compared to predicted putative 
interactors using STRING, known hMiro binding partners identified in the scientific 
literature by manual literature searching and known binding partners of proteins 
homologous to either the hMiro1 or 2 N-terminal GTPase, respectively. Homologous 
proteins were identified by the pBLAST server on NCBI and their known interactors 
identified using the STRING algorithms for curated database searching and literature 
mining. As shown in Figure 5.7 for hMiro1 and 5.8 for hMiro2, predicted interaction 
partners and unique hits for specific conditions were present, reinforcing the possibility 
of these hits as genuine binding partners. Tables  5.6 and 5.7 detail these unique hits. 
Unless otherwise stated, descriptions of the functional aspects of each hit are based on 
those assigned by RefSeq (391).
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Table 5.5. Number of proteins identified for each condition (mean across duplicates), showing 
MASCOT versus X! Tandem. 
 
 
 
Condition MASCOT (n) X! Tandem (n) 
Control 676 694 
hMiro1 V13 498 507 
hMiro1 N18 623 645 
hMiro2 V13 421 430 
hMiro2 N18 846 856 
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Figure 5.6. Number of proteins identified for each condition from the raw 
proteomics results, following hit filtering and conflict resolution in Progenesis.  
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Figure 5.7. Number of hMiro1 proteins identified through proteomics endeavours, 
cross-checked against putative interactors identified by STRING, homology and 
literature searches.  
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Table 5.6. Identification of 13 proteins of interest associated with hMiro1 mutants. Proteins were identified through cross-referencing of experimental 
proteomics data with computer-based prediction methods. The condition in which each protein was uniquely present or enriched is shown, alongside a description 
of protein function. The STRING score provided reflects the combined STRING score when all STRING prediction and search methods are utilised, where ≥0.7 
equates to high confidence and ≥0.9 equates to the highest STRING confidence. 
Identifier Protein function 
STRING 
score 
Miro1V13(+)/STRING   
GPAT, ATASE, PRAT Regulatory allosteric enzyme; catalyses the first step of de novo purine nucleotide biosythetic pathway. 0.999 
SUMO3, HSMT3, smt3A 
Member of the small ubiquitin-related modifier (SUMO) family; becomes covalently conjugated to other proteins via post-translation 
sumolyation. 
0.999 
   
Miro1V13(+)/STRING/ 
Homology 
  
NEDD4-1, RPF1, KIAA0093 E3 ubiquitin protein ligase expressed in neuronal precursor cells; developmentally downregulated in the early central nervous system. 0.999 
   
Miro1N18(-)/STRING   
EF2, EEF-2, SCA26, EF-2 
Member of the GTP-binding translation elongation factor family; facilitates GTP-dependent ribosomal translocation during protein 
synthesis. 
0.999 
B-ALPHA-1, FLJ25113 Major microtubule component displaying enriched expression in morphologically differentiated neuronal cells. 0.986 
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Cortactin, EMS1 Promotes polymerisation and rearrangement of the actin cytoskeleton when stimulated by external stimuli. 0.985 
RAB11A 
Controls intracellular trafficking of the innate immune receptor TLR4. May facilitate protein trafficking. Associated with secretory 
pathways. 
0.984 
Nedd-8, NEDD-8 E3 ubiquitin protein ligase expressed in neuronal precursor cells; developmentally downregulated in the early central nervous system. 0.976 
EPF5, E2EPF, E2-EPF Ubiquitin conjugating enzyme E2 for targeting of proteins for proteasomal degradation. 0.973 
   
Miro1N18(-)/Homology   
SMMHC, KIAA0866, 
AAT4, SMHC, FAA4 
Myosin heavy chain 11; major contractile protein. Converts chemical energy into mechanical energy through ATP hydrolysis. N/A 
   
Miro1N18(-)/STRING/ 
Homology 
  
RhoC, ARHC, RHOH9 Stimulates reorganisation of the actin cytoskeleton and regulates cell shape, attachment, and motility. 0.973 
PSMD4, pUB-R5, AF-1 Non-ATPase subunit of the 19S regulator lid of the 26S proteasome. 0.972 
   
Miro1N18(-)/Literature   
Centromere protein F, 
PRO1779, CENPF 
Protein that associates with the centromere-kinetochore complex; facilitates mitochondrial movement during cytokinesis. N/A 
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Figure 5.8. Number of hMiro2 proteins identified through proteomics endeavours, 
cross-checked against putative interactors identified by STRING, homology and 
literature searches.  
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Table 5.7. Identification of 24 proteins of interest related to hMiro2 signalling through cross-referencing of experimental proteomics data with computer-
based prediction methods. The condition in which each protein was uniquely present or enriched is shown, alongside alternative identifiers for the protein and a 
description of the protein’s known or putative function. The STRING score provided reflects the combined STRING score when all STRING prediction and search 
methods are utilised, with ≥0.7 representing ‘high confidence’ and ≥0.4 representing ‘medium confidence’. 
Identifier Protein function 
STRING 
score 
Miro2V13(+)/STRING  0.999 
PDHE1-B, PDHBD, PHE1B 
E1 alpha 1 sub-unit of the pyruvate dehydrogenase (PDH) complex; catalyses overall conversion of pyruvate to acetyl-CoA and CO2. 
Mutations in this gene are associated with pyruvate dehydrogenase E1-alpha deficiency and X-linked Leigh syndrome. 
0.999 
MC5DN4, COXPD22, 
ATP5A, ATPM, MOM2, 
OMR, hATP1, ATP5AL2, 
ORM, HEL-S-123m 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1; catalyses ATP synthesis during oxidative 
phosphorylation. 
0.999 
PSC5, HC5, PMSB1 Proteasome subunit beta 1.  Component of the proteasome core; tightly linked to TBP (TATA-binding protein). 0.999 
HDH-VIII, G3BP 
G3BP stress granule assembly factor 1; facilitates DNA unwinding and acts as a signalling element of the Ras pathway, binding 
specifically to RasGAP. 
0.999 
S12, P40, MOV34, 
MOV34L, Rpn8 
A non-ATPase subunit of the 19S proteasome regulator lid of the 26S proteasome complex. 0.999 
EPS15R, eps15R 
Epidermal growth factor receptor pathway substrate; constitutive component of clathrin-coated pits that is required for receptor-
mediated endocytosis. Involved in cadherin binding associated with cell-cell adhesion. 
0.999 
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Miro2N18(-)/STRING 
  
S16 Ribosomal protein S16, a protein component of the 40S sub-unit. 0.999 
ERO1LA, Ero1alpha, ERO1-
L, ERO1-L-alpha, ERO1L, 
ERO1-alpha 
Endoplasmic reticulum oxidoreductase 1 alpha; an oxidizing enzyme that exists in the endoplasmic reticulum and is induced under 
hypoxia. 
0.962 
EIEE31, DNM 
Member of the dynamin subfamily of GTP-binding proteins, involved in tubulation and severing of membranes and associated with 
clathrin-mediated endocytosis and other vesicular trafficking processes. 
0.942 
HUWE1, KIAA1578, 
KIAA0312, MULE, LASU1, 
UREB1, URE-B1, Ib772, 
ARF-BP1, HECTH9, 
HSPC272 
E3 ubiquitin ligase known to ubiquitinate the anti-apoptotic protein Mcl1 (myeloid cell leukemia sequence 1 (BCL2-related)). This 
protein also ubiquitinates the p53 tumor suppressor, core histones, and DNA polymerase beta. 
0.9 
VPS23, TSG10 
Apparently inactive homolog of ubiquitin-conjugating enzymes. May act as a negative growth regulator. Appears important for 
genomic stability and cell cycle regulation. 
0.867 
PTPN1, PTP1B 
A founding member of the protein tyrosine phosphatase (PTP) family. Catalyses the hydrolysis of the phosphate monoesters 
specifically on tyrosine residues. 
0.818 
hUba3, hUBA3, NAE2, 
UBE1C 
Member of the E1 ubiquitin-activating enzyme family; associates with AppBp1, an amyloid beta precursor protein binding protein, 
to form a heterodimer, subsequently activating NEDD8, a ubiquitin-like protein, which regulates cell division, signalling and 
embryogenesis. 
0.81 
RAP1A, RAP1, SMGP21, 
C21KG, KREV-1, G-22K, 
KREV1 
Counteracts the mitogenic function of RAS through its ability to interact with RAS GAPs and RAF in a competitive manner. 0.726 
KIAA1794, FLJ10719 Fanconi anemia complementation group I, associated with Fanconi anaemia. 0.651 
Active BCR-related, MDB Contains a GTPase-activating protein domain; appears to play a role in vestibular morphogenesis. 0.472 
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UBCH7, E2-F1, L-UBC, 
UbcM4, UBCE7 
Member of the E2 ubiquitin-conjugating enzyme family known to facilitate the ubiquitination of p53, c-Fos, and the NF-kB precursor 
p105 in vitro. 
0.471 
HEL-S-70p, PURH, AICAR, 
IMPCHASE, AICARFT 
Acts as a 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; enhances the rate of nucleotide 
re-synthesis, increasing adenosine generation from adenosine monophosphate during conditions of myocardial ischemia. 
0.466 
L23A, MDA20 Ribosomal protein L23a; may be one of the target proteins involved in mediating growth inhibition by interferon. 0.999 
L10A, Csa-19, CSA19, 
NEDD6 
Ribosomal protein downregulated in neural precursor cells during development. 0.999 
Calnexin, CNX, IP90, P90 
Calcium-binding, endoplasmic reticulum (ER)-associated protein; interacts transiently with newly synthesized N-linked 
glycoproteins, facilitating protein folding and assembly. Possible roles in facilitating protein folding and quality control. 
0.999 
PTER, HPHRP, RPR-1 Phosphotriesterase-related protein; may be involved in regulation of mitosis and transport of proteins to the cell surface. 0.774 
CIP75, A1U, C1orf6, A1Up, 
UBIN 
 
Ubiquilin 4; involved in regulation of protein degradation via the ubiquitin-proteasome system (UPS). 0.774 
Miro2N18(-)/Homology   
CASP3, CPP32B, SCA-1, 
CPP32, Yama, apopain 
Associated with apoptotitc signalling. Cleaves and activates caspases 6, 7 and 9. Is the principal caspase involved in the cleavage of 
amyloid-beta 4A precursor protein (a protein associated with neuronal death in Alzheimer's disease). 
N/A 
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As shown in Figure 5.9, below, the majority of identified proteins exhibit functions that 
have been previously associated with the hMiro GTPases. A more detailed chart, 
displaying the function of proteins associated with either the V13 (constitutively active) 
or N18 (dominant negative) versions of hMiro1 and hMiro2 is provided on the following 
page as Figure 5.10. 
 
Figure 5.9. Major biological functions of the identified proteins of interest, shown as a 
percentage of the overall number of proteins for either hMiro1 or hMiro2.
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Figure 5.10 Summary of biological function(s) associated with the identified proteins of interest.
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5.3 Discussion 
5.3.1 Summary of results 
Proteomics has become a powerful approach in recent years, providing greater detail on 
cellular function and interactions than genomics alone. Here, a number of promising 
putative interacting proteins for the hMiro GTPases were identified through cell biology 
and proteomics approaches. Interestingly, X!Tandem and MASCOT were found to 
identify a similar number of proteins. However, X!Tandem appeared to consistently 
identify slightly more proteins. Due to the challenges faced by technical issues throughout 
this study, the results obtained were cross-referenced against computer-based predictions 
of hMiro interactors to reduce noise and improve confidence in the results obtained. 
Proteomics data collected from over-expression of constitutively active and dominant 
negative N-terminal GTPase mutants for both hMiro1 and hMiro2 in COS-7 cells was 
compared, using cross-referencing of data from in silico prediction algorithms, manual 
literature searches and known interactors of the five closest homologues of hMiro1 and 
hMiro2, respectively. The majority of the proteins of interest showed a high confidence 
rating in STRING (≥0.7) alongside an enriched or unique expression pattern from the 
proteomics data, with 74% proteins exhibiting the highest STRING confidence values 
(≥0.9). Only 12% of proteins with a STRING score showed medium confidence (≥0.4). 
None of the proteins identified were classified as low confidence hits. Combined with 
experimental proteomics data, these matching computer-predicted interactors represent 
highly conceivable putative interacting proteins for the hMiro GTPases. 
Overall, the results implicate several novel putative interaction partners for hMiro1 and 
hMiro2, with many interactors appearing to be influenced by the GTPase state of the 
hMiro1 or hMiro2 N-terminal GTPase domain. With the exception of the Fanconi anemia 
complementation group I protein and the nucleotide biosynthesis related proteins, all of 
the proteins of interest appear to be involved in biological processes that have been 
associated with hMiro1 or hMiro2 in the primary literature. Interestingly, only one of the 
proteins of interest (CenpF) has been definitively demonstrated in the literature as a 
binding partner of the hMiros, suggesting the possibility that other experimentally-
validated interactors may not be influenced so readily by the status of the hMiro N-
terminal GTPase domain.  
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5.3.2 Indicated differences between hMiro1 and hMiro2 signalling 
Figure 5.9 suggests that hMiro1 plays major roles in signalling for mitochondrial 
transport and re-organisation of the actin cytoskeleton. Conversely, the results showed no 
obvious signs of this with hMiro2. Although hMiro2 has been previously shown to affect 
mitochondrial transport, prior studies indicate that hMiro2 influences mitochondrial 
transport and cell morphology to a much lesser extent than hMiro1; this trend is perhaps 
reflected in Figure 5.9 by the lack of candidate hMiro2 interactors associated with these 
functions. However, hMiro2 remains very poorly characterised in the literature, with its 
functions largely unknown. Correspondingly, the results shown here may represent a true 
indication of possible cellular functions that this enzyme participates in and regulates in 
humans. Closer analysis in Figure 5.10 suggests that the hMiro1 N-terminal GTPase 
domain is more likely to associate with proteins linked to mitochondrial transport and 
actin cytoskeleton re-organisation when this GTPase domain is GDP-bound: over-
expression of the dominant negative hMiro1 mutant (N18) was associated with proteins 
of these functions, while over-expression of the constitutively active hMiro1 (V13) 
mutant was not. Furthermore, hMiro1 N18 experiments were associated with ER-related 
proteins, protein expression and endocytosis while hMiro V13 experiments were not. In 
fact, far fewer proteins of interest were identified for hMiro1 V13 conditions, amongst 
which: 33% were associated with proteasomal functions, 34% with neuronal or 
developmental functions, 17% with metabolism and 17% with nucleotide biosynthesis. A 
similar pattern is seen with hMiro2 V13, with 43% of the associated proteins linked to 
proteasomal degradation. This may indicate that the N-terminal GTPase domain in both 
hMiro1 and hMiro2 is targeted for degradation, or up-regulates proteasomal degradation, 
when GTP-bound, and that this mechanism may be associated with intracellular 
metabolism including ATP generation and nucleotide biosynthesis. Meanwhile, dominant 
negative (GDP-bound) hMiro appears to associated with a broader range of biological 
processes. Notably, however, unlike with hMiro1, proteins associated with endocytosis 
and cell cycle growth were present in hMiro2 V13 conditions. Overall, it appears that 
over-expression of dominant negative versions of the hMiro1 and hMiro2 N-terminal 
GTPase domain is associated with a wide range of biological processes, while over-
expression of the constitutively active version is associated with a much smaller range of 
processes. This implies that the GTP-status of the hMiro1 and hMiro2 N-terminal GTPase 
domains are important for triggering intracellular signalling changes, and that discreet 
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changes in the status of this domain may serve to trigger events such as ubiquitination 
and proteasomal degradation.   
5.3.3 Identified proteins of particular note 
Of the proteins of interest identified, three were particularly noteworthy: RhoC, rUB-R5 
and NEDD4. These proteins were identified as potential interactors across three separate 
search mechanisms, including experimental analysis, homology studies and the extensive 
database searches performed by STRING. NEDD4 was linked to hMiro1-V13 
overexpression, while RhoC and PSMD4 were associated with hMiro1-N18 over-
expression. All 3 of these proteins possessed functions that showed an enriched presence 
in the other proteins of interest, namely: reorganisation of the cytoskeleton (RhoC, 
NEDD4), neuronal cell involvement (NEDD4) and links to ubiquitin-mediated 
proteasomal degradation (NEDD4, PSMD4). However, it should be noted that further 
evidence is required to validate these proteins as true interactors of the hMiros; the 
following sections should be read in consideration of this. 
5.3.3.1 Neuronal precursor developmentally downregulated (NEDD) proteins 
 
Beyond NEDD4, several other neurone-related proteins identified were NEDD proteins 
(NEDD6, NEDD8) or proteins found to act within NEDD-related pathways (hUba3, Ras, 
AppB1). This implies a role for hMiros in neuronal signalling associated with proteins 
that are commonly downregulated in neuronal precursor cells. Intriguingly, NEDD4 was 
the only neurone-related protein to be associated with a V13 mutant; all of the other 
neuronally enriched proteins identified were associated with N18 hMiro mutants, 
suggesting that the status of the N-terminal GTPase domain is important in mediating 
neuronally-enriched signalling pathways. Indeed, while the NEDD proteins were 
originally identified as ‘neural precursor cell expressed, developmentally downregulated’ 
proteins, these proteins are frequently functionally diverse and do not necessarily occur 
within the same signalling pathways. Thus, while a GTP-bound version of the N-terminal 
GTPase domain may influence one pathway, a change of status to the GDP-bound version 
may influence another.  
NEDD4 itself is classified as an E3 ubiquitin ligase localised to the cytoplasm, and has 
been demonstrated to mediate a range of important cellular processes including neuronal 
development, cellular growth and intracellular homeostasis (392). NEDD4 functions 
through ubiquitination ligase activity and other mechanisms which are not fully 
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understood. However, it has been established that NEDD4 can be activated by a variety 
of signalling molecules, and that auto-inhibition can occur in the absence of calcium 
(393). Intriguingly, all of the NEDD-related proteins are developmentally downregulated 
in neuronal cells and many appear to play roles in normal development of the nervous 
system (391). Similar functions have been noted for mammalian and fly Miro, with 
homozygous Miro1-/- ablation in mice resulting in dysfunctional neuronal developmental, 
most critically resulting in incomplete lung innervation (235). It is possible that the 
mammalian Miros may act within pathways that regulate NEDD4 activity, and that 
disruption of Miros during development prevents adequate downregulation of NEDD4 
and other NEDD proteins. Conversely, a functional link between these proteins during 
development may not exist, and the hMiros could represent a ubiquitination target for 
NEDD4. Further experimental work is required to explore these possibilities. Curiously, 
NEDD4 has also been implicated in schizophrenia (394), a serious psychiatric condition 
commonly presenting with delusions, hallucinations and profound disturbances in 
cognition and emotion (395). This is in congruence with the hMiro1, which has been 
previously linked to schizophrenia through interaction with the DISC1 multifunctional 
scaffolding protein (231). Even more interestingly, DISC1 has been linked to stress-
induced psychosis in schizophrenic individuals (396), a clinical feature that is presented 
more frequent in patients harbouring specific NEDD4 genotypes (394). It is therefore 
possible that these proteins act within the same, or related, signalling pathways.  
NEDD4 may also fit into the presently elusive link between Miro proteins and cellular 
metabolism. Prior implications in the Miro GTPases with cellular metabolism have been 
limited to studies in yeast (160), so the presence of several proteins related to cellular 
metabolism is rather intriguing, suggesting that these roles for cellular metabolism may 
be conserved in higher organisms. Several of the proteins of interest identified were 
involved in cellular metabolism, and oxidative stress has been shown to activate NEDD4 
in a pathway leading to the activation of transcription factors (397). One possibility is that 
signalling for excessive production of free radicals arising from oxidative metabolism 
occurs through Miro proteins to proteins such as NEDD4. However, this remains to be 
explored.  
NEDD6 is perhaps less exciting. A ribosomal protein displaying developmental 
downregulation in neuronal precursor cells (398), NEDD6 presently appears to be 
involved in protein expression alone. NEDD8, however, represents an apparently 
multifunctional ubiquitin-like protein (ULP) sharing ∼60% amino acid identity with 
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ubiquitin (399). appears to possess tumour suppressive roles (400) and has been reported 
in the literature as a regulator of caspase-1 (401). Additionally, NEDD8 has been shown 
to play crucial roles in endometrial function (402). 
5.3.3.2 RhoC 
 
The suggested link between RhoC and hMiro1-N18 is also interesting, fitting into the 
theme that dominant negative versions of the hMiro N-terminal GTPase domain are 
involved in a wider range of pathways than the constitutively active versions. Rho 
proteins are typically associated with cytoskeletal reorganisation, although the fine-tuning 
of RhoC activity appears to particularly influence cell motility (403). A link between 
RhoC signalling and the Miro GTPases therefore seems logical, in light of the cell 
migration results obtained in Chapter 4 and previous studies implicating the Miros in cell 
motility and migration. Due to the primary localisation of RhoC at the plasma membrane 
(7), it is unlikely that the Miros directly interact with RhoC. However, these results 
indicate that hMiro1 acts downstream of the RhoC pathway in a manner that may be 
related to the GTPase state of the N-terminal GTPase domain.  
5.3.3.3 PSMD4 and proteasomal degradation signalling components 
 
The notable presence of PSMD4 was initially somewhat puzzling, resisting the trend of 
hMiro V13 mutants being more likely to be associated with components of the 
proteasome complex. PSDM4 is an essential constituent of the 19S proteasomal 
regulatory complex (391,404), responsible for proteasome substrate recognition and 
known to play important roles in sperm-zona pellucida penetration during fertilisation 
(405). However, while this protein is related to the UBS, it is predominantly involved in 
ensuring that only correctly labelled (ubiquitinated) proteins are processed for 
degradation (391).  No components of the UBS directly linked to actual degradation were 
associated with hMiro N18 mutants in this study, although several proteins related to 
ubiquitination or the sorting of ubiquitinated proteins were. Conversely, V13 mutants 
were associated with both ubiquitination proteins and, in the case of hMiro2-V13, 
components of the proteasome protein core directly involved in proteasomal degradation. 
Potentially, this could indicate that Miro proteins that are active in the N-terminal GTPase 
domain are more likely to be ubiquitinated and subsequently degraded by the UBS, while 
that Miro proteins that are inactive in this domain may still be ubiquitinated but are more 
likely to be thoroughly checked prior to degradation. This is conjecture, however. The 
targeting of proteins for proteasomal degradation is complex and influenced by several 
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signalling pathways. Thus, further investigation of the relationship between the Miro N-
terminal GTPase state and propensity towards UBS-mediated degradation is required. 
5.3.3.4 Proteins involved in endoplasmic reticulum signalling 
 
Beyond RhoC, rUB-R5 and NEDD, the two hMiro2-N18 associated proteins linked to 
the endoplasmic reticulum (ERO1LA and calnexin), were particularly interesting. 
ERO1LA, also known as endoplasmic reticulum oxidoreductase 1, pairs oxidation of 
thiols to the reduction of molecular oxygen to produce hydrogen peroxide (H2O2) and has 
been implicated in cancer progression and immune signalling (406-408). ERO1LA has 
also been implicated in the regulation of Ca2+ fluxes at the interface between the 
endoplasmic reticulum and mitochondria (409). Conversely, calnexin is a calcium-
binding protein localised to contact points between mitochondria and the endoplasmic 
reticulum, displaying roles either as a quality control chaperon (when non-palmitoylated) 
or a calcium signalling protein (when palmitoylated) (410). Interestingly, Miro proteins 
have been implicated in intracellular calcium buffering and have been shown to localise 
to ER-mitochondrial contact points. Additionally, the yeast Miro Gem1p interacts with 
the ER-mitochondria encounter structure (ERMES). While a direct association between 
Miro and ERMES in humans has not yet been established, the presence of Calnexin and 
another ER-related protein, ERO1A, in this study is noteworthy, suggesting that the 
hMiros indeed interact with ERMES-like proteins at ER-mitochondria contact points 
(189,216). Other notable groups of proteins identified in this study included proteins 
related to protein expression, which were enriched across various data sources and may 
indicate that regulation of the hMiro signalling pathways occurs, at least partly, at the 
level of expression. Whether the Miro proteins themselves are significantly regulated at 
the level of expression is unknown, though this phenomenon has been demonstrated for 
other atypical GTPases, such as the Rnd proteins and RhoH (30). 
5.3.3.5 Proteins associated with neurodegeneration 
 
Finally, the presence of several Alzheimer’s and cancer related proteins identified in this 
study are noteworthy. The Miro GTPases have been implicated in both neurodegenerative 
diseases and neoplastic disorders when dysregulated. According to the results obtained 
here, the development of these disorders may occur in some situations through the 
GTPase status of the hMiro N-terminal GTPase domain. It is uncertain why an enrichment 
in Alzheimer’s related proteins was demonstrated, but not other proteins associated with 
neurological disorders. While Miro inhibition has been linked to Alzheimer’s through 
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activation of the PAR-1/MARK family kinases and subsequent promotion of pathological 
tau phosphorylation (23), links to other neurological disorders such as Parkinson’s and 
ALS are repeatedly noted in the literature. The enhanced presence of Alzheimer’s-related 
proteins here, however, may partly reflect that Alzheimer’s is the most common form of 
dementia (411) and correspondingly heavily researched. Thus, proteins implicated to 
Alzheimer’s are more likely to be labelled as such in the literature. Regardless, the 
presence of proteins implicated in neoplasia and Alzheimer’s disease is in congruence 
with previous reports of Miro function and the development of these pathologies. Too, it 
is quite possible that some proteins considered ‘Alzheimer’s-related’ actually engage in 
other neuropathological states when dysregulated (412).  
5.4 Conclusions 
The results obtained in this study suggest several novel putative components of Miro-
related signalling pathways. These findings were generally in congruence with prior 
experimental reports, or otherwise reinforced hypothesised functional roles for the 
hMiros. There is strong evidence in this study for neuronally enriched functions for the 
hMiros, particularly with regards to Miro signalling within NEDD-related pathways. This 
may also indicate critical involvement for the hMiros in the developing nervous system, 
a functional role that has only been partially explored in mice and Drosophila. Distinct 
interactors or signalling pathways may be associated with the state of the N-terminal 
GTPase state in the hMiros, with an active N-terminal GTPase state seemingly more 
likely to result in increased UBS-mediated degradation. However, although this study 
indicated several interesting trends, themes and putative interactors, further experimental 
evidence is desirable to validate these results and fully explore the functional 
consequences of changes to these putative interactors on Miro function in vivo.  
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Chapter 6: characterisation of the atypical GTPase human RhoH 
6.1 Introduction 
6.1.1 Objectives 
The main objective of the work undertaken in this chapter was to characterise the highly 
atypical GTPase human RhoH, using techniques established in earlier work for use in 
characterising the human Miro GTPases. An enhanced knowledge and practical ability of 
these techniques guided the development of this chapter. 
6.1.2 RhoH at a glance 
RhoH, also known as translocation three four (TTF), is a highly atypical member of the 
Rho GTPase family that was first identified as a fusion partner with the LAZ3/BCL-6 
gene, a gene commonly disrupted in B-diffuse large cell non-Hodgkin’s lymphoma (413). 
This indicated a medical relevance for RhoH, further reinforced by the observation that 
disruptions in the RhoH gene are associated with specific types of lymphomas and 
multiple myeloma (414-416). RhoH predominantly exhibits haematopoietic expression, 
including bone marrow progenitor cells in addition of differentiated lymphoid and 
myeloid cells (142,413,417), but has also been detected in various tissue samples from 
normal individuals including breast, pancreas and liver tissue (418,419). Amongst 
haematopoietic cells, RhoH displays varied expression even within cell type sub-
populations (417). For example, higher levels of RhoH are seen in type I helper T cells 
relative to the type II sub-population (420). Additionally, high levels of RhoH are shown 
in lymphoid-originating cells relative to primitive progenitor cells and myeloid lineages 
(417,420,421).  
RhoH is highly atypical structurally and functionally, performing unexpected roles for a 
Rho family enzyme. Perhaps most remarkably, RhoH is unable to hydrolyse GTP (420). 
The protein remains in the active GTP-bound state as a result of mutations in glycine-12 
and glutamine-61 (420), residues normally involved in nucleotide binding in classical 
Rho GTPases. Furthermore, in contrast to the typical scheme of regulation for Ras 
superfamily GTPases, RhoH appears to be primarily regulated at the level of 
transcription: T-cell signalling has been shown to transcriptionally alter RhoH expression 
(420), while PMA-treated Jurkat cells consistently showed down-regulation of RhoH 
mRNA (420). Regulation also appears to occur through lysosomal degradation (422), 
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phosphorylation (423), and through the action of other GTPases. Functionally, RhoH is 
currently believed to act as an antagonist for many classical members of the Rho family 
(420). Notably, implications of aberrant RhoH in a variety of blood cancers (31,33,413-
416,424-426), including chronic lymphocytic leukaemia (CLL) (32,33,427), have 
presented this unusual GTPase as a protein of great clinical relevance.  
6.1.3 RhoH domain architecture 
RhoH has not yet been successfully crystallised, therefore a definitive structure is not 
available. However, the amino acid composition of wildtype RhoH in Homo sapiens and 
several other species is known, making it possible to assess this sequence in comparison 
to other small GTPases of interest, including the classical Rho GTPases. A schematic 
diagram of putative RhoH molecular structure is provided in the form of Figure 6.1, 
below. This original figure was produced via study of the amino acid composition of 
human RhoH and information provided in the scientific literature. A comprehensive 
assessment of the 191 amino acid human RhoH sequence in comparison to the classical 
Rho GTPases RhoA, Rac1 and Cdc42 (the closest classical homologue to RhoH) is 
additionally provided in the form of Figure 6.2, allowing for the illustrative comparison 
of RhoH primary structure against that of canonical GTPases of the Rho family.  
 
 
 
 
 
 
Figure 6.1 Schematic diagram of putative RhoH domain architecture. Original diagram 
produced by assessment of the literature pertaining to RhoH and a comparison of the secondary 
structure of human RhoH against other human GTPases of the Rho family. Note that underlined 
residues indicate areas that appear strikingly different when compared to comparative residues in 
canonical Rho GTPases. For example, the serine (S) underlined in the G1 box is highly atypical 
for Rho GTPases, inferring an inability for RhoH to hydrolyse GTP
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Figure 6.2 Comparison of RhoH secondary structure against the canonical Rho GTPases 
Rac1, RhoA and Cdc42. Annotated CLUSTAL OMEGA alignment of the amino acid 
composition of the human homologues of RhoH, RhoA, Cdc42 and Rac1. Asterisks (*) specify 
positions in which single, fully conserved residues are present, while colons (:) denote 
the conservation of residues with strongly similar properties. Periods (.) specify 
conservation of residues with weakly similar properties. Colour coding is used to 
represent the properties of each residue, where red denotes small and hydrophobic 
residues, blue denotes acidic residues, magenta denotes basic residues, green denotes 
residues bearing hydroxyl, sulphydryl or amine groups and grey represents unusual amino 
acid residues. G loops are shaded in grey and marked, while the prenylation (CAAX 
motif) of each protein is shaded grey-brown. Other domains are shown in transparent 
boxed outlined in black (Rho insert domain), yellow (switch I region), orange (switch II 
region), green (ITAM-like motif), blue (polybasic C-terminal region) or brown (LFSINE 
motif). Identifiers for each protein are provided at the end of each sequence. 
As shown in Figure 6.2, several residues in the RhoH primary structure differ largely 
from those seen in classical Rho proteins. For ease of discussion, the main differences 
CLUSTAL O (1.2.4) multiple sequence alignment 
RhoH   -MLSSIKCVLVGDSAVGKTSLLVRFTSETFPEAYKPTVYENTGVDVFMDGIQISLGLWDT  59  
RhoA   MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDT  60 
Cdc42  --MQTIKCVVVGDGAVGKTCLLISYTTNKFPSEYVPTVFDNYAVTVMIGGEPYTLGLFDT  58 
Rac1   --MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDT  58 
             * *:***.* ***.**: ::.: **  * ***::*  . : :.*    *.*:** 
 
 
RhoH   AGNDAFRSIRPLSYQQADVVLMCYSVANHNSFLNLKNKWIGEIRSNLPCTPVLVVATQTD  119 
RhoA   AGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKD  120 
Cdc42  AGQEDYDRLRPLSYPQTDVFLVCFSVVSPSSFENVKEKWVPEITHHCPKTPFLLVGTQID  118 
Rac1   AGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLD  118 
       **:: :  :***** ::**.*:*:*: .  *: *:  **  *:    * .*.::*..: * 
 
 
RhoH   QREMG-------PHRASCVNAMEGKKLAQDVRAKGYLECSALSNRGVQQVFECAVRTAVN  172 
RhoA   LRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQ  180 
Cdc42  LRDDPSTIEKLAKNKQKPITPETAEKLARDLKAVKYVECSALTQRGLKNVFDEAILAALE  178 
Rac1   LRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLC  178 
        *:           :   :.   .  :*. : *  *:**** :: *:: **: *  :.:  
 
 
RhoH   QARRRNRRRLFSINECKIF  191  identifier: AAM21122.1 
RhoA   ARRGKKKSGCLVL------  193  identifier: AAM21117.1 
Cdc42  PPETQPKRKCCIF------  191  identifier: AAM21109.1 
Rac1   PPPVKKRKRKCLLL-----  192  identifier: CAB53579.5 
           : :     :       
G1 G3 
G4 G3 
G2 
G5 
G1 
Rho insert domain 
Switch I 
ITAM-like motif 
Switch II 
C-terminal region 
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between RhoH primary structure and that of classical Rho GTPases are shown in Table 
6.1, below. These differences are subsequently discussed in turn, below.  
Table 6.1. Main differences between RhoH and its closest classical Rho GTPase 
homologue, Cdc42. Consensus residues for notable regions in typical Ras and Rho 
GTPases are shown, alongside corresponding residues in RhoH and its closest 
homologue, Cdc42. 
Feature Consensus residues Residues in RhoH 
Residues in Cdc42 
(closest RhoH 
homologue) 
G1 G10xxxxGK[S/T]17 G11DSAVGKT18 G10DGAVGKT17 
G2 T35 T36 T35 
G3 and Q61 D57xxGQ61 D58TAGN62 D57TAGQ61 
ITAM-
motif 
YxxI/Lx6-12YxxI/L 
Y73QQADVVLMCY8
3 
----------- 
G4 [N/T]116KxD119 T116QTD119 T115QID118 
Rho 
insert 
------- R121EMGPHRAS129 
D122PSTIEKLAKNK1
33 
G5 
[S/C] 
145A[L/T/K]147 
S152AL154 S158AL160 
Polybasi
c region 
------- R175RRNRRR181 K183KRKRK188* 
C-
terminal 
region 
------ L182FSINE187 ------ 
CaaX box C188aaX191 C188KIF191 C188CIF191 
 
* signifies residues in Rac1, as Cdc42 does not possess a polybasic C-terminal domain. 
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Differences in normally well-conserved residues are thought to produce the constitutively 
active nature of RhoH. For example, the presence of a serine (S) at position 12 in place 
of a usually strongly conserved glycine (G) is thought to render RhoH GTPase-deficient 
through steric interference of GAP enzymes (58,428). Glycine-12 is an essential residue 
of the phosphate binding loop in canonical Rho and Ras proteins (2,58,428), and as shown 
in Figure 6.3, the additional steric bulk associated with side chains other than glycine’s 
single hydrogen appears to obstruct the space normally required for the efficient activity 
of GAP regulatory enzymes (59,429).  
 
 
 
 
 
 
 
 
Figure 6.3. Substitution of Glycine-12 in Rho and Ras superfamily enzymes results 
in steric hindrance of GAP. Schematic illustration showing steric occlusion of the GAP 
arginine finger (brown) from the Ras/Rho nucleotide binding site when Glycine-12 is 
substituted for serine. Figure adopted from Mishra et al. (430). 
Beyond Glycine-12, another canonically essential residue for GTP hydrolysis is the 
highly conserved glutamine (Q) typically found at position 61, which is absent in RhoH 
and instead replaced by asparagine (N) (Figure 6.2; Table 6.1). Glutamine-61 is thought 
predominantly to stabilise GAP interactions with Ras superfamily, at least partially 
through organisation with the GAP R789 arginine finger (58). As shown in Figure 6.4, 
the arginine finger provided by GAP interacts with the α- and γ-phosphates GTP, while 
the side chain carbonyl group of Glutamine-61 interacts with the catalytic H2O molecule 
(58,302). The stabilisation provided by the arginine finger enables the Glutamine-61 
residue to extract a hydrogen atom from the H2O, resulting in a negative hydroxyl ion 
(OH-) capable of attacking the GTP γ-phosphate and thus resulting in GAP-mediated GTP 
hydrolysis (58,302). Glutamine-61 mutations in Ras have also been shown to alter the 
switch II region, producing a network of hydrophobic interactions that serve to bury the 
G12 G12S 
GAP arginine finger can 
access the nucleotide binding 
site 
GAP arginine finger is sterically 
occluded from nucleotide binding 
site 
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guanine nucleotide and an essential pre-catalytic water molecule, with this water 
molecule and a Tyrosine-32 normally binding γ-phosphate in wildtype proteins for 
participation in basal GTP hydrolysis (431). These critical substitutions of residues 12 
and 61, normally highly engaged in the canonical GAP-mediated GTP-hydrolytic 
mechanism, are believed to play a central role in the apparent inability of RhoH to 
hydrolyse GTP, rendering the enzyme constitutively active (123). 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. The role of Ras/Rho Glutamine-61 and the GAP arginine finger in GAP-
mediated GTP hydrolysis. Illustration adopted from Lu et al. (58), showing interaction 
of the GAP arginine finger with the α- and γ-phosphates GTP, enabling Glutamine-61 to 
prepare the catalytic H2O molecule (WAT) for the nucleophilic attack of the GTP γ-
phosphate. 
Although RhoH displays critical substitutions of the normally highly conserved Glycine-
12 and Glutamine-61, the other G loop regions appear to be relatively conserved, with the 
highly conserved G2 loop Threonine-35 intact (at position 36 in RhoH) and the G3 
(residues 58–61), G4 (residues 116–119) and G5 (residues 152–154) loops adhering to 
consensus sequences for typical Ras and Rho GTPases (see Table 6.1). In congruence 
with classical Rho GTPases, RhoH also contains a C-terminal ‘CaaX’ box beginning at 
position 188; the CaaX box comprises a conserved domain in Ras and Rho GTPases, 
necessary for intracellular localisation to the plasma membrane (2,63). In RhoH, this 
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‘CaaX’ motif is represented by the CKIF tetrapeptide at the C-terminus (residues 188–
191), with RhoH localisation to the plasma membrane disrupted upon CKIF deletion 
(432). In addition to this CKIF localisation motif, RhoH exhibits a polybasic RRRNRRR 
(residues 175–181) domain followed by a novel C-terminal insert domain, LFSINE 
(residues 182–187); both of these domains have been specified in Figure 6.2 and Table 
6.1. In the classical Rho protein Rac1, a similar polybasic domain to RRRNRRR is 
present (residues 183–188, see Figure 6.2) and appears to be involved in targeting Rac1 
to specific membrane domains such as lipid rafts (433). Indeed, RRRNRRR ablation in 
RhoH significantly disrupts localisation to the plasma membrane (432). This effect was 
also seen with deletion of the LFSINE domain, with LFSINE removal shown to produce 
significant accumulation of RhoH in the cytoplasm (434). Interestingly, the LFSINE 
domain appeared to be necessary for the lysosomal uptake and degradation of RhoH by 
chaperone-mediated autophagy (CMA), with LFSINE-deficient RhoH exhibiting 
resistance to CMA (435). No impairment or enhancement of RhoH function was seen 
when the LFSINE domain was ablated, however, indicating that this domain is involved 
in RhoH stability and regulation but does not directly affect normal RhoH function (435). 
RhoH also contains a small Rho insert domain (residues 121–129; Figure 6.2). The Rho 
insert domain is a surface-exposed alpha helical domain specific to the Rho GTPase 
family and typically composed of 13 amino acid residues between the fifth β-strand and 
fourth α-helix (7). In some Rho GTPases, this Rho insert domain has been demonstrated 
to be involved in Rho protein functionality and the binding of Rho-specific effector 
proteins (436-438). In RhoH, however, this Rho ‘insert domain’ is relatively small and 
does not contain the expected residues for such a domain (7,436). At present, relatively 
little is known of this domain, though it generally remains considered a ‘Rho insert’ 
domain (7). 
Another unique aspect of the RhoH primary structure is the presence of a motif 
resembling the immunoreceptor tyrosine based activation motif (ITAM). ITAM motifs 
(YxxI/Lx6-12YxxI/L) were initially observed on cytoplasmic subunits associated with the 
T and B cell antigen receptors in addition to the FcεRI receptor (439,440). Signalling 
through receptors containing ITAMs via tyrosine phopshorylation is involved in the 
activation of several cellular processes, including degranulation, phagocytosis and 
antibody-dependent cell-mediated cytotoxicity (441). It was previously believed that 
signalling through ITAM predominantly involved activation events, so-called 
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immunoreceptor tyrosine based inhibition motifs (ITIMs) mediated inhibitory events 
(442); ITIMs harbour the following consensus sequence: S/I/V/LxYxxI/V/L (443). 
However, it is now apparent that the situation is more complex. In some contexts, ITAMs 
can modulate inhibitory signals while ITIMs can mediate activation signals (444). 
Furthermore, several ITAM-encoding proteins appear to contain potential 'closet' ITIM-
associated areas within the ITAM motif (444). The consensus sequence for an ITAM 
(YxxI/Lx6-12YxxI/L) differs from that seen in RhoH (YxxA/x6/YxxA). Furthermore, the 
RhoH ITAM-like motif appears to comprise a non-exposed beta sheet, with the initial 
tyrosine residue (Y) locked within a hydrophobic core; unless RhoH is able to undergo a 
conformational change enabling exposure of this region, it is difficult to envision many 
meaningful interactions of this ITAM-like motif with effectors. Despite these differences, 
however, previous studies have indicated that the RhoH ITAM-like motif is able to bind 
effectors upon phosphorylation of its tyrosine residues, much like canonical ITAM motifs 
(445,446). Furthermore, when phosphorylated at the ITAM-like region, RhoH appears to 
bind some traditional ITAM effectors such as Zap-70 (447-450). 
6.1.4 RhoH function 
6.1.4.1 RhoH as an antagonist of classical Rho family GTPases 
 
RhoH is functionally diverse to classical Rho GTPases, and is presently thought to act as 
an antagonist of traditional Rho proteins (421,445). Rho proteins are typically involved 
in the regulating actin cytoskeleton reorganisation (451). In non-haematopoietic cells, 
RhoH did not appear to significantly influence re-organisation of the actin cytoskeleton 
or meaningfully impact cell morphology (420). Furthermore, while Rho-related proteins 
typically act as potent activators of several transcriptional pathways (452-454), RhoH has 
been shown to inhibit p38-MAPK and NF-κB activation (420). Indeed, RhoH specifically 
inhibits the Cdc42, Rac1 or RhoA-induced activation of NF-κB (420), and RhoH over-
expression appears to decrease Rac1 activation (432). The consequences of these effects 
are seen in RhoH over-expression and ablation studies in haematopoietic stem cells 
(HSCs) (417). Increased RhoH expression levels in HSCs resulted in impaired activation 
of Rac GTPases, reduced cellular proliferation and chemotaxis, increased apoptosis and 
defective actin polymerisation (417). Defective haematopoietic reconstitution in 
transplant assays is also demonstrated in the context of RhoH overexpression (417). In 
contrast, suppression of RhoH encourages proliferation, survival and stroma cell-derived 
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factor 1 (SDF-1)-induced migration in HSCs (417) in part through activity of traditional 
Rho proteins. Thus, RhoH acts as an antagonist of several classical Rho proteins.  
6.1.4.2 RhoH in T-cell biology 
 
RhoH plays important roles in T-cell development through regulation of T-cell receptor 
(TCR) signalling (446,455-457). This important regulatory activity is thought 
predominantly to occur through RhoH’s interactions with zeta-chain-associated protein 
kinase 70 (Zap70) (446), a Syk-family protein tyrosine kinase (PTK) normally present in 
the cytoplasm but required at the plasma membrane for its TCR signalling-related 
functions (458). Immunoprecipitation experiments and in vitro binding demonstrated that 
the tandem SH2 domains in Zap70 bind to the ITAM-like motifs in RhoH when the 
tyrosine residues of these motifs are phosphorylated, and that RhoH is required for Zap70 
recruitment to the cytoplasm and immunological synapse (446,455). As shown 
schematically in Figure 6.5, Zap70 delivers critical roles in T cell biology, while RhoH 
dysfunction or ablation produces similar effects.  
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Figure 6.5 RhoH acts upstream of Zap70 to mediate T cell function. References as 
follows: Homozygous RhoH mutation (459), RhoH-/- mice (459), Zap70 deficient patients 
(53)(460-462), Zap70-/- mice (463,464), Zap70-/- Jurkat cell line p116 (465). *Note that 
impaired immune response is inferred from cell line study, here. (43)(54)(61)(54) 
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Indeed, one can infer that RhoH mediates important roles in T cell biology through 
recruitment of Zap70. Perhaps most significantly, RhoH appears to regulate the selection 
and maturation of lymphocytes (455), and has previously been implicated as a central 
signalling molecule in maintaining lymphocytes in their resting state (466). As shown in 
Figure 6.5, interruption of RhoH signalling is capable of producing severe T-cell defects 
and, consequently, impaired immunity (459-465). 
Following activation of the T-cell receptor (TCR), RhoH recruitment of Zap70 is believed 
to enable Zap70-mediated phosphorylation of the linker of activated T-cells (LAT). LAT, 
in turn, activates the “LAT signalosome” (455), facilitating signalling through the TCR 
via recruitment of multiple adaptor proteins and activation downstream signalling events 
(467). RhoH abrogation appears to significantly impair phosphorylation of LAT and the 
LAT-associated proteins Vav1 and PLCγ1 (455). Furthermore, activation of Erk and 
calcium influx, downstream of PLCγ1, appear dramatically diminished in RhoH-depleted 
thymocytes (455,468). This indicates that RhoH specifically interferes with the LAT-
associated branch of Zap70 signalling. Another enzyme of note, however, is the Src-
family tyrosine kinase Lck. Lck significantly enhances the interaction between RhoH and 
Zap70 SH2 domains (423). Additionally, a schematic illustration of RhoH-related 
signalling in T-cells is provided as Figure 6.6. 
Table 6.2. Downstream targets of Zap70 tyrosine phosphorylation that are 
compromised in the absence of RhoH. 
Abbreviation Full identifier Function (when activated by phosphorylation) 
LAT Linker of activated T-cells 
Recruits multiple adaptor and signalling proteins to 
form a signalling complex near the T-cell receptor 
engagement site (467) 
PLCγ1 Phospholipase C γ1 
Catalyses hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) to inositol 1, 4, 5-trisphosphate 
(IP3) and diacylglycerol (DAG). Increase of IP3 
results in elevated intracellular free Ca2+ (469) 
Vav1 Vav1 Haematopoiesis and activation of T and B cells (470) 
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Figure 6.6. Summary of known RhoH interactions in T-cell biology. (a) RhoH inhibits Rac1 
and other classical Rho family GTPases. (b) T-cell receptor (TCR) engagement activates Lck. 
Lck-mediated phosphorylation of cluster of differentiation-3zeta (CD3zeta) subsequently serves 
as a docking site Zap70. The resulting downstream signalling from activated ZaP70 includes 
phosphorylation of the adaptor protein LAT (linker for activation of T cells) and phospholipase 
Cgamma1 (PLCgamma1) and can produce a variety of responses, cell proliferation, calcium 
influx and changes in gene expression. RhoH interacts with Zap70, and this interaction is 
enhanced in the presence of Lck. RhoH is required for recruitment of Zap70 to the TCR and 
subsequent downstream signalling of Zap70 following TCR engagement. Other proteins shown: 
GADS, GRB2-related adaptor downstream of Shc; JNK, Jun N-terminal kinase; SLP76, SH2 
domain-containing leukocyte protein of 76 kDa. Figure obtained from literature (423). 
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Beyond the proteins described in Table 6.2, a non-biased large scale proteomic analysis 
of tyrosine phosphorylation events induced by T-cell and B-cell receptor activation 
showed that RhoH interacts with protein tyrosine kinases Syk and Zap70 in addition to 
phospholipase Cγ2 (PLCγ2) (471). While Zap70 has been extensively linked to T cell 
signalling (458), Syk and PLCγ2 are implicated with B cell receptor signalling (472). 
6.1.4.3 RhoH in malignant B-cell lineages: implications in chronic lymphocytic 
leukaemia (CLL) 
The functional importance of RhoH in T-cell biology is now well established. However, 
RhoH also appears to play functional roles in B-cells and has been implicated in 
malignant B-cell lineages such as chronic lymphocytic leukaemia (CLL). CLL is the most 
prevalent form of leukaemia (473,474) and is characterised by the progressive 
accumulation of monoclonal CD5+ B cells in the blood (473). RhoH expression is 
significantly increased in primary human CLL cells relative to normal B-cells, with this 
increased  RhoH expression positively correlated with Zap70 expression (32). Indeed, a 
regulatory role for Zap70 in B-cell receptor (BCR) signalling in CLL has been 
demonstrated (427), and Zap70 identified as a negative prognostic factor in CLL 
(475,476). Correspondingly, a genetic mouse model for CLL with RhoH depletion 
produced a delayed accumulation of leukemic cells in peripheral blood and reduced 
leukemic burden in lymphoid tissues (32,33). RhoH therefore appears to influence the 
progression and development of CLL (32). Further to this, RhoH ablation prevents 
homing, migration and contact of CLL cells to supportive cells of the microenvironment 
that arbitrate the survival and proliferation of leukemic cells, and  produces aberrant 
localisation and diminished activity of Rac and RhoA (33). These canonical Rho GTPases 
are considered critical for the co-ordinated cell migration of numerous hematopoietic 
cells (423,477,478), which may clarify the impaired migration of RhoH-/- CLL cells (33). 
6.1.4.4 RhoH involvement in other myeloproliferative disorders 
The myeloproliferative disorders comprise a group of haematologic neoplasms thought 
to arise from a transformation in a haematopoietic stem cell (479). When dysfunctional, 
RhoH has been linked extensively to a variety of myeloproliferative disorders. Multiple 
studies have implicated the gene encoding RhoH as a frequent target of genetic alteration, 
with such alterations found in a variety of human cancers (445). Two mechanisms appear 
to account for these genetic alterations: translocation of the RhoH gene (413) and aberrant 
somatic hypermutation (415). However, the underexpression of RhoH has also been 
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implicated in the development in some forms of leukaemia (31,425). Table 6.3 (following 
page) provides an overview of the mechanisms by which RhoH dysfunction has been 
implicated in lymphomas and leukaemias.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 242 
 
Table 6.3. Involvement of aberrant RhoH in lymphomas and leukaemias. 
Form of RhoH dysfunction 
Somatic 
hypermutation 
Chromosomal 
translocation 
RhoH under-
expression 
Nodular lymphocyte 
predominant 
Hodgkin's lymphoma 
Nodal marginal zone 
B-cell lymphoma 
Hairy cell leukaemia 
Classical Hodgkin's 
lymphoma 
Follicular lymphoma 
Acute myeloid 
leukaemia 
Diffuse large B-cell 
lymphoma 
Plasma cell myeloma  
Extranodal marginal 
zone B-cell 
lymphoma (MALT) 
Splenic marginal 
zone B-cell 
lymphoma 
 
Follicular lymphomas   
Nodal marginal zone 
B-cell lymphoma 
  
Chronic lymphocytic 
leukaemia 
  
Splenic marginal 
zone B-cell 
lymphoma 
  
Monomorphic 
lymphoma 
  
HCV and AIDs-
associated non-
Hodgkin's lymphoma 
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6.1.5 DRAK2 as a putative interactor of RhoH 
To date, the molecular interactors of RhoH remain relatively obscure, despite observed 
roles in T-cell biology and, moreover, implications in several forms of leukaemia and 
lymphoma. However, the death-associated protein kinase DRAK2 shows several 
functional overlaps with RhoH; indeed, increasing evidence suggests that these enzymes 
may interact. This section is therefore dedicated to a discussion of the known structural 
and functional aspects of DRAK2 in relation to RhoH.  
6.1.5.1 DRAK2 domain architecture 
 
DRAK2 is a member of the death-associated protein kinase (DAPK) family of 
serine/threonine kinases, comprised of the following members: DAPK1, DAPK2 (DRP-
1), DAPK3 (ZIPK), DRAK1 and DRAK2 (Figure 6.7). As shown in Figure 6.7, these 
proteins vary in size and subcellular localisation, with DAPK2 and DAPK3 sharing the 
highest homology (approximately 80% in the N terminus kinase domain) (480,481). 
DRAK1 and 2, however, share approximately 50% homology with DAPK1, the founding 
member of this family. DAPK1 and DAPK2 contain calmodulin (CaM) regulatory 
domains which bind calmodulin to modulate the DAPK’s catalytic activity. While 
differences in size and localisation exist in the DAPK family, each family member 
appears to be involved in apoptotic stimulation (480). Indeed, DRAK2 has been shown 
to induce apoptosis when over-expressed (482), and its nuclear localisation and 
phosphorylation are implicated in UV-induced cell death (483). Curiously, however, 
DRAK2-/- mice exhibit enhanced rather than attenuated apoptosis (484).  Furthermore, 
this remarkable enzyme is implicated in T-cell biology and CLL development, displaying 
several functional overlaps with RhoH. 
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Figure 6.7. Molecular structure of the DAPK family of serine/threonine kinases. 
Schematic illustrations of the DAPK family, with the sub-cellular localisation of each 
corresponding kinase given to the right of its diagram.  
6.1.5.2 DRAK2 in T-cell biology 
DRAK2 is broadly expressed at low levels, but shows enriched expression in 
haematopoietic cells (485,486) and displays several functional roles in T-cell biology, 
including thymocyte selection (487,488) and apparent modulation of TCR stimulation 
sensitivity (489). Indeed, DRAK2 abrogation in T cells appears to enhance sensitivity to 
TCR-mediated stimulation (489), producing a decreased requirement for co-stimulation. 
This suggests that DRAK2 functions as a negative regulator for TCR signalling, raising 
the threshold for stimulation (490). Related to this, DRAK2 has been implicated in Ca2+ 
mobilisation. In T-cells, 75% of all activation-regulated genes require a Ca2+ influx (491). 
Consequently, a reduction in Ca2+ mobilisation dramatically attenuates (and can prevent) 
T-cell activation and proliferation (491-493). Germline ablation of DRAK2 has been 
shown to produce hyperactive Ca2+ mobilisation, even under sub-optimal TCR 
stimulation (485,494). It has therefore been hypothesised that DRAK2 serves both as a 
rheostat (sensor/regulator) for Ca2+ signalling (487,488) and as a negative regulator of 
TCR signalling (490). In fact, DRAK2 itself is activated by Ca2+ mobilisation (487,488). 
Additionally, ectopic expression of DRAK2 in double positive thymocytes raises the 
threshold for both negative and positive selection (487,488). 
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6.1.5.3 DRAK2 in autoimmunity 
Depletion of the Drak2 gene in animal models produces reduced autoimmune 
susceptibility, with diminished clinical severity shown in animal autoimmune models for 
multiple sclerosis (experimental autoimmune encephalomyelitis) and type I diabetes-
prone-non-obese diabetic (NOD) mice (494-497). This lowered susceptibility towards 
autoimmunity is thought to occur, at least partially, through reduced survival of activated 
effector T-cells, potentially as a result of impaired Ca2+ homeostasis (495-497). However, 
the exact signalling components associated with diminished autoreactive cell survival in 
DRAK2 abrogation remain unknown. Curiously, despite an increased sensitivity to death 
in DRAK2-/- T-cells, pathogen clearance and tumour surveillance are maintained in 
DRAK2-/- mice (494,496,498,499). As DRAK2 does not appear to play essential tumour 
suppressive roles (500), this kinase represents a promising therapeutic target for treating 
organ-specific autoimmunity without producing widespread immunosuppression. 
6.1.5.4 DRAK2 in transplantation 
DRAK2 has been shown to significantly promote allogeneic graft acceptance in two 
separate transplant models without producing general immunosuppression (499). This is 
remarkably medically relevant. Allorecognition of transplated biological material from a 
foreign donor typically results in T-cell activation and destruction of the allograft (501). 
To prevent allograft rejection, transplant patients currently must endure lifelong 
administration of powerful immunosuppressants such as cyclosporine A or FK506, which 
often produce problematic side effects and are associated with greatly diminished quality 
of life (502). Formation of allogeneic memory was diminished in DRAK2-/- T-cells, with 
transferred DRAK2-/- memory T-cells failing to produce allograft rejection in the 
Balb/C->C57BL/BJ murine model (499). Long-term allogeneic skin graft was accepted 
through administration of Cytotoxic T-Lymphocyte Antigen 4 fusion protein (CTLA4-
Ig), which synergised with DRAK2 depletion. Meanwhile, earlier in vitro studies showed 
that DRAK2-/- CD8+ T-cells exhibited a significantly reduced response to allogenic 
stimulation versus wildtype T-cells when evaluated by CFSE dilution (499). These 
studies suggest crucial roles for DRAK2 in primary and memory T-cell responsiveness 
to allografts, and demonstrate the potential of DRAK2 as a target in the prevention of 
allogeneic graft rejection.  
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6.1.6 RhoH and DRAK2: convergence of functional roles and potential clinical 
relevance 
RhoH and DRAK2 are functionally active within the same contexts and often exhibit 
convergent roles. Interestingly, RhoH and DRAK2 appear to play opposing roles in Ca2+ 
mobilisation, with RhoH abrogation associated with decreased Ca2+ mobilisation 
(455,468) and DRAK2 abrogation implicated in hyperactive Ca2+ mobilisation (485,494). 
Significantly, RhoH appears to act as a positive regulator of TCR signalling 
(417,446,455), while DRAK2 exhibits the opposite function and is regarded as a negative 
regulator of TCR signalling (490). Both DRAK2 and RhoH show haematopoetically 
enriched expression patterns and are involved in signalling for T cell development 
including thymocyte selection. While DRAK2 and RhoH appear to share similar 
functional roles and are likely involved mutual signalling pathways, however, no direct 
link between these two proteins has been demonstrated. Akin to RhoH, however, DRAK2 
may play roles in the development of CLL. The founding member of the DAPK family, 
DAPK1, has been previously identified as a heritable pre-disposing factor in CLL (503). 
Moreover, DRAK2 has been previously implicated as a negative regulator of 
transforming growth factor β Receptor I (TGF-βRI), controlling TGF-β/Smads signalling 
in solid tumours (504). A positive correlation between TGF-βRI and DRAK2 mRNA 
levels has recently been identified. Perhaps most strikingly, however, is the recent 
association between DRAK2 expression and CLL patient survival, with patients 
expressing low DRAK2 levels associated with significantly shorter survival (505). While 
this same study found no correlation between RhoH mRNA levels and overall survival in 
CLL patients, RhoH mRNA levels were also found to be positively correlated with levels 
of DRAK2 mRNA. Thus, a functional link between RhoH and DRAK2 may exist that is 
of clinical relevance in CLL. Given these exciting new revelations in the scientific 
literature and the availability of materials at Northumbria University, a series of 
experiments were utilised to further characterise the unusual GTPase RhoH and to assess 
putative interactions between RhoH and DRAK2 in vitro.  
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6.2 Results 
6.2.1 Cloning of full length and truncated versions of human RhoH 
A pCMS-EGFP mammalian expression vector encoding EGFP-tagged full-length human 
RhoH was kindly donated by the Structural Genomics Consortium at the University of 
Oxford, UK. This vector was utilised as a template for the PCR-based cloning of the 
nucleotide sequence encoding full-length human RhoH, in addition to truncated versions 
thereof (Figure 6.8). The pET15b-TEV vector enables the bacterial expression of 
recombinant proteins containing a TEV-cleavable N-terminal hexahistidine tag (His-tag).  
For each cloning procedure, PCR products were generated via the programme described 
in 2.2.2.3 and using the desired primers: either those shown in 2.1.3.9 (for cloning RhoH 
full length), 2.1.3.10 (for cloning RhoH truncation 1, S4–A174) or 2.1.3.11 (for cloning 
RhoH truncation 2, V10–S184). Boundaries for each truncation were chosen based on the 
notion of removing the C-terminal CaaX box in RhoH and in facilitating bacterial 
expression with sequences that were believed to be more soluble and more easily 
expressed by E.coli.  
 
 
 
 
     MLSSIKCVLVGDSAVGKTSLLVRFTSETFPEAYKPTVYENTGVDVFMDGIQISLGLWDTA  60  
     GNDAFRSIRPLSYQQADVVLMCYSVANHNSFLNLKNKWIGEIRSNLPCTPVLVVATQTDQ  120 
     REMGPHRASCVNAMEGKKLAQDVRAKGYLECSALSNRGVQQVFECAVRTAVNQARRRNRR  180 
     RLFSINECKIF  191   
 
 
Figure 6.8. RhoH amino acid sequence, showing cut-off points for the RhoHT1 and 
RhoHT2 truncates. 
 
 
 
 
RhoHT1 start 
RhoHT1 end 
RhoHT2 start 
RhoHT2 end 
G1 G2 G3 
G4 
G5 
Switch I region 
Switch II region 
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In each case, the presence of the NdeI restriction site on the forward primer and the XhoI 
restriction site on the reverse primer, enabling later ligation of these products into 
NdeI/XhoI restriction digested pET15b-TEV. PCR product samples were subjected to 
agarose gel electrophoresis (2.2.3.7) and assessed under UV light following ethidium 
bromide staining (2.2.3.8). As in Figure 6.9, the presence of bands of the correct size 
relative to the Hyperladder I side standard (Bioline) indicated successful PCR-based 
amplification of target sequences. Succesful PCR products were subjected to a standard 
PCR clean-up procedure followed by a 4 hour NdeI/XhoI double digest as previously 
indicated (2.2.3.6). Digested PCR products were then purified by agarose gel purification 
(2.2.3.9), ligated into NdeI/XhoI digested pET15b-TEV and the products of ligation used 
to transform chemically competent TOP10 cells (2.2.2.2). At least 2 colonies from each 
plate of transformed TOP10 E.coli were then screened for the presence of pET15b-TEV 
harbouring the desired RhoH encoding insert; the screening method utilised was 
NdeI/XhoI restriction digestion of a sample of plasmid DNA (pDNA) extracted from each 
colony (2.2.3.2; 2.2.3.6) in order to liberate the insert, followed by agarose gel 
electrophoresis (2.2.3.7), subsequent ethidium bromide staining and UV visualisation 
(2.2.3.8). As exhibited in Figure 6.10, the presence of bands corresponding to the correct 
size for each desired insert indicated a pET15b-TEV plasmid containing the target insert. 
For each RhoH construct of interest, two samples of pDNA appearing to harbour the 
correct insert were shipped for sequencing using the standard T7 promoter primer, with 
the desired sequence indicated in each instance and no unwanted mutations observed. 
Only pDNA confirmed by sequencing was taken forward for subsequent use in expression 
trials and further work. 
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Figure 6.9 PCR products yielded from the PCR-based amplification of RhoH full length, 
RhoH truncation 1 (S4-SA174) and RhoH truncation 2 (V10-S184). 1% agarose gel showing 
electrophoresised PCR products following the PCR-based amplification of RhoH-encoding 
sequences of interest. 
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Figure 6.10 Analytical restriction digest for confirmation of the presence of RhoH-encoding 
sequences into pET15b-TEV. 1% agarose gel showing the presence of RhoH encoding 
sequences in separate pDNA samples isolated from TOP10 E.coli transformants. Marker shown 
in lane 1 (Hyperladder I, BioLine). 
6.2.2 Expression trials 
BL21 (DE3), C41 (DE3), C43 (DE3) and Tuner (DE3) CaCl2 competent E.coli cells were 
transformed with the pDNA for each successful human RhoH clone of interest, namely: 
RhoH full length (RhoHFL), truncation 1 (RhoHT1) or truncation 2 (RhoHT2). 50mL of the 
recombinant E.coli strains were grown in separate flasks to mid-log phase and varying 
concentrations of IPTG administered in order to assess a number of expression conditions 
(either 0.1mM, 0.5mM or 1mM). Following administration of IPTG, the recombinant 
E.coli cells were allowed to express the RhoH construct of interest either at 37oC (4 
hours), 25oC (10 hours) or 18oC (16 hours). This provided a range of expression 
conditions to assess suitable expression strains, IPTG concentrations and expression 
temperatures for each RhoH construct of interest (summary of results provided in the 
form of Table 6.4; SDS-gel showing best expression trial results provided as Figure 6.11). 
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The best conditions indicated by expression trials were subsequently taken forward for 
target protein identification confirmation and expression up-scale and purification, 
enabling the completion of further downstream experiments. For all expression trials, 
cells were harvested and subsequently sonicated until fully broken open as previously 
indicated (section 2.2.2.6). Cell debris was removed by centrifugation and each construct 
was purified initially by immobilised metal affinity chromatography (IMAC). During 
expression trials, manual IMAC was performed (2.2.4.4) wherein only 2 elution buffers 
were used to elute bound proteins: buffers containing either 50mM imidazole or 300mM 
imidazole. This enabled an initial, quick assessment of the expression conditions tested 
without the need for timely purification procedures. 
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Table 6.4. Expression optimisation of recombinant human RhoH constructs. Expression of the three recombinant RhoH constructs (full length, RhoH S3-
A174 and RhoH V10-S184) using LB broth, a variety of E.coli expression DE3 strains (BL21, C41, C43 and Tuner cells), total  IPTG concentrations (0.1mM, 
0.5mM or 1mM) and a temperatures (18oC for 16 hours, 25oC for 10 hours or 37oC for 4 hours) were trialled. - denotes no visible expression, + denotes some 
visible expression, ++ denotes notable expression and +++ denotes excellent recombinant target protein expression. 
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Figure 6.11 Expression trials show promising expression for RhoHFL and RhoHT1. 
12% SDS-PAGE gel showing the most promising results from the expression trials. Note 
that expression of RhoHT2 appears minimal.  
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6.2.3 Confirmation of target protein expression 
In order to confirm that the proteins observed during expression trials corresponded to 
the desired target proteins, the following methods were utilised: Western blotting (using 
anti-human RhoH as the primary antibody) and LC-MS on trypsinised excised SDS-
PAGE gel segments (section 2.2.7.2). Western blotting was performed as previously 
described (2.2.4.8) via application of the ab138123 anti-RhoH polyclonal from AbCam 
as the primary antibody, using the dilutions shown in 2.1.1.4. As shown in Figure 6.12, 
the Western blotting procedure produced chemiluminescent signals at the expected 
molecular weight for RhoHFL and RhoHT1 and RhoHT2, suggesting that the correct target 
proteins had been expressed. However, in order to further improve confidence in the 
identity of the proteins expressed during expression trials, the best condition for each 
construct was repeated and target recombinant proteins purified using manual IMAC 
involving the normal range of elution buffers (2.2.4.4). A purified sample of each 
construct was then run on a 12% SDS-PAGE gel and subjected to gel excision and 
trypsinisation followed by LC-MS (2.2.7.4), with raw data analysed by running the .MGF 
files obtained from Progenesis analysis software through the X! P3 MS/MS ion search 
server (2.2.7.5). As shown in Figures 6.13–6.14, the results from X! P3 indicated that the 
correct target recombinant protein had been over-expressed for RhoHFL and RhoHT1, with 
the top score for each protein corresponding to human RhoH, thus indicating that peptide 
sequences run via LC-MS matched the amino acid sequence of human RhoH as described 
in the National Centre for Biotechnology Information (NCBI) database (sequence 
coverage: 40% for RhoHFL, 37% for RhoHT1). Taken together, the results from Western 
blotting and LC-MS (in addition to pDNA sequencing information and the perceived 
molecular weight of the over-expressed proteins) strongly indicated that the proteins 
over-expressed during expression trials represented the desired target RhoH constructs. 
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Figure 6.12 Anti-RhoH Western blot of RhoH samples obtained from expression 
trials. Western blot of IMAC-purified RhoHFL (lane 3), RhoHT1 (lane 4) and RhoHT2 
(lane 5) samples. Each sample chosen represented what was considered the best 
expression condition for the given construct, as shown in Table 6.4.  
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Figure 6.13 LC-MS results indicating the presence of RhoH in the excised RhoHFL 
SDS-PAGE band. X! P3 MS/MS ion search results using the Global Proteome Machine 
(GPM), preferentially matching RhoH to the peptides run through the LC-MS system 
(with 42% amino acid coverage for RhoH and 60% when corrected for peptide sequences 
that are unlikely to be observed using normal proteomics methods). 
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Figure 6.14 LC-MS results indicating the presence of RhoH in the excised RhoHT1 
SDS-PAGE band. X! P3 MS/MS ion search results using the Global Proteome Machine 
(GPM), preferentially matching RhoH to the peptides run through the LC-MS system 
(with 37% amino acid coverage for RhoH and 51% when corrected for peptide sequences 
that are unlikely to be observed using normal proteomics methods). 
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6.2.4 Expression up-scale and purification 
The most favourable conditions from the expression trials (6.2.2) were up-scaled. Cells 
were harvested, lysed and cell-free supernatant attained as previously discussed (2.2.26). 
The recombinant target proteins were subsequently purified by IMAC using a Nickel 
NTA column attached to an ÄKTA Prime fast protein liquid chromatography (FPLC) 
system (2.2.4.4). Figures 6.15–6.16 show the successful purification of full length 
recombinant human RhoH (RhoHFL), while Figures 6.17–6.18 show the successful 
purification of the RhoHT1 construct (human RhoH S4 – A174). As Large scale expression 
and IMAC purification of RhoHT2 (human RhoH V10 – S184) appeared unsuccessful, with 
an absence of soluble over-expressed protein obtained. Indeed, an assessment of the 
insoluble fractions for each expression and purification indicated that the RhoHT2 
construct was highly insoluble. This notion of insolubility was further supported by 
Western blotting (Figure 6.19), with a strong chemiluminescent signal found in the 
RhoHT2 insoluble fraction sample. Although a certain degree of insolubility can be 
expected when over-expressing proteins, over-expression of soluble RhoHT1 was high 
relative to RhoHT2 and thus RhoHT1 was pursued while further attempts to over-express 
and purify RhoHT2 were discontinued; this enabled a streamlined workflow with RhoHT1 
and RhoHFL in parallel.  
Following IMAC purification, suitably pure fractions of RhoHFL and RhoHT1 were 
concentrated to a single 2mL fraction and each 2mL fraction loaded separately onto a 
2mL superloop for size exclusion chromatography using a HiPrepTM 16/60 SephacrylTM 
S-200 gel filtration column connected to the ÄKTA Prime FPLC system (2.2.4.5). Figures 
6.15 (RhoHFL) and 6.17 (RhoHT1) show that this method produced successful purification 
of these constructs. Pure RhoHFL and RhoHT1 fractions from gel filtration were 
concentrated to the desired concentration for each downstream process. However, it was 
first necessary to again confirm that these purified proteins represented the desired target 
proteins. Western blotting was therefore undertaken on gel purified samples via the 
typical procedure (2.2.4.8; dilutions shown in 2.1.1.4) using the aforementioned 
ab138123 anti-RhoH polyclonal as the primary antibody. As shown in Figure 6.19, the 
presence of bands of the correct molecular weight for each RhoH construct suggested that 
the fractions of pure proteins obtained were indeed fractions of RhoHFL and RhoHT1.  
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Figure 6.15 IMAC purified fractions of RhoHFL obtained from lysed recombinant 
C43 (DE3) E.coli extract. (a) 12% SDS-PAGE gel showing successfully purified 
fractions of RhoHFL obtained from IMAC. (b) Representative chromatogram from IMAC 
purification, with the area of the chromatogram corresponding to the purified RhoHFL 
fractions denoted. 
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Figure 6.16 Successful size exclusion purification of RhoHFL from lysed recombinant 
C43 (DE3) E.coli extract. (a) Successful size exclusion purification of RhoHFL shown 
on an 12% SDS-PAGE gel (b) Representative chromatogram trace from gel filtration 
purification, with the area of the chromatogram corresponding to the purified RhoHFL 
fractions shown. 
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Figure 6.17 Succesful IMAC purification of RhoHT1 from lysed recombinant C43 
(DE3) E.coli extract. (a) 12% SDS-PAGE gel showing successfully purified fractions of 
RhoHT1 obtained f rom IMAC. (b) Representative chromatogram trace from IMAC 
purification, with the area of the chromatogram corresponding to the purified RhoHT1 
fractions shown. 
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Figure 6.18 Gel filtration leading to successful size exclusion purification of RhoHT1 
from lysed recombinant C43 (DE3) E.coli extract. (a) Successful size exclusion 
purification of RhoHT1 exhibited on a 12% SDS-PAGE gel (b) Representative 
chromatogram from the RhoHT1 gel filtration purification; area of the chromatogram 
corresponding to the purified RhoHT1 fractions emphasised. 
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Figure 6.19 Anti-RhoH immunoblots showing presence of RhoH in purified RhoHFL 
and RhoHT1 samples. (a) Immunoblot showing presence of RhoH constructs in either 
insoluble or soluble fractions, as illustrated. (b) Immunoblot showing presence of RhoHFL 
in IMAC and gel filtrated samples, including the concentrated sample taken forward for 
downstream use. (c) Immunoblot showing presence of RhoHT1 in gel purified sample, 
including the concentrated sample taken forward for downstream utilisation. 
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6.2.5 In vitro characterisation 
As discussed in the introduction of this chapter, previous studies in animal models and 
cell lines have provided initial insights to the cellular functions of RhoH. Despite this, 
several aspects of this remarkable GTPase remain uncharacterised. Consequently, several 
attempts to further characterise this enzyme were undertaken in this project. First, 
dynamic light scattering (DLS) was utilised in combination with gel filtration 
chromatography to assess the oligomeric state of this highly atypical GTPase. Secondly, 
numerous attempts to structurally characterise RhoH through x-ray crystallography were 
undertaken. Further to this, in silico modelling of RhoH was performed in the hope of 
elucidating the possible tertiary structure of this highly atypical and medically important 
GTPase. Finally, following promising implications in the literature, several in vitro assays 
were performed using RhoHFL and RhoT1 in the presence of the putative RhoH-regulating 
kinase DRAK2. The results show that RhoH highly difficult to crystallise, but is most 
closely related to the Rho GTPases Cdc42, RhoE and RhoD. In silico modelling of Rho 
Hans assessment of primary structure suggests a GTPase containing some overt classical 
Rho characteristics while also exhibiting unique and remarkably atypical features. No 
clear evidence was obtained for the presence of RhoH multimers and RhoH appears to 
present monomerically in vitro. However, this remains to be confirmed.  
6.2.5.1 RhoH appears to present monomerically 
Canonically, GTPases of the Ras superfamily are monomeric in nature. However, the 
atypical presentation of RhoH prompted an investigation as to whether this monomeric 
nature is also displayed by RhoH. While bioinformatics analysis of the primary structure 
of RhoHFL and RhoHT1 did not imply a strong propensity towards oligomeric states, in 
silico attempts at identifying protein oligomeric state are not routinely used as definitive 
investigative tools. Instead, experimental assessments in the wet lab are considered 
standard and highly necessary. In vitro results obtained throughout this study indicated 
that RhoH indeed presents monomerically. While IMAC-purified RhoH typically 
displayed a band at the expected molecular weight in addition to a band of double this 
expected molecular weight, early analysis by mass spectrometry indicated that the peptide 
comprising this larger protein did not identify with RhoH. Further to this, size exclusion 
chromatography of RhoH via gel filtration chromatography did not produce multiple 
RhoH-identifying peaks. The use of dynamic light scattering (DLS) on RhoH (Appendix 
13) produced poor results due to the apparent inherent propensity for RhoHFL and RhoHT1 
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to aggregate. Despite centrifugation of samples prior to DLS, results suggested the 
presence of a particle of small diameter in addition to two much larger particles likely to 
represent aggregates. Overall, difficulties in handling RhoH led to challenging 
downstream processing. The results obtained indicated that RhoH is monomeric in vitro. 
Future use of analytical ultracentrifugation may allow for further clarification of RhoH 
oligomeric state. However, difficulties in obtaining high protein yield and handing this 
GTPase in vitro, in addition to the lack of promising leads from DLS and gel filtration, 
dissuaded the use of analytical ultracentrifugation; instead, pure samples of this difficult 
protein were prioritised for other downstream experiments.  
6.2.5.2 Human RhoH crystallisation attempts 
Numerous attempts to crystallise RhoHFL and RhoHT1 were undertaken using the manual 
drop method described previously (2.2.4.9). Attempts to maintain pure RhoHFL and 
RhoHT1 at concentrations >2 mg/mL resulted in rapid aggregation of these proteins within 
24 hours; correspondingly, all crystallisation attempts RhoHFL and RhoHT1 were 
concentrated to no more than 2 mg/mL. As both polypeptides were most stable in high 
salt buffers (~500 mM), crystallisation was attempted in the following buffer: 50 mM 
HEPES (pH 7.4), 5 mM DTT, 2% glycerol and either 500 mM or 300 mM NaCl. The 
proteins were concentrated using 15 mL centrifugal concentrators, as previously 
described (2.2.4.6). The following crystallisation screens were utilised (developed by 
Hampton Research Corp., United States): Hampton I, Hampton II and the PEG/Ion 
screen. No positive results were obtained, though a range of drops were observed: most 
drops showed some aggregations, while some drops were clear. No promising crystals 
were observed. Although other Rho GTPases have been previously crystallised, other 
research groups have noted difficulties in crystallising the atypical Rho GTPases. As 
such, in silico modelling approach was adopted as discussed in the following section. 
6.2.5.3 In silico modelling indicates some canonical Rho characteristics for RhoH in 
addition to atypical components 
In recent years, in silico modelling of protein tertiary structure has become increasingly 
sophisticated. It is now possible to generate 3D models using a variety of approaches 
online, with results generated at unprecedented speeds. Table 6.5, summarises the 
modelling results obtained from three separate online modelling servers, with the 
rationale behind the use of each server is provided in brief. Further information derived 
from these modelling servers can be found in Appendix 14. Use of the LOcal Meta 
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Threading-Server (LOMETS) generates models from separate local threading programs 
and automatically displays the top models from each program on the display page. The 
top LOMETS results for RhoHFL and RhoHT1 were rendered in PyMol (Schrödinger Inc., 
United States) for further analysis, as shown in Figure 6.20 and 6.21, respectively. The 
models obtained for RhoHFL (Figure 6.20) and RhoHT1 (Figure 6.21) suggest that RhoH 
is similar to many classical Ras and Rho enzymes with regards to overall structure, 
containing the classical five alpha helices and six beta sheets in the correct order, in 
addition to G loops and switch regions that resembles those observed for other members 
of the Rho family (53,296). Further to this, a Rho insert domain is noticeable in both 
models, appearing as a loop and short alpha helical section between the fifth beta strand 
and fourth alpha helix, as is seen in other Rho enzymes (34). Interestingly, according to 
the models, the ITAM-like motif described in the literature (447-450) appears to more 
accessible than initially suggested by a survey of RhoH’s primary amino acid sequence, 
which indicated that this domain would likely be buried in a hydrophobic core. In terms 
of a comparison of the RhoHT1 model versus the RhoHFL model, an extended C-terminal 
region is seen for RhoHFL, comprising the polybasic, LFSINE and ‘CaaX’ box areas. As 
this area was largely truncated in RhoHT1, this region is not visible in the RhoHT1 model. 
Other than this noticeable difference, the two models are very compatible, as expected. 
To gain further insight as to any major differences between the in silico models for 
RhoHFL and RhoHT1 compared to classical Rho enzymes, both models were superimposed 
against Cdc42, the closest classical homologue to RhoH. Superimposition was achieved 
using the automatic fitting feature in PyMol, which also automatically generates a root 
mean square deviation (RMSD) indicating is the measure of the average distance between 
backbone atoms of the superimposed proteins. The results for RhoHT1 (Figure 6.22) and 
RhoHFL (Figure 6.23) are again, rather similar, showing similar differences to Cdc42 
including differences in the following areas: the P-loop and switch I region (see 6.22b), 
Rho insert region (6.22c) and the β1, β2, β3 and β6 sheet regions (as shown in Figures 
6.22 and 6.23). Although Cdc42 did display with an extended C-terminal region, the C-
terminal region in RhoHFL was even further extended (see 6.23c). The RMSD values 
obtained were 0.514Å and 0.655Å for RhoHT1 and RhoHFL, respectively, suggesting that 
RhoHT1 fits slightly to Cdc42, although this was likely due to the RhoHFL C-terminal 
region. Overall, the results suggest that RhoH broadly resembles another Rho classical 
Rho enzyme, Cdc42, but presents with variances in specific regions (discussed further in 
6.3). 
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Table 6.5 Top-scoring models for the prediction of RhoHFL and RhoHT1 3D structure. 
Modelling 
server 
Rationale for use of server RhoH FL top model RhoHT1 top model 
LOMETS ( LOcal 
MEta-Threading-
Server) 
Free, fast online web service for the prediction of protein structure. 
Generates 3D models via collection of high-scoring target-to-template 
alignments from 9 separate local threading programs (Hsearch, 
MUSTER, pGenTHREADER, FFAS-3D, PPAS, PROSPECT2, PRC, 
SP3 and SPARKS-X). 
  
HHPred 
100x faster than many leading servers and assessed as one of best 
servers for template-based protein structure prediction in the 2010 
Critical Assessment of protein Structure Prediction (CASP).  
  
Raptor X 
Excels at aligning hard targets according to the 2010 CASP9 
experiments. RaptorX generates the significantly better alignments for 
the hardest 50 CASP9 template-based modelling targets than other 
servers including those using consensus and refinement methods. 
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Figure 6.20. In silico model of RhoHFL 3D structure. Top LOMETS result for RhoHFL, 
showing (a) anterior and (b) alternative views in addition to (c) a close-up of the nucleotide 
binding site (with relevant residues shown) and (d) a schematic diagram of RhoH domain 
architecture, with significant amino acid residues shown in red. The colour scheme utilised in 
(d) is also applicable to (a–c). Mg2+ (shown as a green sphere) and GCP, a non-hydrolysable 
analogue of GTP, are shown in (a–c) and are positioned as a direct result of superimposition of 
Cdc42 with the RhoFL model (Cdc42 hidden, but GCP and Mg2+ visible). RhoHFL Model 
rendered in PyMol (Schrödinger Inc., United States).  
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Figure 6.21. In silico model of RhoHT1 3D structure. Top LOMETS result for RhoHFL, 
showing rendered 3D models of RhoHT1 (a) anterior and (b) alternative views. Additionally, (c) 
shows a schematic diagram of the RhoHT1 construct domain architecture, with significant amino 
acid residues shown in red. The colour scheme utilised in (c) is also applicable to (a) and (b). 
Mg2+ (shown as a green sphere) and GCP, a non-hydrolysable analogue of GTP, are shown in 
(a) and (b), and are positioned as a direct result of superimposition of Cdc42 with the RhoFL 
model (Cdc42 hidden, but GCP and Mg2+ visible). RhoHT1 model rendered in PyMol 
(Schrödinger Inc., United States).  
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Figure 6.22. Visualisation of a 3D model of RhoHT1 (blue) superimposed with the known 
3D crystallographic structure of Cdc42 (red). Cdc42 (PDB: 2QRZ) aligned and 
superimposed against the top LOMETs model of RhoHT1, with a (a) full structure shown 
alongside close-up visualisation of: (b) the P-loop (G1) and switch I region, (c) the Rho insert 
domain, (d) the β6 sheet and (e) the β2 and β3 sheets. The Cdc42 structure was bound Mg2+ and 
GCP, a non-hydrolysable GTP analogue. Models were rendered and superimposed in PyMol 
(Schrödinger Inc., United States). The overall root mean square deviation (RMSD) for this 
superimposition was automatically generated by PyMol and is provided above (a). 
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Figure 6.23. Superimposition of a 3D model of RhoHFL (blue) against the known 3D 
crystallographic structure of Cdc42 (red). Top LOMETs model of RhoHFL, aligned and 
superimposed against the 3D structure of classical Rho GTPase Cdc42 (PDB: 2QRZ), with an 
(a) anterior visualisation shown, in addition to a close-up of (b) the β1 sheet region and (c) the 
C-terminal regions of each protein. The Cdc42 structure shown was bound Mg2+ and the non-
hydrolysable GTP analogue GCP. Models were rendered and superimposed in PyMol 
(Schrödinger Inc., United States). The overall root mean square deviation (RMSD) is provided 
below (a), following automatic generatation in the PyMol molecular visualisation system. 
 
 
(b) 
(c) 
β1 
β1 
C-terminal 
region 
C-terminal 
region 
Rho 
insert 
G1 /   
P-loop G2 / Switch I 
β1  
β2  
β3  
(a) 
 272 
 
6.2.6 Phosphorylation assays 
In parallel with the large scale expression and purification of RhoHFL (full length) and 
RhoHT1 (S4–A174), two constructs of the death-related kinase DRAK2 were expressed and 
purified: DRAK2FL (full length) and DRAK2XTAL (M1–K327).This was possible through 
the kind donation of pNIC28-Bsa4 vectors bearing the nucleotides encoding either 
DRAK2FL or DRAK2XTAL, respectively, courtesy of the Oxford University Structural 
Genomics Consortium.  The scheme of expression and purification of these constructs 
was guided by prior expression trials, resulting in a recombinant protein yield of 
~2mg/mL from 1–2 L C43 culture and single bands on SDS-PAGE gels (IMAC and gel 
filtration purification utilised; see Figure 6.24–6.27).  
As discussed in 6.1, DRAK2 is a strong putative RhoH interaction partner and it is 
believed that this kinase may phosphorylate RhoH. As such, a series of phosphorylation 
assays were implemented as discussed in 2.2.7.1., with samples taken at time zero (0 min), 
10 minutes and 45 minutes after initiation of the reaction. As discussed in detail 
previously (2.2.5.3), the reaction mixture consisted of a set concentration of kinase (10µM 
or 20µM) in combination with either 5 times or 10 times the amount of RhoH construct; 
the reaction occurred in gel filtration buffer (2.1.5.3.3) supplemented with 2mM MgCl2 
and 1mM ATP. Samples were collected in 1.5mL eppendorphs and frozen immediately 
at -80oC upon collection. When required, samples were then thawed and an appropriate 
amount of SDS-PAGE buffer (2.1.5.1.5) added. The samples were subjected to SDS-
PAGE electrophoresis (2.2.4.1) and Western blotting was performed (2.2.4.8) using the 
ab17464 Anti-phosphoSer/phosphoThr polyclonal (AbCam, United Kingdom) in the 
dilutions shown in Table 2.4 (2.1.1.4). To ensure loading consistency for Western 
blotting, select blots were stripped and re-probed with either an anti-RhoH or anti-
DRAK2 primary antibody in the dilutions shown in Table 2.4 (2.1.1.4). Additionally, all 
SDS-PAGE gels used in Western blotting were also dyed in Coomassie blue (2.2.4.2) 
post-transfer as a means to further assess the loading efficiency of samples. Overall, the 
Western blotting results (Figures 6.28–6.35) from these assays indicate that both 
DRAK2FL and DRAK2XTAL are capable of phosphorylating RhoH, with both RhoHFL and 
RhoHT1 forming suitable targets. This effect was seen across all variations of the 
phosphorylation assay tested. Interestingly, however, DRAK2FL appeared to become 
auto-phosphorylated throughout these assays, while DRAK2XTAL did not. 
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Figure 6.24 Successful IMAC purification of DRAK2FL from lysed recombinant C43 
(DE3) E.coli extract. (a) 12% SDS-PAGE gel showing IMAC-purified fractions of 
DRAK2FL. (b) Representative chromatogram trace from IMAC purification, with the area 
of the chromatogram corresponding to the purified DRAK2FL fractions shown. 
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Figure 6.25 Successful size exclusion purification of DRAK2FL from lysed recombinant C43 
(DE3) E.coli extract. (a) 12% SDS-PAGE gel showing successful size exclusion purification of 
DRAK2FL (b) Representative chromatogram from the DRAK2FL size exclusion (gel filtration) 
purification; area of the chromatogram corresponding to the purified DRAK2FL fractions clearly 
displayed. 
Size exclusion purification of DRAK2FL by gel filtration 
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Figure 6.26 IMAC purification of DRAK2XTAL from lysed recombinant C43 (DE3) 
E.coli extract. (a) 12% SDS-PAGE gel showing successfully IMAC-purified fractions 
of DRAK2XTAL. (b) Representative chromatogram trace from IMAC purification, with 
the area of the chromatogram corresponding to the purified DRAK2XTAL fractions 
displayed. 
Purification of DRAK2XTAL by ion-metal affinity 
chromatography (IMAC) 
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Figure 6.27 Successful size exclusion purification of DRAK2XTAL from lysed recombinant 
C43 (DE3) E.coli extract. (a) 12% SDS-PAGE gel showing successful size exclusion 
purification of DRAK2XTAL (b) Representative chromatogram from the DRAK2XTAL size 
exclusion (gel filtration) purification; area of the chromatogram corresponding to the purified 
DRAK2XTAL fractions clearly displayed 
Size exclusion purification of DRAK2XTAL by gel filtration 
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Figure 6.28 20µM DRAK2FL phosphorylates RhoHFL and appears capable of 
autophosphorylation. (a) Anti-PhosphoSer/PhosphoThr Western blot, showing phosphorylation 
of RhoHFLby 20µM DRAK2FL in the presence of either 5 times (50µM) or ten times (100µM) 
RhoHFL. Stripping and reprobing this blot with (b) anti-DRAK2 and subsequently (c) anti-RhoH 
indicated that loading of the DRAK2 and RhoH was controlled. 
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Figure 6.29 10µM DRAK2FL phosphorylates RhoHFL and appears to undergo 
autophosphorylation. Anti-PhosphoSer/PhosphoThr Western blot, showing phosphorylation of 
RhoHFLby DRAK2FL in the presence of either 5 times (50µM) or ten times (100µM) RhoHFL.  
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Figure 6.30 20µM DRAK2FL phosphorylates RhoHT1 and appears to undergo 
autophosphorylation. Anti-PhosphoSer/PhosphoThr Western blot from phosphorylation assays, 
indicating phosphorylation of RhoHT1 by 20µM DRAK2FL in the presence of either 5 times 
(50µM) or ten times (100µM) RhoHT1. 
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Figure 6.31 10µM DRAK2FL appears to autophosphorylate in the presence of magnesium 
and ATP, and is able to phosphorylate DRAK2FL. Anti-PhosphoSer/PhosphoThr Western blot, 
denoting phosphorylation of RhoHT1 by 10µM DRAK2FL in the presence of either 5 times (50µM) 
or ten times (100µM) RhoHT1.  
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Figure 6.32 Phosphorylation of RhoHFL by 20µM DRAK2XTAL in the presence of magnesium 
and ATP. Anti-PhosphoSer/PhosphoThr immunoblot, showing phosphorylation of RhoHFL by 
20µM DRAK2XTAL.  
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Figure 6.33 RhoHFL is phosphorylated by 10µM DRAK2XTAL in the presence of magnesium 
and ATP. Anti-PhosphoSer/PhosphoThr Western, indicating phosphorylation of RhoHFL by 
10µM DRAK2XTAL.  
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Figure 6.34 Phosphorylation of RhoHT1 by 20µM DRAK2XTAL in the presence of magnesium 
and ATP. (a) Anti-PhosphoSer/PhosphoThr immunoblot, exhibiting phosphorylation of RhoHT1 
by 20µM DRAK2XTAL.  
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Figure 6.35 10µM DRAK2XTAL phosphorylates RhoHT1 in the presence of magnesium and 
ATP. (a) Anti-PhosphoSer/PhosphoThr Western blot indicating phosphorylation of RhoHT1 by 
20µM DRAK2XTAL in the presence of either 5 times (50µM) or ten times (100µM) RhoHFL. 
Stripping and reprobing this blot with (b) anti-DRAK2 and (c) anti-RhoH utilised as loading 
controls.  
Anti-PhosphoSer/PhosphoThr Western Blot: 
10µM DRAK2XTAL + 5 x and 10 x RhoHT1 
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Unless otherwise indicated, the term ‘phosphorylation’ will subsequently be used to 
indicate serine/threonine phosphorylation only. In Figures 6.28 and 6.29, two distinct 
bands are consistently observed at positions suggesting that both RhoHFL and DRAK2FL 
are phosphorylated throughout the assays; this effect is also observed in Figures 6.30 and 
6.31, indicating that both DRAK2FL and RhoHT1 were phosphorylated throughout the 
experiments. In Figures 6.32 and 6.33, RhoHFL appears to have undergone 
phosphorylation; correspondingly, Figures 6.34 and 6.35 indicate that RhoHT1 is 
phosphorylated under these experimental conditions. A pattern therefore emerges: while 
DRAK2FL appeared to be consistently phosphorylated in these studies, DRAK2XTAL did 
not. One potential explanation could be that DRAK2FL experiences autophosphorylation 
in residues not present in the DRAK2XTAL truncate. Serine-12 in DRAK2 has been 
previously identified as an important residue for regulatory autophopshorylation, 
although serine and threonine residues at positions 328, 333, 348, 351 and 362 have also 
been implicated as targets for DRAK2 autophosphorylation (487). As DRAK2XTAL is 
truncated at residue 327, it may simply be that DRAK2FL is experiencing 
autophosphorylation at these other reported serine and/or threonine residues. 
Alternatively, DRAK2XTAL may be partaking in serine-12 autophosphorylaton at a level 
not detectable with the conditions tested and methodology applied. Whatever the case, 
the results obtained may indicate that serine and/or threonine residues after position 327, 
the cut-off boundary for DRAK2XTAL, engage in autophosphorylation in vitro under these 
experimental conditions in a detectable manner. One weakness with the phosphorylation 
assay data are the presence of bands at time zero. Since the proteins used in these assays 
were all gel purified (producing single bands on SDS-PAGE gels), it is unlikely that the 
bands present at time zero indicate phosphorylation of an off-target protein. One 
explanation may be that some serine and/or threonine residues experienced 
phosphorylation by endogenous E.coli kinases prior to purification; indeed, 
phosphorylation of proteins by kinases has been known to survive the gel filtration 
process (506). Generally, however, an increasing signal was observed over time in the 
anti-PhosphoSer/PhosphoThr blots; this indicates that phosphorylation of RhoHFL, 
RhoHT1 and DRAK2FL was indeed progressively occurring.  
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6.3 Conclusions and discussion 
6.3.1 RhoH characteristics in vitro 
The data exhibited in this chapter show that both full length human RhoH (RhoHFL) and 
the corresponding human RhoH truncate S4–A174 (RhoHT1) express well in E.coli 
expression strains BL21 (DE3), C41 (DE3) and C43 (DE3). However, these enzymes are 
difficult to process downstream and display the propensity to aggregate even in the 
presence of optimised buffers. The use of protease inhibitors and swift purification 
prevented normal degradation of RhoH in this context. Although not directly comparable, 
it is interesting to note that the half-life of full length RhoH in Jurkat human T 
lymphocytes has previously been described as less than 3 hours, with truncations of RhoH 
lacking the CaaX box or polybasic domain displaying an even shorter half-life in these 
cells (435). Interestingly, RhoHT1 tended to exhibit a longer half-life than its full length 
counterpart in vitro. Indeed, submission of the RhoHFL and RhoHT1 amino acid sequences 
into the XtalPred-RF online server yielded instability index (II) scores of 41.26 and 27.59, 
respectively (507). This indicated that RhoHFL is unlikely to show stability in vitro while 
RhoHT1 may show a degree of stability. It is possible that while a truncated version of 
RhoH is inherently more stable than RhoHFL, displacement of RhoH from its site of action 
at the plasma membrane (due to a RhoHT1-like C-terminal truncation) produces an 
enhanced vulnerability to targeted degradation in living cells. However, this remains to 
be confirmed experimentally. It should also be noted that it was difficult to definitively 
assess the half-life of human RhoHFL and RhoHT1 in vitro due to aggregation issues and 
the use of protease inhibitors. Regardless of this, the available time for downstream use 
of both RhoHFL and RhoHT1 before excessive aggregation and degradation was low. 
Typically, a window of ~36 hours was available following IMAC purification in order to 
acquire meaningful data. This brought great difficulties with regards to crystallisation, 
with a distinct absence of meaningful crystals in all tested conditions. Regardless of this 
short timeframe for action, crystallisation prediction scores for both RhoHFL and RhoHT1 
primary sequences inputted into the XtalPred-RF online server indicated that these 
proteins would be difficult to crystallise with or without the presence of a hexahistidine 
tag. The one anomaly for this was RhoHT1 under the expert pool (EP) method of 
prediction, which implied a high likelihood of RhoHT1 crystallisation. Intriguingly, the 
random forest (RF) crystallisation prediction score for RhoHT1 suggested somewhat the 
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opposite of the EP method, indicating that RhoHT1 did not show a particularly promising 
likelihood for crystallisation.  
In silico modelling attempts produced 3D structures broadly similar to typical Ras 
superfamily G domains. Akin to classical small GTPases, five alpha helices and six beta 
sheets were observed. Additionally, two regions resembling the classical switch I and II 
regions were shown. Superimposition of RhoHT1 and RhoHFL against the canonical Rho 
GTPase Cdc42 (296) showed that both proteins fit well against Cdc42 general structure, 
with RMSD values of 0.514Å and 0.655Å. The most noticeable differences between the 
RhoH models and Cdc42 were observed in the P loop and switch I regions, producing a 
tighter nucleotide binding site in the RhoH models; this may contribute to the 
constitutively GTP-bound state of RhoH (420), alongside the G13S and Q62N 
substitutions in RhoH (shown in Figure 6.20) believed to maintain RhoH in a 
constitutively active state (58,420,428) relative to typical Ras and Rho enzymes due to 
steric interference of the catalytic arginine finger of GAP regulatory enzymes (2,58,428). 
Interestingly, while RhoH appeared monomeric in vitro, this still remains to be fully 
explored. Indeed, many proteins harbouring ITAM motifs act as dimers intracellularly. 
Thus, it is possible that RhoH may be capable of dimerisation within the cell. Ultimately, 
analytical ultracentrifugation would provide a definitive answer to RhoH’s ability to 
dimerise in vitro. However, the results obtained indicate that RhoH shows a monomeric 
appearance in vitro. 
6.3.4 DRAK2 as a regulator of RhoH 
RhoH does not follow the tight canonical scheme of regulation exhibited by the majority 
of Ras superfamily GTPases, instead displaying constitutive activity due to point 
mutations at glycine-12 and glutamine-61. However, several other means of regulating 
this enzyme appear to exist, including phosphorylation. While phosphorylation of the 
tyrosine residues of the RhoH ITAM-like motifs appears to be important for Zap70 
recruitment, many canonical Rho GTPases are phosphorylated by serine/threonine 
kinases (420,508-510) and it is likely that RhoH also undergoes regulation through 
phosphorylation at serine or threonine residues. In T lymphocytes, RhoH and DRAK2 
appear to exhibit several shared functional roles and downstream effectors, suggesting 
that they act within the same or similar signalling pathways (6.1.6). Additionally, these 
proteins have both been independently implicated in the development of chronic 
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lymphocytic leukaemia (CLL). This information, together with recent reports that RhoH 
mRNA levels positively correlate with levels of DRAK2 mRNA (505), prompted the in 
vitro phosphorylation assays undertaken in this project which demonstrate that both 
DRAK2 and the DRAK2XTAL (1-327) truncate are capable of phosphorylating RhoHFL 
and RhoHT1. Although this interaction remains to be experimentally confirmed in vivo, 
these results indicate that RhoH may be regulated by DRAK2, inviting new avenues of 
research for exploring RhoH kinase interaction partners. Indeed, this information may 
prove useful in developing future novel therapeutics against some forms of CLL. 
Curiously, DRAK2FL consistently exhibited autophosphorylation in these studies, while 
DRAK2XTAL did not. This suggests that crucial serine or threonine residues necessary for 
DRAK2 autophosphorylation are not present in the DRAK2XTAL construct. Serine 12 in 
DRAK2 has been previously identified as an important residue for regulatory 
autophopshorylation, although serine and threonine residues at positions 328, 333, 348, 
351 and 362 have also been implicated as targets for DRAK2 autophosphorylation (487). 
As DRAK2XTAL is truncated at residue 327, it may simply be that DRAK2FL is 
experiencing autophosphorylation at these other reported serine residues. Alternatively, 
DRAK2XTAL may be partaking in serine-12 autophosphorylaton at a level not detectable 
with the conditions tested and methodology applied. Whatever the case, the results 
obtained suggest that serine residues after position 327, the cut-off boundary for 
DRAK2XTAL, engage in autophosphorylation in vitro under these experimental conditions 
in a detectable manner. 
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7: Concluding remarks 
7.1 Summary 
Despite implications in serious pathologies such as neoplastic disorders or 
neurodegenerative disease, many atypical GTPases of the Ras superfamily remain largely 
uncharacterised at the functional, structural or biochemical level. Here, a range of 
experimental approaches were utilised to elucidate the molecular function and interactors 
of three highly atypical human Rho GTPases: hMiro1, hMiro2 and RhoH. The results 
demonstrate, for the first time, the hydrolytic activities of the hMiro1 and hMiro2 
individual GTPase domains, and show that the hMiro C-terminal GTPase domains are 
capable of substrate promiscuity, displaying hydrolytic activity against ATP and UTP in 
addition to GTP. Novel kinetic parameters are provided pertaining to the basal hydrolytic 
activity of these domains, with the domains broadly exhibiting similar GTP hydrolytic 
efficiencies to those of unstimulated classical Rho GTPases.  RNAi ablation of the hMiros 
led to a reduction in the migration of live PC3 cancer cells and produced distinctive 
phenotypes of perinuclear mitochondrial aggregation (hMiro1 and hMiro2 RNAi) and 
bloating (dual RNAi of both hMiros), while biophysical characterisation of the hMiroXTAL 
constructs suggested that the hMiros exist monomerically and possess average thermal 
stability. Cell studies and proteomics analysis of over-expressed hMiro mutants indicated 
important roles for the state of the hMiro GTPase domains in tuning cell signalling, with 
active and inactive GTPase domains associating with diverse interactors and signalling 
components. Through these studies, several novel hMiro interactors were indicated. 
Computer-based prediction of hMiro signalling partners enhanced the proteomics data 
obtained and brought greater legitimacy to the data set, with several unique binding 
partners indicated for each condition. Finally, in vitro binding between DRAK2 serine 
threonine kinase and RhoH, another Rho family atypical GTPase was shown for the first 
time. The implications for DRAK2 and RhoH binding in vivo are significant, with a 
clinical relevance indicated for chronic lymphocytic leukaemia (CLL). 
7.2 Perspectives and future directions 
Although the results obtained throughout this work have provided novel insights to the 
molecular functions and interactors associated with the human Miros and RhoH, new 
functions for the atypical GTPases continue to emerge in the literature. These functions 
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often provide more questions than answers: numerous cellular processes regulated by the 
Ras superfamily, and particularly atypical GTPases of this superfamily, remain to be 
completely elucidated. 
Here, a glimpse of hMiro molecular interactors was achieved through proteomic studies, 
though a more complete insight would be possible with utilisation of hMiro knockdown 
samples and the full panel of mutants engineered. Expanding these omics studies even 
further could enable the elucidation of hMiro-centred signalling interactions in serious 
pathologies. If possible, an assessment of the influence of hMiro1 and hMiro2 GTPase 
domain state on whole cell metabolomics would be highly interesting: particularly given 
the poorly understood links between the Miro GTPases and metabolism. Further to this, 
an assessment of the influence of hMiro1 and hMiro2 on the proteomics of neuronal cells 
would be intriguing, particularly if the proteome was mapped throughout neuronal 
development and during ageing in the context of Miro abrogation, as the former has been 
implicated in neonatal death and the latter has been consistently associated with the 
development of neurodegenerative symptoms in animal models. Of course, validating the 
signalling pathways and the underlying molecular mechanism mediated by hMiro and 
RhoH would be of great value to investigate new avenues for therapeutics to treat B cell 
leukaemias and neurodegeneration amongst others. 
The characterisation performed here for RhoH suggests that this enzyme may be regulated 
by serine/threonine kinases. However, no search for RhoH serine/threonine kinase 
interactors currently exists. Exploiting this uncharted avenue with the likes of kinase 
arrays, mutational analyses and mass spectrometry would likely identify further novel 
kinases associated with RhoH and their sites of phosphorylation on this unusual GTPase. 
Furthermore, to assess whether the novel in vitro interactions discovered between RhoH 
and DRAK2 occur in vivo and in a clinically relevant manner, it would be interesting to 
expand the work performed in chapter 6 to encompass the processing of neoplastic 
samples derived from CLL patients. Comparing these samples to normal controls from 
healthy individuals would establish whether a clinical significance exists for the 
association between RhoH and DRAK2.  
Finally, approaches to further characterise other atypical GTPases of the Ras superfamily 
would be highly informative. Many of these unusual enzymes engage in the development 
of serious pathological states. Despite this, these GTPases and their interactors generally 
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remain poorly understood. Further efforts to characterise these remarkable enzymes and 
their binding partners would likely yield great benefit in understanding many cellular 
processes, including pathological processes implicated in diseases such as various 
malignancies and neurodegenerative disorders. 
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Appendices 
Appendix 1: General laboratory equipment use 
Sterilisation 
Autoclave sterilisation was achieved at 121°C for 30 min using a bench-top Prestige 
Medical 2100 Classic autoclave or 121°C for 40 min in a Rodwell Gemini front-loading 
autoclave. 
Filter sterilisation was performed through a 0.2 µm Minisart® filter unit (Sartorius) 
attached to a sterile syringe of appropriate volume (Plastipak®, Becton Dickinson) 
Incubators 
For bacterial growth in liquid cultures, an Innova 44 orbital shaker Brunswick Scientific 
(BRS) was utilised. Growth of bacteria on solid media was performed in a static 
GallenKamp incubator. 
pH meter 
A Jenway Ion Meter 3340 (calibrated with buffers at pH 4.0, 7.0 and 9.2) was utilised for 
all alterations of solution pH. 
Micro-centrifugation 
Centrifugation of volumes up to 2 mL was achieved using a small Sigma (SIG) 1-15 
benchtop micro-centrifuge. A MSE Microcentaur bench-top centrifuge was utilised to 
centrifuge PCR tubes. 
Agarose gel electrophoresis 
Electrophoresis of DNA was undertaken using an electrophoresis system (BR) powered 
by a power PAC 300 apparatus (BR). 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel kit 
A Mini-PROTEAN™ 3 Cell kit powered (BR) by a power PAC 300 apparatus (BR) was 
utilised for SDS-PAGE purposes. 
Sonication 
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A MSE Soniprep 150 ultra-sonication machine (Sanyo) was utilised for sonication. 
Spectrophotometer  
Spectrophotometric measurements were made using a UV-visible HeȜios α Spectronic 
Unicam spectrophotometer (TS). 
PCR 
All PCR reactions were performed using a Mastercycler® gradient thermocycler 
(Eppendorf). 
Vortexing 
A Fisher Scientific (FIS) whirlmixer was used to vortex samples. 
Waterbath 
Grant (SUB series) incubator water baths were used to incubate samples at digitally 
controlled temperatures. 
Pippetting 
Gilson P2-P5000 pipettes were used to accurately pipette samples and reagents from 0.01-
5000 µL 
Weighing Reagents 
A Mettler AT250 analytical balance used to measure µg quantities of chemicals and 
reagents. 
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Appendix 2: Gel filtration calibration curve 
 
Figure A2.1 Typical gel filtration calibration curve. Obtained from the sephacryl™ S-200 HR HiPrep™ 16/60 column used, attached to an automated 
FPLC system using the  following the protocol outlined in the methods section.
 327 
 
Appendix 3: PCR protocols 
Optimised PCR programmes for each sequence cloned are shown in the following 
tables. Most programmes were based on recommendations suggested by Novagen for 
PCR using KOD polymerase. Optimised reactions typically comprised: 10 ng template, 
0.3 µM of each primer and 25 µL KOD Hot Start Mastermix (Novagen, United 
Kingdom) brought to a final volume of 50 µL with PCR grade water. In each case, 2% 
DMSO was utilised for optimisation of sequence amplification. 
Table A3.1 PCR programmes utilised for the amplification of hMiro1 and hMiro2 full-
length wildtype encoding sequences. 
hMiro1FL  hMiro2FL  
Step Command Step Command 
1 94oC for 2 minutes 1 94oC for 2 minutes 
2 94oC for 15 seconds  2 94oC for 15 seconds  
3 62oC for 30 seconds 3 60oC for 30 seconds 
4 72oC for 40 seconds 4 72oC for 40 seconds 
5 Repeat steps 2-4 for 30 cycles 5 Repeat steps 2-4 for 30 cycles 
6 4oC hold 6 4oC hold 
 
 
 
 
 
 
 
 
 
 328 
 
Table A3.2 PCR programmes utilised for the amplification of hMiro1 and hMiro2 N-
terminal (NT) GTPase encoding sequences. 
hMiro1NT (K3 – P169) hMiro2NT (R3 – P169) 
Step Command Step Command 
1 94oC for 2 minutes 1 94oC for 2 minutes 
2 94oC for 15 seconds  2 94oC for 15 seconds  
3 62oC for 30 seconds 3 62oC for 30 seconds 
4 72oC for 40 seconds 4 72oC for 40 seconds 
5 Repeat steps 2-4 for 30 cycles 5 Repeat steps 2-4 for 30 cycles 
6 4oC hold 6 4oC hold 
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Table A3.3 PCR programmes utilised for the amplification of hMiro1 and hMiro2 C-
terminal GTPase (CT) encoding sequences. 
hMiro1CT (Q415-P580) hMiro2CT (Q413-F589) 
Step Command Step Command 
1 94oC for 2 minutes 1 94oC for 2 minutes 
2 94oC for 15 seconds  2 94oC for 15 seconds  
3 58oC for 30 seconds 3 62oC for 30 seconds 
4 72oC for 40 seconds 4 72oC for 40 seconds 
5 Repeat steps 2-4 for 30 cycles 5 Repeat steps 2-4 for 30 cycles 
6 4oC hold 6 4oC hold 
 
Table A3.4 PCR programmes utilised for the amplification of hMiro1XTAL and hMiro2XTAL 
encoding sequences. 
RhoHFL RhoHT1 
Step Command Step Command 
1 94oC for 2 minutes 1 94oC for 2 minutes 
2 94oC for 15 seconds  2 94oC for 15 seconds  
3 49oC for 30 seconds 3 53oC for 30 seconds 
4 72oC for 40 seconds 4 72oC for 40 seconds 
5 Repeat steps 2-4 for 30 cycles 5 Repeat steps 2-4 for 30 cycles 
6 4oC hold 6 4oC hold 
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Table A3.5 PCR programmes utilised for the amplification of RhoHFL, RhoHT1 and 
RhoHT2 encoding sequences. 
RhoHFL RhoHT1 and RhoHT2 
Step Command Step Command 
1 94oC for 2 minutes 1 94oC for 2 minutes 
2 94oC for 15 seconds  2 94oC for 15 seconds  
3 58oC for 30 seconds 3 54oC for 30 seconds 
4 72oC for 40 seconds 4 72oC for 40 seconds 
5 Repeat steps 2-4 for 30 cycles 5 Repeat steps 2-4 for 30 cycles 
6 4oC hold 6 4oC hold 
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Appendix 4: Mutant primers for site-directed mutagenesis (SDM) 
Primers used for site-directed mutagenesis (SDM) are provided below. These primers 
were utilised with a number of hMiro templates to produce the desired panel of mutants 
displayed in Chapter 5. 
 
Oligonucleotide primer for G425V hMiro1 mutagenesis 
Forward: 5’-GTTCAGATGTAATGTAATTGTGGTGAAAAACTGTGGGAAAAG-3’ 
Reverse: 5’-CTTTTCCCACAGTTTTTCACCACAATTACATTACATCTGAAC-3’ 
 
Oligonucleotide primer for S432N hMiro1 mutagenesis 
Forward: 5’- GAAAAACTGTGGGAAAAATGGAGTTCTTCAGGCTC-3’ 
Reverse: 5’-GAGCCTGAAGAACTCCATTTTTCCCACAGTTTTTC-3’ 
 
Oligonucleotide primer for G423V hMiro2 mutagenesis 
Forward: 5’-GTTCAGATGTAATGTAATTGTGGTGAAAAACTGTGGGAAAAG-3’ 
Reverse: 5’-CTTTTCCCACAGTTTTTCACCACAATTACATTACATCTGAAC-3’ 
 
Oligonucleotide primer for S430N hMiro2 mutagenesis 
Forward: 5’- GAAAAACTGTGGGAAAAATGGAGTTCTTCAGGCTC-3’ 
Reverse: 5’-GAGCCTGAAGAACTCCATTTTTCCCACAGTTTTTC-3’ 
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Appendix 5: Cell line data 
Table A5.1. Cell line data. 
Cell Description Tissue Karyotype Gender Species 
COS7 Kidney cell line Kidney --- M 
Cercopithecus 
aethiops 
MCF-7 Mammary gland adenocarcinoma Breast Cancer F Homo sapiens 
hVSMC 
Human vascular smooth muscle 
cells 
Vascular (aortic) Normal M Homo sapiens 
PC3 
Prostate cancer cell derived from 
grade IV patient 
Prostate Cancer M Homo sapiens 
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HEK-293 
Embryonic kidney (contains 
adenovirus 5 DNA) 
Kidney --- U Homo sapiens 
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Appendix 6: Additional growth components for VSMCs 
Vascular smooth muscle cells (VSMCs) were maintained in vascular cell basal media 
(Lonza, United Kingdom) supplemented with the components shown in Table A7.1 to 
produce complete media for these cells. This complete media was to be kept at 4oC in the 
dark and was stable for 30 days under these conditions. 
Table A6.1. Additional growth components for VSMC culture. 
Component Volume Final Concentration 
rh FGF-basic 0.5 mL 5 ng/mL 
rh Insulin 0.5 mL 5 µg/mL 
Ascorbic acid 0.5 mL 50 µg/mL 
L-glutamine 25.0 mL 10 mM 
rh EGF 0.5 mL 5 ng/mL 
Fetal Bovine Serum 25.0 mL 5% 
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Appendix 7: X!Tandem search parameters 
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Appendix 8: MASCOT search parameters 
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Appendix 9: Kinetic assays calculations 
Interpretation of raw malachite green data (Cayman Chemicals) 
For interpretation of malachite green raw data, the slope of the standard curve shown in 
Figure 4.2 (Chapter 4) was utilised, where the amount of phosphate produced in nMoL 
per 50µL at each time point was calculated as follows: 
 
𝑃ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 (𝑛𝑀 𝑝𝑒𝑟 50𝜇𝐿) =
(Abs635 + 0.0067)
0.6712
 
 
The value obtained was subsequently divided by 50 to obtain a value in nM. Conversion 
of values to µM was then undertaken by multiplying the value by 1 x 103. Finally, the 
relative blank value was taken away from this value, to give a true representation of the 
amount of phosphate produced by enzymatic hydrolysis. 
Interpretation of raw data from PiColourLock™ Gold experiments 
For interpretation of raw data from the PiColourLock™ Gold assays, the slope of the 
standard curve shown in Figure 4.3 (Chapter 4) was used. Here, µM of free inorganic 
phosphate could be derived immediately from the standard curve. Absorbance was read 
at discreet time points, as previously indicated in the literature, to produce bar charts 
representing µM phosphate produced per unit time. 
Calculation of kinetic parameters 
All kinetic parameters obtained were produced from the Lineweaver-Burke (LB) plots 
shown in Chpater 4. From these plots, the following  kinetic parameters were derived: 
Vmax was derived from the y-intercept of each LB plot, which gave 1/Vmax 
Km was derived from multiplying the gradient of the respective LB plot by Vmax 
Kcat was derived from dividing Vmax by the total concentration of enzyme used per well 
Kcat/Km was derived from dividing the value for  Kcat with the value obtained for Km
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Appendix 10: Further xCELLigence information 
Further information regarding the general set-up and system report generation for 
xCELLigence is given below. 
   
   
   
   
   
   
   
   
   
Created By: ADMINISTRATOR  
Creation 
Date: 
02/07/2016 14:05  
File Name: 
C:\Documents and Settings\RTCAOperator\My Documents\Rosemary 
projects\30Jun16migration.plt 
Exp ID: 1606301736D2  
   
System Information:  
Software 
Version: 
1.2.1.1002  
Analyzer 
Model: 
3x16  
Analyzer SN: 3.21111E+11  
FW Version: V2.2  
Station 
Model: 
3x16  
Station SN: 3.21111E+11  
Station FW: V2.2  
Self Test Val: 99.9842  
 
Seq. Step 
Step-
Status 
Sweep-
Status 
Sweeps Interval Unit Total Time 
1 Step_1 DONE 1 1 1 Minute 00:00:12 
2 Step_2 DONE 100 100 15 Minute 25:36:45 
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Figure A10.1. PC3 migration assays derived from each separate replicate set. 
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Appendix 11: STRING data example 
Table A11.1 STRING data output example.   
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Appendix 12: Proteomics data examples 
Table A12.1. Sample of data from hMiro1N18 set. 
Accession Peptides Score Fractions Description 
Average 
Normalised 
Abundances 
Miro1N18 
SPTN1_HUMAN  76 (74) 2223.03 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
5.17E+07 
PLEC_HUMAN 66 (56) 2063.35 12345678 
Plectin OS=Homo 
sapiens GN=PLEC 
PE=1 SV=3 
1.37E+07 
FLNA_HUMAN 57 (49) 1627.81 12345678 
Filamin-A OS=Homo 
sapiens GN=FLNA 
PE=1 SV=4 
4.64E+07 
FLNC_HUMAN 49 (38) 1369.78 12345678 
Filamin-C OS=Homo 
sapiens GN=FLNC 
PE=1 SV=3 
4.93E+07 
SPTB2_HUMAN 43 (40) 1220.9 12345678 
Spectrin beta chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTBN1 PE=1 
SV=2 
2.18E+07 
FLNB_HUMAN 45 (36) 1043.61 12345678 
Filamin-B OS=Homo 
sapiens GN=FLNB 
PE=1 SV=2 
1.44E+07 
HS90B_HUMAN 24 (16) 774.5 12345678 
Heat shock protein 
HSP 90-beta 
OS=Homo sapiens 
GN=HSP90AB1 
PE=1 SV=4 
2.70E+07 
HS90A_HUMAN 20 (8) 624.91 12345678 
Heat shock protein 
HSP 90-alpha 
OS=Homo sapiens 
GN=HSP90AA1 
PE=1 SV=5 
1.01E+07 
LMNA_HUMAN 10 599.01 12345678 
Prelamin-A/C 
OS=Homo sapiens 
GN=LMNA PE=1 
SV=1 
1.40E+07 
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Table A12.2. Sample of data from hMiro1V13 set. 
Accession Peptides Score Fractions Description 
Average 
Normalised 
Abundances 
Miro1V13 
SPTN1_HUMAN 17 897.03 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
6.62E+06 
FLNC_HUMAN 12 (11) 653.53 12345678 
Filamin-C OS=Homo 
sapiens GN=FLNC 
PE=1 SV=3 
1.22E+07 
HS90B_HUMAN 11 (9) 629.04 12345678 
Heat shock protein 
HSP 90-beta 
OS=Homo sapiens 
GN=HSP90AB1 
PE=1 SV=4 
4.72E+07 
K1C9_HUMAN 11 609.64 12345678 
Keratin, type I 
cytoskeletal 9 
OS=Homo sapiens 
GN=KRT9 PE=1 
SV=3 
2.64E+07 
FLNA_HUMAN 11 585.1 12345678 
Filamin-A 
OS=Homo sapiens 
GN=FLNA PE=1 
SV=4 
1.94E+07 
HS90A_HUMAN 10 552.86 12345678 
Heat shock protein 
HSP 90-alpha 
OS=Homo sapiens 
GN=HSP90AA1 
PE=1 SV=5 
6.04E+07 
GANAB_MACFA 10 546.68 12345678 
Neutral alpha-
glucosidase AB 
OS=Macaca 
fascicularis 
GN=GANAB PE=2 
SV=1 
8.71E+06 
LMNA_HUMAN 10 533.73 12345678 
Prelamin-A/C 
OS=Homo sapiens 
GN=LMNA PE=1 
SV=1 
8.66E+06 
SPTN1_HUMAN 17 897.03 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
6.62E+06 
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Table A12.3. Sample of data from hMiro2N18 set. 
Accession Peptides Score Fractions Description 
Average 
Normalised 
Abundances 
Miro2N18 
FLNC_HUMAN 22 (21) 1187.45 12345678 
Filamin-C OS=Homo 
sapiens GN=FLNC 
PE=1 SV=3 
3.78E+07 
SPTN1_HUMAN 19 996.59 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
2.34E+07 
HSP7C_HUMAN 12 (10) 738.94 12345678 
Heat shock cognate 
71 kDa protein 
OS=Homo sapiens 
GN=HSPA8 PE=1 
SV=1 
2.45E+08 
HS90A_HUMAN 13 732.06 12345678 
Heat shock protein 
HSP 90-alpha 
OS=Homo sapiens 
GN=HSP90AA1 
PE=1 SV=5 
2.00E+08 
K2C6C_HUMAN 10 721.34 12345678 
Keratin, type II 
cytoskeletal 6C 
OS=Homo sapiens 
GN=KRT6C PE=1 
SV=3 
1.58E+08 
K1C16_HUMAN 12 (11) 714.76 12345678 
Keratin, type I 
cytoskeletal 16 
OS=Homo sapiens 
GN=KRT16 PE=1 
SV=4 
1.69E+08 
GRP78_HUMAN 14 714.28 12345678 
78 kDa glucose-
regulated protein 
OS=Homo sapiens 
GN=HSPA5 PE=1 
SV=2 
1.40E+08 
VINC_HUMAN 12 697.62 12345678 
Vinculin OS=Homo 
sapiens GN=VCL 
PE=1 SV=4 
2.11E+07 
FLNC_HUMAN 22 (21) 1187.45 12345678 
Filamin-C OS=Homo 
sapiens GN=FLNC 
PE=1 SV=3 
3.78E+07 
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Table A12.4. Sample of data from hMiro2V13 set. 
Accession Peptides Score Fractions Description 
Average 
Normalised 
Abundances 
Miro2V13 
FLNC_HUMAN 11 630.67 12345678 
Filamin-C 
OS=Homo sapiens 
GN=FLNC PE=1 
SV=3 
6.28E+06 
HS90A_HUMAN 10 (6) 541.87 12345678 
Heat shock protein 
HSP 90-alpha 
OS=Homo sapiens 
GN=HSP90AA1 
PE=1 SV=5 
1.17E+07 
SPTN1_HUMAN 10 510.85 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
1.85E+06 
HS90B_HUMAN 9 (3) 476.65 12345678 
Heat shock protein 
HSP 90-beta 
OS=Homo sapiens 
GN=HSP90AB1 
PE=1 SV=4 
2.96E+06 
LMNA_HUMAN 8 441.45 12345678 
Prelamin-A/C 
OS=Homo sapiens 
GN=LMNA PE=1 
SV=1 
3.34E+06 
ALDOA_HUMAN 7 429.86 12345678 
Fructose-
bisphosphate 
aldolase A 
OS=Homo sapiens 
GN=ALDOA PE=1 
SV=2 
9.95E+06 
ACTB_CHLAE 7 417.23 12345678 
Actin, cytoplasmic 1 
OS=Chlorocebus 
aethiops GN=ACTB 
PE=2 SV=1 
1.09E+08 
K1C18_HUMAN 7 (5) 412.06 12345678 
Keratin, type I 
cytoskeletal 18 
OS=Homo sapiens 
GN=KRT18 PE=1 
SV=2 
4.29E+06 
FLNC_HUMAN 11 630.67 12345678 
Filamin-C 
OS=Homo sapiens 
GN=FLNC PE=1 
SV=3 
6.28E+06 
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Table A12.5. Sample of data from control set. 
Accession Peptides Score Fractions Description 
Average 
Normalised 
Abundances 
Control 
SPTN1_HUMAN 24 1316.49 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
1.24E+07 
K1C10_HUMAN 13 (11) 785.52 12345678 
Keratin, type I 
cytoskeletal 10 
OS=Homo sapiens 
GN=KRT10 PE=1 
SV=6 
3.37E+07 
K1C9_HUMAN 13 753.14 12345678 
Keratin, type I 
cytoskeletal 9 
OS=Homo sapiens 
GN=KRT9 PE=1 
SV=3 
2.96E+07 
LMNA_HUMAN 12 702.24 12345678 
Prelamin-A/C 
OS=Homo sapiens 
GN=LMNA PE=1 
SV=1 
1.81E+07 
K2C1_HUMAN 13 679.11 12345678 
Keratin, type II 
cytoskeletal 1 
OS=Homo sapiens 
GN=KRT1 PE=1 
SV=6 
5.32E+07 
EF2_CALJA 12 665.73 12345678 
Elongation factor 2 
OS=Callithrix jacchus 
GN=EEF2 PE=2 
SV=1 
3.73E+07 
HS90A_HUMAN 11 641.77 12345678 
Heat shock protein 
HSP 90-alpha 
OS=Homo sapiens 
GN=HSP90AA1 
PE=1 SV=5 
9.50E+07 
ENOA_HUMAN 10 (9) 620.33 12345678 
Alpha-enolase 
OS=Homo sapiens 
GN=ENO1 PE=1 
SV=2 
1.40E+08 
SPTN1_HUMAN 24 1316.49 12345678 
Spectrin alpha chain, 
non-erythrocytic 1 
OS=Homo sapiens 
GN=SPTAN1 PE=1 
SV=3 
1.24E+07 
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Appendix 13: RhoH DLS data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A13.1 DLS results for RhoHT1 showing size distribution by (a) volume, (b) number 
and (c) intensity. Triplicate set 1. 
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Figure A13.2 DLS results for RhoHT1 showing size distribution by (a) volume, (b) number 
and (c) intensity. Triplicate set 2. 
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Figure A13.3 DLS results for RhoHT1 showing size distribution by (a) volume, (b) number 
and (c) intensity. Triplicate set 3. 
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Appendix 14: Further LOMETS results 
 
 
 
 
 
 
 
 
 
 
 
Figure A14.1 Top-scoring models for the prediction of RhoHFL according to the the LOcal MEta-Threading-Server (LOMETS) online server. 
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Figure A14.2 Top-scoring models for the prediction of RhoHFL according to the the LOcal MEta-Threading-Server (LOMETS) online server. 
